(S1 (S (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NP (NN cytokine)) (NN expression))) (PP (IN in) (NP (NNS leukocytes))) (PP (IN by) (NP (NP (NN binding)) (PP (IN of) (NP (JJ thrombin-stimulated) (NNS platelets))))) (. .)))))
(S1 (S (NP (NP (NN BACKGROUND) (: :)) (S (NP (VBN Activated) (NNS platelets)) (VP (VP (VBP tether)) (CC and) (VP (VBP activate)) (NP (JJ myeloid) (NNS leukocytes))) (. .)))))
(S1 (S (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (JJ potential) (NN relevance)) (PP (IN of) (NP (DT this) (NN mechanism))) (PP (IN in) (NP (NP (JJ acute) (JJ myocardial) (NN infarction)) (PRN (-LRB- -LRB-) (NP (NN AMI)) (-RRB- -RRB-)))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (NP (NP (NN cytokine)) (NN induction)) (PP (IN by) (NP (JJ leukocyte-platelet) (NN adhesion)))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ leukocyte-platelet) (NNS conjugates))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN AMI))))))) (. .))))
(S1 (S (NP (NP (NP (NNS METHODS)) (CC AND) (NP (NNS RESULTS)) (: :)) (NP (PRP We)) (VP (VBD obtained) (NP (JJ peripheral) (JJ venous) (NN blood) (NNS samples)) (PP (PP (IN in) (NP (NP (NP (CD 20) (NNS patients)) (PP (IN with) (NP (NN AMI)))) (PP (PP (IN before)) (CC and) (PP (ADVP (RB daily)) (IN for) (NP (NP (CD 5) (NNS days)) (PP (IN after) (NP (JJ direct) (NP (NP (JJ percutaneous) (JJ transluminal) (JJ coronary) (NN angioplasty)) (PRN (-LRB- -LRB-) (NP (NN PTCA)) (-RRB- -RRB-)))))))))) (CC and) (PP (IN in) (NP (NP (CD 20) (NNS patients)) (VP (VBG undergoing) (NP (JJ elective) (NN PTCA))))))) (. .))))
(S1 (S (S (PP (IN Throughout) (NP (DT the) (NN study) (NN period))) (, ,) (NP (NP (NP (NN CD41) (NN immunofluorescence)) (PP (IN of) (NP (NNS leukocytes)))) (PRN (-LRB- -LRB-) (NP (NN flow) (NN cytometry)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (NP (VBN increased) (JJ leukocyte-platelet) (NN adhesion)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN AMI))))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ control) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NP (NN mean) (CC +/-) (NN SE)) (PP (IN of) (NP (NN fluorescence)))) (PRN (-LRB- -LSB-) (NP (NNS channels)) (-RRB- -RSB-))) (PP (IN before) (NP (NN PTCA)))) (: :) (NP (NP (CD 77) (CC +/-) (CD 16)) (CC versus) (NP (CD 35) (CC +/-) (CD 9))) (: ;) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD .003))))) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (JJ thrombin-stimulated) (JJ fixed) (NNS platelets)) (VP (VBD bound) (PP (TO to) (NP (NP (NNS neutrophils)) (CC and) (NP (NNS monocytes))))) (. .))))
(S1 (S (S (PP (IN Within) (NP (CD 2) (NNS hours))) (, ,) (NP (DT this)) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN increased) (NN mRNA)) (PP (IN for) (NP (NP (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (, ,) (CD 1) (NN beta)) (, ,) (NP (NN IL-8)) (, ,) (CC and) (NP (NN monocyte) (NN chemoattractant) (NN protein) (-LRB- -LRB-) (NN MCP) (-RRB- -RRB-) (CD -1)))) (PP (IN in) (NP (JJ unfractionated) (NP (NNS leukocytes))))))) (. .))))
(S1 (S (S (PP (IN After) (NP (CD 4) (NNS hours))) (, ,) (S (S (NP (NP (NP (NP (NN IL-1) (NN beta))) (CC and) (NP (NP (NN IL-8))) (NP (NN concentration))) (PP (IN of) (NP (DT the) (JJ cell-free) (NN supernatant)))) (VP (VBD had) (VP (VBN increased) (PP (IN by) (NP (NP (QP (CD 268) (CC +/-) (CD 36)) (NN %)) (CC and) (NP (QP (CD 210) (CC +/-) (CD 7)) (NN %)))) (, ,) (ADVP (RB respectively))))) (, ,) (CC and) (S (NP (JJ cellular) (NP (NN MCP-1)) (NN content)) (VP (VBD had) (VP (VBN increased) (PP (IN by) (NP (QP (CD 170) (CC +/-) (CD 8)) (NN %))))))) (. .))))
(S1 (S (S (NP (NP (NN Addition)) (PP (IN of) (NP (VBN activated) (NNS platelets))) (PP (TO to) (NP (JJ adherent) (NP (NNS monocytes))))) (VP (VP (VBD had) (NP (DT a) (JJ similar) (NN effect))) (CC and) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ nuclear) (NN factor-kappa) (NN B)) (NN activation)))))) (. .))))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN binding))) (PP (IN by) (NP (JJ anti-P) (NN selectin) (NNS antibodies)))) (VP (VBD reduced) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (VBN activated) (NNS platelets))) (PP (IN on) (NP (NP (NN cytokine)) (NN production))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NN AMI))))) (, ,) (NP (JJ leukocyte-platelet) (NN adhesion)) (VP (VBZ is) (VP (VBN increased)))) (. .))))
(S1 (S (S (NP (NP (NN Binding)) (PP (IN of) (NP (VBN activated) (NNS platelets)))) (VP (VBZ induces) (NP (NP (NN IL-1) (NN beta)) (, ,) (NP (NN IL-8)) (, ,) (CC and) (NP (NN MCP-1))) (PP (IN in) (NP (NNS leukocytes)))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ leukocyte-platelet) (NN adhesion)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ inflammatory) (NNS responses))) (PP (IN in) (NP (NN AMI))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Defective) (NP (NN survival)) (CC and) (NP (NN activation))) (PP (IN of) (NP (NNS thymocytes))) (PP (IN in) (NP (NP (JJ transgenic) (NNS mice)) (VP (VBG expressing) (NP (NP (DT a) (NP (RB catalytically) (JJ inactive) (NN form))) (PP (IN of) (NP (JJ Ca2+/calmodulin-dependent) (NN protein) (NN kinase) (CD IV))))))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN generated) (NP (NP (JJ transgenic) (NNS mice)) (SBAR (WHNP (WDT that)) (S (VP (VBP express) (NP (NP (DT a) (NP (RB catalytically) (JJ inactive) (NN form))) (PP (IN of) (NP (NP (JJ Ca2+/calmodulin-dependent) (NN protein) (NN kinase) (CD IV)) (PRN (-LRB- -LRB-) (NP (NN CaMKIV)) (-RRB- -RRB-))))) (PP (ADVP (RB specifically)) (IN in) (NP (JJ thymic) (NN T) (NNS cells))))))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (DT this) (NN protein)))) (VP (VBZ results) (PP (IN in) (NP (DT a) (ADJP (RB markedly) (VBN reduced)) (JJ thymic) (NN cellularity))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (DT the) (VBG remaining) (NNS cells)))) (VP (VBZ is) (ADJP (JJ normal) (PP (VBN based) (PP (IN on) (NP (NP (NN evaluation)) (PP (IN of) (NP (NP (DT the) (NP (NP (NN CD4))) (CC and) (NP (NP (NN CD8))) (NP (NN cell) (NN surface) (NNS antigens))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN used)) (S (VP (TO to) (VP (VB gauge) (NP (NN T) (NN cell) (NN development)))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (VBN Isolated) (NP (JJ thymic) (NN T) (NNS cells))) (PP (IN from) (NP (DT the) (JJ transgenic) (NNS mice)))) (ADVP (RB also)) (VP (VBP show) (NP (DT a) (ADJP (RB dramatically) (VBN decreased)) (NN survival) (NN rate)) (SBAR (WHADVP (WRB when)) (S (VP (VBN evaluated) (PP (IN in) (NP (NP (NN culture)) (PP (IN under) (NP (NP (NNS conditions)) (SBAR (WHNP (WDT that)) (S (VP (VBP do) (RB not) (VP (VB favor) (NP (NN activation)))))))))))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN challenged) (PP (IN with) (NP (NP (DT an) (VBG activating) (NN stimulus)) (PP (JJ such) (IN as) (NP (NP (NN alpha-CD3)) (CC or) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NN phorbol) (NN ester)) (CC plus) (NP (NN ionophore)))))))))))) (, ,) (S (NP (DT the) (NNS cells)) (VP (VBP are) (ADVP (RB severely)) (VP (VBN compromised) (PP (IN in) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB produce) (NP (NP (DT the) (NP (NN cytokine))) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Reduction)) (PP (IN of) (NP (NP (NN IL-2)) (NN production)))) (VP (VBZ is) (ADJP (JJ secondary) (PP (TO to) (NP (DT the) (NN inability) (S (VP (TO to) (VP (VP (VB phosphorylate) (NP (DT the) (NP (NP (NN cAMP) (NN response) (NN element) (NN binding) (NN protein)) (, ,) (NP (NN CREB))))) (, ,) (CC and) (VP (VBP induce) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT the) (NP (JJ immediate) (JJ early) (NNS genes))) (PP (JJ such) (IN as) (NP (NN Fos) (NN B))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN required)) (S (VP (TO to) (VP (VB transactivate) (NP (DT the) (NP (NN IL-2) (NN promoter)))))))))))))))))))) (. .))))
(S1 (S (S (SBAR (IN Because) (S (S (NP (NN transgene) (NN expression)) (VP (VBD was) (VP (VBN regulated) (PP (IN by) (NP (NP (DT the) (NP (JJ proximal) (NN promoter))) (PP (IN of) (NP (DT the) (NP (JJ murine) (NN lck) (NN gene))))))))) (CC and) (S (NP (DT this) (NN promoter)) (VP (VBZ is) (VP (VBN inactivated) (PP (IN in) (NP (NP (NN T) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP exit) (NP (DT the) (NN thymus)))))))))))) (, ,) (S (NP (DT the) (NP (JJ mutant) (NN hCaMKIV))) (VP (VBZ is) (RB not) (ADJP (JJ present) (PP (IN in) (NP (JJ peripheral) (NN T) (NNS cells)))))) (. .))))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NP (NN T) (NNS lymphocytes)) (ADJP (JJ present) (PP (IN in) (NP (DT the) (NN spleen))))) (VP (MD can) (VP (VB be) (VP (VBN activated) (ADVP (RB normally)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT either) (NN stimulus)) (VP (VBN mentioned) (ADVP (RB above))))))))) (, ,) (S (VP (VBG demonstrating) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (NP (JJ inactive) (NN CaMKIV)))) (PP (IN on) (NP (NN activation)))) (VP (VBP are) (ADJP (JJ reversible)))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NN CaMKIV)) (VP (MD may) (VP (VB represent) (NP (DT a) (ADJP (RB physiologically) (JJ relevant)) (NP (NN CREB) (NN kinase))) (PP (IN in) (NP (NN T) (NNS cells))))))) (CC and) (SBAR (IN that) (S (NP (DT the) (NN enzyme)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN required)) (S (VP (TO to) (VP (VB ensure) (NP (NP (JJ normal) (NN expansion)) (PP (IN of) (NP (NN T) (NNS cells))) (PP (IN in) (NP (DT the) (NN thymus)))))))))))) (. .))))
(S1 (S (S (SBAR (IN Whereas) (S (NP (NP (DT the) (NN pathway)) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (JJ latter) (NN role))))) (VP (VBZ is) (ADVP (RB yet)) (S (VP (TO to) (VP (VB be) (VP (VBN elucidated)))))))) (, ,) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB include) (NP (NP (NN CREB)) (NN phosphorylation)))))))) (. .))))
(S1 (S (S (S (NP (DT The) (NP (NN class) (CD II) (NN trans-activator) (NN CIITA))) (VP (VBZ interacts) (PP (IN with) (NP (DT the) (NP (JJ TBP-associated) (NN factor) (NN TAFII32))))) (. .)))))
(S1 (S (S (S (NP (DT The) (NP (NP (NN class) (CD II) (NN trans-activator)) (PRN (-LRB- -LRB-) (NP (NN CIITA)) (-RRB- -RRB-)))) (VP (VBZ is) (NP (NP (DT the) (JJ main) (JJ transcriptional) (NN co-activator)) (PP (IN for) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN MHC) (NN class) (CD II) (NNS proteins))))))) (. .)))))
(S1 (S (S (NP (PRP$ Its) (NP (JJ N-terminal) (CD 125) (NN amino) (NNS acids))) (VP (VBP function) (PP (IN as) (NP (DT an) (NP (JJ independent) (JJ transcriptional) (NN activation) (NN domain))))) (. .))))
(S1 (S (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (NP (DT the) (NP (JJ primary) (NN amino) (NN acid) (NN sequence))) (PP (IN of) (NP (DT the) (NP (NN activation) (NN domain))))))) (VP (VBP predict) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (CD three) (NP (NNS alpha-helices))))) (, ,) (S (NP (DT each)) (PP (IN with) (NP (NP (DT a) (JJ high) (NN proportion)) (PP (IN of) (NP (JJ acidic) (NNS residues))))))) (. .))))
(S1 (S (S (S (VP (VBG Using) (NP (JJ site-directed) (NN mutagenesis)))) (, ,) (S (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (CD two)) (PP (IN of) (NP (DT these) (VBN predicted) (NP (NNS alpha-helices))))) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NP (ADJP (ADJP (JJ full)) (ADJP (JJ transcriptional))) (NN activation)) (PP (IN by) (NP (NN CIITA))))))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT a) (NP (NN CIITA) (NN protein))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT both) (JJ functional) (NP (NNS alpha-helices))) (VP (VBP have) (VP (VBN been) (VP (VBN deleted))))))) (VP (VBZ displays) (NP (DT a) (JJ dominant) (JJ negative) (NN phenotype))) (. .))))
(S1 (S (S (NP (NP (DT This) (NP (NN activation) (NN domain))) (PP (IN of) (NP (NN CIITA)))) (VP (VBZ interacts) (PP (IN with) (NP (NP (NP (DT the) (NP (CD 32) (NN kDa) (NN subunit))) (PP (IN of) (NP (DT the) (NP (JJ general) (NN transcription) (NN complex)) (NP (NN TFIID))))) (, ,) (NP (NN TAFII32))))) (. .))))
(S1 (S (S (NP (NP (VBN Decreased) (JJ transcriptional) (NN activation)) (PP (IN by) (NP (NP (JJ N-terminal) (NNS deletions)) (PP (IN of) (NP (NN CIITA)))))) (VP (VBZ is) (VP (VBN correlated) (ADVP (RB directly)) (PP (IN with) (NP (NP (PRP$ their) (VBN reduced) (NN binding)) (PP (TO to) (NP (NN TAFII32))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NN TAFII32)) (CC and) (NP (NN CIITA))))) (VP (VBP are) (ADJP (JJ responsible) (PP (IN for) (NP (NP (NN activation)) (PP (IN of) (NP (NN class) (CD II) (NNS genes)))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Specific) (NN complex) (NN formation)) (PP (IN between) (NP (NP (DT the) (NP (NN type) (CD II) (JJ bare) (NN lymphocyte) (JJ syndrome-associated) (NNS transactivators))) (NP (NP (NN CIITA)) (CC and) (NP (NN RFX5))))) (. .)))))
(S1 (S (S (S (NP (NP (NP (CD Two)) (PP (IN of) (NP (DT the) (NNS genes))) (ADJP (JJ defective) (PP (IN in) (NP (DT the) (CD five) (NN complementation) (NNS groups)))) (VP (VBN identified) (PP (IN in) (NP (DT the) (NN class) (JJ II-negative) (JJ bare) (NN lymphocyte) (NN syndrome))))) (CC or) (NP (JJ corresponding) (JJ laboratory) (NNS mutants))) (VP (VBP have) (VP (VBN been) (VP (VBN cloned)))) (. .)))))
(S1 (S (S (NP (CD One) (NN gene)) (VP (VBZ encodes) (NP (NP (NP (DT a) (NN protein)) (, ,) (NP (NN RFX5))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (NP (NP (DT a) (NN member)) (PP (IN of) (NP (DT the) (NP (NN RFX) (NN family) (IN of) (NN DNA) (NN binding) (NNS proteins)))))))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (JJ other)) (, ,) (NP (NN CIITA)) (, ,)) (VP (VBZ encodes) (NP (NP (DT a) (JJ large) (NN protein)) (PP (IN with) (NP (DT a) (VBN defined) (NP (JJ acidic) (JJ transcriptional) (NN activation) (NN domain))))))) (: ;) (S (NP (DT this) (NN protein)) (VP (VBZ does) (RB not) (VP (VB interact) (PP (IN with) (NP (NN DNA)))))) (. .))))
(S1 (S (S (NP (NP (NN Expression) (NNS plasmids)) (VP (VBG encoding) (NP (NP (NNS regions)) (PP (IN of) (NP (NN RFX5))) (VP (VBN fused) (PP (TO to) (NP (DT the) (NP (NN GAL4) (NN DNA) (NN binding) (NN domain)))))))) (VP (VBD activated) (NP (NN transcription)) (PP (IN from) (NP (NP (DT a) (NN reporter) (NN construct)) (VP (VBG containing) (NP (NN GAL4) (NNS sites))))) (PP (IN in) (NP (NP (DT a) (NN cotransfection) (NN assay)) (PP (IN in) (NP (DT the) (NP (NN Raji) (JJ human) (NN B) (NN cell) (NN line))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT these) (NP (NNS plasmids))) (VP (VBD produced) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN in) (NP (NN HeLa) (NNS cells)))) (PP (ADVP (RB only)) (IN in) (NP (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NN interferon) (NN gamma)) (NN stimulation)))) (, ,) (NP (NP (DT a) (NN condition)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NN expression)) (PP (IN of) (NP (CC both) (NP (NN CIITA)) (CC and) (NP (NN class) (CD II) (JJ major) (NN histocompatibility) (NN complex) (NN surface) (NNS proteins))))) (VP (VBP are) (VP (VBN induced.))))))))))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (DT these) (NP (NNS plasmids))) (VP (VBD were) (RB not) (ADJP (JJ active) (PP (IN in) (NP (NP (NN RJ2.2.5)) (, ,) (NP (NP (DT an) (ADJP (ADVP (FW in) (FW vitro)) (VBN mutagenized)) (NN derivative)) (PP (IN of) (NP (NN Raji))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT both) (NNS copies)) (PP (IN of) (NP (NN CIITA)))) (VP (VBP are) (ADJP (JJ defective)))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Transcriptional) (NN activation)) (PP (IN by) (NP (DT the) (NP (NN RFX5) (NN fusion) (NN protein))))) (VP (MD could) (VP (VB be) (VP (VBN restored) (PP (IN in) (NP (NN RJ2.2.5))) (PP (IN by) (NP (NP (NN cotransfection)) (PP (IN with) (NP (DT a) (NP (NN CIITA) (NN expression) (NN plasmid))))))))) (. .))))
(S1 (S (S (ADVP (RB Finally)) (, ,) (NP (NP (DT a) (JJ direct) (NN interaction)) (PP (IN between) (NP (NP (NN RFX5)) (CC and) (NP (NN CIITA))))) (VP (VBD was) (VP (VBN detected) (PP (IN with) (NP (DT the) (NP (NN yeast) (JJ two-hybrid)) (CC and) (NP (JJ far-Western) (NN blot)) (NP (NNS assays)))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN RFX5)) (VP (MD can) (VP (VB activate) (NP (NN transcription)) (PP (ADVP (RB only)) (IN in) (NP (NP (NN cooperation)) (PP (IN with) (NP (NN CIITA))))))) (. .))))
(S1 (S (S (NP (NP (NN RFX5)) (CC and) (NP (NN CIITA))) (VP (VBP associate) (S (VP (TO to) (VP (VB form) (NP (NP (DT a) (NN complex)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG activating) (NP (NP (NN transcription)) (PP (IN from) (NP (NN class) (CD II) (JJ major) (NN histocompatibility) (NN complex) (NNS promoters))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN complex))) (, ,) (S (S (NP (NN promoter) (NN specificity)) (VP (VBZ is) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN DNA) (NN binding) (NN domain)) (PP (IN of) (NP (NN RFX5)))))))) (CC and) (S (NP (DT the) (JJ general) (NN transcription) (NN apparatus)) (VP (VBZ is) (VP (VBN recruited) (PP (IN by) (NP (NP (DT the) (NP (JJ acidic) (NN activation) (NN domain))) (PP (IN of) (NP (NN CIITA))))))))) (. .))))
(S1 (S (S (S (S (NP (NN CCAAT/enhancer) (NN binding) (NN protein) (NN epsilon)) (VP (VBZ is) (ADVP (RB preferentially)) (VP (VBN up-regulated) (PP (IN during) (NP (JJ granulocytic) (NN differentiation)))))) (CC and) (S (NP (PRP$ its) (JJ functional) (NN versatility)) (VP (VBZ is) (VP (VBN determined) (PP (IN by) (NP (NP (NP (JJ alternative) (NN use)) (PP (IN of) (NP (NNS promoters)))) (CC and) (NP (JJ differential) (NN splicing))))))) (. .)))))
(S1 (S (S (S (NP (NN CCAAT/enhancer) (NN binding) (NN protein) (-LRB- -LRB-) (NN C/EBP) (-RRB- -RRB-) (NN epsilon)) (VP (VP (VBZ is) (NP (NP (DT a) (ADJP (RB recently) (VBN cloned)) (NN member)) (PP (IN of) (NP (NP (DT the) (NP (NN C/EBP) (NN family))) (PP (IN of) (NP (NN transcription) (NNS factors))))))) (CC and) (VP (VBZ is) (VP (VBN expressed) (PP (ADVP (RB exclusively)) (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (JJ hematopoietic) (NN origin)))))))) (. .)))))
(S1 (S (S (NP (DT The) (NP (JJ human) (NN C/EBPepsilon) (NN gene))) (VP (VBZ is) (VP (VBN transcribed) (PP (IN by) (NP (NP (CD two) (JJ alternative) (NP (NNS promoters))) (, ,) (NP (NP (NN Palpha)) (CC and) (NP (NN Pbeta))))))) (. .))))
(S1 (S (S (NP (NP (DT A) (NN combination)) (PP (IN of) (NP (NP (JJ differential) (NN splicing)) (CC and) (NP (NP (JJ alternative) (NN use)) (PP (IN of) (NP (NNS promoters))))))) (VP (VBZ generates) (NP (NP (CD four) (NP (NN mRNA) (NNS isoforms))) (, ,) (PP (IN of) (NP (NP (NP (CD 2.6) (NN kb)) (CC and) (NP (CD 1.3-1.5) (NN kb))) (PP (IN in) (NP (NN size))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS transcripts)) (VP (MD can) (VP (VB encode) (NP (NP (CD three) (NNS proteins)) (PP (IN of) (NP (NP (VBN calculated) (JJ molecular) (NN mass)) (NP (NP (CD 32.2) (NN kDa)) (, ,) (NP (CD 27.8) (NN kDa)) (, ,) (CC and) (NP (CD 14.3) (NN kDa)))))))) (. .))))
(S1 (S (S (ADVP (RB Accordingly)) (, ,) (NP (NP (NN Western) (NNS blots)) (PP (IN with) (NP (NP (NNS antibodies)) (ADJP (JJ specific) (PP (IN for) (NP (NP (DT the) (JJ DNA-binding) (NN domain)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ common) (PP (TO to) (NP (DT all) (NNS forms)))))))))))) (, ,)) (VP (VBP identify) (NP (JJ multiple) (NNS proteins))) (. .))))
(S1 (S (S (NP (NN C/EBPepsilon) (NN mRNA)) (VP (VBD was) (ADVP (RB greatly)) (VP (VBN induced) (PP (IN during) (NP (NP (ADJP (ADJP (FW in) (FW vitro)) (ADJP (JJ granulocytic))) (NN differentiation)) (PP (IN of) (NP (JJ human) (JJ primary) (JJ CD34-LRB-+-RRB-) (NNS cells))))))) (. .))))
(S1 (S (S (NP (NP (JJ Retinoic) (NN acid) (NN treatment)) (PP (IN of) (NP (NN HL60) (JJ promyelocytic) (NN leukemia) (NNS cells))) (PP (IN for) (NP (CD 24) (NN hr)))) (VP (VBD induced) (NP (NP (NN C/EBPepsilon) (NN mRNA)) (NNS levels)) (PP (IN by) (NP (RB 4-fold))) (, ,) (SBAR (IN while) (S (NP (JJ prolonged) (NN treatment)) (ADVP (RB gradually)) (VP (VBD reduced) (NP (NN mRNA) (NN expression)) (PP (TO to) (NP (JJ pretreatment) (NNS levels))))))) (. .))))
(S1 (S (S (NP (NP (JJ Transient) (NN transfection) (NNS experiments)) (PP (IN with) (NP (NP (NN expression) (NNS vectors)) (PP (IN for) (NP (NP (CD two)) (PP (IN of) (NP (DT the) (NNS isoforms)))))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT the) (NP (JJ 32.2-kDa) (NN protein))) (VP (VBZ is) (NP (NP (DT an) (NN activator)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NN granulocyte) (JJ colony-stimulating) (NN factor) (NN receptor) (NN promoter)))))) (, ,) (SBAR (IN while) (S (NP (DT the) (NP (JJ 14.3-kDa) (NN protein))) (VP (VBZ is) (RB not)))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN C/EBPepsilon)) (VP (VP (VBZ is) (VP (VBN regulated) (PP (IN in) (NP (DT a) (JJ complex) (NN fashion))))) (CC and) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (JJ myeloid) (NN differentiation))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (JJ Transcriptional) (NN activity)) (CC and) (NP (JJ constitutive) (JJ nuclear) (NN localization))) (PP (IN of) (NP (NP (DT the) (NP (NN ETS) (NN protein))) (NP (NN Elf-1)))) (. .)))))
(S1 (S (S (S (NP (NN Elf-1)) (VP (VBZ is) (NP (NP (DT a) (NP (JJ lymphoid-specific) (NN transcription) (NN factor))) (SBAR (WHNP (WDT that)) (S (VP (VBZ belongs) (PP (TO to) (NP (DT the) (NP (NN ETS) (NN protein) (NN family))))))))) (. .)))))
(S1 (S (S (NP (PRP It)) (VP (MD can) (VP (VB bind) (PP (TO to) (NP (NP (NN DNA) (NN target) (NNS sequences)) (PP (IN within) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN cytokine) (NNS genes))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN Elf-1)) (VP (VBZ is) (ADVP (RB constitutively)) (ADJP (JJ localized) (PP (IN in) (NP (NP (DT the) (NN nucleus)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN amino) (NNS acids) (CD 86-265)))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NN Gal4-Elf-1) (NN fusion) (NNS proteins)))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (JJ N-terminal) (CD 86) (NN amino) (NNS acids)) (PP (IN of) (NP (NN Elf-1)))) (VP (VBP contain) (NP (NP (DT a) (NP (JJ transcriptional) (NN activation) (NN domain))) (, ,) (SBAR (WHNP (NP (DT the) (NN activity)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBZ is) (VP (VBN attenuated) (PP (IN by) (NP (DT an) (NP (JJ internal) (NN repression) (NN domain))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NN Elf-1)) (VP (VP (VBZ interacts) (PP (ADVP (RB specifically)) (IN with) (NP (DT the) (NP (NN E74) (NN target) (NN sequence))))) (CC and) (VP (MD can) (VP (VB stimulate) (NP (NP (NN transcription)) (VP (VBN driven) (PP (IN by) (NP (NP (DT the) (NP (NN E74) (NN site))) (ADJP (JJ independent) (PP (IN of) (NP (JJ mitogenic) (NN signaling))))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN Elf-1)) (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB stimulate) (NP (NP (NN gene) (NN transcription)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NP (NN development)) (CC and) (NP (NN activity))) (PP (IN of) (NP (NNS lymphocytes)))))))))))))))) (. .))))
(S1 (S (S (S (NP (NN Histamine)) (VP (VBZ modulates) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN c-fos))) (PP (IN through) (NP (NP (JJ cyclic) (NN AMP) (NN production)) (PP (IN via) (NP (DT the) (NP (NN H2) (NN receptor)))))) (PP (IN in) (NP (DT the) (NP (JJ human) (JJ promonocytic) (NN cell) (NN line) (NN U937)))))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN histamine)) (CC and) (NP (PRP$ its) (NNS agonists)))) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NP (NN c-fos)) (CC and) (NP (NN c-myc)) (NP (NNS proto-oncogenes)))) (PP (IN at) (NP (DT the) (NP (ADJP (JJ transcriptional))) (CC and) (NP (ADJP (JJ translational))) (NP (NNS levels)))) (PP (IN in) (NP (DT the) (NP (JJ human) (JJ promonocytic) (NN U937) (NN cell) (NN line)))))))) (. .)))))
(S1 (S (S (NP (NN Histamine)) (ADVP (RB transiently)) (VP (VBD increased) (NP (NP (NN cAMP)) (CC and) (NP (NP (NN c-fos)) (NN expression))) (PP (IN through) (NP (NN H2) (NNS receptors)))) (. .))))
(S1 (S (S (S (NP (NN Dibutyryl) (NN cAMP)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN c-fos) (NN mRNA)) (CC and) (NP (NP (NN protein)))))) (, ,) (CC and) (S (NP (NNS levels)) (VP (VBD remained) (ADJP (JJ elevated) (PP (ADVP (RB even)) (IN after) (NP (NP (CD 12) (NN hr)) (PP (IN of) (NP (NN treatment)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Dose-dependence) (NNS studies)) (VP (VBG using) (NP (NP (NN histamine)) (CC and) (NP (NN dimaprit))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN EC50) (NNS values)) (PP (IN for) (NP (NP (NN cAMP) (NN production)) (CC and) (NP (NP (NN c-fos)) (NN increase))))) (VP (VBD were) (ADJP (JJ similar))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN cAMP)) (VP (MD might) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (NN c-fos)) (NN induction))) (PP (IN via) (NP (NN H2) (NNS receptors))))))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NNS studies)) (VP (VBD carried) (PRT (IN out)) (S (VP (VBG using) (NP (NP (NN H7)) (, ,) (NP (DT a) (NP (NN protein) (NN kinase) (NN A/protein) (NN kinase) (NN C) (NN inhibitor))))))) (, ,)) (VP (VBD blocked) (NP (NP (NN c-fos)) (NN induction)) (, ,) (SBAR (IN whereas) (S (NP (DT no) (NN effect)) (VP (VBD was) (VP (VBN observed) (PP (IN with) (NP (NP (NN bisindolylmaleimide)) (, ,) (NP (DT a) (JJ specific) (NP (NN protein) (NN kinase) (NN C)) (NN inhibitor))))))))) (. .))))
(S1 (S (S (NP (NP (DT No) (NN modification)) (PP (IN of) (NP (NP (NN c-myc)) (NN expression)))) (VP (MD could) (VP (VB be) (VP (VBN detected) (PP (IN on) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN histamine)) (CC or) (NP (PRP$ its) (NNS analogues))))))))) (. .))))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (JJ dibutyryl) (NN cAMP)) (VP (VBD induced) (NP (NP (DT a) (NN down-regulation)) (PP (IN of) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (DT this) (NP (NN proto-oncogene)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ dibutyryl) (NN cAMP)) (VP (VBD inhibited) (NP (NN cell) (NN growth)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (, ,) (SBAR (IN whereas) (S (NP (NN histamine)) (VP (VBD failed) (S (VP (TO to) (VP (VB affect) (NP (NP (NP (NN proliferation)) (CC and) (NP (NN differentiation))) (PP (IN of) (NP (NN U937) (NNS cells))))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Cells)) (ADJP (JJ pretreated) (PP (IN with) (NP (NN dimaprit))))) (VP (VBD showed) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN cAMP) (NN response)) (PP (TO to) (NP (NP (JJ subsequent) (NN addition)) (PP (IN of) (NP (NN H2) (NNS agonists)))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN cAMP) (NN response)) (PP (TO to) (NP (NN prostaglandin) (NN E2)))) (VP (VBD remained) (ADJP (JJ unaltered)))))) (. .))))
(S1 (S (S (NP (NP (DT This) (JJ homologous) (NN mechanism)) (PP (IN of) (NP (NP (NN H2) (NN receptor)) (NN desensitization)))) (VP (VBD was) (NP (NN time) (JJ dependent))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN histamine)) (VP (VP (VBZ activates) (NP (NP (JJ several) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN differentiation)))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN cAMP)) (CC and) (NP (NP (NN c-fos)) (NN production)))))) (, ,) (CC but) (VP (VBZ fails) (S (VP (TO to) (VP (VB promote) (NP (NP (NN differentiation)) (PP (IN of) (NP (NN U937) (NNS cells))))))) (, ,) (ADVP (ADVP (RB apparently)) (JJ due) (PP (TO to) (NP (NP (DT the) (JJ rapid) (NN desensitization)) (PP (IN of) (NP (NN H2) (NNS receptors))))))))))) (. .))))
(S1 (S (S (S (NP (JJ Human) (NN cytomegalovirus)) (VP (VBZ induces) (NP (NP (NP (NN interleukin-8)) (NN production)) (PP (IN by) (NP (NP (DT a) (NP (JJ human) (JJ monocytic) (NN cell) (NN line))) (, ,) (NP (NN THP-1))))) (, ,) (PP (IN through) (S (VP (VBG acting) (ADVP (RB concurrently)) (PP (IN on) (NP (NP (NP (NN AP-1-)) (CC and) (NP (JJ NF-kappaB-binding)) (NP (NNS sites))) (PP (IN of) (NP (DT the) (NP (NN interleukin-8) (NN gene)))))))))) (. .)))))
(S1 (S (S (S (NP (NP (NP (NN Cytomegalovirus)) (PRN (-LRB- -LRB-) (NP (NN CMV)) (-RRB- -RRB-))) (NN infection)) (VP (VBD induced) (NP (NP (NP (NP (NN interleukin-8)) (PRN (-LRB- -LRB-) (NP (NN IL-8)) (-RRB- -RRB-))) (NN gene) (NN transcription)) (PP (IN in) (NP (NP (DT a) (NP (JJ human) (JJ monocytic) (NN cell) (NN line))) (, ,) (NP (NN THP-1) (NNS cells))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (NN IL-8)) (NN secretion)))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (JJ functional) (NN analysis)) (PP (IN of) (NP (DT the) (NP (NN IL-8) (NN gene))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (CC both) (NP (NN AP-1-)) (CC and) (NP (NN NF-kappaB) (JJ factor-binding)) (NP (NNS elements))) (VP (VBD were) (VP (VBN involved) (PP (IN in) (S (VP (VBG conferring) (NP (DT the) (NN responsiveness)) (PP (TO to) (NP (NN CMV))))))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN CMV)) (VP (VBD induced) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (NP (NN NF-kappaB))) (CC and) (NP (NN AP-1) (NNS complexes))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN CMV)) (VP (VBZ activates) (NP (DT these) (NP (JJ transcriptional) (NNS factors))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN IL-8)) (NN gene) (NN expression))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (JJ Concomitant) (NN downregulation)) (PP (IN of) (NP (NP (NP (NP (NN IgH) (JJ 3') (NN enhancer)) (NN activity)) (CC and) (NP (NP (NN c-myc)) (NN expression))) (PP (IN in) (NP (DT a) (NN plasmacytoma) (NN x) (NN fibroblast) (NN environment))))) (: :)) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NN dysregulation)) (PP (IN of) (NP (VBN translocated) (NP (NN c-myc))))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (NN immunoglobulin) (JJ heavy) (NN chain) (-LRB- -LRB-) (NN IgH) (-RRB- -RRB-) (NN gene)) (NN expression)))) (VP (VBZ is) (VP (VBN controlled) (PP (IN by) (NP (NP (DT a) (NP (NN B) (JJ cell-specific) (NN promoter))) (, ,) (NP (JJ intronic) (NN enhancer)) (CC and) (NP (NP (JJ additional) (NP (NN B) (JJ cell-specific) (NN enhancer) (NNS elements))) (VP (VBN identified) (ADVP (RB recently)) (PP (IN in) (NP (NP (DT the) (JJ 3') (NN end)) (PP (IN of) (NP (DT the) (NP (NN IgH) (NN locus)))))))))))) (. .)))))
(S1 (S (S (S (NP (NP (NP (CD One)) (PP (IN of) (NP (DT the) (JJ latter) (NNS elements)))) (, ,) (NP (DT the) (NP (NN IgH) (JJ 3') (NN enhancer))) (, ,)) (VP (VBZ is) (PP (IN of) (NP (JJ particular) (NN interest))))) (: :) (S (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (PRP it)) (VP (VBZ is) (ADJP (ADJP (NN B) (JJ cell-specific)) (CC and) (ADJP (JJ active) (PP (ADVP (RB only)) (IN in) (NP (JJ late) (NN B) (NN cell) (NN development))))))) (: ;) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (PP (PP (IN in) (NP (JJ rodent) (NNS plasmacytomas))) (CC and) (PP (IN in) (NP (DT some) (JJ human) (NP (NN Burkitt) (POS 's)) (NNS lymphomas)))) (NP (PRP it)) (VP (VBZ is) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (NP (NP (NN locus) (NN control) (NN region)) (PRN (-LRB- -LRB-) (NP (NN LCR)) (-RRB- -RRB-)))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (NN deregulation)) (PP (IN of) (NP (DT the) (NP (NN c-myc) (NN oncogene))))))))))))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN translocation)) (PP (IN into) (NP (DT the) (NP (NN IgH) (NN locus)))))))))) (: ;) (CC and) (S (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP control) (NP (NP (NN Ig) (NN gene) (NN class)) (NN switch) (NN recombination)))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN used) (NP (DT a) (JJ somatic) (NN cell) (NN hybridization) (NN approach))) (S (VP (TO to) (ADVP (RB genetically)) (VP (VB analyse) (NP (NP (NN regulation)) (PP (IN of) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (NP (NN IgH) (JJ 3') (NN enhancer))))))))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN mouse) (NN MPC11) (NN plasmacytoma) (NNS cells)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NP (NN IgH) (JJ 3') (NN enhancer))) (VP (VBZ is) (ADJP (JJ active))))) (, ,)) (VP (VBP are) (VP (VBN fused) (PP (IN with) (NP (NNS fibroblasts))))))) (, ,) (S (NP (NN Ig) (NN expression)) (VP (VBZ is) (VP (VBN extinguished) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN transcription)))))))) (. .))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (PP (IN in) (NP (DT a) (NP (NN MPC11) (NN plasmacytoma) (NN x) (NN fibroblast) (NN environment)))) (, ,) (NP (DT the) (NP (NN IgH) (JJ 3') (NN enhancer))) (VP (VBZ is) (ADJP (RB transcriptionally) (JJ inactive)))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN binding)) (PP (IN of) (NP (NP (JJ several) (NP (NN B) (JJ cell-specific) (NN transcription) (NNS factors))) (, ,) (ADJP (JJ essential) (PP (IN for) (NP (NP (NN IgH) (JJ 3') (NN enhancer)) (NN activity)))))) (, ,)) (VP (VBZ is) (VP (VBG lacking)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB explain) (NP (JJ 3') (NN enhancer) (NN inactivity)))))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NNS repressors)))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN excluded)))))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (NP (DT the) (JJ high) (NN expression) (NN level)) (PP (IN of) (NP (NN c-myc)))) (, ,) (ADVP (JJ characteristic) (PP (IN of) (NP (NP (DT the) (JJ parental) (NP (NN MPC11) (NNS cells))) (VP (VBG carrying) (NP (DT the) (NP (NN t-LRB-12;15-RRB-) (NN translocation))))))) (, ,)) (VP (VBZ is) (VP (VBN down-regulated) (PP (IN in) (NP (DT the) (NNS hybrids))) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (JJ unfused) (NP (NNS fibroblasts)))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN inactivation)) (PP (IN of) (NP (DT the) (NP (NN IgH) (JJ 3') (NN enhancer))))) (VP (VBZ is) (NP (NP (DT a) (JJ multifactorial) (NN process)) (VP (VBG affecting) (NP (NP (JJ several) (NP (NN transcription) (NNS factors))) (SBAR (WHNP (WDT that)) (S (VP (VBP control) (NP (NP (DT the) (NP (ADJP (JJ cell-specific))) (CC and) (NP (ADJP (JJ developmental))) (NP (NN activity))) (PP (IN of) (NP (DT the) (NP (NN enhancer)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NP (NN Construction)) (CC and) (NP (JJ biological) (NN characterization))) (PP (IN of) (NP (NP (DT an) (NP (NN interleukin-12) (NN fusion) (NN protein))) (PRN (-LRB- -LRB-) (NP (NN Flexi-12)) (-RRB- -RRB-)))) (: :)) (NP (NP (NN delivery)) (PP (TO to) (NP (JJ acute) (JJ myeloid) (JJ leukemic) (NNS blasts))) (S (VP (VBG using) (NP (JJ adeno-associated) (NN virus))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Interleukin-12)) (PRN (-LRB- -LRB-) (NP (NN IL-12)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (NP (NN cytokine))) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ exhibits) (NP (NP (JJ pleiotropic) (NNS effects)) (PP (IN on) (NP (NP (NNS lymphocytes)) (CC and) (NP (JJ natural) (NN killer) (NNS cells)))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (NP (NN promise)) (PP (IN for) (NP (NP (DT the) (NN immunotherapy)) (PP (IN of) (NP (NN cancer))))))))))))))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (DT the) (NP (JJ immune) (JJ costimulatory) (NN molecule))) (NP (NP (NN B7.1)) (CC and) (NP (NN IL-12)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ synergistic) (PP (IN for) (NP (NN T) (NN cell) (NN activation)))))))))) (. .))))
(S1 (S (S (PP (IN By) (S (VP (VBG transfecting) (NP (NN tumor) (NNS cells)) (PP (IN with) (NP (CC both) (NP (NN IL-12)) (CC and) (NP (NN B7.1)) (NP (NNS cDNAs))))))) (, ,) (NP (NP (PRP it))) (VP (MD may) (VP (VB be) (ADJP (JJ possible)) (S (VP (TO to) (VP (VB use) (NP (DT these) (VBN modified) (NNS targets)) (PP (IN as) (NP (NNS vaccines)))))))) (. .))))
(S1 (S (S (NP (NP (DT A) (JJ major) (NN obstacle)) (PP (IN in) (S (VP (VBG designing) (S (NP (DT a) (NN vector)) (VP (TO to) (VP (VB deliver) (NP (DT these) (NNS genes))))))))) (VP (VBZ results) (PP (IN from) (NP (NP (DT the) (NN structure)) (PP (IN of) (NP (NN IL-12)))))) (. .))))
(S1 (S (S (NP (JJ Functional) (NP (NN IL-12))) (VP (VBZ is) (NP (NP (DT a) (NP (NN heterodimer))) (VP (VBN composed) (PP (IN of) (NP (NP (CD two) (JJ distinct) (NNS subunits)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN encoded) (PP (IN by) (NP (NP (JJ separate) (NNS genes)) (PP (IN on) (NP (JJ different) (NNS chromosomes)))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Production)) (PP (IN of) (NP (JJ functional) (NN IL-12)))) (VP (VBZ requires) (NP (NP (DT the) (VBN coordinated) (NN expression)) (PP (IN of) (NP (DT both) (NNS genes))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBZ presents) (NP (JJ several) (NNS problems)) (PP (IN in) (NP (NP (NNS vectors)) (, ,) (ADVP (RB particularly)) (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (JJ additional) (NNS genes)) (, ,) (NP (CC either) (NP (DT a) (NP (JJ co-stimulatory) (NN gene))) (CC or) (NP (DT a) (JJ selectable) (NN marker))) (, ,)) (VP (VBP are) (VP (VBN inserted))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN constructed) (NP (NP (NP (DT a) (JJ single) (NP (NN cDNA))) (SBAR (WHNP (WDT that)) (S (VP (VBZ encodes) (NP (DT a) (NP (JJ single-chain) (NN protein))))))) (, ,) (VP (VBN called) (S (NP (NN Flexi-12)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ retains) (NP (NP (DT all)) (PP (IN of) (NP (NP (DT the) (JJ biological) (NNS characteristics)) (PP (IN of) (NP (NP (JJ recombinant) (NP (NN IL-12))) (PRN (-LRB- -LRB-) (NP (NN rIL-12)) (-RRB- -RRB-))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ monomeric) (NN polypeptide)) (NP (NN Flexi-12))) (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VP (VB induce) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (NN phytohemagglutinin) (-LRB- -LRB-) (NN PHA) (-RRB- -RRB-) (NNS blasts))))) (, ,) (VP (VB induce) (NP (NN PHA) (NNS blasts)) (S (VP (TO to) (VP (VB secrete) (NP (NP (NN interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-))))))) (CC and) (ADVP (RB additionally)) (, ,) (PP (IN by) (NP (NN preincubation))) (, ,) (VP (VB enhance) (NP (NP (DT the) (NN killing)) (PP (IN of) (NP (NN K562) (NNS targets))) (PP (IN by) (NP (NNS PBLs)))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS phenomena)) (VP (VBP are) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT that)) (VP (VBN seen) (PP (IN with) (NP (NN rIL-12)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB also)) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NP (DT the) (NP (NN STAT) (CD 4) (NN transcription) (NN factor))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ unique) (PP (TO to) (NP (DT the) (NP (NN IL-12)) (NN signaling) (NN pathway)))))))))))))) (, ,)) (VP (VBZ occurs) (PP (IN with) (NP (NN Flexi-12))) (PP (IN at) (NP (NP (NNS levels)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN seen) (PP (IN with) (NP (NN rIL-12)))))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VP (VBN packaged) (NP (NN Flexi-12)) (PP (IN into) (NP (DT a) (JJ recombinant) (NP (NP (JJ adeno-associated) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN AAV)) (-RRB- -RRB-)))))) (CC and) (VP (VBN used) (NP (DT this) (NN vector)) (S (VP (TO to) (VP (VB infect) (NP (JJ acute) (JJ myeloid) (JJ leukemic) (-LRB- -LRB-) (NN AML) (-RRB- -RRB-) (NNS blasts)))))))) (. .))))
(S1 (S (S (NP (JJ Infected) (NP (NN AML) (NNS blasts))) (VP (VBD produced) (NP (NP (NP (QP (IN between) (CD 2) (CC and) (CD 6)) (NN ng)) (PP (IN of) (NP (NN IL-12/10) (-LRB- -LRB-) (CD 6) (-RRB- -RRB-) (NNS cells)))) (PP (IN per) (NP (NN ml)))) (PP (IN per) (NP (CD 48) (NN hr)))) (. .))))
(S1 (S (S (NP (DT These) (NNS studies)) (ADVP (RB also)) (VP (VBP confirm) (SBAR (IN that) (S (NP (NN AAV)) (VP (VBZ is) (NP (NP (DT an) (JJ efficient) (NN delivery) (NN vehicle)) (PP (IN for) (NP (NNS cytokines))) (PP (TO to) (NP (JJ leukemic) (NNS cells)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Direct) (NN analysis)) (PP (IN of) (NP (NP (DT these) (VBN modified) (NNS cells)) (VP (VBG acting) (PP (IN as) (NP (NN tumor) (NNS vaccines))))))) (VP (VBZ is) (ADJP (JJ underway))) (. .))))
(S1 (S (S (S (NP (NP (NN ETS1)) (, ,) (NP (NN NFkappaB)) (CC and) (NP (NN AP1))) (ADVP (RB synergistically)) (VP (VBP transactivate) (NP (DT the) (NP (JJ human) (NN GM-CSF) (NN promoter)))) (. .)))))
(S1 (S (S (S (NP (NP (NN Activation)) (PP (IN of) (NP (NN helper) (NN T) (NNS cells)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJ coordinate) (NN expression)) (PP (IN of) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS cytokines)) (VP (VBN involved) (PP (IN in) (NP (NP (NP (NN differentiation)) (, ,) (NP (NN proliferation)) (CC and) (NP (NN activation))) (PP (IN of) (NP (DT the) (JJ haematopoietic) (NN system))))))))))))) (. .)))))
(S1 (S (S (NP (NP (JJ Granulocyte-macrophage) (NN colony) (NN stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN GM-CSF)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (CD one) (JJ such) (NP (NN cytokine))) (, ,) (SBAR (WHNP (WP$ whose) (VBN increased) (NN expression)) (S (VP (VBZ results) (PP (ADVP (RB mostly)) (IN from) (NP (NP (NNS increases)) (PP (IN in) (NP (NN transcription)))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Cis-acting) (NNS elements)) (PP (IN with) (NP (NP (NN NFkappaB)) (, ,) (NP (NN AP1)) (CC and) (NP (ADJP (JJ ETS-like))) (NP (VBG binding) (NNS motifs))))) (VP (VP (VBP have) (VP (VBN been) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NN promoter) (NN region)) (PP (IN of) (NP (DT the) (NP (NN GM-CSF) (NN gene))))))))) (, ,) (CC and) (VP (VBP are) (ADJP (ADJP (JJ important)) (CC or) (ADJP (JJ essential)) (PP (IN for) (NP (NP (JJ transcriptional) (NN activity)) (PP (VBG following) (NP (NN T) (NN cell) (NN activation)))))))) (. .))))
(S1 (S (S (NP (NN ETS1)) (VP (VBZ is) (NP (NP (DT a) (NP (NN transcription) (NN factor))) (PP (IN of) (NP (DT the) (NP (NN ETS) (NN family)))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (NN T) (NNS cells))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN shown) (SBAR (IN that) (S (NP (NN ETS1)) (VP (MD can) (VP (VB transactivate) (NP (NN GM-CSF)) (PP (IN in) (NP (NN Jurkat) (NN T) (NNS cells)))) (, ,) (CC but) (SBAR (ADVP (RB only)) (IN after) (NP (DT the) (NNS cells)) (VP (VBP have) (VP (VBN been) (VP (VBN stimulated) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NP (NN PMA)) (CC and) (NP (NN ionomycin))) (, ,) (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP mimic) (NP (NN T) (NN cell) (NN activation))))))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (NP (PRP we)) (VP (VBD proposed) (SBAR (IN that) (S (NP (NP (NN ETS1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN expressed) (ADVP (RB constitutively)) (PP (IN in) (NP (NN Jurkat) (NNS cells))))))) (, ,)) (VP (MD may) (VP (VB act) (PP (IN in) (NP (NP (NN concert)) (PP (IN with) (NP (NN PMA/ionomycin) (JJ inducible) (NNS factors)))))))))) (. .))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NN ETS1)) (VP (MD can) (VP (VB transactivate) (NP (DT a) (NP (NN GM-CSF) (NN reporter) (NN construct))) (PP (IN in) (NP (JJ unstimulated) (NP (NN Jurkat) (NNS cells)))) (, ,) (PP (VBG providing) (SBAR (IN that) (S (NP (CC either) (NP (NP (NN NFkappaB))) (CC or) (NP (NP (NN AP1))) (NP (NN transcription) (NNS factors))) (VP (VBP are) (VP (VBN supplied) (PP (IN by) (NP (NN co-transfection))))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP confirm) (SBAR (IN that) (S (NP (NP (NN binding)) (PP (IN of) (NP (JJ endogenous) (NP (NN NFkappaB)) (CC and) (NP (NN AP1))))) (VP (VBZ is) (VP (VBN induced) (PP (VBG following) (NP (NP (NN PMA/ionomycin) (NN treatment)) (PP (IN of) (NP (NN T) (NNS cells)))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Transactivation)) (PP (IN by) (NP (NP (NN ETS1)) (, ,) (NP (NN NFkappaB)) (CC and) (NP (NN AP1))))) (VP (VBZ is) (ADJP (JJ synergistic)))) (, ,) (CC and) (S (NP (NP (NN mutation)) (PP (IN of) (NP (DT the) (JJ individual) (VBG binding) (NNS sites)))) (VP (VBZ reveals) (SBAR (IN that) (S (NP (NP (DT the) (JJ transcriptional) (NNS activities)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (VBP are) (ADJP (JJ interdependent))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ constitutive) (NP (NN ETS1))) (, ,) (CC and) (NP (JJ inducible) (NP (NN NFkappaB)) (CC and) (NP (NN AP1))) (, ,)) (VP (VBP cooperate) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJR higher) (NN order) (NP (JJ transcriptional) (NN complex))) (PP (IN in) (NP (VBN activated) (NP (NN T) (NNS cells)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Relief)) (PP (IN of) (NP (NP (NN cyclin) (NN A)) (NN gene) (JJ transcriptional) (NN inhibition))) (PP (IN during) (NP (NP (NN activation)) (PP (IN of) (NP (JJ human) (JJ primary) (NN T) (NNS lymphocytes))) (PP (IN via) (NP (NP (NP (NN CD2))) (CC and) (NP (NP (NN CD28))) (NP (NN adhesion) (NNS molecules)))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Cyclin) (NN A)) (NN transcription)) (VP (VBZ is) (UCP (ADJP (NP (NN cell) (NN cycle)) (JJ regulated)) (CC and) (VP (VBN induced) (PP (IN by) (NP (NN cell) (JJ proliferative) (NNS signals)))))) (. .)))))
(S1 (S (S (S (VP (TO To) (VP (VB understand) (NP (NP (DT the) (NNS mechanisms)) (VP (VBN underlined) (PP (IN in) (NP (NP (DT this) (NN regulation)) (PP (IN in) (NP (JJ normal) (JJ human) (NNS cells)))))))))) (, ,) (S (NP (PRP we)) (VP (VBP have) (VP (VBN analysed) (NP (NP (ADJP (FW in) (FW vivo)) (JJ protein-DNA) (NNS interactions)) (PP (IN at) (NP (NP (DT the) (NP (NN Cyclin) (NN A)) (NN locus)) (PP (IN in) (NP (JJ primary) (NN T) (NNS lymphocytes))))))))) (. .))))
(S1 (S (S (NP (NP (NN Stimulation)) (PP (IN of) (NP (VBN purified) (NN T) (NNS lymphocytes))) (PP (IN by) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (JJ monoclonal) (NNS antibodies))))) (VP (VBN directed) (PP (IN at) (NP (NP (NP (NN CD2))) (CC and) (NP (NP (NN CD28))) (NP (NN adhesion) (NNS molecules)))))) (VP (VBZ gives) (NP (NN rise)) (PP (TO to) (NP (DT a) (ADJP (JJ long) (JJ lasting)) (NN proliferation))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN accessory) (NNS cells)))))) (. .))))
(S1 (S (S (NP (NN Cyclin) (NN A)) (VP (VBD was) (VP (VBN observed) (PP (IN after) (NP (NP (CD 4) (NNS days)) (PP (IN of) (NP (NP (NN costimulation)) (PP (IN with) (NP (NP (JJ anti) (NN CD2)) (CC +) (NP (NN CD28))))))))) (SBAR (IN whereas) (S (NP (NP (NN stimulation)) (PP (IN by) (NP (NP (NP (JJ anti) (NN CD2))) (CC or) (NP (NP (JJ anti) (NN CD28))) (ADVP (RB alone))))) (VP (VBD was) (RB not) (ADJP (JJ effective)))))) (. .))))
(S1 (S (S (NP (ADJP (ADJP (FW In) (FW vivo)) (ADJP (JJ genomic))) (NN DMS) (NN footprinting)) (VP (VBD revealed) (ADVP (RB upstream) (PP (IN of) (NP (DT the) (JJ major) (NP (NN transcription) (NN initiation) (NNS sites))))) (, ,) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD three)) (NP (NN protein) (NN binding) (NNS sites))) (, ,) (SBAR (WHNP (NP (CD two)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD were) (ADVP (RB constitutively)) (VP (VBN occupied))))))))) (. .))))
(S1 (S (S (NP (PRP They)) (VP (VBP bind) (ADVP (FW in) (FW vitro)) (ADVP (RB respectively)) (NP (NP (NP (NN ATF-1))) (CC and) (NP (NN NF-Y) (NNS proteins)))) (. .))))
(S1 (S (S (NP (DT The) (JJ third) (NN site)) (VP (VBD was) (VP (VBN occupied) (PP (PP (IN in) (NP (JJ quiescent) (NNS cells))) (CC or) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN stimulated) (PP (IN by) (NP (NP (NP (JJ anti) (NN CD2))) (CC or) (NP (NP (JJ anti) (NN CD28))) (ADVP (RB alone)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ mitogenic) (NN combination)) (PP (IN of) (NP (NP (JJ anti) (NN CD2)) (CC +) (NP (JJ anti) (NN CD28))))) (VP (VBD released) (NP (DT the) (NN footprint)) (SBAR (IN as) (S (NP (NNS cells)) (VP (VBD were) (VP (VBN committed) (PP (TO to) (NP (NN proliferation)))))))) (. .))))
(S1 (S (S (ADVP (JJ Consistent) (PP (IN with) (NP (DT theses) (NNS results)))) (, ,) (S (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN prepared) (PP (IN from) (NP (JJ quiescent) (NNS cells))))) (VP (VBD formed) (NP (NP (DT a) (JJ specific) (NN complex)) (PP (IN with) (NP (DT this) (NN element)))) (, ,) (SBAR (IN whereas) (S (NP (NP (NNS extracts)) (VP (VBN prepared) (PP (IN from) (NP (NP (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ anti) (NN CD2)) (CC +) (NP (JJ anti) (NN CD28))))))))) (VP (VBD failed) (S (VP (TO to) (VP (VB do) (ADVP (RB so))))) (SBAR (IN after) (S (NP (NNS cells)) (VP (VBD entered) (NP (DT a) (JJ proliferative) (NN state)))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (JJ Molecular) (NN cloning)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (NP (NP (DT a) (NP (NN cDNA))) (, ,) (NP (NN CHEMR1))) (, ,) (VP (VBG encoding) (NP (NP (DT a) (NP (NN chemokine) (NN receptor))) (PP (IN with) (NP (NP (DT a) (NN homology)) (PP (TO to) (NP (NP (DT the) (NP (JJ human) (NN C-C) (NN chemokine) (NN receptor))) (, ,) (NP (NN CCR-4)))))))))) (. .)))))
(S1 (S (S (S (NP (NNS Chemokines)) (VP (VBP refer) (PP (TO to) (NP (NP (DT a) (ADJP (RB rapidly) (VBG expanding)) (NN family)) (PP (IN of) (NP (JJ small) (NP (NNS cytokines)))) (SBAR (WHNP (WP$ whose) (JJ primary) (NN function)) (S (VP (VBZ is) (NP (NP (NN recruitment)) (PP (IN of) (NP (NNS leukocytes))) (PP (TO to) (NP (JJ inflammatory) (NNS sites)))))))))) (. .)))))
(S1 (S (S (NP (DT These)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB bind) (PP (TO to) (NP (NN seven-transmembrane-domain) (VBG containing) (NNS receptors)))))))) (. .))))
(S1 (S (S (NP (NP (NP (DT A) (NP (NN cDNA) (NN clone))) (, ,) (NP (NN CHEMR1))) (, ,) (VP (VBG resembling) (NP (DT the) (JJ typical) (NP (NN G) (JJ protein-coupled) (NN receptor)))) (, ,)) (VP (VBD was) (VP (VBN isolated) (PP (IN from) (NP (DT a) (NP (NN mouse) (JJ cytotoxic) (NN T-lymphocyte) (-LRB- -LRB-) (NN CTL) (-RRB- -RRB-) (NN library)))))) (. .))))
(S1 (S (S (NP (NP (NN Northern) (NN blot) (NN analysis)) (PP (IN in) (NP (NN mouse) (NN cell) (NNS lines)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (PRP$ its) (NN expression)) (VP (VBZ is) (VP (VBN found) (PP (IN in) (NP (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS cells)))) (, ,) (PP (VBG including) (NP (NP (NN T) (NNS cells)) (, ,) (NP (NN B) (NNS cells)) (, ,) (CC and) (NP (NNS macrophages))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN CHEMR1) (NN gene))) (NP (NN Scya3r2))) (VP (VBZ is) (NP (NP (DT a) (NP (JJ single-copy) (NN gene))) (SBAR (WHNP (WP$ whose) (JJ open) (NN reading) (NN frame)) (S (VP (VP (MD may) (VP (VB be) (PP (IN in) (NP (DT a) (JJ single) (NN exon))))) (CC and) (VP (VBZ maps) (PP (TO to) (NP (NP (DT the) (JJ distal) (NN region)) (PP (IN of) (NP (NN mouse) (NN Chr) (CD 9))) (SBAR (WHADVP (WRB where)) (S (NP (NP (NP (DT the) (NP (NN mouse) (NN macrophage) (JJ inflammatory) (NN protein-1alpha) (-LRB- -LRB-) (NN MIP-1alpha) (-RRB- -RRB-) (NN receptor) (NN gene))) (NP (NN Scya3r))) (CC and) (NP (CD two) (JJ related) (NP (NN C-C) (NN chemokine) (JJ receptor-like) (NNS genes)))) (VP (VBP reside)))))))))))) (. .))))
(S1 (S (S (NP (NN Amino) (NN acid) (NN sequence) (NN comparison)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NN CHEMR1)) (VP (VBZ is) (ADJP (NP (CD 84) (NN %)) (JJ identical) (PP (TO to) (NP (JJ human) (NN CCR-4)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NN CHEMR1)) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (NP (DT a) (NP (NN mouse) (NN CCR-4)))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Binding) (NNS assays)) (VP (VBG using) (NP (NP (JJ 125I-labeled) (NN C-C) (NNS chemokines)) (PP (IN in) (NP (JJ mammalian) (NNS cells)))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NN CHEMR1)) (VP (VBD did) (RB not) (VP (VB bind) (NP (NP (NN MIP-1alpha)) (, ,) (NP (NN RANTES)) (, ,) (CC or) (NP (NN MIP-1beta)))) (, ,) (SBAR (IN whereas) (S (NP (NN CCR-1)) (VP (VBZ binds) (NP (NP (NN MIP-1alpha)) (CC and) (NP (NN RANTES)))))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NN result)) (VP (VBZ is) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (VBN reported) (NNS properties)) (PP (IN of) (NP (JJ human) (NN CCR-4))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN CHEMR1)) (VP (MD may) (VP (VB be) (NP (NP (NP (DT a) (NN receptor)) (PP (IN for) (NP (JJ unidentified) (NP (NN C-C) (NN chemokine))))) (CC or) (NP (NP (DT a) (JJ low-affinity) (NN receptor)) (PP (IN for) (NP (NN MIP-1alpha)))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Biphasic) (NN control)) (PP (IN of) (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NN triggering)) (PP (IN of) (NP (NP (NN HLA-DR) (NNS antigens)) (VP (VBN expressed) (PP (IN on) (NP (NN B) (NNS cells))))))))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN regulation)) (PP (IN of) (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (PP (VBG following) (NP (NP (DT the) (NN triggering)) (PP (IN of) (NP (NN HLA-DR) (NNS antigens))) (PP (IN by) (NP (NN mAb) (NN L243)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PP (IN at) (NP (JJ various) (NNS times))) (PP (IN in) (NP (NN Raji) (NNS cells)))))) (. .)))))
(S1 (S (S (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBD demonstrated) (NP (NP (DT a) (JJ strong) (NN increase)) (PP (IN of) (NP (NP (NP (NN NF-kappa) (NN B)) (NN DNA) (NN binding)) (PP (IN after) (NP (NP (NN triggering)) (PP (IN of) (NP (NN HLA-DR) (NNS antigens))))))))) (. .))))
(S1 (S (S (S (VP (VBG Using) (NP (NN TNF-alpha-activity) (NN neutralizing) (NNS antibodies)))) (, ,) (S (NP (DT the) (NNS authors)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN upregulation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB depend) (, ,) (PP (IN at) (NP (JJR later) (NN time) (NN point))) (, ,) (PP (IN on) (NP (NP (DT an) (JJ autocrine) (NN effect)) (PP (IN of) (NP (NP (NN TNF-alpha)) (VP (VBN secreted) (PP (VBG following) (NP (NP (NN triggering)) (PP (IN of) (NP (NN HLA-DR) (NNS antigens))))))))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (NP (NN TNF-alpha)) (JJ independent) (PP (IN in) (NP (DT the) (JJ early) (NN time) (NN point))))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN upregulation)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (NN binding) (NN activity)))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP (NP (DT the) (NN triggering)) (PP (IN of) (NP (NP (VBN selected) (NP (NNS epitopes))) (PP (IN of) (NP (NN HLA-DR) (NNS antigens))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN fact))) (, ,) (NP (NP (NN mAb) (NN L243)) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NP (JJ staphylococcal) (NNS superantigens))) (, ,) (NP (JJ staphylococcal) (NN exotoxin) (JJ toxic) (NN shock) (NN syndrome) (NN toxin-I)) (CC or) (NP (JJ staphylococcal) (NN enterotoxin) (NN B))) (, ,)) (VP (VBP regulate) (NP (DT the) (NP (NN NF-kappa) (NN B)) (NN binding) (NN activity))) (. .))))
(S1 (S (S (S (NP (NP (FW Anti-Ehrlichia) (FW chaffeensis) (NN antibody)) (VP (VBN complexed) (PP (IN with) (NP (FW E.) (FW chaffeensis))))) (VP (VBZ induces) (NP (JJ potent) (NP (JJ proinflammatory) (NN cytokine) (NN mRNA)) (NN expression)) (PP (IN in) (NP (JJ human) (NNS monocytes))) (PP (IN through) (NP (NP (NP (JJ sustained) (NN reduction)) (PP (IN of) (NP (NN IkappaB-alpha)))) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))))))) (. .)))))
(S1 (S (S (S (NP (FW Ehrlichia) (FW chaffeensis)) (VP (VP (VBZ is) (NP (NP (DT an) (ADJP (ADJP (JJ obligatory)) (ADJP (JJ intracellular))) (NN bacterium)) (SBAR (WHNP (WDT that)) (S (VP (VBZ infects) (NP (NP (NNS monocytes)) (CC and) (NP (NNS macrophages)))))))) (CC and) (VP (VBZ is) (NP (NP (DT the) (JJ etiologic) (NN agent)) (PP (IN of) (NP (JJ human) (NN ehrlichiosis)))) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))) (. .)))))
(S1 (S (S (NP (PRP$ Our) (JJ previous) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN exposure)) (PP (IN of) (NP (JJ human) (NNS monocytes))) (PP (TO to) (NP (FW E.) (FW chaffeensis)))) (VP (VBZ induces) (NP (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NP (NP (NN interleukin-1beta)) (PRN (-LRB- -LRB-) (NP (NN IL-1beta)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN IL-8))) (, ,) (CC and) (NP (NN IL-10) (NNS genes)))) (ADVP (FW in) (FW vitro))) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))) (CC and) (NP (NN IL-6)) (NP (NNS mRNAs)))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (FW anti-E.) (FW chaffeensis) (NN antibody)) (VP (VBN complexed) (PP (IN with) (NP (FW E.) (FW chaffeensis)))))) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ major) (JJ proinflammatory) (NNS cytokines))) (PP (IN in) (NP (JJ human) (NNS monocytes)))))) (VP (VBD was) (VP (VBN examined))) (. .))))
(S1 (S (S (S (NP (JJ Human) (JJ monocytic) (NN cell) (NN line) (NN THP-1)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (FW E.) (FW chaffeensis)) (SBAR (WHNP (WDT which)) (S (VP (VBD had) (VP (VBN been) (ADJP (JJ preincubated) (PP (IN with) (NP (JJ human) (FW anti-E.) (FW chaffeensis) (NN serum))) (PP (IN for) (NP (CD 2) (NN h))))))))))))) (, ,) (CC and) (S (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN cytokine) (NNS mRNAs)))) (VP (VBD were) (VP (VBN evaluated) (PP (IN by) (NP (JJ competitive) (JJ reverse) (NN transcription-PCR)))))) (. .))))
(S1 (S (S (NP (NP (FW Anti-E.) (FW chaffeensis) (NN antibody)) (VP (VBN complexed) (PP (IN with) (NP (FW E.) (FW chaffeensis))))) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NP (NN mRNA) (NN expression)) (PP (IN of) (NP (NN IL-1beta))) (PP (IN in) (NP (NN THP-1) (NNS cells))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN TNF-alpha)) (CC and) (NP (NN IL-6)) (NP (NNS mRNAs))))) (VP (VBD was) (ADVP (RB also)) (VP (VBN induced))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS levels)) (PP (IN of) (NP (VBN secreted) (NP (NN IL-1beta)) (, ,) (NP (NN TNF-alpha)) (, ,) (CC and) (NP (NN IL-6)))) (PP (IN during) (NP (NP (CD 24) (NN h)) (PP (IN of) (NP (NN stimulation)))))) (VP (VBD were) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NP (FW Escherichia) (FW coli) (NN lipopolysaccharide)) (PP (IN at) (NP (CD 1) (NN microg/ml)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Fab) (NN fragment)) (PP (IN of) (NP (NP (FW anti-E.) (FW chaffeensis) (NN immunoglobulin) (NN G)) (VP (VBN complexed) (PP (IN with) (NP (FW E.) (FW chaffeensis))))))) (VP (VBD did) (RB not) (VP (VB induce) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (CD three) (NNS cytokines))))) (, ,) (S (VP (VBG indicating) (SBAR (SBAR (IN that) (S (NP (JJ ehrlichial) (NN binding)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (NN IL-1beta) (NN mRNA)) (NN expression))))))) (CC and) (SBAR (IN that) (S (NP (NP (NN binding)) (PP (IN of) (NP (DT the) (NP (JJ immune) (NN complex)))) (PP (TO to) (NP (DT the) (NP (NN Fc) (NN gamma) (NN receptor))))) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (NP (NP (NN TNF-alpha))) (CC and) (NP (NP (NN IL-6) (NN mRNA))) (NP (NN expression))) (CC and) (NP (VBD enhanced) (NP (NN IL-1beta) (NN mRNA)) (NN expression)))))))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NP (JJ prolonged) (NN degradation)) (PP (IN of) (NP (NN IkappaB-alpha)))) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))))) (VP (VBD were) (VP (VBN demonstrated) (PP (IN in) (NP (NP (NN THP-1) (NNS cells)) (VP (VBN exposed) (PP (TO to) (NP (NP (FW anti-E.) (FW chaffeensis) (NN serum)) (CC and) (NP (FW E.) (FW chaffeensis))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN result)) (VP (VBZ implies) (SBAR (IN that) (S (NP (NP (NN development)) (PP (IN of) (NP (FW anti-E.) (FW chaffeensis) (NN antibody))) (PP (IN in) (NP (NNS patients)))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (JJ major) (JJ proinflammatory) (NNS cytokines)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NN ehrlichiosis)))) (CC and) (NP (NP (JJ immune) (NNS responses)) (PP (TO to) (NP (PRP it)))))))))))))) (. .))))
(S1 (S (S (S (NP (JJ S-allyl) (NN cysteine)) (VP (VBZ inhibits) (NP (NP (NN activation)) (PP (IN of) (NP (JJ nuclear) (NN factor) (NN kappa) (NN B))) (PP (IN in) (NP (JJ human) (NN T) (NNS cells))))) (. .)))))
(S1 (S (S (S (NP (JJ Reactive) (NN oxygen) (NNS species)) (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (NN signal) (NN transduction) (NNS pathways)) (VP (VBG leading) (PP (TO to) (NP (NP (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (NN activation)) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN gene) (NN transcription))))))))))))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD reported) (SBAR (IN that) (S (NP (NP (DT a) (JJ garlic) (NN compound)) (, ,) (NP (NP (JJ S-allyl) (NN cysteine)) (PRN (-LRB- -LRB-) (NP (NN SAC)) (-RRB- -RRB-))) (, ,)) (VP (VBZ protects) (NP (JJ bovine) (JJ pulmonary) (NN artery) (JJ endothelial) (NNS cells)) (PP (IN from) (NP (NP (JJ oxidant) (NN injury)) (VP (VBN induced) (PP (IN by) (NP (NP (NN hydrogen) (NN peroxide)) (PRN (-LRB- -LRB-) (NP (NN H2O2)) (-RRB- -RRB-))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD determined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN SAC))) (PP (IN on) (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (PP (IN in) (NP (NP (JJ human) (NN T) (NNS lymphocytes)) (PRN (-LRB- -LRB-) (NP (NN Jurkat) (NNS cells)) (-RRB- -RRB-)))) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))) (CC and) (NP (NN H2O2))))))))) (. .))))
(S1 (S (S (NP (NP (VBN Activated) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (JJ nuclear) (NNS extracts)))) (VP (VBD was) (VP (VBN measured) (PP (IN by) (NP (NP (DT an) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)) (VP (VBG using) (NP (JJ 32P-labeled) (NN probe))))))) (. .))))
(S1 (S (S (NP (NN SAC)) (ADVP (RB consistently)) (VP (VBD exhibited) (NP (NP (DT a) (JJ dose-dependent) (NN inhibition)) (PP (IN of) (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (VP (VBN induced) (PP (IN by) (NP (CC both) (NP (NN TNF-alpha)) (CC and) (NP (NN H2O2))))))))) (. .))))
(S1 (S (S (NP (NP (NN Supershift)) (PP (IN with) (NP (JJ specific) (NNS antibodies))) (PP (TO to) (NP (NN NF-kappa) (NN B) (NNS subunits)))) (VP (VBD confirmed) (SBAR (IN that) (S (NP (DT the) (JJ inducible) (VBN retarded) (NNS bands)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN EMSA)) (CC and) (NP (NP (NN p65-p50) (NN heterodimer)) (PP (IN of) (NP (DT the) (NP (NN NF-kappa) (NN B/Rel) (NN protein))))))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN SAC)) (VP (MD may) (VP (VB act) (PP (IN via) (NP (JJ antioxidant) (NNS mechanisms)))) (S (VP (TO to) (VP (VB block) (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (PP (IN in) (NP (NN Jurkat) (NNS cells))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Effect)) (PP (IN of) (NP (NN adenovirus) (CD 2))) (PP (IN on) (NP (NP (JJ cellular) (NN gene) (NN activation)) (PP (IN in) (NP (NP (JJ blood-derived) (NNS monocytes)) (CC and) (NP (NP (NNS macrophages))))))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NN adenovirus) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Ad2)) (-RRB- -RRB-))) (NN infection))) (PP (IN on) (NP (NP (JJ human) (NNS monocytes)) (CC and) (NP (JJ monocyte-derived) (NNS macrophages))))) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NN TNF-alpha)) (CC and) (NP (NN IL-1) (NN beta)))))))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (NNS monocytes))) (, ,) (NP (DT the) (NN virus)) (VP (VBD was) (VP (VBN bound) (PP (TO to) (NP (DT the) (NN surface))) (PP (IN without) (S (VP (VBG being) (VP (VBN internalized))))))) (. .))))
(S1 (S (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NN Ad2)) (VP (VBD was) (VP (VBN internalized) (PP (IN by) (NP (NNS macrophages))))) (. .))))
(S1 (S (S (NP (NP (DT No) (NN virus) (NN replication)) (CC and) (NP (NP (DT no) (NN transcription)) (PP (IN of) (NP (DT the) (NP (NN Ad2) (JJ early) (NNS genes)))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (DT either)) (PP (IN of) (NP (DT the) (NNS cells))))))) (. .))))
(S1 (S (S (NP (NN Ad2) (NN infection)) (VP (VBD induced) (NP (NP (JJ transient) (NN increase)) (PP (IN in) (NP (NP (DT the) (NP (NN mRNA)) (NNS levels)) (PP (IN for) (NP (NP (NN TNF-alpha)) (CC and) (NP (NN IL-1) (NN beta))))))) (PP (PP (IN in) (NP (CC both) (NP (NNS monocytes)))) (CC and) (PP (IN in) (NP (NNS macrophages)))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NNS kinetics)) (PP (IN of) (NP (DT the) (NN transcription)))) (VP (VBD was) (ADJP (RB slightly) (JJ different)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN production)) (PP (IN of) (NP (DT both) (NP (NNS cytokines)))) (, ,) (VP (VBN measured) (PP (IN by) (NP (NN ELISA) (NNS tests)))) (, ,)) (VP (VBD was) (VP (VBN enhanced) (PP (IN in) (NP (NNS monocytes))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NNS macrophages))) (, ,) (NP (NP (DT a) (JJ slight) (NN enhancement)) (PP (IN of) (NP (NP (NN TNF-alpha)) (NN production)))) (VP (VBD was) (VP (VBN seen)) (, ,) (SBAR (IN whereas) (S (NP (NN IL-1) (NN beta)) (VP (VBD was) (RB not) (VP (VBN detected)))))) (. .))))
(S1 (S (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ cellular) (NNS genes)) (VP (MD might) (VP (VB be) (VP (VBN activated) (PP (IN by) (NP (NN Ad2) (NN virus) (NN infection))) (PP (IN in) (NP (NP (JJ nonpermissive) (NNS cells)) (SBAR (WHADVP (WRB where)) (S (NP (DT no) (NP (JJ viral) (NN gene) (NNS products))) (VP (MD could) (VP (VB be) (VP (VBN detected)))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN AP-1)) (VP (VBN derived) (PP (IN from) (NP (NP (JJ mature) (NNS monocytes)) (CC and) (NP (NP (NNS astrocytes))))))) (ADVP (RB preferentially)) (VP (VBZ interacts) (PP (IN with) (NP (DT the) (NP (NN HTLV-I) (NN promoter)) (JJ central) (NP (CD 21) (NN bp) (NN repeat))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (DT the) (JJ cellular) (NP (NN transcription) (NNS factors))) (VP (VBG interacting) (PP (IN with) (NP (NP (DT the) (NP (JJ human) (NN T) (NN cell) (JJ lymphotropic) (NN virus) (NN type) (CD I) (-LRB- -LRB-) (NN HTLV-I) (-RRB- -RRB-) (JJ long) (JJ terminal) (NN repeat))) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-)))))))) (VP (VBZ is) (ADJP (JJ essential) (PP (TO to) (S (VP (VBG dissecting) (NP (NP (DT the) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (JJ viral) (NN transcription)))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (ADJP (JJ pertinent) (PP (TO to) (NP (NP (DT the) (NP (ADJP (JJ oncogenic))) (CC and) (NP (ADJP (JJ neuropathogenic))) (NP (NNS processes))) (VP (VBN associated) (PP (IN with) (NP (NP (NN HTLV-I) (NN infection)) (PP (IN in) (NP (CC both) (DT the) (NP (ADJP (JJ immune))) (CC and) (NP (ADJP (JJ nervous))) (NP (NNS systems)))))))))))))))))))) (. .)))))
(S1 (S (S (NP (NP (NP (NP (JJ Electrophoretic) (NN mobility) (NN shift)) (PRN (-LRB- -LRB-) (NP (NN EMS)) (-RRB- -RRB-))) (NNS analyses)) (VP (VBG utilizing) (NP (NP (NNS oligonucleotides)) (ADJP (JJ homologous) (PP (TO to) (NP (NP (DT each)) (PP (IN of) (NP (NP (DT the) (NP (CD 21) (NN bp) (NN repeat) (NNS elements))) (VP (VBN reacted) (PP (IN with) (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN derived) (PP (IN from) (NP (NP (NN cell) (NNS lines)) (PP (IN of) (NP (NP (ADJP (JJ lymphocytic))) (, ,) (NP (ADJP (JJ monocytic))) (, ,) (NP (ADJP (JJ neuronal))) (, ,) (CC and) (NP (ADJP (JJ glial))) (NP (NN cell) (NN origin)))))))))))))))))) (VP (VBP have) (VP (VBN demonstrated) (NP (NP (JJ differential) (NN binding)) (PP (IN of) (NP (JJ cellular) (NNS factors))) (PP (TO to) (NP (NP (DT the) (CD three) (NP (CD 21) (NN bp) (NNS repeats))) (PRN (-LRB- -LRB-) (NP (CD 1-4)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN ATF/CREB))) (CC and) (NP (NN Sp) (NN family) (NNS members))) (VP (VBD interacted) (PP (IN with) (NP (DT the) (NP (CD 21) (NN bp) (NNS repeats)))) (S (VP (TO to) (VP (VB form) (NP (NP (JJ DNA-protein) (NNS complexes)) (ADJP (JJ common) (PP (TO to) (NP (NP (DT all) (NN cell) (NNS types)) (VP (VBN examined)))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT a) (JJ unique) (NP (JJ DNA-protein) (NN complex))) (VP (VBD was) (VP (VBN detected)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN promoter) (JJ central) (NP (CD 21) (NN bp) (NN repeat))) (VP (VBD was) (VP (VBN reacted) (PP (IN with) (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN derived) (PP (IN from) (NP (CC either) (NP (DT the) (NP (NN U-373) (NN MG) (NN glioblastoma) (NN cell) (NN line))) (CC or) (NP (DT the) (NP (NN THP-1) (JJ mature) (JJ monocytic) (NN cell) (NN line))))))))))))) (. .))))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (NN nucleotide) (NP (NN sequence) (NNS requirements)) (CC and) (NP (NN immunoreactivity))))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT this) (NP (JJ DNA-protein) (NN complex))) (VP (VBZ is) (VP (VBN comprised) (PP (IN of) (NP (NP (DT the) (NP (NN AP-1)) (NNS components)) (, ,) (NP (NP (NN Fos)) (CC and) (NP (NN Jun)))))))))) (. .))))
(S1 (S (S (S (NP (NP (DT An) (NP (JJ acute) (JJ myeloid) (NN leukemia) (NN gene))) (, ,) (NP (NN AML1)) (, ,)) (VP (VBZ regulates) (NP (NP (JJ transcriptional) (NN activation)) (CC and) (NP (JJ hemopoietic) (JJ myeloid) (NN cell) (NN differentiation))) (ADVP (RB antagonistically)) (PP (IN by) (NP (CD two) (ADJP (JJ alternative) (JJ spliced)) (NNS forms)))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NP (NN AML1) (NN gene))) (PP (IN on) (NP (NN chromosome) (CD 21)))) (VP (VP (VBZ is) (VP (VBN disrupted) (PP (IN in) (NP (NP (DT the) (NP (NN -LRB-8;21-RRB--LRB-q22;q22-RRB-)) (CC and) (NP (NN -LRB-3;21-RRB--LRB-q26;q22-RRB-)) (NP (NNS translocations))) (VP (VBN associated) (PP (IN with) (NP (JJ myelogenous) (NNS leukemias)))))))) (CC and) (VP (VBZ encodes) (NP (DT a) (NP (JJ DNA-binding) (NN protein))))) (. .)))))
(S1 (S (S (PP (IN From) (NP (NN AML1) (NN gene))) (, ,) (NP (NP (NP (CD two) (JJ representative) (NNS forms)) (PP (IN of) (NP (NNS proteins)))) (, ,) (NP (NP (NN AML1a)) (CC and) (NP (NN AML1b))) (, ,)) (VP (VBP are) (VP (VBN produced) (PP (IN by) (NP (DT an) (JJ alternative) (NN splicing))))) (. .))))
(S1 (S (S (S (NP (DT Both) (NNS forms)) (VP (VBP have) (NP (JJ DNA-binding) (NN domain)))) (, ,) (CC but) (S (NP (NN AML1a)) (VP (VBZ lacks) (NP (NP (DT a) (JJ putative) (JJ transcriptional) (NN activation) (NN domain)) (SBAR (WHNP (WDT which)) (S (NP (NN AML1b)) (VP (VBZ has))))))) (. .))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NP (NN AML1a)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB solely)) (VP (VBZ has) (NP (DT no) (NNS effects)) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN regulator)))))) (, ,)) (ADVP (RB dominantly)) (VP (VBZ suppresses) (NP (JJ transcriptional) (NN activation)) (PP (IN by) (NP (NN AML1b)))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NN AML1a)) (VP (VBZ exhibits) (NP (NP (DT the) (JJR higher) (NN affinity)) (PP (IN for) (NP (JJ DNA-binding))) (SBAR (IN than) (S (NP (NN AML1b)))))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (NP (NP (NP (DT a) (NP (JJ dominant) (JJ negative) (NN form))) (PP (IN of) (NP (NN AML1)))) (, ,) (NP (NN AML1a)) (, ,)) (ADVP (RB totally)) (VP (VBD suppressed) (NP (NP (JJ granulocytic) (NN differentiation)) (VP (ADVP (RB otherwise)) (VBN induced) (PP (IN by) (NP (NN granulocyte) (JJ colony-stimulating) (NN factor))))) (SBAR (WHADVP (WRB when)) (S (NP (NN AML1a)) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NN 32Dc13) (JJ murine) (JJ myeloid) (NNS cells)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Such) (NN differentiation) (NN block)) (PP (IN by) (NP (NN AML1a)))) (VP (VBD was) (VP (VBN canceled) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN overexpression)) (PP (IN of) (NP (NN AML1b))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (ADVP (RB strongly)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (ADVP (RB transcriptionally) (JJ active)) (NN form)) (PP (IN of) (NP (NN AML1)))) (VP (VBZ is) (ADJP (JJ essential) (PP (IN for) (NP (DT the) (JJ myeloid) (NN cell) (NN differentiation)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT an) (JJ altered) (NN expression) (NN level)) (PP (IN of) (NP (NN AML1)))) (PP (IN along) (PP (IN with) (NP (NP (DT the) (JJ myeloid) (NN differentiation)) (PP (IN in) (NP (JJ several) (NP (JJ hemopoietic) (NN cell) (NNS lines)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT these) (NNS cases))) (, ,) (ADVP (IN at) (JJS least)) (, ,) (NP (DT the) (NP (NN AML1)) (NN expression) (NN level)) (VP (VBZ is) (NP (NP (DT a) (JJ potential) (NN regulator)) (PP (IN for) (NP (JJ myeloid) (NN cell) (NN differentiation))))) (. .))))
(S1 (S (S (S (PP (IN Of) (NP (DT the) (NP (JJ GATA-binding) (NNS proteins)))) (, ,) (NP (RB only) (NP (NN GATA-4))) (ADVP (RB selectively)) (VP (VBZ regulates) (NP (DT the) (NP (JJ human) (NN IL-5) (NN gene) (NN promoter))) (PP (IN in) (NP (NP (NN IL-5) (NN producing) (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (VBP express) (NP (JJ multiple) (JJ GATA-binding) (NNS proteins)))))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Interleukin-5)) (PRN (-LRB- -LRB-) (NP (NN IL-5)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VP (VBN produced) (PP (IN by) (NP (NN T) (NNS lymphocytes)))) (CC and) (VP (VBN known) (S (VP (TO to) (VP (VB support) (NP (NP (NN B) (NN cell) (NN growth)) (CC and) (NP (NP (JJ eosinophilic) (NN differentiation)) (PP (IN of) (NP (DT the) (NP (NN progenitor) (NNS cells)))))))))))) (. .)))))
(S1 (S (S (S (VP (VBG Using) (NP (NP (NN ATL-16T) (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (VBP express) (NP (NN IL-5) (NN mRNA)))))))) (, ,) (S (NP (PRP we)) (VP (VBP have) (VP (VBN identified) (NP (NP (DT a) (NN region)) (, ,) (PP (IN within) (NP (DT the) (NP (JJ human) (NN IL-5) (NN gene) (NN promoter)))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ regulates) (NP (NP (NN IL-5) (NN gene)) (NN transcription))))))))) (. .))))
(S1 (S (S (NP (DT This) (NP (JJ cis-acting) (NN sequence))) (VP (VP (VBZ contains) (NP (NP (NP (DT the) (NP (NN core) (NN binding) (NN motif))) (, ,) (NP (NN -LRB-A/T-RRB-GATA-LRB-A/G-RRB-))) (, ,) (PP (IN for) (NP (NN GATA-binding) (NN family) (NNS proteins))))) (CC and) (ADVP (RB thus)) (VP (VBZ suggests) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (DT these) (NN family) (NNS members)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VP (VBP describe) (NP (NP (DT the) (NN cloning)) (PP (IN of) (NP (NP (JJ human) (NN GATA-4)) (PRN (-LRB- -LRB-) (NP (NN hGATA-4)) (-RRB- -RRB-)))))) (CC and) (VP (VBP show) (SBAR (IN that) (S (NP (NN hGATA-4)) (ADVP (RB selectively)) (VP (VBZ interacts) (PP (IN with) (NP (NP (DT the) (NP (CD -70) (NN GATA) (NN site))) (PP (IN within) (NP (DT the) (NP (NN IL-5) (JJ proximal) (NN promoter) (NN region))))))))))) (. .))))
(S1 (S (S (PP (IN By) (NP (NN promoter) (NP (NN deletion)) (CC and) (NP (NN mutation)) (NP (NNS analyses)))) (, ,) (NP (PRP we)) (VP (VBD established) (NP (DT this) (NN region)) (PP (IN as) (NP (DT a) (NP (JJ positive) (JJ regulatory) (NN element))))) (. .))))
(S1 (S (S (NP (NN Cotransfection) (NNS experiments)) (VP (VBD revealed) (SBAR (IN that) (S (NP (CC both) (NP (NP (NN hGATA-4))) (CC and) (NP (NN PMA/A23187)) (NP (NN stimulation))) (VP (VBP are) (ADJP (JJ necessary) (PP (IN for) (NP (DT the) (NP (NN IL-5) (NN promoter)) (NN activation)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN requirement)) (PP (IN of) (NP (NP (DT another) (NP (JJ regulatory) (NN element))) (VP (VBN called) (S (NP (NN CLE0)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ lies) (ADVP (RB downstream) (PP (IN of) (NP (DT the) (NP (CD -70) (NN GATA) (NN site)))))))))) (, ,)) (VP (VBD was) (ADVP (RB also)) (VP (VBN demonstrated))) (. .))))
(S1 (S (S (S (NP (NN ATL-16T) (NNS cells)) (VP (VBP express) (NP (NP (NN mRNA)) (PP (IN of) (NP (NP (CD three) (NP (JJ GATA-binding) (NNS proteins))) (, ,) (NP (NP (NN hGATA-2)) (, ,) (NP (NN hGATA-3)) (CC and) (NP (NN hGATA-4)))))))) (, ,) (CC and) (S (NP (NP (DT each)) (PP (IN of) (NP (PRP them)))) (VP (VBZ has) (NP (DT a) (NN potential) (S (VP (TO to) (VP (VB bind) (PP (TO to) (NP (DT the) (NP (NN consensus) (NN -LRB-A/T-RRB-GATA-LRB-G/A-RRB-) (NN motif)))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (S (VP (VBG using) (NP (NN ATL-16T) (JJ nuclear) (NN extract)))) (, ,) (S (NP (PRP we)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN GATA-4)) (VP (VBZ is) (NP (NP (DT the) (RB only) (NP (JJ GATA-binding) (NN protein))) (SBAR (WHNP (WDT that)) (S (VP (VBZ forms) (NP (JJ specific) (NP (JJ DNA-protein) (NN complex))) (PP (IN with) (NP (DT the) (NP (CD -70) (NN GATA) (NN site))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)) (PP (IN with) (NP (NP (NNS extracts)) (PP (IN of) (NP (NP (NN COS) (NNS cells)) (VP (VBG expressing) (NP (JJ GATA-binding) (NNS proteins)))))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NN GATA-4)) (VP (VBZ has) (NP (NP (NP (DT the) (JJS highest) (NN binding) (NN affinity)) (PP (TO to) (NP (DT the) (NP (CD -70) (NN GATA) (NN site))))) (PP (IN among) (NP (DT the) (CD three) (NP (JJ GATA-binding) (NNS proteins))))))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NN transactivation) (NN ability)) (VP (VBD was) (VP (VBN compared) (PP (IN among) (NP (DT the) (CD three))))))) (, ,) (S (NP (NN GATA-4)) (VP (VBD showed) (NP (DT the) (JJS highest) (NN activity)))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT the) (JJ selective) (NN role)) (PP (IN of) (NP (NN GATA-4))) (PP (IN in) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NP (NN IL-5) (NN gene)))) (PP (IN in) (NP (NP (DT a) (NN circumstance)) (SBAR (WHADVP (WRB where)) (S (NP (NP (JJ multiple) (NNS members)) (PP (IN of) (NP (DT the) (NP (JJ GATA-binding) (NNS proteins))))) (VP (VBP are) (VP (VBN expressed))))))))))) (. .))))
(S1 (S (S (S (NP (NP (VBN Increased) (NN expression)) (PP (IN of) (NP (NN Gs-LRB-alpha-RRB-)))) (VP (VBZ enhances) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NP (NN adenylyl) (NN cyclase)) (NN signal) (NN transduction) (NN cascade))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Expression)) (PP (IN of) (NP (NP (DT the) (JJ stimulatory) (NP (NN G) (NN protein))) (, ,) (NP (NN G-LRB-S-RRB-alpha)))) (, ,)) (VP (MD can) (VP (VB vary) (PP (IN over) (NP (DT a) (JJ 3-fold) (NN range))) (PP (PP (IN in) (NP (JJ human) (NNS tissues))) (CC and) (PP (IN in) (NP (JJ rodent) (JJ central) (JJ nervous) (NN system)))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (NN fact))) (, ,) (NP (NP (DT the) (NN offspring)) (PP (IN of) (NP (NNS alcoholics)))) (VP (VBP have) (NP (NP (JJR higher) (NNS levels)) (PP (IN of) (NP (NP (NP (NN G-LRB-S-RRB-alpha)) (NN expression)) (PP (IN in) (NP (JJ certain) (NNS tissues)))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN offspring)) (PP (IN of) (NP (NNS nonalcoholics))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN research)))) (VP (VBD was) (S (VP (TO to) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (DT a) (JJ causal) (NN relationship)) (VP (VBZ exists) (PP (IN between) (NP (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NN G-LRB-S-RRB-alpha)))))) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NP (NP (NN adenylyl) (NN cyclase)) (PRN (-LRB- -LRB-) (NP (NN AC)) (-RRB- -RRB-))) (NN cascade)))))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NN methodology)) (VP (VBD employed) (NP (NP (JJ transient) (NN transfection)) (PP (IN of) (NP (NN HEK) (CD 293) (NNS cells))) (PP (IN with) (NP (NP (DT a) (NN cDNA)) (PP (IN for) (NP (NP (DT the) (JJ 52-kDa) (NN form)) (PP (IN of) (NP (NN G-LRB-S-RRB-alpha))))))) (PP (IN under) (NP (NP (NN regulation)) (PP (IN by) (NP (JJ inducible) (NN metallothionein) (NNS promoters))))))) (. .))))
(S1 (S (S (NP (NNS Transfectants)) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (NP (VBG varying) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 0-125) (NN microM)) (-RRB- -RRB-))) (PP (IN of) (NP (NN zinc) (NN sulfate))) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (DT a) (JJ 3-fold) (NN range)) (PP (IN of) (NP (NN membrane) (NP (NN G-LRB-S-RRB-alpha)) (NN expression))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN range)) (PP (IN of) (NP (NP (NP (NN G-LRB-S-RRB-alpha)) (NN expression)) (VP (VBN produced))))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB mimic) (NP (NP (DT a) (ADJP (RB physiologically) (JJ relevant)) (NN spectrum)) (PP (IN of) (NP (NP (NP (NN G-LRB-S-RRB-alpha)) (NN expression)) (PP (IN in) (NP (NP (NNS membranes)) (VP (VBN derived) (PP (IN from) (NP (NP (JJ human) (NNS tissues)) (CC and) (NP (NN rat) (NN brain))))))))))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (NP (NP (NN induction)) (PP (IN of) (NP (NP (NN G-LRB-S-RRB-alpha)) (NN expression)))) (VP (VBD increased) (NP (NP (ADJP (JJ constitutive))) (CONJP (RB as) (RB well) (IN as)) (NP (VBN stimulated)) (NP (NN cAMP) (NN accumulation)))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN induction)) (PP (IN of) (NP (NP (NN G-LRB-S-RRB-alpha)) (NN expression)))) (VP (VBD increased) (NP (NP (NP (NNS events)) (ADJP (JJ distal) (PP (TO to) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NN cAMP))))))) (PP (VBG including) (NP (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN factor)) (, ,) (NP (NN cAMP) (NN response) (NN element) (NN binding) (NN protein))))) (CC and) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (JJ cAMP-dependent) (NN reporter) (NNS genes)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN summary))) (, ,) (NP (DT these) (NNS studies)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NN G-LRB-S-RRB-alpha)) (NN expression)))) (VP (VBZ has) (NP (DT a) (JJ marked) (NN impact)) (PP (IN on) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN activity)) (PP (IN of) (NP (NP (DT the) (NN AC) (NN cascade)) (PP (IN from) (NP (DT the) (NN membrane))) (PP (IN through) (PP (TO to) (NP (DT the) (NN nucleus)))))))))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (NNS individuals)) (SBAR (WHNP (WP who)) (S (VP (VBP differ) (PP (IN in) (NP (NP (NN G-LRB-S-RRB-alpha)) (NN expression))))))) (VP (MD may) (ADVP (RB also)) (VP (VB differ) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ certain) (NP (JJ cAMP-dependent) (NNS genes)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Expression)) (PP (IN of) (NP (NN transcription) (NNS factors))) (PP (IN during) (NP (NP (ADJP (NN sodium) (NN phenylacetate) (VBD induced)) (JJ erythroid) (NN differentiation)) (PP (IN in) (NP (NN K562) (NNS cells))))) (. .)))))
(S1 (S (S (S (PP (IN During) (NP (NP (CD 15) (NNS days)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN of) (NP (NN K562) (NNS cells))) (PP (IN with) (NP (NN sodium) (NN phenylacetate))))))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT the) (JJ cellular) (NP (NN hemoglobin)) (NN concentration)))) (PP (IN with) (NP (NP (DT a) (JJ similar) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN gamma-globin) (NN mRNA)))))))) (. .)))))
(S1 (S (S (NP (JJ Morphological) (NNS studies)) (VP (VBD demonstrated) (NP (NP (JJ characteristic) (NNS features)) (PP (IN of) (NP (JJ erythroid) (NP (NN differentiation)) (CC and) (NP (NN maturation)))))) (. .))))
(S1 (S (S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT the) (NP (NN cell) (NN surface) (NNS antigenes))) (NP (NP (NN CD33)) (, ,) (NP (NN CD34)) (, ,) (NP (NN CD45)) (, ,) (NP (NN CD71)) (CC and) (NP (NN glycophorin) (NN A))))))))))) (. .))))
(S1 (S (S (ADVP (RB Likewise)) (, ,) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT the) (NP (JJ erythroid) (NN transcription) (NNS factors))) (NP (NP (NN GATA-1)) (, ,) (NP (NN GATA-2)) (, ,) (NP (NN NF-E2)) (, ,) (NP (NN SCL)) (CC and) (NP (NN RBTN2))))) (, ,) (NP (NP (DT all)) (VP (VBN expressed) (PP (IN in) (NP (JJ untreated) (NP (NN K562) (NNS cells)))))))) (, ,)) (VP (VBD did) (RB not) (VP (VB increase) (PP (IN during) (NP (ADJP (NN sodium) (NN phenylacetate) (JJ induced)) (JJ erythroid) (NN differentiation))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NP (DT the) (NP (JJ nuclear) (NNS factors))) (NP (NP (NN Evi-1)) (CC and) (NP (NN c-myb)))) (, ,) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (JJ erythroid) (NN differentiation)))))))) (, ,)) (VP (VBD did) (RB not) (VP (VB decrease))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NN sodium) (NN phenylacetate) (NN treatment)) (PP (IN of) (NP (NN K562) (NNS cells)))) (VP (VP (VBZ increases) (NP (NN gamma-globin) (NN mRNA))) (CC and) (VP (VBZ induces) (NP (NN cell) (NN maturation))) (SBAR (IN as) (S (VP (VBN judged) (PP (IN by) (NP (NP (NN morphology))))))) (PP (IN without) (S (VP (VBG affecting) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (NP (JJ erythroid) (NN transcription) (NNS factors))) (, ,) (SBAR (WHNP (NP (DT some)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ beta-like) (NN globin) (NNS genes))))))))))))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Glucocorticoid) (NNS receptors)) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))) (PP (IN in) (NP (NP (NN relation)) (PP (PP (TO to) (NP (NN age))) (CC and) (PP (TO to) (NP (NN sport) (NN activity)))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS GR)) (-RRB- -RRB-))) (VP (VP (VBP are) (NP (JJ ubiquitous) (NNS molecules))) (CC and) (VP (VBP are) (ADJP (JJ present) (ADVP (RB also)) (PP (PP (IN in) (NP (DT the) (NN hippocampus))) (CC and) (PP (IN in) (NP (JJ several) (JJ other) (NP (ADJP (JJ nervous))) (CC and) (NP (ADJP (JJ immune))) (NP (NNS tissues)))))))) (. .)))))
(S1 (S (S (NP (NP (JJ Peripheral) (NN blood) (JJ mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS PBMCs)) (-RRB- -RRB-))) (VP (VBP are) (NP (NP (DT a) (JJ good) (NN model)) (PP (IN for) (NP (NP (NNS studies)) (PP (IN of) (NP (NP (NNS GR)) (PP (IN in) (NP (NNS humans))))))))) (. .))))
(S1 (S (S (NP (NNS Glucocorticoids)) (VP (VP (VBP are) (ADJP (JJ important) (PP (IN for) (S (VP (VBG maintaining) (NP (NP (ADJP (JJ cellular))) (CC and) (NP (ADJP (JJ humoral))) (NP (NN homeostasis)))))))) (CC and) (VP (VBP are) (NP (NP (JJ key) (NNS mediators)) (PP (IN of) (NP (ADJP (JJ neuroendocrine-immune) (JJ regulatory)) (NNS interactions)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN increase)) (PP (IN of) (NP (NN cortisol)))) (VP (VP (VBZ is) (ADJP (JJ immunosuppressive))) (CC and) (VP (VBZ reduces) (NP (NP (NNS GR)) (NN concentration))) (PP (CC both) (IN in) (NP (NP (ADJP (JJ nervous))) (CC and) (NP (ADJP (JJ immune))) (NP (NNS systems))))) (. .))))
(S1 (S (S (NP (NP (NN Variation)) (PP (IN of) (NP (NNS glucocorticoids))) (PP (IN in) (NP (NP (ADJP (ADJP (JJ healthy)) (ADJP (JJ aged))) (NNS subjects)) (CC and) (NP (NNS athletes))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown)))) (. .))))
(S1 (S (S (S (VP (VBN Prompted) (PP (IN by) (NP (DT these) (NNS results))))) (, ,) (S (NP (PRP we)) (VP (VBP have) (VP (VBN investigated) (PP (IN in) (NP (NN man))) (NP (NP (DT a) (JJ possible) (NN relationship)) (PP (IN between) (NP (NP (NP (NP (NNS GR)) (NN binding) (NN capacity)) (PP (IN in) (NP (DT the) (NP (NNS PBMCs))))) (CC and) (NP (NN age))))) (, ,) (PP (IN in) (NP (NP (NN relation)) (ADVP (RB also)) (PP (TO to) (NP (NN plasma) (NP (NN testosterone)) (CC and) (NP (NN cortisol))))))))) (. .))))
(S1 (S (S (NP (DT The) (JJ same) (NNS parameters)) (VP (VBP have) (VP (VBN been) (VP (VBN examined) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NN soccer) (NNS players))))) (PP (IN for) (NP (NP (NN comparison)) (PP (IN with) (NP (DT the) (JJ sedentary) (NN group)))))))) (. .))))
(S1 (S (S (NP (NP (NNS GR)) (NN binding) (NN capacity)) (VP (VBD was) (ADJP (ADJP (ADJP (JJR higher)) (PP (IN in) (NP (JJR younger) (NNS subjects))) (PP (IN than) (PP (IN in) (NP (JJR older) (NNS ones))))) (, ,) (CC and) (ADJP (ADJP (JJR lower)) (PP (IN in) (NP (NP (DT the) (NN group)) (PP (IN of) (NP (NNS athletes))))) (PP (IN than) (PP (IN in) (NP (DT the) (NP (ADJP (JJR younger))) (CC and) (NP (ADJP (JJR older))) (NP (JJ sedentary) (NNS subjects)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ sedentary) (NN group))) (NP (DT a) (JJ negative) (NN correlation)) (VP (VBD was) (ADJP (JJ present) (PP (IN between) (NP (NP (NP (NNS GR)) (NN binding) (NN capacity)) (CC and) (NP (NN age)))))) (. .))))
(S1 (S (S (S (S (NP (NN Plasma) (NN cortisol)) (VP (VBD was) (ADJP (JJR higher)))) (CC and) (S (NP (NN testosterone)) (ADJP (JJR lower)) (PP (IN in) (NP (DT the) (NNS athletes))))) (: ;) (S (NP (PRP they)) (VP (VBD were) (VP (VP (ADVP (RB negatively)) (VBN correlated) (PP (IN in) (NP (NNS athletes)))) (CC and) (VP (ADVP (RB positively)) (VBN correlated) (PP (IN in) (NP (DT the) (JJ sedentary) (NNS subjects))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS results)) (PP (IN for) (NP (NNS athletes)))) (VP (VBP agree) (PP (IN with) (NP (PRP$ their) (ADJP (JJR lower) (JJ anabolic/catabolic)) (NN balance)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NP (VBN reduced) (NP (NNS GR)) (NNS levels)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (NN age)) (CC and) (NP (NN sport) (NN activity))))))))) (VP (MD could) (VP (VB involve) (NP (NP (NP (DT a) (NN loss)) (CC or) (NP (DT an) (NN involution))) (PP (IN of) (NP (NN receptor) (NN synthesis)))))) (. .))))
(S1 (S (S (ADVP (RB However)) (NP (NP (JJ other) (NNS possibilities)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ altered) (NN distribution)) (PP (IN of) (NP (NN lymphocyte) (NNS subpopulations))) (PP (PP (IN with) (NP (JJ different) (NN receptor) (NNS concentrations))) (CC and) (PP (IN with) (NP (JJ different) (NP (NN cytokine)) (NN production)))))) (, ,)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN excluded)))) (. .))))
(S1 (S (S (NP (ADJP (JJ Several) (JJ neuroendocrine-immune)) (NNS interactions)) (VP (MD could) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (NP (VBN reduced) (NP (NNS GR)) (NNS levels)) (PP (IN with) (NP (NP (NN age)) (CC and) (NP (NN sport) (NN activity))))) (PP (IN in) (NP (NN man)))))))) (. .))))
(S1 (S (NP (NP (NP (NN Rescue)) (PP (IN by) (NP (NNS cytokines))) (PP (IN of) (NP (NP (JJ apoptotic) (NN cell) (NN death)) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NN IL-2)) (NN deprivation)) (PP (IN of) (NP (JJ human) (JJ antigen-specific) (NN T) (NN cell) (NNS clones)))))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN control)) (PP (IN of) (NP (NP (NN cell) (NN survival)) (CC and) (NP (NN cell) (NN death))))) (VP (VBZ is) (PP (IN of) (NP (JJ central) (NN importance))) (PP (IN in) (NP (NP (NNS tissues)) (PP (IN with) (NP (JJ high) (NN cell) (NN turnover))) (PP (JJ such) (IN as) (NP (DT the) (JJ lymphoid) (NN system)))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS cytokines))) (PP (IN on) (NP (NP (NP (NN IL-2)) (JJ deprivation-induced) (NN apoptosis)) (PP (IN of) (NP (NP (JJ human) (JJ antigen-specific) (NN T) (NN helper) (NNS clones)) (PP (IN with) (NP (JJ different) (NP (NN cytokine)) (NN production) (NNS profiles)))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NN IL-2)) (, ,) (NP (NP (NN interferon-alpha)) (PRN (-LRB- -LRB-) (NP (NN IFN-alpha)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN IFN-beta))) (VP (VBD inhibited) (NP (NP (NP (NN IL-2)) (NN deprivation) (NN apoptosis)) (PP (IN in) (NP (NP (NN Th0)) (, ,) (NP (NN Th1)) (, ,) (CC and) (NP (NN Th2)) (NP (NNS clones))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (SBAR (IN that) (S (NP (NN IL-2)) (VP (VBZ protects) (NP (NN T) (NN cell) (NNS clones)) (PP (IN from) (NP (NP (NN IL-2)) (NN deprivation) (NN apoptosis))) (S (VP (VBG accompanying) (NP (NP (NP (JJ active) (NN proliferation)) (CC and) (NP (VBN enhanced) (NN expression))) (PP (IN of) (NP (NP (NP (NN P53))) (, ,) (NP (NP (NN Rb))) (CC and) (NP (NN Bcl-xL) (NNS proteins))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (S (S (NP (NN IFN-alpha/beta)) (VP (VBD rescued) (NP (NN T) (NN cell) (NNS clones)) (PP (IN from) (NP (NN apoptosis))) (PP (IN without) (NP (JJ active) (NN proliferation))))) (, ,) (CC and) (S (NP (NP (NN expression)) (PP (IN of) (NP (NP (JJ apoptosis-associated) (NNS proteins)) (VP (VBN tested) (ADVP (RB so) (JJ far)))))) (VP (VBD was) (ADJP (JJ unaffected))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (NN T) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NN IL-2))))) (VP (VBD contained) (NP (NP (DT those)) (ADJP (JJ located) (PP (IN in) (NP (NP (NN S) (CC +) (NN G2/M) (NNS phases)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ vast) (NN majority)) (PP (IN of) (NP (NP (NN T) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NN IFN-alpha/beta))))))) (VP (VBD were) (ADJP (JJ located) (PP (IN in) (NP (NN G0/G1) (NN phase))))))))))))))) (. .))))
(S1 (S (S (NP (NN IFN-alpha/beta)) (ADVP (RB specifically)) (VP (VBD induced) (NP (NP (NN tyrosine) (NN phosphorylation)) (CC and) (NP (NP (NN translocation)) (PP (IN into) (NP (NP (NN nucleus)) (PP (IN of) (NP (NN signal) (NNS transducers) (CC and) (NNS activators) (IN of) (NN transcription) (-LRB- -LRB-) (NN STAT) (-RRB- -RRB-) (CD 2) (NN protein))))))) (PP (IN in) (NP (DT the) (NP (NN T) (NN cell) (NNS clones))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN over-expression)) (PP (IN of) (NP (NN STAT2))) (PP (IN by) (NP (NP (NN transfection)) (PP (IN of) (NP (DT the) (NN cDNA)))))) (VP (VBD prevented) (NP (NP (NN apoptosis)) (PP (IN of) (NP (DT the) (NP (NN T) (NN cell) (NNS clones)))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (JJ present) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (NN IFN-alpha)) (CC and) (NP (NN -beta))) (VP (VBP mediate) (NP (JJ anti-apoptotic) (NN effect)) (PP (IN through) (NP (NP (JJ other) (NNS pathways)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NN IL-2))))))) (PP (IN in) (NP (NN growth) (NN factor) (NN deprivation) (NN apoptosis))))))) (. .))))
(S1 (S (NP (NP (NP (NN Lipopolysaccharide) (NN induction)) (PP (IN of) (NP (DT the) (NP (NN tumor) (NN necrosis) (NN factor-alpha) (NN promoter)))) (PP (IN in) (NP (JJ human) (JJ monocytic) (NNS cells))) (. .)))))
(S1 (S (NP (NP (NN Regulation)) (PP (IN by) (NP (NP (NP (NN Egr-1))) (, ,) (NP (NP (NN c-Jun))) (, ,) (CC and) (NP (NP (NN NF-kappaB))) (NP (NN transcription) (NNS factors)))) (. .))))
(S1 (S (S (S (NP (NP (NN Biosynthesis)) (PP (IN of) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))))) (VP (VBZ is) (PP (ADVP (RB predominantly)) (IN by) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (NP (JJ monocytic) (NN lineage))))))) (. .)))))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ various) (NP (JJ cis-acting) (JJ regulatory) (NNS elements)))) (PP (IN in) (NP (NP (DT the) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-))) (NN induction)) (PP (IN of) (NP (DT the) (NP (JJ human) (NN TNF-alpha) (NN promoter)))) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (JJ monocytic) (NN lineage))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Functional) (NN analysis)) (PP (IN of) (NP (NP (JJ monocytic) (NN THP-1) (NNS cells)) (VP (VBN transfected) (PP (IN with) (NP (NP (NNS plasmids)) (VP (VBG containing) (NP (NP (JJ various) (NNS lengths)) (PP (IN of) (NP (NN TNF-alpha) (NN promoter))))))))))) (VP (VBD localized) (NP (NP (NP (NN enhancer) (NNS elements)) (PP (IN in) (NP (NP (DT a) (NN region)) (PRN (-LRB- -LRB-) (NP (NP (CD -182) (TO to) (CD -37) (NN base) (NNS pairs)) (PRN (-LRB- -LRB-) (NP (NN bp)) (-RRB- -RRB-))) (-RRB- -RRB-))))) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (VP (VBN required) (PP (IN for) (NP (NP (JJ optimal) (NN transcription)) (PP (IN of) (NP (DT the) (NP (NN TNF-alpha) (NN gene)))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NN LPS))))))))))))) (. .))))
(S1 (S (S (S (NP (CD Two) (NNS regions)) (VP (VBD were) (VP (VBN identified)))) (: :) (S (S (NP (NP (NN region) (CD I)) (PRN (-LRB- -LRB-) (NP (CD -182) (TO to) (CD -162) (NN bp)) (-RRB- -RRB-))) (VP (VBD contained) (NP (DT an) (VBG overlapping) (NP (NN Sp1/Egr-1) (NN site))))) (, ,) (CC and) (S (NP (NP (NN region) (CD II)) (PRN (-LRB- -LRB-) (NP (CD -119) (TO to) (CD -88)) (-RRB- -RRB-))) (VP (VBD contained) (NP (NP (NP (NN CRE))) (CC and) (NP (NN NF-kappaB) (-LRB- -LRB-) (VBN designated) (NN kappaB3) (-RRB- -RRB-) (NNS sites)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ unstimulated) (NP (NN THP-1)))) (, ,) (NP (NP (JJ CRE-binding) (NN protein)) (CC and) (, ,) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (, ,) (NP (NN c-Jun) (NNS complexes))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB bind) (PP (TO to) (NP (DT the) (NP (NN CRE) (NN site))))))))) (. .))))
(S1 (S (S (NP (NN LPS) (NN stimulation)) (VP (VBD increased) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (JJ c-Jun-containing) (NNS complexes))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN LPS) (NN stimulation)) (VP (VBD induced) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (JJ cognate) (NP (JJ nuclear) (NNS factors)))) (PP (TO to) (NP (NP (DT the) (NP (NP (NN Egr-1))) (CC and) (NP (NN kappaB3)) (NP (NNS sites))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (VP (VBN identified) (PP (IN as) (NP (NP (NN Egr-1)) (CC and) (NP (NN p50/p65)))) (, ,) (ADVP (RB respectively)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN CRE)) (CC and) (NP (NN kappaB3)) (NP (NNS sites))) (PP (IN in) (NP (NN region) (CD II)))) (ADVP (RB together)) (VP (VBD conferred) (NP (NP (JJ strong) (NN LPS) (NN responsiveness)) (PP (TO to) (NP (DT a) (NP (JJ heterologous) (NN promoter))))) (, ,) (SBAR (IN whereas) (S (ADVP (RB individually)) (NP (PRP they)) (VP (VBD failed) (S (VP (TO to) (VP (VB provide) (NP (JJ transcriptional) (NN activation))))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (VP (VBG increasing) (NP (NP (DT the) (NN spacing)) (PP (IN between) (NP (DT the) (NP (NN CRE) (CC and) (DT the) (NN kappaB3) (NNS sites))))))) (ADVP (RB completely)) (VP (VBD abolished) (NP (NN LPS) (NN induction)) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ cooperative) (NN interaction)) (PP (IN between) (NP (NP (NN c-Jun) (NNS complexes)) (CC and) (NP (NN p50/p65)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ maximal) (NN LPS) (NN induction)) (PP (IN of) (NP (DT the) (NP (NN TNF-alpha) (NN promoter))))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NP (VBN concerted) (NN participation)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD two)) (JJ separate) (NP (JJ cis-acting) (JJ regulatory) (NNS elements))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (JJ Inducible) (NP (NN expression)) (CC and) (NP (NN phosphorylation))) (PP (IN of) (NP (NN coactivator) (NN BOB.1/OBF.1))) (PP (IN in) (NP (NN T) (NNS cells)))) (S (-LRB- -LSB-) (VP (VB see) (NP (NNS comments))) (-RRB- -RSB-))))))
(S1 (S (S (S (NP (NP (NN BOB.1/OBF.1))) (VP (VBZ is) (NP (NP (DT a) (NP (JJ transcriptional) (NN coactivator))) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ is) (ADVP (RB constitutively)) (VP (VBN expressed) (PP (IN in) (NP (NN B) (NNS cells))))) (CC and) (VP (VBZ interacts) (PP (IN with) (NP (DT the) (NP (NN Oct1)) (CC and) (NP (NN Oct2)) (NP (NN transcription) (NNS factors)))))))))) (. .)))))
(S1 (S (S (PP (IN Upon) (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN Jurkat) (NN T) (NNS cells)) (CC and) (NP (JJ primary) (JJ murine) (NNS thymocytes)))) (PP (IN with) (NP (NP (NN phorbol) (NNS esters)) (CC and) (NP (NN ionomycin)))))) (, ,) (NP (NP (NN BOB.1/OBF.1)) (NP (NN expression)) (CC and) (NP (NN transactivation) (NN function))) (VP (VBD were) (VP (VBN induced))) (. .))))
(S1 (S (S (S (NP (NN BOB.1/OBF.1)) (VP (VBD was) (VP (VBN phosphorylated) (PP (IN at) (NP (NN Ser184))) (ADVP (CC both) (ADVP (FW in) (FW vivo)) (CC and) (ADVP (FW in) (FW vitro)))))) (, ,) (CC and) (S (NP (DT this) (NN modification)) (VP (VBD was) (VP (VBN required) (PP (IN for) (NP (JJ inducible) (NN activation)))))) (. .))))
(S1 (S (S (NP (NP (NN Mutation)) (PP (IN of) (NP (NN Ser184)))) (ADVP (RB also)) (VP (VBD diminished) (NP (NP (NN transactivation) (NN function)) (PP (IN in) (NP (NN B) (NNS cells)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT the) (VBG activating) (NN phosphorylation)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ inducible) (PP (IN in) (NP (NN T) (NNS cells)))))))) (VP (VBZ is) (ADJP (RB constitutively) (JJ present) (PP (IN in) (NP (NN B) (NNS cells)))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN BOB.1/OBF.1)) (VP (VBZ is) (NP (NP (DT a) (NP (JJ transcriptional) (NN coactivator))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB critically)) (VP (VBN regulated) (PP (IN by) (NP (JJ posttranslational) (NNS modifications)))) (S (VP (TO to) (VP (VB mediate) (NP (ADJP (NN cell) (JJ type-specific)) (NN gene) (NN expression)))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NNS Cytokines)) (: :)) (NP (NP (JJ shared) (NP (NNS receptors))) (, ,) (NP (JJ distinct) (NNS functions))) (. .)))))
(S1 (S (S (S (S (SBAR (IN That) (S (NP (NP (DT the) (NN signal) (NN transduction) (NNS pathways)) (VP (VBN used) (PP (IN by) (NP (NP (DT the) (NP (NNS cytokines))) (NP (NP (NN IL-2)) (CC and) (NP (NN IL-15))))))) (VP (VBP are) (ADJP (JJ identical))))) (VP (MD would) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT these) (NP (NNS cytokines))) (VP (VBP have) (NP (JJ redundant) (NNS roles)) (PP (IN in) (NP (JJ lymphoid) (NN development))))))))) (: ;) (S (ADVP (RB instead)) (, ,) (NP (NN IL-2)) (VP (VBZ is) (NP (NP (DT the) (NN guardian)) (PP (IN of) (NP (JJ thymus-derived) (NN T-cell) (NN homeostasis)))) (, ,) (SBAR (IN while) (S (NP (NN interleukin-15)) (VP (VBZ promotes) (NP (NP (JJ extrathymic) (NN development)) (PP (IN of) (NP (NP (NN T)) (CC and) (NP (NN NK)) (NP (NNS cells)))))))))) (. .)))))
(S1 (S (NP (NP (NP (NN Association)) (PP (IN between) (NP (NP (NP (NP (NN expression)) (PP (IN of) (NP (JJ intercellular) (NN adhesion) (NN molecule-1)))) (CC and) (NP (NP (NN integration)) (PP (IN of) (NP (JJ human) (JJ T-cell-leukemia) (NN virus) (NN type) (CD 1))))) (PP (IN in) (NP (JJ adult) (NN T-cell) (NN leukemia) (NNS cells))))) (. .)))))
(S1 (S (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN known) (SBAR (IN that) (S (NP (NP (DT the) (NN expression) (NNS levels)) (PP (IN of) (NP (NP (JJ intercellular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN ICAM-1)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ adult) (NN T) (NN cell) (NN leukemia) (-LRB- -LRB-) (NN ATL) (-RRB- -RRB-) (NNS cells)))) (VP (VBP are) (ADJP (JJ high)) (, ,) (SBAR (IN whereas) (S (NP (NP (DT those)) (PP (IN in) (NP (NN T-lymphoid) (NNS cells)))) (VP (VBP are) (RB not))))))))) (. .)))))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP influence) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (NN ICAM-1)) (NNS molecules)))))))))))) (, ,) (S (NP (NP (NP (NN Northern) (NN blot) (NN analysis)) (SBAR (S (VP (TO to) (VP (VB measure) (NP (NP (DT the) (NN expression) (NN level)) (PP (IN of) (NP (NN ICAM-1) (NNS mRNAs))))))))) (CC and) (NP (NP (NN Southern) (NN blot) (NN hybridization)) (SBAR (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NN integration)) (PP (IN of) (NP (NP (NP (JJ human) (JJ T-cell-leukemia) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HTLV-1)) (-RRB- -RRB-))) (NN provirus)))))))))) (VP (VBD were) (VP (VBN done)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS levels)) (PP (IN of) (NP (NP (NP (NN ICAM-1) (NN mRNA)) (NN expression)) (PP (IN of) (NP (NN ATL) (NNS cells)))))) (VP (VBD were) (ADJP (ADJP (RB generally) (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NN T-lymphoid) (NNS cells))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NN ILT-mat) (NNS cells)) (CC and) (NP (JJ ATL16T-LRB---RRB-) (NNS cells)) (, ,)) (SBAR (IN although) (S (NP (PRP they)) (VP (VBD were) (NP (NN ATL) (NNS cells))))) (, ,) (VP (VBD showed) (NP (ADJP (RB rather) (JJ low)) (NP (NN surface) (NP (NN ICAM-1)) (NN expression)) (CC and) (NP (NP (NN ICAM-1) (NN mRNA)) (NN expression)))) (. .))))
(S1 (S (S (NP (NN Southern) (NN blot) (NN hybridization)) (VP (VBD showed) (SBAR (IN that) (S (NP (RB only) (NP (CD two)) (CC and) (NP (CD four)) (NP (NNS bands))) (VP (VBD were) (VP (VBN found) (PP (IN in) (NP (NP (NP (NN ILT-mat))) (CC and) (NP (JJ ATL16T-LRB---RRB-) (NNS cells)))) (, ,) (ADVP (RB respectively))) (, ,) (SBAR (IN whereas) (S (NP (QP (JJR &gt;) (CD 10)) (NNS bands)) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (JJ other) (NP (NN ATL) (NNS cells)))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NP (JJ monoclonal) (NN integration)) (PP (IN of) (NP (NN HTLV-1) (NN provirus))) (PP (TO to) (NP (NP (DT the) (NN genome)) (PP (IN of) (NP (NN T) (NN cell)))))) (, ,) (ADVP (RB especially)) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN integration) (NNS sites)))) (, ,)) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS factors)) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN ICAM-1) (NNS molecules)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Role)) (PP (IN of) (NP (DT the) (NP (NN X2) (NN box)))) (PP (IN in) (NP (NP (VBN activated) (NN transcription)) (PP (IN from) (NP (DT the) (NP (NN DRA) (NN promoter)))) (PP (IN in) (NP (NN B) (NNS cells))))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT the) (ADJP (JJ evolutionary) (VBN conserved)) (NP (NN X2) (NN box)))) (PP (IN in) (NP (NP (DT the) (NP (NN promoter))) (PP (IN of) (NP (NP (DT the) (NP (NN HLA-DRA) (NN gene))) (PP (IN from) (NP (NP (DT the) (NP (NP (JJ human) (JJ major) (NN histocompatibility) (NN complex)) (PRN (-LRB- -LRB-) (NP (NN MHC)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (VBG resting)) (CC and) (NP (VBN activated)) (NP (NN B) (NNS cells)))))))))))) (. .)))))
(S1 (S (S (NP (NP (NN NF-X2)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ contains) (NP (NP (NNS members)) (PP (IN of) (NP (NP (DT the) (NP (NN AP-1/ATF/CREB) (NNS families))) (PP (IN of) (NP (NN transcription) (NNS factors))))))))) (, ,)) (VP (VBZ interacts) (PP (IN with) (NP (NP (NP (DT the) (NP (NN X2) (NN box))) (PRN (-LRB- -LRB-) (NP (NN 5'-TGCGTCA-3')) (-RRB- -RRB-))) (PP (IN from) (NP (NP (NNS positions) (QP (CD -97) (TO to) (CD -91))) (PP (IN in) (NP (DT the) (NP (NN DRA) (NN promoter))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (VBG resting) (NP (NN Raji) (NNS cells)))) (, ,) (NP (NP (NP (ADJP (JJ little))) (PP (TO to) (NP (DT no)) (NP (NN binding)))) (PP (TO to) (NP (DT the) (NP (NN X2) (NN box))))) (VP (VBD was) (VP (VBN observed))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ sharp) (NN contrast))) (, ,) (PP (IN in) (NP (NP (NN B) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (NN phorbol) (NN ester)) (NP (NP (NN 12-O-tetradecanoylphorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (JJ strong) (NNS interactions)) (PP (IN between) (NP (NP (DT the) (NP (NN X2) (NN box))) (CC and) (NP (NP (NN NF-X2)) (VP (VBG containing) (NP (NN c-Fos))))))) (VP (VBD were) (VP (VBN observed))) (. .))))
(S1 (S (S (SBAR (IN As) (S (VP (VBN determined) (PP (IN by) (NP (NP (JJ transient) (NN expression)) (CC and) (NP (NN RNA)) (NP (NNS analyses))))))) (, ,) (S (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (NN protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))))) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NNS rates)) (PP (IN of) (NP (NP (NN transcription)) (PP (PP (IN from) (NP (DT the) (JJ wild-type) (NP (NN DRA) (NN promoter)))) (CC but) (PP (RB not) (IN from) (NP (NP (DT a) (NP (NN DRA) (NN promoter))) (VP (VBG bearing) (NP (JJ clustered) (NN point) (NNS mutations)) (PP (IN in) (NP (DT the) (NP (NN X2) (NN box))))))))))))) (. .))))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (DT the) (NN co-expression)) (PP (IN with) (NP (DT a) (JJ dominant) (JJ negative) (NP (NN c-Fos))))) (VP (VBD abolished) (NP (NP (DT the) (NN responsiveness)) (PP (TO to) (NP (NN TPA))))))) (, ,) (S (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (VBN activated) (NN transcription)) (PP (IN of) (NP (DT the) (NP (NN DRA) (NN gene))))) (VP (VBZ depends) (PP (IN on) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (DT the) (NP (NN X2) (NN box))) (CC and) (NP (NP (NN NF-X2)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ contains) (NP (NN c-Fos))))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NP (NN Transcription) (NN factor)) (NN binding) (NNS sites)) (ADVP (JJ downstream) (PP (IN of) (NP (DT the) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (NN transcription) (NN start) (NN site)))))) (VP (VBP are) (ADJP (JJ important) (PP (IN for) (NP (NN virus) (NN infectivity))))) (. .)))))
(S1 (S (S (S (SBAR (WHADVP (WRB When)) (S (ADJP (RB transcriptionally) (JJ active)))) (, ,) (S (NP (DT the) (NP (NP (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-))) (NP (NN promoter))) (VP (VBZ contains) (NP (NP (DT a) (JJ nucleosome-free) (NN region)) (VP (VBG encompassing) (NP (CC both) (NP (DT the) (NP (NN promoter/enhancer) (NN region))) (CC and) (NP (NP (NP (DT a) (JJ large) (NN region)) (PRN (-LRB- -LRB-) (NP (NP (CD 255) (NNS nucleotides)) (PRN (-LRB- -LSB-) (NP (NN nt)) (-RRB- -RSB-))) (-RRB- -RRB-))) (ADVP (JJ downstream) (PP (IN of) (NP (DT the) (NP (NN transcription) (NN start) (NN site))))))))))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN identified) (NP (NP (JJ new) (VBG binding) (NNS sites)) (PP (IN for) (NP (NN transcription) (NNS factors))) (ADVP (RB downstream) (PP (IN of) (NP (NP (DT the) (NP (NN transcription) (NN start) (NN site))) (PRN (-LRB- -LRB-) (NP (NN nt) (CD 465) (TO to) (CD 720)) (-RRB- -RRB-))))))))) (: :) (NP (NP (NP (CD three) (NP (NN AP-1) (NNS sites))) (PRN (-LRB- -LRB-) (NP (NP (CD I)) (, ,) (NP (CD II)) (, ,) (CC and) (NP (CD III))) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NP (JJ AP3-like) (NN motif))) (PRN (-LRB- -LRB-) (NP (NN AP3-L)) (-RRB- -RRB-))) (, ,) (NP (DT a) (NP (JJ downstream) (NN binding) (NN factor) (-LRB- -LRB-) (NN DBF) (-RRB- -RRB-) (NN site))) (, ,) (CC and) (NP (VBN juxtaposed) (NN Sp1) (NNS sites))) (. .))))
(S1 (S (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (SBAR (IN that) (S (NP (DT the) (NP (NN DBF) (NN site))) (VP (VBZ is) (NP (DT an) (NP (JJ interferon-responsive) (NN factor) (-LRB- -LRB-) (NN IRF) (-RRB- -RRB-) (NN binding) (NN site)))))) (CC and) (SBAR (IN that) (S (NP (DT the) (NP (NN AP3-L) (NN motif))) (VP (VBZ binds) (NP (NP (DT the) (NP (JJ T-cell-specific) (NN factor))) (NP (NN NF-AT)))))))) (. .))))
(S1 (S (S (NP (NP (NNS Mutations)) (SBAR (WHNP (WDT that)) (S (VP (VBP abolish) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (DT each) (NN factor))) (PP (TO to) (NP (PRP$ its) (JJ cognate) (NN site)))))))) (VP (VBP are) (VP (VBN introduced) (PP (IN in) (NP (DT an) (JJ infectious) (NN HIV-1) (JJ molecular) (NN clone)))) (S (VP (TO to) (VP (VB study) (NP (NP (PRP$ their) (NN effect)) (PP (IN on) (NP (NN HIV-1) (NP (NN transcription)) (CC and) (NP (NN replication))))))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Individual) (NN mutation)) (PP (IN of) (NP (DT the) (NP (NN DBF)) (CC or) (NP (NP (NN AP3-L))) (NP (NN site))))) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (JJ double) (NP (NN mutation) (NN AP-1-LRB-III-RRB-/AP3-L)))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NN HIV-1) (NN replication)) (PP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ wild-type) (NN virus)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS proviruses)) (VP (VBG carrying) (NP (NNS mutations)) (PP (IN in) (NP (DT the) (NP (NN Sp1) (NNS sites)))))) (VP (VBD were) (ADJP (RB totally) (JJ defective) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NN replication))))))) (. .))))
(S1 (S (S (NP (NN Virus) (NN production)) (VP (VBD occurred) (PP (IN with) (NP (NP (ADJP (RB slightly) (VBN delayed)) (NNS kinetics)) (PP (IN for) (NP (NP (NNS viruses)) (VP (VBG containing) (NP (JJ combined) (NNS mutations)) (PP (PP (IN in) (NP (NP (DT the) (NP (NN AP-1-LRB-III-RRB-))) (, ,) (NP (NP (NN AP3-L))) (, ,) (CC and) (NP (NN DBF) (NNS sites)))) (CC and) (PP (IN in) (NP (DT the) (NP (NP (NN AP3-L))) (CC and) (NP (NNS DBF-sites)))))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NNS viruses)) (VP (VBN mutated) (PP (PP (IN in) (NP (DT the) (NP (NP (NN AP-1-LRB-I,II,III-RRB-))) (CC and) (NP (NN AP3-L) (NNS sites)))) (CC and) (PP (IN in) (NP (DT the) (NP (NN AP-1-LRB-I,II,III-RRB-)) (, ,) (NP (NP (NN AP3-L))) (, ,) (CC and) (NP (NN DBF) (NNS sites))))))) (VP (VBD exhibited) (NP (DT a) (ADJP (ADJP (RB severely) (JJ defective)) (ADJP (JJ replicative))) (NN phenotype)))))) (. .))))
(S1 (S (S (NP (DT No) (JJ RNA-packaging) (NN defect)) (VP (MD could) (VP (VB be) (VP (VBN measured) (PP (IN for) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ mutant) (NNS viruses))))))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (NN quantification)) (PP (IN of) (NP (PRP$ their) (NP (NN HIV) (JJ genomic) (NN RNA)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Measurement)) (PP (IN of) (NP (NP (DT the) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (DT the) (NP (NN HIV-1) (NN promoter)))) (PP (IN after) (NP (NP (JJ transient) (NN transfection)) (PP (PP (IN of) (NP (DT the) (NP (NN HIV-1) (NN provirus) (NN DNA)))) (CC or) (PP (IN of) (NP (JJ long) (JJ terminal) (JJ repeat-luciferase) (NNS constructs))))))))) (VP (VBD showed) (NP (NP (DT a) (JJ positive) (NN correlation)) (PP (IN between) (NP (NP (NP (DT the) (JJ transcriptional)) (CC and) (NP (DT the) (NN replication)) (NP (NNS defects))) (PP (IN for) (NP (JJS most) (NNS mutants))))))) (. .))))
(S1 (S (NP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (JJ nuclear) (NN factor-kappa) (NN B))) (PP (IN in) (NP (NP (NN cytokine) (NN gene)) (NN regulation))) (. .)))))
(S1 (S (S (S (NP (NN Transcription) (NNS factors)) (VP (VBP are) (NP (NP (JJ DNA-binding) (NNS proteins)) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (NN gene) (NN expression))))))) (. .)))))
(S1 (S (S (NP (NP (JJ Nuclear) (NN factor-kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ critical) (NP (NN transcription) (NN factor))) (PP (IN for) (NP (NP (JJ maximal) (NN expression)) (PP (IN of) (NP (NP (JJ many) (NP (NNS cytokines))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS diseases)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (JJ adult) (JJ respiratory) (NN distress) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN ARDS)) (-RRB- -RRB-))) (CC and) (NP (NN sepsis) (NN syndrome)))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN Activation)) (CC and) (NP (NN regulation))) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBP are) (ADVP (RB tightly)) (VP (VBN controlled) (PP (IN by) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NP (JJ inhibitory) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (NN I) (NN kappa) (NN B)) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBP sequester) (NP (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (JJ immune/inflammatory) (NN effector) (NNS cells))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (VP (VBZ involves) (NP (NP (NP (VBN signaled) (NN phosphorylation)) (, ,) (NP (NN ubiquitination)) (, ,) (CC and) (NP (NN proteolysis))) (PP (IN of) (NP (NN I) (NN kappa) (NN B))))) (. .))))
(S1 (S (S (NP (VBN Liberated) (NP (NN NF-kappa) (NN B))) (VP (VBZ migrates) (PP (TO to) (NP (NP (DT the) (NN nucleus)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (PRP it)) (VP (VP (VBZ binds) (PP (TO to) (NP (JJ specific) (NN promoter) (NNS sites)))) (CC and) (VP (VBZ activates) (NP (NN gene) (NN transcription))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBZ initiates) (NP (NP (CC both) (NP (ADJP (JJ extracellular))) (CC and) (NP (ADJP (JJ intracellular))) (NP (JJ regulatory) (NNS events))) (SBAR (WHNP (WDT that)) (S (VP (VBP result) (PP (IN in) (NP (NP (NN autoregulation)) (PP (IN of) (NP (DT the) (JJ inflammatory) (NN cascade))) (PP (IN through) (NP (NP (NN modulation)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (NN activation)))))))))))) (. .))))
(S1 (S (S (ADVP (RB Recently)) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN linked) (PP (TO to) (NP (NN ARDS)))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP (DT a) (ADJP (JJ critical) (JJ proximal)) (NN step)) (PP (IN in) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (JJ neutrophilic) (NN inflammation))) (PP (IN in) (NP (NN animal) (NNS models)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (MD can) (VP (VB be) (VP (VBN inhibited) (ADVP (FW in) (FW vivo)) (PP (IN by) (NP (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNS antioxidants)) (, ,) (NP (NNS corticosteroids))))) (, ,) (CC and) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (NN endotoxin)) (NN tolerance))))))))) (. .))))
(S1 (S (S (NP (NP (NN Identification)) (PP (IN of) (NP (NP (RBR more) (NP (ADJP (JJ specific))) (CC and) (NP (ADJP (JJ efficacious))) (NP (NNS inhibitors))) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (NN activation)))))) (VP (MD might) (VP (VB prove) (ADJP (JJ beneficial) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (ADJP (ADJP (JJ cytokine-mediated)) (ADJP (JJ inflammatory))) (NNS diseases)))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Pancreatic) (NN islet) (NN expression) (NNS studies)) (CC and) (NP (NP (JJ polymorphic) (NN DNA) (NNS markers)) (PP (IN in) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NN hepatocyte) (JJ nuclear) (NP (NN factor-3alpha)) (, ,) (NP (NN -3beta)) (, ,) (NP (NN -3gamma)) (, ,) (NP (NN -4gamma)) (, ,) (CC and) (NP (CD -6))))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NNS genes)) (VP (VBG encoding) (NP (NP (DT the) (ADJP (RB functionally) (JJ related)) (NP (NN hepatocyte) (JJ nuclear) (NNS factors))) (NP (NP (NN HNF-1alpha)) (CC and) (NP (NN HNF-4alpha)))))) (VP (VBP play) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (JJ normal) (JJ pancreatic) (NN beta-cell) (NN function)))) (. .)))))
(S1 (S (S (NP (NP (NNS Mutations)) (PP (IN in) (NP (DT these) (NP (JJ liver-enriched) (NN transcription) (NNS factors))))) (VP (VBP result) (PP (IN in) (NP (NP (NP (NP (CD two) (NNS forms)) (PP (IN of) (NP (JJ early-onset) (NN type) (CD 2) (NNS diabetes))) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ maturity-onset) (NNS diabetes)) (PP (IN of) (NP (DT the) (JJ young)))) (PRN (-LRB- -LSB-) (NP (NN MODY)) (-RRB- -RSB-))) (-RRB- -RRB-))) (, ,) (NP (NP (NN MODY3)) (CC and) (NP (NN MODY1)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN characterized) (PP (IN by) (NP (NP (ADJP (JJ impaired) (JJ glucose-stimulated)) (NN insulin) (NN secretion)) (, ,) (NP (RB early) (NN disease) (NN onset)) (, ,) (CC and) (NP (JJ autosomal) (JJ dominant) (NN inheritance))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ transcriptional) (NN hierarchy)) (PP (IN of) (NP (NNS HNFs)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (JJ other) (NNS proteins)) (PP (IN of) (NP (DT the) (JJ regulatory) (NN cascade)))) (VP (MD might) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (NP (JJ other) (NNS forms)) (PP (IN of) (NP (NN MODY)))) (CC and/or) (NP (JJ late-onset) (NN type) (CD 2) (NNS diabetes)))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN HNF-3alpha)) (, ,) (NP (NN -3beta)) (, ,) (NP (NN -3gamma)) (, ,) (NP (NN -4gamma)) (, ,) (CC and) (NP (CD -6))) (VP (VBP are) (VP (VBN expressed) (PP (IN in) (NP (JJ pancreatic) (NNS beta-cells)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP report) (NP (NP (NP (NP (DT the) (NP (NN identification)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (NP (JJ simple) (JJ tandem) (NN repeat) (NN DNA) (NNS polymorphisms)) (PP (IN in) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NN HNF-3alpha)) (, ,) (NP (NP (NN -3beta))) (, ,) (NP (NP (NN -3gamma))) (, ,) (NP (NP (NN -4gamma))) (, ,) (CC and) (NP (NP (CD -6)))))))))) (CC and) (NP (NP (DT the) (NN mapping)) (PP (IN of) (NP (NN HNF-6))) (PP (TO to) (NP (NP (NN chromosome) (NNS bands)) (NP (NN 15q21.1-21.2)))))) (PP (IN by) (NP (NN fluorescence) (ADJP (FW in) (FW situ)) (NN hybridization))))) (. .))))
(S1 (S (S (NP (DT These) (NNS markers)) (VP (MD will) (VP (VB be) (ADJP (JJ useful))) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ genetic) (NN variation)) (PP (IN in) (NP (DT these) (NNS genes)))))) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN type) (CD 2) (NNS diabetes))))))))) (. .))))
(S1 (S (S (S (NP (NP (NP (ADJP (FW In) (FW vivo)) (NN footprinting)) (CC and) (NP (JJ mutational) (NN analysis))) (PP (IN of) (NP (DT the) (NP (JJ proximal) (NN CD19) (NN promoter))))) (VP (VBP reveal) (NP (NP (JJ important) (NNS roles)) (PP (IN for) (NP (NP (DT an) (NP (NN SP1/Egr-1) (NN binding) (NN site))) (CC and) (NP (NP (DT a) (JJ novel) (NN site)) (VP (VBN termed) (S (NP (DT the) (NP (NN PyG) (NN box)))))))))) (. .)))))
(S1 (S (S (S (NP (NP (NN CD19)) (NN expression)) (VP (VBZ begins) (PP (IN at) (NP (NP (DT the) (JJ pro-B) (NN cell) (NN stage)) (PP (IN of) (NP (NN B) (NN cell) (NN development)))))) (. .)))))
(S1 (S (S (SBAR (IN As) (FRAG (ADJP (JJ such)))) (S (NP (PRP it)) (VP (VBZ serves) (PP (IN as) (NP (NP (DT a) (JJ good) (NN prototype)) (PP (IN for) (NP (NP (NN B) (JJ cell-specific) (NNS genes)) (SBAR (WHNP (WP$ whose) (NN expression)) (S (VP (VBZ begins) (PP (ADVP (RB shortly)) (IN after) (NP (NN lineage) (NN commitment)))))))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB understand) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBG controlling) (NP (NP (NN CD19)) (NN gene) (NN expression))))))) (, ,) (S (NP (PRP we)) (VP (VP (VBD isolated)) (CC and) (VP (ADVP (RB functionally)) (VBD characterized)) (NP (DT the) (NP (NN CD19) (NN promoter)))) (S (VP (VBG using) (NP (NP (ADJP (FW in) (FW vivo)) (NN footprinting)) (, ,) (NP (NN gel) (NN shift) (NNS assays)) (, ,) (CC and) (NP (NN transfection) (NNS studies)))))) (. .))))
(S1 (S (S (NP (NP (NN Reporter) (NNS constructs)) (VP (VBG spanning) (NP (NP (NNS portions)) (PP (IN of) (NP (DT the) (NN promoter)))))) (VP (VBD identified) (NP (NP (DT a) (NP (NN region) (IN between) (CD -85) (CC and) (CD -200))) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (NN reporter) (NN gene) (NN activity)) (PP (IN in) (NP (JJ lymphoid) (NNS cells))))))))))) (. .))))
(S1 (S (S (NP (ADJP (FW In) (FW vivo)) (NN footprinting)) (VP (VBD identified) (NP (NP (NP (JJ protected) (NNS regions)) (PP (IN over) (NP (DT the) (JJ known) (JJ high) (NN affinity) (NP (NN B) (NN cell) (JJ lineage-specific) (NN activator) (NN protein) (-LRB- -LRB-) (NN BSAP) (-RRB- -RRB-) (NN site))))) (, ,) (NP (NP (DT the) (NP (JJ low) (NN affinity) (NN BSAP) (NN site))) (, ,) (NP (NP (DT a) (NP (NN SP1/Egr-1) (NN site))) (VP (VBN termed) (S (NP (DT the) (NP (NN CD19) (NN GC) (NN box)))))) (, ,) (CC and) (NP (NP (CD two) (JJ novel) (NNS sites)) (VP (VBN named) (S (NP (NP (DT the) (NP (NN AT) (NN box)) (CC and) (NP (NN PyG) (NN box)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Phorbol) (NN ester) (NN treatment)) (PP (IN of) (NP (DT a) (NP (JJ pre-B) (NN cell) (NN line))))) (VP (VP (VBD up-regulated) (NP (NP (NN CD19)) (NN expression))) (, ,) (VP (VBD induced) (NP (NN Egr-1))) (, ,) (CC and) (VP (VBD enhanced) (NP (DT the) (NN footprint)) (PP (IN over) (NP (DT the) (NN GC) (NN box))))) (. .))))
(S1 (S (S (NP (NN Gel) (NN shift) (NNS assays)) (VP (VBD demonstrated) (S (NP (NP (NN SP1)) (CC and) (NP (NN Egr-1))) (VP (VBG binding) (PP (TO to) (NP (DT the) (NP (NN CD19) (NN GC) (NN box)))))) (, ,) (SBAR (IN while) (S (NP (JJ unknown) (JJ nuclear) (NNS proteins)) (VP (VBD bound) (NP (DT the) (NP (NN PyG)) (CC and) (NP (NN AT)) (NP (NNS boxes))))))) (. .))))
(S1 (S (S (NP (NP (NNS Mutations)) (PP (PP (IN in) (NP (DT the) (NP (NN AT) (NN box)))) (CC or) (PP (IN in) (NP (DT the) (NP (NN BSAP) (NNS sites)))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NN CD19)) (NP (NN reporter) (NN construct)) (NN activity))) (, ,) (SBAR (IN while) (S (S (NP (NP (DT a) (NN mutation)) (PP (IN of) (NP (DT the) (NP (NN GC) (NN box))))) (VP (VBD reduced) (NP (PRP it) (ADVP (RB modestly))))) (, ,) (CC and) (S (NP (DT a) (NP (NN PyG) (NN box)) (NN mutation)) (VP (VBD reduced) (NP (PRP it) (ADVP (RB dramatically)))))))) (. .))))
(S1 (S (S (NP (NN BSAP)) (VP (VBD failed) (S (VP (TO to) (VP (VB trans-activate) (NP (NN CD19) (NN promoter) (NNS constructs)) (PP (IN in) (NP (NP (NN B) (NNS cells)) (CC or) (NP (JJ non-B) (NNS cells))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (JJ cis) (NNS elements)) (PP (JJ such) (IN as) (NP (DT the) (NP (NN PyG)) (CC and) (NP (NN GC)) (NP (NNS boxes))))) (VP (VBP are) (ADVP (RB also)) (ADJP (JJ necessary) (PP (IN for) (NP (JJ high) (NN level) (NP (NN CD19) (NN promoter)) (NN expression)))))))))) (. .))))
(S1 (S (NP (NP (NP (DT A) (ADJP (ADJP (VBN conserved)) (ADJP (JJ tissue-specific))) (NN structure)) (PP (IN at) (NP (DT a) (NP (JJ human) (NN T-cell) (NN receptor) (NN beta-chain) (NN core) (NN promoter)))) (. .)))))
(S1 (S (S (S (NP (DT The) (NP (NN T-cell) (NN receptor) (-LRB- -LRB-) (NN TCR) (-RRB- -RRB-) (NN beta-chain) (NNS promoters))) (VP (VBP have) (VP (VBN been) (VP (VBN characterized) (PP (IN as) (NP (NP (JJ nonstructured) (JJ basal) (NNS promoters)) (SBAR (WHNP (WDT that)) (S (VP (VBP carry) (NP (DT a) (ADJP (ADJP (JJ single)) (ADJP (VBN conserved))) (NP (JJ ubiquitous) (JJ cyclic) (JJ AMP-responsive) (NN element))))))))))) (. .)))))
(S1 (S (S (NP (NP (PRP$ Our) (NN investigation)) (PP (IN of) (NP (DT the) (NP (JJ human) (NN TCR) (NN beta) (NN gene))))) (VP (VBZ uncovers) (NP (NP (DT a) (ADJP (ADJP (RB surprisingly) (JJ complex)) (CC and) (ADJP (JJ tissue-specific))) (NN structure)) (PP (IN at) (NP (DT the) (NP (NN TCR) (NN Vbeta) (NN 8.1) (NN promoter)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN core)) (PP (IN of) (NP (DT the) (NP (NN promoter)))) (PRN (-LRB- -LRB-) (NP (NNS positions) (CD -42) (TO to) (CD +11)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN recognized) (PP (PP (IN by) (NP (NP (DT the) (NP (JJ lymphoid) (JJ cell-specific) (NN transcription) (NNS factors))) (NP (NP (NN Ets-1)) (, ,) (NP (NN LEF1)) (, ,) (CC and) (NP (NN AML1))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN by) (NP (NN CREB/ATF-1))))) (, ,) (SBAR (IN as) (S (VP (VBZ is) (VP (VBN demonstrated) (PP (IN in) (NP (NP (NN gel) (NN shift)) (CC and) (NP (NN footprinting)) (NP (NNS experiments))))))))) (. .))))
(S1 (S (S (PP (IN With) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NN LEF1))))) (, ,) (NP (DT these) (NNS factors)) (VP (VBP activate) (NP (NN transcription)) (PP (IN in) (NP (NN T) (NNS cells)))) (. .))))
(S1 (S (S (NP (NP (VBG Binding) (NNS sites)) (PP (IN at) (NP (DT the) (NN core) (NN region)))) (VP (VBP show) (NP (NP (JJ little) (NN conservation)) (PP (IN with) (NP (NN consensus) (NNS sites))))) (. .))))
(S1 (S (S (ADVP (RB Nonetheless)) (, ,) (NP (NP (NN CREB)) (, ,) (NP (NN Ets-1)) (, ,) (CC and) (NP (NN AML1))) (VP (VP (VBP bind)) (CC and) (VP (VBP activate) (ADVP (ADVP (RB cooperatively)) (CC and) (ADVP (RB very) (RB efficiently)))) (PP (IN through) (NP (NP (DT the) (NP (JJ nonconsensus) (VBG binding) (NNS sites))) (PP (IN at) (NP (DT the) (NP (NN core) (NN promoter) (NN region))))))) (. .))))
(S1 (S (S (NP (ADJP (ADJP (JJ Moderate)) (ADJP (JJ ubiquitous))) (NN activation)) (VP (VBZ is) (ADVP (RB further)) (VP (VBN induced) (PP (IN by) (NP (NP (NN CREB/ATF)) (CC and) (NP (NN Sp1)) (NP (NNS factors)))) (PP (IN through) (NP (JJ proximal) (JJ upstream) (NNS elements))))) (. .))))
(S1 (S (S (NP (DT The) (NP (JJ tissue-specific) (NN core) (NN promoter) (NN structure))) (VP (VBZ is) (ADVP (RB apparently)) (VP (VBN conserved) (PP (IN in) (NP (NP (JJ other) (NP (RB T-cell-specifically) (VBN expressed) (NNS genes))) (PP (JJ such) (IN as) (NP (DT the) (NP (NN CD4) (NN gene)))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (CC both) (NP (DT the) (NP (NN enhancer))) (CC and) (NP (DT the) (NP (NN promoter)))) (VP (VBP have) (NP (NP (DT a) (ADJP (ADJP (JJ complex)) (ADJP (JJ tissue-specific))) (NN structure)) (SBAR (WHNP (WP$ whose) (JJ functional) (NN interplay)) (S (VP (VBZ potentiates) (NP (JJ T-cell-specific) (NN transcription)))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Opposite) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (JJ PML-retinoic) (NN acid) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN RAR) (NN alpha)) (-RRB- -RRB-)))) (CC and) (NP (NN PLZF-RAR) (NN alpha) (NN fusion) (NNS proteins)))) (PP (IN on) (NP (JJ retinoic) (NN acid) (NN signalling))) (. .)))))
(S1 (S (S (S (NP (NP (NP (NN Fusion) (NNS proteins)) (VP (VBG involving) (NP (NP (DT the) (NP (NP (JJ retinoic) (NN acid) (NP (NN receptor) (NN alpha))) (PRN (-LRB- -LRB-) (NP (NN RAR) (NN alpha)) (-RRB- -RRB-)))) (CC and) (NP (DT the) (NP (NN PML)))))) (CC or) (NP (NN PLZF) (JJ nuclear) (NN protein))) (VP (VBP are) (NP (NP (DT the) (JJ genetic) (NNS markers)) (PP (IN of) (NP (NP (JJ acute) (JJ promyelocytic) (NNS leukemias)) (PRN (-LRB- -LRB-) (NP (NNS APLs)) (-RRB- -RRB-)))))) (. .)))))
(S1 (S (S (S (NP (NP (NNS APLs)) (PP (IN with) (NP (NP (DT the) (NP (NN PML-RAR) (NN alpha))) (CC or) (NP (DT the) (NP (NN PLZF-RAR) (NN alpha) (NN fusion) (NN protein)))))) (VP (VBP are) (ADJP (RB phenotypically) (JJ indistinguishable) (PP (IN except) (SBAR (IN that) (S (NP (PRP they)) (VP (VBP differ) (PP (IN in) (NP (NP (PRP$ their) (NN sensitivity)) (PP (TO to) (NP (JJ retinoic) (NN acid) (-LRB- -LRB-) (NN RA) (-RRB- -RRB-) (JJ -induced) (NN differentiation)))))))))))) (: :) (S (S (NP (NP (NN PML-RAR) (NN alpha)) (NNS blasts)) (VP (VBP are) (ADJP (JJ sensitive) (PP (TO to) (NP (NN RA)))))) (CC and) (S (NP (NNS patients)) (VP (VBP enter) (NP (NN disease) (NN remission)) (PP (IN after) (NP (NN RA) (NN treatment))) (, ,) (SBAR (IN while) (S (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN PLZF-RAR) (NN alpha))))) (VP (VBP do) (RB not))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB here)) (VP (VBP report) (SBAR (IN that) (S (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (PP (IN like) (NP (NP (NN PML-RAR) (NN alpha)) (NN expression))) (, ,) (NP (NP (NN PLZF-RAR) (NN alpha)) (NN expression)) (VP (VBZ blocks) (NP (NP (JJ terminal) (NN differentiation)) (PP (IN of) (NP (NP (JJ hematopoietic) (NN precursor) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NP (NN U937)) (CC and) (NP (NN HL-60))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ different) (NNS stimuli)) (PRN (-LRB- -LRB-) (NP (NP (NN vitamin) (NN D3)) (, ,) (NP (NP (VBG transforming) (NN growth) (NN factor)) (NP (NN beta1))) (, ,) (CC and) (NP (NN dimethyl) (NN sulfoxide))) (-RRB- -RRB-)))))))) (: ;) (S (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (NP (NN PML-RAR) (NN alpha)) (, ,) (CONJP (CC but) (RB not)) (NP (NN PLZF-RAR) (NN alpha)) (, ,)) (VP (VP (VBZ increases) (NP (NP (NN RA) (NN sensitivity)) (PP (IN of) (NP (JJ hematopoietic) (NN precursor) (NNS cells))))) (CC and) (VP (VBZ restores) (NP (NP (NN RA) (NN sensitivity)) (PP (IN of) (NP (JJ RA-resistant) (JJ hematopoietic) (NNS cells))))))) (: ;) (S (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (NP (NP (NN PML-RAR) (NN alpha)) (CC and) (NP (NN PLZF-RAR) (NN alpha))) (VP (VBP have) (NP (JJ similar) (NN RA) (NN binding) (NNS affinities)))) (: ;) (CC and) (S (LST (-LRB- -LRB-) (LS iv) (-RRB- -RRB-)) (NP (NN PML-RAR) (NN alpha)) (VP (VBZ enhances) (NP (NP (NP (DT the) (NN RA) (NN response)) (PP (IN of) (NP (NN RA) (NN target) (NNS genes)))) (PRN (-LRB- -LRB-) (NP (NP (DT those)) (PP (IN for) (NP (NP (NN RAR) (NN beta)) (, ,) (NP (NN RAR) (NN gamma)) (, ,) (CC and) (NP (NP (NN transglutaminase) (NN type) (CD II)) (PRN (-LRB- -LSB-) (NP (NN TGase)) (-RRB- -RSB-)))))) (-RRB- -RRB-))) (ADVP (FW in) (FW vivo)) (, ,) (SBAR (IN while) (S (NP (NP (NN PLZF-RAR) (NN alpha)) (NN expression)) (VP (VBZ has) (NP (CC either) (NP (NP (DT no) (NN effect)) (PRN (-LRB- -LRB-) (NP (NN RAR) (NN beta)) (-RRB- -RRB-))) (CC or) (NP (NP (DT an) (JJ inhibitory) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (NN RAR) (NN gamma)) (CC and) (NP (NN type) (CD II) (NN TGase))) (-RRB- -RRB-)))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NP (NN PML-RAR) (NN alpha)) (CC and) (NP (NN PLZF-RAR) (NN alpha))) (VP (VBP have) (NP (NP (NP (ADJP (ADJP (JJ similar)) (PRN (-LRB- -LRB-) (ADJP (JJ inhibitory)) (-RRB- -RRB-))) (NNS effects)) (PP (IN on) (NP (JJ RA-independent) (NN differentiation)))) (CC and) (NP (NP (ADJP (ADJP (JJ opposite)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ stimulatory)) (CC or) (ADJP (JJ inhibitory))) (-RRB- -RRB-))) (NNS effects)) (PP (IN on) (NP (JJ RA-dependent) (NN differentiation)))))))) (CC and) (SBAR (IN that) (S (NP (PRP they)) (VP (VBP behave) (ADVP (FW in) (FW vivo)) (PP (IN as) (NP (NP (JJ RA-dependent) (NNS enhancers)) (CC or) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (JJ RA-responsive) (NNS genes)))))) (, ,) (ADVP (RB respectively))))))) (. .))))
(S1 (S (S (NP (NP (PRP$ Their) (JJ different) (NNS activities)) (PP (IN on) (NP (DT the) (NN RA) (NN signalling) (NN pathway)))) (VP (MD might) (VP (VB underlie) (NP (NP (DT the) (JJ different) (NNS responses)) (PP (IN of) (NP (NP (NP (NN PML-RAR) (NN alpha))) (CC and) (NP (NP (NN PLZF-RAR) (NN alpha))) (NP (NNS APLs)))) (PP (TO to) (NP (NN RA) (NN treatment)))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN PLZF-RAR) (NN alpha) (NN fusion) (NN protein))) (VP (VBZ contains) (NP (NP (NP (DT an) (RB approximately) (NP (JJ 120-amino-acid) (JJ N-terminal) (NN motif))) (PRN (-LRB- -LRB-) (VP (VBN called) (S (NP (DT the) (NP (NN POZ) (NN domain))))) (-RRB- -RRB-))) (, ,) (SBAR (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADVP (RB also)) (VP (VBN found) (PP (IN in) (NP (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN zinc) (NN finger) (NNS proteins)))) (CC and) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NN poxvirus) (NNS proteins)))))))))) (CC and) (SBAR (WHNP (WDT which)) (S (VP (VBZ mediates) (NP (JJ protein-protein) (NNS interactions)))))))) (. .))))
(S1 (S (S (NP (NP (NN Deletion)) (PP (IN of) (NP (DT the) (NP (NN PLZF) (NN POZ) (NN domain))))) (ADVP (RB partially)) (VP (VBD abrogated) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN PLZF-RAR) (NN alpha))) (PP (PP (IN on) (NP (JJ RA-induced) (NN differentiation))) (CC and) (PP (IN on) (NP (JJ RA-mediated) (NP (NN type) (CD II) (NN TGase)) (NN up-regulation))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (JJ POZ-mediated) (NN protein) (NNS interactions)) (VP (MD might) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (ADJP (ADJP (JJ inhibitory)) (ADJP (JJ transcriptional))) (NNS activities)) (PP (IN of) (NP (NN PLZF-RAR) (NN alpha))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (NN expression)) (PP (IN in) (NP (JJ monocytic) (NNS cells))))) (PP (IN by) (NP (NP (FW Cryptococcus) (FW neoformans)) (CC and) (NP (FW Candida) (FW albicans)))) (. .)))))
(S1 (S (S (S (SBAR (IN Because) (S (NP (NP (NN candidiasis)) (CC and) (NP (NN cryptococcosis))) (VP (VBP are) (ADJP (JJ common) (PP (IN in) (NP (ADJP (JJ human) (NN immunodeficiency) (NN virus) (-LRB- -LRB-) (NN HIV) (-RRB- -RRB-) (JJ -infected)) (NNS persons))))))) (, ,) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (FW Cryptococcus) (FW neoformans)) (CC and) (NP (FW Candida) (FW albicans)))) (PP (IN on) (NP (NP (NN HIV) (NN expression)) (PP (IN in) (NP (JJ monocytic) (NNS cells)))))) (VP (VBD was) (VP (VBN examined)))) (. .)))))
(S1 (S (S (NP (NP (NN Stimulation)) (PP (IN of) (NP (NP (DT the) (RB latently) (NP (JJ HIV-infected) (JJ myelomonocytic) (NN cell) (NN line))) (NP (NN OM-10.1)))) (PP (IN with) (NP (NP (FW C.) (FW neoformans)) (CC and) (NP (FW C.) (FW albicans)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (ADJP (ADJP (JJ pooled)) (ADJP (JJ human))) (NN serum)))))) (VP (VBD caused) (NP (NP (DT a) (JJ ratio-dependent) (NN increase)) (PP (IN in) (NP (NN HIV) (NN production))))) (. .))))
(S1 (S (S (NP (NP (NN Induction)) (PP (IN of) (NP (NN HIV))) (PP (IN by) (NP (FW C.) (FW neoformans)))) (VP (VBD was) (VP (VBN enhanced) (PP (IN by) (NP (JJ anti-capsular) (NN antibody)))) (, ,) (SBAR (IN while) (S (NP (NP (NN induction)) (PP (IN by) (NP (DT both) (NNS organisms)))) (VP (VBD was) (VP (VBN inhibited) (PP (IN by) (NP (JJ anti-TNF-alpha) (NN antibody)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (NN THP-1) (NNS cells)) (VP (VBN transfected) (PP (IN with) (NP (NN HIV) (NN plasmid) (NNS constructs)))))) (, ,) (NP (DT both) (NNS organisms)) (VP (VBD induced) (NP (NN transcription)) (PP (IN from) (NP (NP (DT the) (NP (NN HIV) (JJ long) (JJ terminal) (NN repeat))) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (ADJP (JJ dependent) (PP (IN on) (NP (JJ intact) (NP (NN NF-kappaB) (NN binding) (NNS sequences))))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (FW C.) (FW neoformans)) (CC and) (NP (FW C.) (FW albicans))) (VP (VBP enhance) (NP (NP (NN HIV) (NN expression)) (PP (IN in) (NP (JJ monocytic) (NNS cells)))) (PP (IN through) (NP (DT a) (ADJP (ADJP (NN TNF-alpha-)) (CC and) (ADJP (JJ NF-kappaB-dependent))) (NN mechanism)))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ HIV-infected) (NNS patients))) (, ,) (NP (JJ such) (NN enhancement)) (VP (VP (MD may) (ADVP (RB further)) (VP (VB impair) (NP (NN host) (NN immunity)))) (CC and) (VP (MD could) (VP (VB accelerate) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NN HIV) (NN disease))))))) (. .))))
(S1 (S (S (S (S (NP (NP (DT A) (JJ human) (NN homologue)) (PP (IN of) (NP (DT the) (NP (FW Drosophila) (NN Toll) (NN protein))))) (VP (VBZ signals) (NP (NP (NN activation)) (PP (IN of) (NP (JJ adaptive) (NN immunity)))))) (S (-LRB- -LSB-) (VP (VB see) (NP (NNS comments))) (-RRB- -RSB-))))))
(S1 (S (S (S (NP (NP (NN Induction)) (PP (IN of) (NP (DT the) (JJ adaptive) (JJ immune) (NN response)))) (VP (VBZ depends) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ co-stimulatory) (NNS molecules)) (CC and) (NP (NNS cytokines)))) (PP (IN by) (NP (JJ antigen-presenting) (NNS cells)))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP control) (NP (NP (DT the) (JJ initial) (NN induction)) (PP (IN of) (NP (DT these) (NNS signals))) (PP (IN upon) (NP (NN infection)))))))) (VP (VBP are) (ADVP (RB poorly)) (VP (VBN understood))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN proposed) (SBAR (IN that) (S (NP (PRP$ their) (NN expression)) (VP (VBZ is) (VP (VBN controlled) (PP (IN by) (NP (NP (DT the) (ADJP (ADJP (JJ non-clonal)) (, ,) (CC or) (ADJP (JJ innate))) (, ,) (NN component)) (PP (IN of) (NP (NN immunity))) (SBAR (WHNP (WDT that)) (S (VP (VBD preceded) (PP (IN in) (NP (NN evolution))) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT an) (JJ adaptive) (JJ immune) (NN system))) (PP (IN in) (NP (NNS vertebrates)))))))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP report) (ADVP (RB here)) (NP (NP (DT the) (NP (NN cloning)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (NP (DT a) (NP (JJ human) (NN homologue))) (PP (IN of) (NP (NP (NP (DT the) (NP (FW Drosophila) (NN toll) (NN protein))) (PRN (-LRB- -LRB-) (NP (NN Toll)) (-RRB- -RRB-))) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB induce) (NP (DT the) (JJ innate) (JJ immune) (NN response)) (PP (IN in) (NP (JJ adult) (FW Drosophila))))))))))))))))) (. .))))
(S1 (S (S (PP (IN Like) (NP (FW Drosophila) (NP (NN Toll)))) (, ,) (NP (JJ human) (NN Toll)) (VP (VBZ is) (NP (NP (DT a) (NN type) (CD I) (JJ transmembrane) (NN protein)) (PP (IN with) (NP (NP (NP (DT an) (JJ extracellular) (NN domain)) (VP (VBG consisting) (PP (IN of) (NP (DT a) (NP (JJ leucine-rich) (NN repeat) (-LRB- -LRB-) (NN LRR) (-RRB- -RRB-) (NN domain)))))) (, ,) (CC and) (NP (NP (DT a) (NP (JJ cytoplasmic) (NN domain))) (ADJP (JJ homologous) (PP (TO to) (NP (NP (DT the) (JJ cytoplasmic) (NN domain)) (PP (IN of) (NP (DT the) (NP (JJ human) (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -1) (NN receptor)))))))))))) (. .))))
(S1 (S (S (NP (CC Both) (NP (FW Drosophila) (NP (NN Toll))) (CC and) (NP (DT the) (NN IL-1) (NN receptor))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB signal) (PP (IN through) (NP (DT the) (NP (NN NF-kappaB)) (NN pathway)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT a) (ADJP (RB constitutively) (JJ active)) (NN mutant)) (PP (IN of) (NP (JJ human) (NN Toll))) (VP (VBN transfected) (PP (IN into) (NP (JJ human) (NN cell) (NNS lines))))) (VP (MD can) (VP (VB induce) (NP (NP (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN NF-kappaB)))) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ NF-kappaB-controlled) (NNS genes))) (PP (IN for) (NP (NP (DT the) (NP (JJ inflammatory) (NNS cytokines))) (NP (NP (NN IL-1)) (, ,) (NP (NN IL-6)) (CC and) (NP (NN IL-8))))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (NP (JJ co-stimulatory) (NN molecule)) (NP (NN B7.1))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ naive) (NN T) (NNS cells)))))))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (NN B-cell) (NN commitment)) (PP (PP (TO to) (NP (NN plasma) (NNS cells))) (CC or) (PP (TO to) (NP (NN memory) (NN B) (NNS cells)))))) (. .)))))
(S1 (S (S (S (PP (IN During) (NP (JJ humoral) (JJ immune) (NNS responses))) (, ,) (NP (NN B-lymphocyte) (NN activation)) (VP (VBZ is) (VP (VBN followed) (PP (IN by) (NP (NP (NN differentiation)) (PP (IN along) (NP (CC either) (NP (DT the) (NN plasma) (NN cell) (NN pathway)) (CC or) (NP (DT the) (NN memory) (NN B-cell) (NN pathway)))))))) (. .)))))
(S1 (S (S (NP (JJ Recent) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ CD40-CD40) (NN ligand)) (, ,) (NP (JJ OX-OX40) (NN ligand)) (, ,) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NNS cytokines)) (CC and) (NP (JJ intracellular) (JJ transcriptional) (NNS factors)))))) (VP (MD may) (ADVP (DT all)) (VP (VB contribute) (PP (TO to) (NP (NN B-lymphocyte) (NN differentiation) (NN control)))))))) (. .))))
(S1 (S (S (S (NP (NP (DT A) (VBN shortened) (NN life) (NN span)) (PP (IN of) (NP (JJ EKLF-/-) (JJ adult) (NNS erythrocytes))) (, ,) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN deficiency)) (PP (IN of) (NP (NN beta-globin) (NNS chains)))))) (, ,)) (VP (VBZ is) (VP (VBN ameliorated) (PP (IN by) (NP (JJ human) (NN gamma-globin) (NNS chains))))) (. .)))))
(S1 (S (S (S (S (VP (VBG Using) (NP (JJ homologous) (NN recombination)))) (, ,) (S (NP (NP (DT both) (NP (NN EKLF) (NNS alleles))) (PP (IN in) (NP (JJ murine) (JJ embryonic) (NN stem) (-LRB- -LRB-) (NN ES) (-RRB- -RRB-) (NNS cells)))) (VP (VBD were) (VP (VBN inactivated)))) (. .)))))
(S1 (S (S (NP (DT These) (NP (JJ EKLF-/-) (NN ES) (NNS cells))) (VP (VBD were) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG undergoing) (NP (ADJP (FW in) (FW vitro)) (NN differentiation)) (S (VP (TO to) (VP (VB form) (NP (NP (JJ definitive) (JJ erythroid) (NNS colonies)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (NP (NN size)) (CC and) (NP (NN number)))) (PP (TO to) (NP (NP (DT those)) (VP (VBN formed) (PP (IN by) (NP (JJ wild-type) (NN ES) (NNS cells))))))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (S (S (NP (DT the) (NP (JJ EKLF-/-) (NNS colonies))) (VP (VBD were) (ADVP (RB poorly)) (VP (VBN hemoglobinized)))) (CC and) (S (NP (NP (VBN enucleated) (NNS erythrocytes)) (PP (IN in) (NP (DT these) (NNS colonies)))) (VP (VBD contained) (NP (JJ numerous) (NN Heinz) (NNS bodies))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (NNS analyses)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (ADJP (JJ adult))) (CC and) (NP (JJ embryonic) (NN globin) (NNS genes))) (VP (VBD were) (ADVP (RB appropriately)) (VP (VBN regulated) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (NN beta) (NN h1-globin)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD continued) (S (VP (TO to) (VP (VB be) (VP (VBN expressed) (PP (IN at) (NP (DT a) (ADJP (RB very) (JJ low)) (NN level))))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN ratio)) (PP (IN of) (NP (JJ adult) (NN beta-globin/alpha-globin) (NN mRNA))) (PP (IN in) (NP (DT the) (NP (JJ mutant) (NN ES) (NNS cells))))) (VP (VBD was) (NP (NP (CD 1/15)) (PP (IN of) (NP (NP (DT that)) (PP (IN in) (NP (JJ wild-type) (NN ES) (NNS cells))))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NP (JJ EKLF-/-) (NNS cells))) (VP (VBD were) (VP (VBN injected) (PP (IN into) (NP (NNS blastocysts))))))) (, ,) (S (NP (PRP they)) (VP (VBD did) (RB not) (VP (VB contribute) (PP (IN at) (NP (DT a) (JJ detectable) (NN level))) (PP (TO to) (NP (NP (DT the) (JJ mature) (NN erythrocyte) (NN compartment)) (PP (IN of) (NP (DT the) (JJ chimeric) (NNS animals))))) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (NN analysis)) (PP (IN of) (NP (NP (NP (NN glucose) (NN phosphate) (NN isomerase-1) (-LRB- -LRB-) (NN GPI-1) (-RRB- -RRB-) (NNS isozymes)) (CC and) (NP (NNS hemoglobins))) (SBAR (WHNP (WDT that)) (S (VP (VBP distinguish) (NP (NN ES) (JJ cell-derived) (NNS erythrocytes)) (PP (IN from) (NP (NN host) (NP (JJ blastocyst-derived) (NNS erythrocytes))))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ semiquantitative) (NN RT-PCR) (NN analysis)) (PP (IN of) (NP (NP (NN RNA)) (PP (IN from) (NP (NP (NNS reticulocytes)) (PP (IN of) (NP (DT the) (JJ same) (JJ chimeric) (NNS animals)))))))) (VP (VBD suggested) (SBAR (IN that) (S (NP (DT the) (NP (NN ES) (JJ cell-derived) (NNS reticulocytes))) (VP (VBD were) (ADJP (JJ present) (PP (IN at) (NP (NP (DT a) (NN level)) (PP (IN of) (NP (NP (CD 6) (NN %)) (PP (TO to) (NP (CD 8) (NN %)))))))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (DT the) (NP (JJ EKLF-/-) (NNS erythrocytes))) (PP (IN in) (NP (JJ adult) (NNS animals)))) (VP (MD must) (VP (VB be) (ADJP (JJ short-lived) (, ,) (ADVP (ADVP (RB apparently)) (JJ due) (PP (TO to) (NP (NP (NP (DT the) (NN imbalance)) (PP (IN of) (NP (NP (NN beta-)) (CC versus) (NP (NN alpha-globin)) (NP (NNS chains))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (NN precipitation)) (PP (IN of) (NP (JJ excess) (NP (NN alpha-globin) (NNS chains)))) (S (VP (TO to) (VP (VB form) (NP (NN Heinz) (NNS bodies)))))))))))))))))) (. .))))
(S1 (S (S (ADVP (JJ Consistent) (PP (IN with) (NP (DT this) (NN hypothesis)))) (, ,) (S (NP (DT the) (JJ short) (NN life) (NN span)) (VP (VBD was) (VP (VBN ameliorated) (PP (IN by) (NP (NP (NN introduction)) (PP (IN into) (NP (DT the) (NP (JJ EKLF-/-) (NN ES) (NNS cells)))) (PP (IN of) (NP (DT a) (NP (JJ human) (NN LCR/gamma-globin) (NN gene))))))) (, ,) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN ES) (JJ cell-derived) (NNS reticulocytes)) (CONJP (RB as) (RB well) (IN as)) (NP (JJ mature) (NNS erythrocytes)))) (PP (IN in) (NP (NP (DT the) (NN blood)) (PP (IN of) (NP (DT the) (JJ chimeric) (NNS animals)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B/Rel)) (JJ nuclear) (NN activity)) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes))))) (PP (IN by) (NP (JJ anti-HLA) (NN class) (CD I) (JJ monoclonal) (NNS antibodies))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Monoclonal) (NNS antibodies)) (PP (IN against) (NP (NP (CC either) (NP (ADJP (JJ monomorphic))) (CC or) (NP (ADJP (JJ polymorphic))) (NP (NNS determinants))) (PP (IN of) (NP (NN class) (CD I) (NN antigen)))))) (VP (VBD induced) (PP (IN in) (NP (NP (NN PBMC)) (CC and) (NP (RB highly) (NP (VBN purified) (NN T) (NNS lymphocytes))))) (NP (NP (DT the) (JJ nuclear) (NN activity)) (PP (IN of) (NP (NN NF-kappa) (NN B/Rel) (NNS complexes))))) (. .)))))
(S1 (S (S (NP (DT These)) (VP (VBD included) (NP (NP (CC both) (NP (NP (NN p50/p50))) (CC and) (NP (NN p50/p65) (NNS dimers))) (, ,) (VP (VBN recognized) (PP (IN by) (NP (JJ specific) (NNS antibodies))) (PP (IN in) (NP (NN EMSA)))))) (. .))))
(S1 (S (S (S (NP (DT The) (VBN induced) (NP (NNS complexes))) (VP (VBD were) (ADJP (JJ detectable) (PP (IN in) (NP (NP (NNS extracts)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBN incubated) (PP (IN with) (NP (NP (JJ anti-class) (CD I) (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN mAb)) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 1.5) (NN h))))))))))) (: ;) (S (NP (DT the) (NN induction)) (VP (VBD was) (UCP (ADJP (JJ maximal) (PP (IN at) (NP (CD 5) (NN h)))) (, ,) (ADJP (JJ persistent) (PP (IN at) (NP (CD 16) (NN h)))) (CC and) (VP (ADVP (DT no) (JJR longer)) (VBN observed) (PP (IN at) (NP (CD 40) (NN h))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN mAb))) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP (NP (NN NF-kappa) (NN B/Rel)) (JJ nuclear) (NN activity)) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN incubated) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN 3,4-dichloroisocoumarin)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (NN I) (NN kappa) (NN B-alpha)) (NN degradation))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Together)) (, ,) (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN class) (CD I) (NN triggering)) (VP (MD can) (VP (VB induce) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B/Rel)) (JJ nuclear) (NN activity)))) (PP (IN in) (NP (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes)))) (, ,) (S (ADVP (RB thereby)) (VP (VBG modulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN regulated) (PP (IN by) (NP (DT these) (NP (NN transcription) (NNS factors)))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN EBF)) (CC and) (NP (NN E47))) (VP (VBP collaborate) (S (VP (TO to) (VP (VB induce) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NP (JJ endogenous) (NN immunoglobulin) (JJ surrogate) (JJ light) (NN chain) (NNS genes))))))))) (. .)))))
(S1 (S (S (S (NP (NP (NP (JJ Early) (NN B) (NN cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN EBF)) (-RRB- -RRB-))) (CC and) (NP (NN E47))) (VP (VBP participate) (PP (IN in) (NP (NP (DT the) (JJ transcriptional) (NN control)) (PP (IN of) (NP (JJ early) (NN B) (NN lymphocyte) (NN differentiation)))))) (. .)))))
(S1 (S (S (PP (IN With) (NP (NP (DT the) (NN aim)) (PP (IN of) (S (VP (VBG identifying) (NP (NP (JJ genetic) (NNS targets)) (PP (IN for) (NP (DT these) (NN transcription) (NNS factors))))))))) (, ,) (NP (PRP we)) (ADVP (RB stably)) (VP (VBD transfected) (NP (NP (NNS cDNAs)) (VP (VBG encoding) (NP (NP (NN EBF)) (CC or) (NP (NP (DT a) (JJ covalent) (NN homodimer)) (PP (IN of) (NP (NN E47))))))) (, ,) (ADVP (ADVP (RB individually)) (CC or) (ADVP (RB together))) (, ,) (PP (IN into) (NP (NP (JJ immature) (JJ hematopoietic) (NN Ba/F3) (NNS cells)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP lack) (NP (DT both) (NNS factors)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN combination))) (, ,) (NP (NP (NN EBF)) (CC and) (NP (NN E47))) (VP (VBP induce) (NP (NP (JJ efficient) (NN expression)) (PP (IN of) (NP (NP (DT the) (NP (JJ endogenous) (NN immunoglobulin) (JJ surrogate) (JJ light) (NN chain) (NNS genes))) (, ,) (NP (NP (NN lambda5)) (CC and) (NP (NN VpreB)))))) (, ,) (SBAR (IN whereas) (S (NP (JJ other) (NP (JJ pre-B) (JJ cell-specific) (NNS genes))) (VP (VBP remain) (ADJP (JJ silent)))))) (. .))))
(S1 (S (S (NP (ADJP (ADVP (JJ Multiple) (RB functionally)) (JJ important)) (NP (NN EBF)) (CC and) (NP (NN E47)) (NP (NN binding) (NNS sites))) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (DT the) (NP (NN lambda5) (NN promoter/enhancer) (NN region))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NN lambda5)) (VP (VBZ is) (NP (NP (DT a) (ADJP (ADJP (JJ direct)) (ADJP (JJ genetic))) (NN target)) (PP (IN for) (NP (DT these) (NP (NN transcription) (NNS factors))))))))))) (. .))))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (NP (DT these) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN EBF)) (CC and) (NP (NN E47))) (VP (VBP synergize) (S (VP (TO to) (VP (VB activate) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NNS genes)))) (SBAR (WHNP (WDT that)) (S (VP (VBP define) (NP (NP (DT an) (JJ early) (NN stage)) (PP (IN of) (NP (DT the) (NP (NN B) (NN cell) (NN lineage))))))))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Nuclear) (NNS levels)) (PP (IN of) (NP (NN NF-kappaB)))) (VP (VBP correlate) (PP (IN with) (NP (NP (JJ syncytium-forming) (NN capacity)) (PP (IN of) (NP (NP (NN 8e51) (NNS cells)) (, ,) (VP (VBG expressing) (NP (DT a) (JJ defective) (NN HIV) (NN virus)))))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NP (JJ double) (NN NF-kappaB) (NN site))) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NP (NN LTR))) (PP (IN of) (NP (DT the) (NP (NP (JJ human) (NN immunodeficiency) (NN virus-1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB be) (ADJP (JJ necessary) (PP (IN for) (NP (JJ efficient) (JJ viral) (NN transcription)))))))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN report))) (NP (PRP we)) (VP (VBP present) (NP (NP (DT the) (NN characterisation)) (PP (IN of) (NP (NP (NN NF-kappaB) (NNS subunits)) (VP (VBN engaged) (PP (IN in) (NP (NP (NNS complexes)) (VP (VBG binding) (PP (TO to) (NP (NP (DT the) (NP (NN HIV-1) (NN NF-kappaB) (NN site))) (PP (IN in) (NP (NP (JJ human) (NN 8e51) (NNS T-cells)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBP harbour) (NP (DT a) (JJ defective) (NN HIV-1))))))))))))))))) (. .))))
(S1 (S (S (NP (QP (IN At) (JJS least) (CD four)) (ADJP (ADJP (JJ different)) (ADJP (JJ specific))) (NP (NN NF-kappaB) (NNS complexes))) (VP (VBP are) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (NN nucleus)) (PP (IN of) (NP (DT these) (NNS cells))))))) (. .))))
(S1 (S (S (PP (IN With) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ specific) (NNS antibodies))))) (NP (PRP we)) (VP (VBP have) (VP (VBN determined) (NP (NP (DT the) (NN composition)) (PP (IN of) (NP (DT each) (NN complex))))) (S (VP (VBG using) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays))))) (. .))))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBP show) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ several) (NP (NN NF-kappaB) (NN family) (NNS members) (, ,))))) (PP (IN with) (S (NP (DT the) (VBG transactivating) (NP (NN RelA))) (VP (VBG being) (VP (VBN engaged) (PP (IN in) (NP (JJ multiple) (NNS complexes)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN importance)) (PP (IN of) (NP (NN NF-kappaB) (NNS complexes))) (PP (IN in) (NP (JJ viral) (NNS functions)))) (VP (VBZ has) (VP (VBN been) (VP (VBN established))) (S (VP (VBG comparing) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN NF-kappaB) (JJ DNA-binding) (NNS complexes)))) (PP (IN with) (NP (NP (JJ syncytia-forming) (NN activity)) (PP (IN of) (NP (NN 8e51) (NNS cells)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN fact))) (, ,) (NP (NP (NN 8e51) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBD had) (ADVP (RB almost)) (VP (VBN lost) (NP (PRP$ their) (JJ syncytia-forming) (NN capacity))))))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB contain) (NP (NP (ADJP (QP (IN at) (JJS least) (CD 10) (NNS times) (RBR less)) (JJ active)) (NP (NN NF-kappaB) (JJ DNA-binding) (NN complex))) (SBAR (IN than) (S (NP (DT the) (NP (RB actively) (VBG fusing) (NNS cells))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NN correlation)) (VP (VBZ is) (ADJP (JJ specific)) (SBAR (IN as) (S (NP (NP (DT the) (NN level)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD three)) (JJ other) (NP (NN transcription) (NNS factors))))) (VP (VBD did) (RB not) (VP (VB change)))))) (. .))))
(S1 (S (NP (NP (NP (JJ Differential) (NN interaction)) (PP (IN of) (NP (JJ nuclear) (NNS factors))) (PP (IN with) (NP (DT the) (NP (JJ leukocyte-specific) (NN pp52) (NN promoter)))) (PP (IN in) (NP (NP (NN B)) (CC and) (NP (NN T)) (NP (NNS cells)))) (. .)))))
(S1 (S (S (S (NP (DT The) (ADJP (ADJP (JJ leukocyte-specific)) (, ,) (ADJP (JJ cytoskeleton-binding))) (NP (NP (NN pp52)) (PRN (-LRB- -LRB-) (NP (NP (NN LSP-1)) (, ,) (NP (NN WP-34))) (-RRB- -RRB-))) (NN protein)) (VP (VBZ is) (ADVP (RB widely)) (VP (VBN expressed) (PP (IN in) (NP (NP (JJ multiple) (NN leukocyte) (NNS lineages)) (, ,) (PP (VBG including) (NP (NP (NP (NN B)) (CC and) (NP (NN T)) (NP (NNS lymphocytes))) (, ,) (NP (NNS granulocytes)) (, ,) (CC and) (NP (NNS macrophages)))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD detected) (NP (NP (DT a) (NP (JJ tissue-specific) (NN promoter))) (VP (VBG preceding) (NP (NP (DT the) (NN exon)) (VP (VBG encoding) (NP (NP (DT the) (NP (NN N) (NN terminus))) (PP (IN of) (NP (DT the) (NP (NN pp52) (NN leukocyte) (NN protein)))))))))) (. .))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP describe) (NP (NP (NP (DT the) (JJ functional) (NN characterization)) (PP (IN of) (NP (DT this) (NN promoter)))) (CC and) (NP (NP (NN identification)) (PP (IN of) (NP (NP (DT the) (NNS factors)) (PP (IN in) (NP (NP (NP (NN B)) (CC and) (NP (NN T)) (NP (NNS cells))) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (PRP$ its) (NN activity)))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN pp52) (NN promoter))) (VP (VBZ contains) (NP (NP (NP (DT an) (NN initiator)) (VP (VBG specifying) (NP (NP (DT the) (JJ unique) (NP (JJ 5') (NN terminus))) (PP (IN of) (NP (NN pp52) (NN mRNA)))))) (, ,) (NP (NP (JJ tandem) (NNS pairs)) (PP (IN of) (NP (NP (NN Ets)) (CC and) (NP (NN SP1)) (NP (NNS motifs))))) (, ,) (CC and) (NP (DT a) (NP (JJ lone) (NN C/EBP) (NN motif))))) (. .))))
(S1 (S (S (NP (PDT All) (DT these) (NNS motifs)) (VP (VP (VBP are) (ADJP (JJ essential))) (CC and) (VP (ADVP (RB collectively)) (VBP control) (NP (JJ transcriptional) (NN activity)))) (. .))))
(S1 (S (S (NP (NP (NN DNA) (NN binding) (NNS studies)) (CC and) (NP (NN Ab) (NN supershift) (NNS assays))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (JJ different) (NNS combinations)) (PP (IN of) (NP (NNS factors)))) (VP (VBP interact) (PP (IN with) (NP (DT these) (NNS motifs))) (PP (IN in) (NP (NP (NN B) (NNS cells)) (CC vs) (NP (NN T) (NNS cells)))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN Ets) (NNS motifs))) (VP (VBP are) (ADVP (RB preferentially)) (VP (VBN bound) (PP (IN by) (NP (NN PU-1))) (PP (IN in) (NP (NP (NN B) (NN cell) (NNS extracts)) (PP (IN from) (NP (NP (DT all) (NNS stages)) (PP (IN of) (NP (NN development)))))))) (, ,) (SBAR (IN whereas) (S (NP (DT a) (JJ different) (NP (NN Ets) (NN family) (NN member))) (VP (VBZ reacts) (PP (IN with) (NP (DT these) (NNS motifs))) (PP (IN in) (NP (NN T) (NN cell) (NNS extracts))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN C/EBP) (NN motif))) (VP (VP (VBZ is) (VP (VBN bound) (PP (IN by) (NP (NN Ig/EBP-1))) (PP (IN in) (NP (NP (JJ pre-B) (NN cell)) (CC and) (NP (NN T) (NN cell)) (NP (NNS extracts)))))) (, ,) (CC but) (VP (VBZ is) (VP (VBN replaced) (PP (IN by) (NP (NP (JJ nuclear) (NN factor-IL-6beta)) (CC or) (NP (DT a) (NP (JJ nuclear) (NN factor-IL-6beta-Ig/EBP-1) (NN heterodimer))))) (PP (IN in) (NP (NN plasmacytoma) (NN cell) (NNS extracts)))))) (. .))))
(S1 (S (S (PP (IN Despite) (NP (NP (PRP$ its) (VBN reported) (NN role)) (PP (IN as) (NP (NP (DT a) (JJ negative) (NN regulator)) (PP (IN of) (NP (NN transcription))))))) (, ,) (NP (NN Ig/EBP-1)) (VP (VBZ appears) (S (VP (TO to) (VP (VB exert) (NP (DT a) (JJ stimulatory) (NN effect)) (PP (IN on) (NP (DT this) (NP (NN promoter)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VP (VBP reveal) (NP (NP (DT the) (NNS features)) (VP (VBG controlling) (NP (DT the) (NP (NN pp52) (NN promoter))) (PP (IN in) (NP (NP (NN B)) (CC and) (NP (NN T)) (NP (NNS cells))))))) (CC and) (VP (VBP provide) (NP (NP (DT the) (NN foundation)) (PP (IN for) (S (VP (VBG determining) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT this) (NP (NN promoter)))) (PP (IN in) (NP (JJ other) (NP (NN leukocyte) (NNS lineages))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Synthetic) (NNS glucocorticoids)) (SBAR (WHNP (WDT that)) (S (VP (VBP dissociate) (NP (NP (NN transactivation)) (CC and) (NP (NP (NN AP-1)) (NN transrepression))))))) (VP (VBP exhibit) (NP (JJ antiinflammatory) (NN activity)) (ADVP (FW in) (FW vivo))) (. .)))))
(S1 (S (S (S (NP (NP (DT Some)) (PP (IN of) (NP (DT the) (ADJP (ADJP (RBS most) (JJ potent)) (ADJP (ADJP (JJ antiinflammatory)) (CC and) (ADJP (JJ immunosuppressive)))) (NNS agents)))) (VP (VBP are) (NP (JJ synthetic) (NNS glucocorticoids))) (. .)))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ major) (NN side) (NNS effects)) (ADVP (RB severely)) (VP (VBP limit) (NP (PRP$ their) (JJ therapeutic) (NN use))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (ADJP (ADJP (JJ improved)) (ADJP (JJ glucocorticoid-based))) (NNS drugs)))) (VP (MD will) (VP (VB require) (NP (NP (DT the) (NN separation)) (PP (IN of) (NP (ADJP (JJ beneficial)))) (PP (IN from) (NP (JJ deleterious) (NNS effects)))))) (. .))))
(S1 (S (S (NP (NP (CD One) (NN possibility)) (PP (IN toward) (NP (DT this) (NN goal)))) (VP (VBZ is) (S (VP (TO to) (VP (VB try) (S (VP (TO to) (VP (VB dissociate) (NP (NP (NP (CD two) (JJ main) (NNS activities)) (PP (IN of) (NP (NNS glucocorticoids)))) (, ,) (PP (FW i.e.)) (NP (NP (NN transactivation)) (CC and) (NP (NN transrepression))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Screening)) (PP (IN of) (NP (NP (DT a) (NN library)) (PP (IN of) (NP (NNS compounds))))) (S (VP (VBG using) (NP (NP (NN transactivation)) (CC and) (NP (NP (NN AP-1)) (NN transrepression)) (NP (NNS models))) (PP (IN in) (NP (ADJP (RB transiently) (VBN transfected)) (NNS cells)))))) (VP (VBD identified) (NP (NP (VBN dissociated) (NNS glucocorticoids)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP exert) (NP (NP (JJ strong) (NP (NN AP-1)) (NN inhibition)) (CC but) (NP (NP (ADJP (JJ little))) (CC or) (NP (DT no)) (NP (NN transactivation))))))))) (. .))))
(S1 (S (S (ADVP (RB Importantly)) (, ,) (PP (IN despite) (NP (JJ high) (NN ligand) (NN binding) (NN affinity))) (, ,) (NP (NP (DT the) (ADJP (JJ prototypic) (VBN dissociated)) (NN compound)) (, ,) (NP (NN RU24858)) (, ,)) (VP (VP (VBD acted) (PP (IN as) (NP (DT a) (JJ weak) (NN agonist)))) (CC and) (VP (VBD did) (RB not) (ADVP (RB efficiently)) (VP (VB antagonize) (NP (NP (JJ dexamethasone-induced) (NN transcription)) (PP (IN in) (NP (VBN transfected) (NNS cells))))))) (. .))))
(S1 (S (S (NP (JJ Similar) (NNS results)) (VP (VBD were) (VP (VBN obtained) (PP (IN in) (NP (JJ hepatic) (NN HTC) (NNS cells))) (PP (IN for) (NP (NP (DT the) (NN transactivation)) (PP (IN of) (NP (NP (NP (DT the) (NP (JJ endogenous) (NN tyrosine) (NN amino) (NN transferase) (NN gene))) (PRN (-LRB- -LRB-) (NP (NN TAT)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS enzymes)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ glucocorticoid-dependent) (NN stimulation)) (PP (IN of) (NP (NN neoglucogenesis)))))))))))))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB investigate) (SBAR (IN whether) (S (NP (VBN dissociated) (NNS glucocorticoids)) (VP (VBD retained) (NP (NP (DT the) (ADJP (ADJP (JJ antiinflammatory)) (CC and) (ADJP (JJ immunosuppressive))) (NN potential)) (PP (IN of) (NP (JJ classic) (NNS glucocorticoids)))))))))) (, ,) (S (NP (JJ several) (NP (ADJP (FW in) (FW vitro))) (CC and) (NP (ADJP (FW in) (FW vivo))) (NP (NNS models))) (VP (VBD were) (VP (VBN used)))) (. .))))
(S1 (S (S (ADVP (RB Indeed)) (, ,) (NP (NP (NN secretion)) (PP (IN of) (NP (DT the) (NP (JJ proinflammatory) (NN lymphokine) (NN interleukin-1beta))))) (VP (VBD was) (ADVP (RB severely)) (VP (VBN inhibited) (PP (IN by) (NP (VBN dissociated) (NNS glucocorticoids))) (PP (IN in) (NP (JJ human) (JJ monocytic) (NN THP) (CD 1) (NNS cells))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (PP (IN in) (NP (CD two) (ADJP (FW in) (FW vivo)) (NNS models))) (, ,) (NP (DT these) (NNS compounds)) (VP (VBD exerted) (NP (NP (DT an) (ADJP (ADJP (JJ antiinflammatory)) (CC and) (NP (JJ immunosuppressive))) (NN activity)) (ADJP (ADJP (IN as) (JJ potent)) (PP (IN as) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ classic) (NN glucocorticoid)) (NP (NN prednisolone))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (MD may) (VP (VP (VB lead) (PP (TO to) (NP (NP (DT an) (NN improvement)) (PP (IN of) (NP (ADJP (ADJP (JJ antiinflammatory)) (CC and) (ADJP (JJ immunosuppressive))) (NNS therapies)))))) (CC and) (VP (VB provide) (NP (NP (DT a) (JJ novel) (NN concept)) (PP (IN for) (NP (NN drug) (NN discovery))))))) (. .))))
(S1 (S (NP (NP (NP (NN Activation) (NN domain) (NNS requirements)) (PP (IN for) (NP (NP (NN disruption)) (PP (IN of) (NP (JJ Epstein-Barr) (NN virus) (NN latency))) (PP (IN by) (NP (NN ZEBRA))))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Latent) (NN infection)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN by) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))))) (VP (MD can) (VP (VB be) (VP (VBN disrupted) (PP (IN by) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NP (NN EBV) (NN ZEBRA) (NN protein))))))))) (. .)))))
(S1 (S (S (NP (NP (NN ZEBRA)) (, ,) (NP (DT a) (JJ transcriptional) (NN activator)) (, ,)) (VP (VBZ initiates) (NP (DT the) (NN EBV) (JJ lytic) (NN cascade)) (PP (IN by) (S (VP (VBG activating) (NP (JJ viral) (NN gene) (NN expression)))))) (. .))))
(S1 (S (S (NP (NN ZEBRA)) (VP (VP (VBZ is) (ADVP (RB also)) (ADJP (JJ indispensable) (PP (IN for) (NP (JJ viral) (NN replication))))) (CC and) (VP (VBZ binds) (ADVP (RB directly)) (PP (TO to) (NP (NP (DT the) (NN EBV) (JJ lytic) (NN origin)) (PP (IN of) (NP (NN replication))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS studies)) (VP (VBN described) (ADVP (RB herein)))) (VP (VBP demonstrate) (SBAR (IN that) (FRAG (DT the) (NN activation) (NN domain)))) (. .))))
(S1 (S (S (NP (NP (NN ZEBRA)) (NN activation)) (VP (MD can) (VP (VB be) (VP (VBN replaced) (PP (IN by) (NP (DT a) (JJ heterologous) (NP (ADJP (JJ acidic))) (, ,) (NP (ADJP (JJ proline-rich))) (, ,) (CC or) (NP (ADJP (JJ glutamine-rich))) (NP (NN activation) (NN domain))))))) (. .))))
(S1 (S (S (NP (NP (NN ZEBRA)) (NN activation) (NN domain) (NN swap) (NNS constructs)) (VP (VBP retain) (NP (NP (NP (NN ZEBRA)) (POS 's)) (JJ native) (NNS abilities) (S (VP (VP (TO to) (VP (VB activate) (NP (JJ specific) (NP (NN EBV) (NNS promoters))))) (, ,) (VP (TO to) (VP (VB disrupt) (NP (NN EBV) (NN latency)))) (, ,) (CC and) (VP (TO to) (VP (VB stimulate) (NP (NP (NN replication)) (PP (IN at) (NP (DT the) (NP (NN EBV) (JJ lytic) (NN origin))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Additional) (NN work)) (, ,) (VP (VBG employing) (NP (NP (NP (ADJP (JJ sequential))) (CC and) (NP (ADJP (JJ internal))) (NP (NNS deletions))) (PP (IN of) (NP (NP (NP (NN ZEBRA)) (POS 's)) (NP (JJ N-terminal) (NN activation) (NN domain)))))) (, ,)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (PRP$ its) (JJ separate) (NNS activities)) (VP (VP (VBP are) (RB not) (ADJP (JJ attributable) (PP (TO to) (NP (JJ specific) (NP (NNS subdomains)))))) (CC but) (VP (VP (VBP are) (VP (VBN spread) (PP (IN throughout) (NP (PRP$ its) (NP (NN N) (NN terminus)))))) (CC and) (ADVP (RB therefore)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN inactivated) (PP (IN by) (S (VP (VBG deleting) (NP (JJ localized) (NNS regions))))))))))))) (. .))))
(S1 (S (S (S (NP (NN Transcription) (NN factor) (NN GATA-3)) (VP (VP (VBZ is) (ADVP (RB differentially)) (VP (VBN expressed) (PP (IN in) (NP (JJ murine) (NP (NN Th1)) (CC and) (NP (NN Th2)) (NP (NNS cells)))))) (CC and) (VP (VBZ controls) (NP (NP (JJ Th2-specific) (NN expression)) (PP (IN of) (NP (DT the) (NP (NN interleukin-5) (NN gene))))))) (. .)))))
(S1 (S (S (S (NP (NP (NP (NN Interleukin-5)) (PRN (-LRB- -LRB-) (NP (NN IL-5)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN produced) (PP (PP (IN by) (NP (JJ CD4-LRB-+-RRB-) (NN T) (NN helper) (CD 2) (-LRB- -LRB-) (NN Th2) (-RRB- -RRB-) (NNS cells))) (, ,) (CC but) (PP (RB not) (IN by) (NP (NN Th1) (NNS cells)))))))) (, ,)) (VP (VBZ plays) (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN eosinophilia))) (PP (IN in) (NP (NN asthma)))))) (. .)))))
(S1 (S (S (PP (IN Despite) (NP (VBG increasing) (NN evidence) (SBAR (IN that) (S (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (JJ many) (NNS diseases)))) (VP (VBZ is) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN ratio)) (PP (IN of) (NP (NP (NP (DT the) (CD two) (NNS subsets)) (PP (IN of) (NP (JJ CD4-LRB-+-RRB-) (NN T) (NN helper) (NNS cells)))) (, ,) (NP (NP (NN Th1)) (CC and) (NP (NN Th2))))))))))))) (, ,) (NP (NP (DT the) (JJ molecular) (NN basis)) (PP (IN for) (NP (NP (NN Th1-)) (CC and) (NP (JJ Th2-specific)) (NP (NN gene) (NN expression))))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN elucidated)))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD established) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN for) (NP (NP (DT the) (NP (NN transcription) (NN factor))) (NP (NN GATA-3)))) (PP (IN in) (NP (NP (NP (NN IL-5) (NN promoter)) (NN activation)) (PP (IN in) (NP (NN EL-4) (NNS cells))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP express) (NP (CC both) (NP (NN Th1-)) (CC and) (NP (JJ Th2-type)) (NP (NNS cytokines)))))))))) (. .))))
(S1 (S (S (NP (NP (PRP$ Our) (NNS studies)) (VP (VBN reported) (ADVP (RB here)))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN GATA-3)) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NP (NN IL-5)) (NN gene))) (PP (IN in) (NP (FW bona) (FW fide) (NN Th2) (NNS cells)))))))))) (. .))))
(S1 (S (S (SBAR (IN Whereas) (S (NP (NP (NNS mutations)) (PP (IN in) (NP (DT the) (NP (NN GATA-3)) (NN site)))) (VP (VBD abolished) (NP (NP (ADJP (JJ antigen-))) (CC or) (NP (ADJP (JJ cAMP-stimulated))) (NP (NP (NN IL-5) (NN promoter) (NN activation)) (PP (IN in) (NP (NN Th2) (NNS cells)))))))) (, ,) (S (NP (NP (JJ ectopic) (NN expression)) (PP (IN of) (NP (NN GATA-3))) (PP (PP (IN in) (NP (NN Th1) (NNS cells))) (CC or) (PP (IN in) (NP (DT a) (NP (JJ non-lymphoid) (, ,) (JJ non-IL-5-producing) (NN cell) (NN line)))))) (VP (VBD activated) (NP (DT the) (NP (NN IL-5) (NN promoter))))) (. .))))
(S1 (S (S (PP (IN During) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (NP (JJ naive) (JJ CD4-LRB-+-RRB-) (NN T) (NNS cells)) (VP (VBN isolated) (PP (IN from) (NP (NN T) (NN cell) (NN receptor) (JJ transgenic) (NNS mice)))))))) (, ,) (S (S (NP (NP (NN GATA-3)) (NN gene) (NN expression)) (VP (VP (VBD was) (VP (VBN up-regulated) (PP (IN in) (NP (VBG developing) (NP (NN Th2) (NNS cells)))))) (, ,) (CC but) (VP (VBD was) (VP (VBN down-regulated) (PP (IN in) (NP (NN Th1) (NNS cells))))))) (, ,) (CC and) (S (NP (NP (NN antigen-) (CC or) (JJ cAMP-activated) (NN Th2) (NNS cells)) (PRN (-LRB- -LRB-) (CONJP (CC but) (RB not)) (NP (NP (NN Th1) (NNS cells))) (-RRB- -RRB-))) (VP (VBD expressed) (NP (DT the) (NP (NN GATA-3) (NN protein)))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN GATA-3)) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN balance)) (PP (IN between) (NP (NP (NP (NN Th1))) (CC and) (NP (NN Th2) (NNS subsets)))))) (PP (IN in) (NP (JJ immune) (NNS responses))))) (. .))))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (NN GATA-3)) (NN activity)))) (VP (VBZ has) (NP (JJ therapeutic) (NN potential)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN asthma)) (CC and) (NP (JJ other) (JJ hypereosinophilic) (NNS diseases))))))) (. .))))
(S1 (S (NP (NP (NP (NN Transcription) (NNS factors)) (PP (IN in) (NP (JJ immune-mediated) (NN disease))) (. .)))))
(S1 (S (S (S (NP (NP (NP (DT A) (JJ large) (NN amount)) (PP (IN of) (NP (JJ detailed) (NN information)))) (PP (IN about) (NP (NP (DT the) (NP (JJ intracellular) (NNS proteins))) (VP (VBG regulating) (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (CC and) (NP (NP (DT the) (JJ cellular) (NN response)) (PP (TO to) (NP (NP (NN NF-kappa) (NN B)) (NN activation))))))))) (VP (VBZ has) (VP (VBN emerged) (ADVP (RB recently)))) (. .)))))
(S1 (S (S (NP (NP (ADJP (JJ Several) (JJ small)) (NNS molecules)) (, ,) (NP (DT an) (NP (JJ antisense) (NN oligonucleotide))) (, ,) (CC and) (NP (NP (NN gene) (JJ therapeutic) (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NP (NN NF-kappa) (NN b)) (NN activation))))))) (VP (VBP have) (VP (VBN been) (VP (VBN described)))) (. .))))
(S1 (S (S (PP (IN Despite) (NP (DT this))) (, ,) (NP (EX there)) (VP (VBP are) (ADVP (RB still)) (NP (JJ significant) (NNS gaps)) (PP (IN in) (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (NP (DT this) (NN process)) (CC and) (NP (PRP$ its) (NNS consequences))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN characterization)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (VP (ADVP (RB selectively)) (VBG regulating) (NP (NP (NN cytokine) (NN production)) (PP (IN by) (NP (JJ CD4+) (NN T) (NN cell) (NNS subsets)))))))) (VP (VBZ is) (PP (IN at) (NP (DT a) (ADJP (RB very) (JJ early)) (NN stage)))) (. .))))
(S1 (S (S (NP (CD Three) (NP (VBG interacting) (NNS proteins))) (VP (VBP have) (ADVP (RB recently)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB contribute) (PP (TO to) (NP (NP (JJ subset-restricted) (NN expression)) (PP (IN of) (NP (DT the) (NP (NN IL-4) (NN gene)))))))))))) (. .))))
(S1 (S (S (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ other) (NNS elements)) (VP (VBG regulating) (NP (NP (NN IL-4) (NN gene)) (NN expression)))))) (, ,) (ADVP (RB however)) (, ,) (CC and) (S (NP (NP (DT the) (JJ relative) (NN importance)) (PP (IN of) (NP (DT these) (ADJP (RB recently) (VBN identified)) (NNS proteins)))) (VP (VBZ has) (S (ADVP (RB yet)) (VP (TO to) (VP (VB be) (VP (VBN determined))))))) (. .))))
(S1 (S (S (S (NP (NN alpha-Tocopheryl) (NN succinate)) (VP (VBZ inhibits) (NP (NP (JJ monocytic) (NN cell) (NN adhesion)) (PP (TO to) (NP (JJ endothelial) (NNS cells)))) (PP (IN by) (S (VP (VBG suppressing) (NP (NP (NN NF-kappa) (NN B)) (NN mobilization)))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN adherence)) (PP (IN of) (NP (NNS monocytes))) (PP (TO to) (NP (VBN activated) (NN endothelium)))) (VP (VBZ is) (NP (NP (DT an) (JJ early) (NN event)) (PP (IN in) (NP (NN atherogenesis))))) (. .)))))
(S1 (S (S (SBAR (IN Because) (S (NP (NNS antioxidants)) (VP (VBP have) (VP (VBN been) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ antiatherosclerotic) (NN potential))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NP (NN alpha-tocopherol)) (PRN (-LRB- -LRB-) (NP (NN TCP)) (-RRB- -RRB-))) (CC and) (NP (PRP$ its) (NP (NN acetate)) (CC and) (NP (NN succinate)) (NP (NNS esters))))) (PP (IN on) (NP (NP (NN monocyte) (NN adhesion)) (PP (TO to) (NP (NP (JJ cytokine-stimulated) (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS HUVEC)) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (S (NP (JJ Endothelial) (NNS cells)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NP (NN TCP)) (, ,) (NP (NP (NN alpha-tocopherol) (NN acetate)) (PRN (-LRB- -LRB-) (NP (NN TCP) (NN acetate)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN alpha-tocopheryl) (NN succinate)) (PRN (-LRB- -LRB-) (NP (NN TCP) (NN succinate)) (-RRB- -RRB-))))) (PP (IN before) (NP (NP (NN stimulation)) (PP (IN with) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NP (NN TNF-alpha)) (: ;) (NP (NP (CD 10) (NN U/ml)) (, ,) (NP (CD 6) (NN h)))) (-RRB- -RRB-))) (CC or) (NP (NP (NN interleukin-1) (NN beta)) (PRN (-LRB- -LRB-) (NP (NP (NN IL-1) (NN beta)) (: ;) (NP (NP (CD 10) (NN U/ml)) (, ,) (NP (CD 6) (NN h)))) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Cytokine-stimulated) (NN cell) (NN surface) (NN expression)) (PP (PP (IN of) (NP (NP (NP (JJ vascular) (NN cell) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NP (NN VCAM-1)) (, ,) (NP (NN CD106))) (-RRB- -RRB-))) (CC and) (NP (NP (NN E-selectin)) (PRN (-LRB- -LRB-) (NP (NP (NN ELAM-1)) (, ,) (NP (NN CD62E))) (-RRB- -RRB-))))) (, ,) (CC but) (PP (RB not) (IN of) (NP (NP (JJ intercellular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NP (NN ICAM-1)) (, ,) (NP (NN CD54))) (-RRB- -RRB-)))))) (, ,) (VP (VBD was) (ADVP (ADVP (NN time-)) (CC and) (ADVP (NN dose-)) (ADVP (RB dependently))) (VP (VBN inhibited) (PP (PP (IN by) (NP (NN TCP) (NN succinate))) (CC but) (PP (RB not) (IN by) (NP (NP (NN TCP)) (CC or) (NP (NN TCP) (NN acetate))))))) (. .))))
(S1 (S (S (NP (NP (NN TCP) (JJ succinate)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN microM)) (, ,) (NP (CD 24) (NN h))) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NP (NP (NP (JJ TNF-induced) (NN VCAM-1))) (CC and) (NP (NP (NN E-selectin))) (NP (NN expression))) (PP (PP (PP (IN from) (NP (NP (DT a) (JJ specific) (NN mean) (NN fluorescence) (NN intensity)) (PP (IN of) (NP (QP (CD 151) (CC +/-) (CD 28)))))) (PP (TO to) (NP (QP (CD 12) (CC +/-) (CD 4)) (NP (NNS channels))))) (CC and) (PP (PP (IN from) (NP (PP (NP (QP (CD 225) (CC +/-) (CD 38)))))) (PP (TO to) (NP (QP (CD 79) (CC +/-) (CD 21)) (NP (NNS channels)))))) (, ,) (ADVP (RB respectively)))) (. .))))
(S1 (S (S (NP (NP (NN Succinate)) (ADVP (RB alone))) (VP (VBD had) (NP (DT no) (NN effect))) (. .))))
(S1 (S (S (NP (VBN Decreased) (NP (NN adhesion) (NN molecule)) (NN expression)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (JJ monocytic) (NN cell) (NN adhesion))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN TCP) (NN succinate)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN microM)) (, ,) (NP (CD 72) (NN h))) (-RRB- -RRB-))) (, ,) (CONJP (CC but) (RB not)) (NP (NP (NN TCP)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN microM)) (, ,) (NP (CD 72) (NN h))) (-RRB- -RRB-))) (, ,)) (VP (VP (VBD reduced) (NP (NP (NP (NN U-937) (NN cell)) (NN adhesion)) (PP (TO to) (NP (JJ TNF-alpha-stimulated) (-LRB- -LRB-) (CD 10) (NN U/ml) (, ,) (CD 6) (NN h) (-RRB- -RRB-) (NNS HUVEC)))) (PP (IN by) (NP (NP (CD 30) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR &lt;) (NP (CD 0.025)))) (-RRB- -RRB-))))) (CC and) (VP (NP (PP (TO to) (NP (NN IL-1) (JJ beta-stimulated) (NNS HUVEC)))) (PP (IN by) (NP (NP (CD 56) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR &lt;) (NP (CD 0.010)))) (-RRB- -RRB-)))))) (. .))))
(S1 (S (S (NP (NP (JJ Electrophoretic) (JJ mobility-shift) (NNS assays)) (PP (IN of) (NP (NP (NNS HUVEC)) (NP (JJ nuclear) (NNS proteins))))) (VP (VBD revealed) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NP (JJ TNF-alpha-stimulated) (JJ nuclear) (NN factor-kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (NN activation))) (PP (IN after) (NP (NP (NN pretreatment)) (PP (IN of) (NP (NNS HUVEC))) (PP (PP (IN with) (NP (NN TCP) (NN succinate))) (CC but) (PP (RB not) (IN with) (NP (NP (NN TCP)) (, ,) (NP (NN TCP) (NN acetate)) (, ,) (CC or) (NP (NN succinate)) (ADVP (RB alone))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT the) (NN vitamin) (NN E) (NN derivative) (NN TCP) (NN succinate)) (VP (VBZ prevents) (NP (NP (JJ monocytic) (NN cell) (NN adhesion)) (PP (TO to) (NP (JJ cytokine-stimulated) (NP (JJ endothelial) (NNS cells))))) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))))))) (, ,) (S (ADVP (RB further)) (VP (VBG emphasizing) (NP (NP (DT the) (JJ antiatherosclerotic) (NN potential)) (PP (IN of) (NP (NN lipid) (JJ soluble) (NNS antioxidants)))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (NP (NN inosine-5'-monophosphate) (NN dehydrogenase) (NN type) (CD II)) (NN gene) (NN expression)) (PP (IN in) (NP (JJ human) (NN T) (NNS cells))))) (. .)))))
(S1 (S (NP (NP (NN Role)) (PP (IN for) (NP (DT a) (JJ novel) (NP (JJ 5') (JJ palindromic) (NN octamer) (NN sequence)))) (. .))))
(S1 (S (S (S (NP (NP (NN Expression)) (PP (IN of) (NP (NP (DT the) (NN gene)) (VP (VBG encoding) (NP (NP (JJ human) (NN inosine-5'-monophosphate) (NN dehydrogenase) (-LRB- -LRB-) (NN IMPDH) (-RRB- -RRB-) (NN type) (CD II)) (, ,) (NP (NP (DT an) (NP (NN enzyme))) (VP (VBG catalyzing) (NP (DT the) (JJ rate-limiting) (NN step)) (PP (IN in) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NN guanine) (NNS nucleotides))))))))))) (, ,)) (VP (VP (VBZ is) (VP (VBN increased) (NP (JJR more) (IN than) (RB 10-fold)) (PP (IN in) (NP (VBN activated) (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes))))) (CC and) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NN T) (NN cell) (NN activation)))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NP (JJ 5'-regulatory) (NNS sequences))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ important) (PP (IN for) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT this) (NN gene))) (PP (IN in) (NP (NN T) (NNS cells)))))))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN DNase) (CD I)) (NN mapping)) (PP (IN of) (NP (JJ genomic) (NN DNA)))) (VP (VBD identified) (NP (DT a) (NP (JJ hypersensitive) (NN element))) (PP (IN near) (NP (DT the) (NP (NN transcription) (NN initiation) (NN site))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Fine) (NN mapping)) (PP (IN by) (NP (ADJP (FW in) (FW vivo)) (NN footprinting)))) (VP (VBD demonstrated) (NP (NP (CD five) (NN transcription) (NN factor) (NN binding) (NNS sites)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN occupied) (PP (IN in) (NP (CC both) (NP (VBG resting)) (CC and) (NP (VBN activated) (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes))))))))))) (: ;) (S (NP (DT these)) (VP (VBP are) (NP (NP (JJ tandem) (NN CRE) (NNS motifs)) (, ,) (NP (DT a) (NP (NN Sp1) (NN site))) (, ,) (NP (DT an) (JJ overlapping) (NP (NN Egr-1/Sp1) (NN site))) (, ,) (CC and) (NP (DT a) (JJ novel) (NP (NP (JJ palindromic) (NN octamer) (NN sequence)) (PRN (-LRB- -LRB-) (NP (NN POS)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (DT The) (JJ tandem) (NP (NN CRE)) (CC and) (NP (NN POS)) (NP (NNS sites))) (VP (VBP are) (PP (IN of) (NP (ADJP (ADJP (JJ major)) (ADJP (JJ functional))) (NN importance))) (SBAR (IN as) (S (VP (VBN judged) (PP (IN by) (NP (NP (ADJP (JJ mutational))) (CC and) (NP (ADJP (JJ electrophoretic))) (NP (NN mobility) (NN shift) (NNS analyses)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP provide) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NP (JJ human) (NN IMPDH) (NN type) (CD II) (NN gene))))) (VP (VBZ is) (ADVP (RB predominantly)) (VP (VBN regulated) (PP (IN by) (NP (NP (NP (DT the) (NP (JJ nuclear) (NNS factors))) (NP (NN ATF-2))) (CC and) (NP (DT an) (ADJP (ADVP (RB as) (RB yet)) (JJ unidentified)) (NP (JJ POS-binding) (NN protein))))))))))) (. .))))
(S1 (S (S (NP (ADJP (ADJP (JJ Additional)) (ADJP (JJ major))) (JJ protein-DNA) (NNS interactions)) (VP (VBP do) (RB not) (VP (VB occur) (PP (IN within) (NP (DT the) (NN promoter) (NN region))) (PP (IN after) (NP (NN T) (NN lymphocyte) (NN activation)))) (, ,) (S (VP (VBG indicating) (NP (NP (NP (DT a) (NN requirement)) (PP (IN for) (NP (NP (JJ additional) (JJ protein-protein) (NNS interactions)) (CC and/or) (NP (NP (JJ post-translational) (NNS modifications)) (PP (IN of) (NP (JJ pre-bound) (NN transcription) (NNS factors))))))) (SBAR (S (VP (TO to) (VP (VB account) (PP (IN for) (NP (NP (DT the) (VBN observed) (NN increase)) (PP (IN in) (NP (NN IMPDH) (NN type) (CD II) (NN gene) (NN expression))))))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Transcriptional) (NN regulation)) (PP (IN during) (NP (NN myelopoiesis))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (VBN coordinated) (NN production)) (PP (IN of) (NP (DT all) (NP (NN blood) (NNS cells)))) (PP (IN from) (NP (DT a) (NP (JJ common) (NN stem) (NN cell))))) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB highly) (VBN regulated)) (NN process)) (VP (VBG involving) (NP (NP (JJ successive) (NNS stages)) (PP (IN of) (NP (NP (NN commitment)) (CC and) (NP (NN differentiation)))))))) (. .)))))
(S1 (S (S (PP (PP (IN From) (NP (NP (NNS analyses)) (PP (IN of) (NP (NP (NNS mice)) (ADJP (JJ deficient) (PP (IN in) (NP (NN transcription) (NN factor) (NNS genes)))))))) (CC and) (PP (IN from) (NP (NP (DT the) (NNS characterizations)) (PP (IN of) (NP (NP (NN chromosome) (NNS breakpoints)) (PP (IN in) (NP (JJ human) (NNS leukemias)))))))) (, ,) (NP (NP (PRP it))) (VP (VBZ has) (VP (VBN become) (ADJP (JJ evident)) (SBAR (IN that) (S (NP (NN transcription) (NNS factors)) (VP (VBP are) (NP (NP (JJ important) (NNS regulators)) (PP (IN of) (NP (NN hematopoiesis))))))))) (. .))))
(S1 (S (S (PP (IN During) (NP (NP (NN myelopoiesis)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ includes) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (ADJP (JJ granulocytic))) (CC and) (NP (ADJP (JJ monocytic))) (NP (NNS lineages)))))))))) (, ,) (NP (NP (NN transcription) (NNS factors)) (PP (IN from) (NP (JJ several) (NNS families)))) (VP (VBP are) (ADJP (JJ active))) (, ,) (PP (VBG including) (NP (NP (NN AML1/CBF) (NN beta)) (, ,) (NP (NN C/EBP)) (, ,) (NP (NN Ets)) (, ,) (NP (NN c-Myb)) (, ,) (NP (NN HOX)) (, ,) (CC and) (NP (NN MZF-1)))) (. .))))
(S1 (S (S (S (NP (NP (JJ Few)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (VBP are) (VP (VBN expressed) (PP (ADVP (RB exclusively)) (IN in) (NP (JJ myeloid) (NNS cells)))))) (: ;) (S (ADVP (RB instead)) (NP (PRP it)) (VP (VBZ appears) (SBAR (IN that) (S (NP (PRP they)) (ADVP (RB cooperatively)) (VP (VBP regulate) (NP (NP (NN transcription)) (PP (IN of) (NP (JJ myeloid-specific) (NNS genes))))))))) (. .))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP discuss) (NP (NP (JJ recent) (NNS advances)) (PP (IN in) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN during) (NP (NN myelopoiesis))))))) (. .))))
(S1 (S (S (S (NP (NP (NP (NN Transcription) (NN factor)) (NP (NN Egr-1))) (NN activity)) (VP (VBZ down-regulates) (NP (NP (NP (NN Fas)) (CC and) (NP (NN CD23)) (NP (NN expression))) (PP (IN in) (NP (NN B) (NNS cells))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Activation)) (PP (IN of) (NP (JJ mature) (NP (NN B) (NNS cells)))) (PP (IN via) (NP (NP (NN Ag) (NN receptor)) (NN cross-linking)))) (VP (VBZ induces) (NP (NP (JJ transient) (NN expression)) (PP (IN of) (NP (NP (DT the) (NP (NN transcription) (NN factor))) (NP (NN Egr-1)))))) (. .)))))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT the) (VBG activating) (NNS signals)) (VP (VBG leading) (PP (TO to) (NP (NP (NN Egr-1)) (NN induction))))) (VP (VBP have) (VP (VBN been) (VP (VBN studied) (ADVP (RB extensively))))))) (, ,) (S (NP (JJ little)) (VP (VBZ is) (VP (VBN known))) (PP (IN about) (NP (NP (DT the) (NNS genes)) (SBAR (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN placed) (ADVP (RBR further) (RB downstream) (PP (IN within) (NP (DT this) (NN activation) (NN cascade)))))))) (CC and) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB transcriptionally)) (VP (VBN regulated) (PP (IN by) (NP (NN Egr-1))))))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB identify) (NP (JJ such) (NP (NN target) (NNS genes)))))) (, ,) (S (NP (PRP we)) (VP (VBD established) (NP (JJ Egr-1-overexpressing) (NNS transfectants)) (PP (PP (IN from) (NP (DT the) (NP (JJ murine) (NN B) (NN cell) (NN line) (NN K46)))) (CC and) (PP (IN from) (NP (JJ human) (NN Ramos) (NN B) (NNS cells)))))) (. .))))
(S1 (S (S (NP (NP (DT All) (NNS clones)) (VP (VBN derived) (PP (IN from) (NP (NN K46) (NN B) (NNS cells))))) (VP (VBD showed) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NN CD44))))) (. .))))
(S1 (S (S (ADVP (RBS Most) (RB interestingly)) (, ,) (NP (NP (NN expression)) (PP (PP (IN of) (NP (NP (NN CD95)) (PRN (-LRB- -LRB-) (NP (NN Fas/Apo-1)) (-RRB- -RRB-)))) (CC and) (PP (IN of) (NP (NN CD23))))) (VP (VBD was) (VP (VBN down-regulated) (PP (IN in) (NP (DT all) (NP (NN K46) (NNS transfectants)))))) (. .))))
(S1 (S (S (PP (IN As) (NP (DT a) (NN consequence))) (, ,) (NP (PRP they)) (VP (VBD became) (ADJP (JJ resistant) (PP (TO to) (NP (NP (NN apoptosis)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ anti-CD95) (NN Ab)) (NN treatment)))))))) (. .))))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (DT the) (NP (JJ Egr-1-expressing) (NN Ramos) (NNS cells))) (VP (VBD showed) (NP (NP (VBN reduced) (NNS levels)) (PP (IN of) (NP (NP (NN CD95)) (NN expression))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN Egr-1)) (VP (VBZ seems) (S (VP (TO to) (VP (VB control) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ downstream) (NN target) (NNS genes)))) (PP (CONJP (RB not) (RB only)) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN activator))) (, ,) (CONJP (CC but) (RB also)) (PP (IN as) (NP (DT a) (NP (NN repressor) (NN molecule))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN B) (NNS cells))) (, ,) (NP (NN Egr-1)) (ADVP (RB therefore)) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (S (VP (VBG integrating) (NP (NP (DT the) (JJ short-lived) (NN signal)) (VP (VBN delivered) (PP (IN by) (NP (NP (NN triggering)) (PP (IN of) (NP (DT the) (NP (NN Ag) (NN receptor)))))))) (PP (IN into) (NP (NP (JJ phenotypic) (NNS changes)) (, ,) (PP (VBG including) (NP (NP (NP (NN repression)) (PP (IN of) (NP (NN CD95)))) (CC and) (NP (NP (NN CD23)) (NN transcription)))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (JJ Genomic) (NP (NN organization)) (, ,) (NP (NN sequence))) (, ,) (CC and) (NP (JJ transcriptional) (NN regulation))) (PP (IN of) (NP (DT the) (NP (JJ human) (NN eotaxin) (NN gene)))) (. .)))))
(S1 (S (S (S (NP (NN Eotaxin)) (VP (VBZ is) (NP (NP (DT an) (NP (NN eosinophil) (JJ specific) (NN beta-chemokine))) (VP (VBN assumed) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (ADJP (ADJP (JJ eosinophilic)) (ADJP (JJ inflammatory))) (NNS diseases)) (PP (JJ such) (IN as) (NP (NP (JJ atopic) (NN dermatitis)) (, ,) (NP (JJ allergic) (NN rhinitis)) (, ,) (NP (NN asthma)) (CC and) (NP (JJ parasitic) (NNS infections))))))))))))) (. .)))))
(S1 (S (S (NP (PRP$ Its) (NN expression)) (VP (VBZ is) (ADJP (ADJP (NN stimulus-)) (CC and) (ADJP (JJ cell-specific)))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB here)) (VP (VBP describe) (NP (DT the) (JJ genomic) (NP (NP (NN organisation)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 3) (NP (NNS exons))) (PP (IN of) (NP (NP (CD 132)) (, ,) (NP (CD 112)) (CC and) (NP (CD 542)) (NP (NN bp))))) (CC and) (NP (NP (CD 2) (NP (NNS introns))) (PP (IN of) (NP (NP (CD 1211)) (CC and) (NP (CD 378)) (NP (NN bp)))))) (-RRB- -RRB-))) (CC and) (NP (NP (NN sequence)) (PP (VBG including) (NP (NP (CD 3) (NN kb)) (PP (IN of) (NP (NN DNA))) (PP (IN from) (NP (NP (DT the) (JJ immediate) (NP (JJ 5') (JJ upstream) (NN region))) (PP (IN of) (NP (DT the) (NP (JJ human) (NN eotaxin) (NN gene))))))))))) (. .))))
(S1 (S (S (PP (IN Among) (NP (NP (DT the) (NP (JJ regulatory) (NN promoter) (NNS elements))) (VP (ADVP (RB potentially)) (VP (VBG regulating) (NP (NP (NN eotaxin) (NN gene)) (NN expression))) (CC and/or) (VP (VBG mediating) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ anti-inflammatory) (NNS drugs)))))))) (NP (PRP we)) (VP (VBD identified) (NP (NP (NN consensus) (NNS sequences)) (VP (VBN known) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (JJ nuclear) (NNS factors)) (PP (IN like) (NP (NP (NN NF-IL6)) (, ,) (NP (NN AP-1)) (, ,) (NP (DT a) (NP (NN NF-kappa-B) (JJ like) (NN consensus) (NN sequence))) (CC and) (NP (NP (NN gamma-interferon-)) (CONJP (RB as) (RB well) (IN as)) (NP (NN glucocorticoid)) (NP (NN response) (NNS elements))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NN Vitamin) (NN D) (NN receptor)) (: :)) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (NP (JJ allele-specific) (NN mRNA) (NN stability)) (PP (IN in) (NP (NP (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADJP (JJ heterozygous) (PP (IN for) (NP (DT the) (NP (NN Taq) (NN I) (NN restriction) (NN enzyme)) (NN polymorphism)))))))))))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Allelic) (NNS variations)) (PP (IN of) (NP (DT the) (NP (NN vitamin) (NN D) (NN receptor) (-LRB- -LRB-) (NN VDR) (-RRB- -RRB-) (NN gene))))) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NN prostate) (NN cancer)) (PP (IN in) (NP (NNS men)))) (CC and) (NP (NP (NN osteoporosis)) (PP (IN in) (NP (JJ postmenopausal) (NNS women)))))))))))) (. .)))))
(S1 (S (S (S (NP (NP (CD Three) (NP (NNS RFLPs))) (PRN (-LRB- -LRB-) (NP (NP (NN TaqI)) (, ,) (NP (NN ApaI)) (, ,) (NP (NN BsmI))) (-RRB- -RRB-))) (VP (VBP define) (NP (CD two) (JJ common) (NNS haplotypes)))) (: :) (NP (NP (NN BAt)) (CC and) (NP (NN baT))) (. .))))
(S1 (S (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (NP (NNS polymorphisms))))) (VP (VBP change) (NP (DT the) (NP (VBN translated) (NN protein)))) (. .))))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NN sequence) (NNS variations)) (PP (IN in) (NP (NP (DT the) (NP (JJ 3') (NN UTR))) (PP (IN of) (NP (NN VDR)))))) (VP (VBP have) (VP (VBN been) (VP (VBN linked) (PP (TO to) (NP (DT the) (JJ different) (NNS haplotypes)))))))) (, ,) (S (NP (NNS investigators)) (VP (VBP have) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (DT the) (NN stability)) (PP (IN of) (NP (NN VDR) (NN mRNA)))) (VP (VBZ is) (VP (VBN influenced) (PP (IN by) (NP (JJ allelic) (NNS variations)))))))))) (. .))))
(S1 (S (S (NP (JJ Indirect) (NN evidence)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NN allele) (NN T)) (VP (VBZ is) (ADJP (ADJP (RBR less) (JJ stable)) (PP (IN than) (NP (NN allele) (NN t)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (DT a) (NN RT-PCR) (JJ based) (NN approach)) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN stability)) (PP (IN of) (NP (NP (DT the) (NP (JJ big) (NN T)) (CC and) (NP (JJ small) (NN t)) (NP (NN allele))) (PP (IN in) (NP (NP (JJ normal) (JJ heterozygous) (NNS lymphocytes)) (CC and) (NP (NP (DT the) (NP (JJ heterozygous) (NN cell) (NNS lines))) (NP (NP (NP (NN NB4)) (PRN (-LRB- -LRB-) (NP (JJ myeloid) (NN leukemia)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN PC-3)) (CC and) (NP (NN DU) (CD 145))) (PRN (-LRB- -LRB-) (NP (NN prostate) (NNS cancers)) (-RRB- -RRB-)))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT all) (CD three) (NNS cases))) (, ,) (NP (PRP we)) (VP (VBD did) (RB not) (VP (VB find) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (NN stability)))))) (. .))))
(S1 (S (S (S (ADVP (RB Interestingly)) (, ,) (NP (PRP we)) (ADVP (RB consistently)) (VP (VBD observed) (NP (NP (ADJP (NP (CD 30) (NN %)) (JJR less)) (NP (NN RT-PCR) (NN product))) (VP (VBN derived) (PP (IN from) (NP (NP (DT the) (NP (JJ small) (NN t) (NN allele) (NN mRNA))) (PP (IN in) (NP (JJ steady) (NN state))))))))) (, ,) (NP (NP (DT a) (NN finding)) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBZ speaks) (PP (IN against) (NP (NP (DT a) (JJR higher) (NN stability)) (PP (IN of) (NP (DT the) (NP (JJ small) (NN t) (NN allele) (NN mRNA)))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (NP (NP (NP (DT a) (NN variation)) (PP (IN in) (NP (JJ transcriptional) (NN regulation)))) (CONJP (RB rather) (IN than)) (NP (NP (NN mRNA) (NN stability)) (PP (IN between) (NP (DT the) (NP (NNS alleles))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (NP (NP (DT an) (JJ unknown) (NN gene)) (CC or) (NP (NNS genes))) (PP (IN in) (NP (NP (NN linkage)) (PP (IN with) (NP (DT the) (NP (NNS polymorphisms))))))) (VP (VP (VBZ is) (PRN (-LRB- -LRB-) (VP (VBP are)) (-RRB- -RRB-))) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (NN risk)) (PP (IN of) (NP (NN prostate) (NN cancer)))) (CC and) (NP (NP (NN VDR)) (NP (NNS polymorphisms)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NN Rel/NF-kappa) (NN B)) (NP (NN transcription) (NNS factors))) (CC and) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NN apoptosis)))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN process)) (PP (IN of) (NP (NN apoptosis)))) (VP (VBZ is) (VP (VBN used)) (S (VP (TO to) (VP (VB eliminate) (NP (JJ unwanted) (NNS cells)) (PP (IN from) (NP (NP (DT a) (JJ wide) (NN variety)) (PP (IN of) (NP (NNS organisms))))))))) (. .)))))
(S1 (S (S (NP (NP (JJ Various) (JJ extracellular) (NNS signals)) (, ,) (VP (ADVP (RB often)) (VBG converging) (PP (IN in) (NP (JJ common) (JJ intracellular) (NNS pathways)))) (, ,)) (VP (MD can) (VP (VB induce) (NP (NN apoptosis)) (PP (IN in) (NP (DT a) (JJ cell-type-specific) (NN fashion))))) (. .))))
(S1 (S (S (NP (NP (JJ Recent) (NN work)) (PP (IN from) (NP (JJ several) (NNS laboratories)))) (VP (VBZ has) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN Rel/NF-kappa) (NN B)) (NP (NN transcription) (NNS factors))) (VP (VBP regulate) (NP (NN apoptosis)) (PP (IN in) (NP (JJ many) (NN cell) (NNS types)))))))) (. .))))
(S1 (S (S (S (PP (IN In) (NP (JJS most) (NNS cells))) (, ,) (NP (NP (NN Rel/NF-kappa) (NN B)) (NP (NN transcription) (NNS factors))) (VP (VBP appear) (S (VP (TO to) (VP (VB mediate) (NP (NP (JJ survival) (NNS signals)) (SBAR (WHNP (WDT that)) (S (VP (VBP protect) (NP (NNS cells)) (PP (IN from) (NP (NN apoptosis)))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (PP (IN under) (NP (DT some) (NNS circumstances))) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (MD may) (ADVP (RB also)) (VP (VB promote) (NP (NN apoptosis))))) (. .))))
(S1 (S (NP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NN Rel/NF-kappa) (NN B) (NNS proteins))) (PP (IN in) (NP (NP (JJ viral) (NN oncogenesis)) (CC and) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ viral) (NN transcription)))))) (. .)))))
(S1 (S (S (S (NP (NN Rel/NF-kappa) (NN B)) (VP (VP (VBZ is) (NP (NP (DT a) (NP (JJ ubiquitous) (NN transcription) (NN factor))) (SBAR (WHNP (WDT that)) (S (VP (VBZ consists) (PP (IN of) (NP (JJ multiple) (NN polypeptide) (NNS subunits)))))))) (, ,) (CC and) (VP (VBZ is) (ADJP (JJ subject) (PP (TO to) (NP (NP (JJ complex) (JJ regulatory) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP involve) (NP (NP (JJ protein-protein) (NNS interactions)) (, ,) (NP (NN phosphorylation)) (, ,) (NP (NN ubiquitination)) (, ,) (NP (JJ proteolytic) (NN degradation)) (, ,) (CC and) (NP (JJ nucleocytoplasmic) (NN translocation))))))))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (JJ sophisticated) (NN control)) (PP (IN of) (NP (NP (NN Rel/NF-kappa) (NN B)) (NN activity)))) (VP (VBZ is) (RB not) (ADJP (JJ surprising)) (SBAR (IN since) (S (NP (DT this) (NP (NN transcription) (NN factor))) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT a) (JJ wide) (NN array)) (PP (IN of) (NP (NP (JJ cellular) (NNS responses)) (PP (TO to) (NP (JJ extracellular) (NNS cues))))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (NN growth)) (, ,) (NP (NN development)) (, ,) (NP (NN apoptosis)) (, ,) (CC and) (NP (NN pathogen) (NN invasion)))))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (PRP it))) (VP (VBZ is) (RB not) (ADJP (JJ unexpected)) (SBAR (IN that) (S (NP (DT this) (ADJP (ADJP (JJ versatile)) (ADJP (JJ cellular) (JJ homeostatic))) (NN switch)) (VP (MD would) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ viral) (NNS pathogens)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP have) (VP (VBN evolved) (NP (NP (NNS mechanisms)) (SBAR (S (VP (TO to) (VP (VB utilize) (NP (NP (JJ various) (NNS aspects)) (PP (IN of) (NP (NP (NN Rel/NF-kappa) (NN B)) (NN activity)))))))))) (S (VP (TO to) (VP (VB facilitate) (NP (NP (PRP$ their) (NN replication)) (, ,) (NP (NN cell) (NN survival)) (CC and) (ADVP (RB possibly)) (NP (NP (NN evasion)) (PP (IN of) (NP (JJ immune) (NNS responses))))))))))))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN review)) (VP (MD will) (VP (VB cover) (NP (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN utilized) (PP (IN by) (NP (JJ mammalian) (JJ oncogenic) (NNS viruses)))) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NN Rel/NF-kappa) (NN B)) (NP (NN transcription) (NNS factors)))))))))))) (CC and) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN Rel/NF-kappa) (NN B))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ viral) (NN gene) (NP (NN expression)) (CC and) (NP (NN replication)))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NNS Mutations)) (PP (IN in) (NP (DT the) (NP (NN TSC2) (NN gene)))) (: :)) (NP (NP (NN analysis)) (PP (IN of) (NP (DT the) (JJ complete) (VBG coding) (NN sequence))) (VP (VBG using) (NP (DT the) (NP (NP (NN protein) (NN truncation) (NN test)) (PRN (-LRB- -LRB-) (NP (NN PTT)) (-RRB- -RRB-)))))) (. .)))))
(S1 (S (S (S (NP (NP (NNS Mutations)) (PP (IN in) (NP (NP (DT the) (NP (NN TSC2) (NN gene))) (PP (IN on) (NP (NN chromosome) (NN 16p13.3)))))) (VP (VBP are) (ADJP (JJ responsible) (PP (IN for) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (PP (IN of) (NP (JJ familial) (NP (NP (JJ tuberous) (NN sclerosis)) (PRN (-LRB- -LRB-) (NP (NN TSC)) (-RRB- -RRB-))))))))) (. .)))))
(S1 (S (S (NP (DT The) (NN gene)) (VP (VBZ has) (NP (NP (CD 41) (JJ small) (NNS exons)) (VP (VP (VBG spanning) (PP (NP (CD 45) (NN kb)) (IN of) (NP (JJ genomic) (NN DNA)))) (CC and) (VP (VBG encoding) (NP (DT a) (NP (CD 5.5) (NN kb) (NN mRNA))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Large) (NN germline) (NNS deletions)) (PP (IN of) (NP (NN TSC2)))) (VP (VBP occur) (PP (IN in) (NP (NP (QP (JJR &lt;) (CD 5)) (NN %)) (PP (IN of) (NP (NNS cases))))))) (, ,) (CC and) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ small) (JJ intragenic) (NNS mutations)))) (VP (VBP have) (VP (VBN been) (VP (VBN described))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD analysed) (NP (NP (NN mRNA)) (PP (IN from) (NP (NP (CD 18) (JJ unrelated) (NNS cases)) (PP (IN of) (NP (NN TSC)))))) (PP (IN for) (NP (NN TSC2) (NNS mutations))) (S (VP (VBG using) (NP (DT the) (NP (NP (NN protein) (NN truncation) (NN test)) (PRN (-LRB- -LRB-) (NP (NN PTT)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (CD Three) (NNS cases)) (VP (VBD were) (VP (VBN predicted) (S (VP (TO to) (VP (VB be) (NP (NN TSC2) (NNS mutations)) (UCP (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NN linkage) (NN analysis))))) (CC or) (SBAR (IN because) (S (NP (NP (DT a) (NN hamartoma)) (PP (IN from) (NP (DT the) (NN patient)))) (VP (VBD showed) (NP (NP (NN loss)) (PP (IN of) (NP (NP (NN heterozygosity)) (PP (IN for) (NP (NN 16p13.3) (NNS markers))))))))))))))) (. .))))
(S1 (S (S (NP (NP (CD Three) (VBG overlapping) (NP (NN PCR) (NNS products))) (, ,) (VP (VBG covering) (NP (NP (DT the) (JJ complete) (VBG coding) (NN sequence)) (PP (IN of) (NP (NN mRNA))))) (, ,)) (VP (VBD were) (VP (VP (VBN generated) (PP (IN from) (NP (JJ lymphoblastoid) (NN cell) (NNS lines)))) (, ,) (VP (VBN translated) (PP (IN into) (NP (NN 35S-methionine) (JJ labelled) (NN protein)))) (, ,) (CC and) (VP (VBN analysed) (PP (IN by) (NP (NN SDS-PAGE)))))) (. .))))
(S1 (S (S (S (NP (NP (NN PCR) (NNS products)) (VP (VBG showing) (NP (NN PTT) (NNS shifts)))) (VP (VBD were) (ADVP (RB directly)) (VP (VBN sequenced)))) (, ,) (CC and) (S (NP (NNS mutations)) (VP (VBN confirmed) (PP (IN by) (NP (NN restriction) (NN enzyme) (NN digestion))) (SBAR (WHADVP (WRB where)) (FRAG (ADJP (JJ possible)))))) (. .))))
(S1 (S (S (NP (CD Six) (NN PTT) (NNS shifts)) (VP (VBD were) (VP (VBN identified))) (. .))))
(S1 (S (S (S (NP (NP (CD Five)) (PP (IN of) (NP (DT these)))) (VP (VBD were) (VP (VBN caused) (PP (IN by) (NP (NP (NNS mutations)) (VP (VBN predicted) (S (VP (TO to) (VP (VB produce) (NP (DT a) (NP (VBN truncated) (NN protein)))))))))))) (: :) (S (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (S (S (NP (DT a) (JJ sporadic) (NN case)) (VP (VBD showed) (NP (NP (DT a) (NP (CD 32) (NN bp) (NN deletion))) (PP (IN in) (NP (NN exon) (CD 11)))))) (, ,) (CC and) (S (NP (NP (DT a) (NP (JJ mutant) (NN mRNA))) (PP (IN without) (NP (NN exon) (CD 11)))) (VP (VBD was) (VP (VBN produced))))) (: ;) (S (NP (DT the) (JJ normal) (NN exon) (CD 10)) (VP (VBD was) (ADVP (RB also)) (VP (VBN spliced) (PRT (RP out)))))) (: ;) (S (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (DT a) (JJ sporadic) (NN case)) (VP (VBD had) (NP (NP (DT a) (NP (CD 1) (NN bp) (NN deletion)) (PP (IN in) (NP (NN exon) (CD 12)))) (PRN (-LRB- -LRB-) (NP (NN 1634delT)) (-RRB- -RRB-))))) (: ;) (S (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (NP (DT a) (NP (JJ TSC2-linked) (NN mother) (CC and) (NN daughter) (NN pair))) (VP (VBD had) (NP (NP (NP (NP (DT a) (NN G) (TO --&gt;) (NN T) (NN transversion)) (PP (IN in) (NP (NN exon) (CD 23)))) (PRN (-LRB- -LRB-) (NP (NN G2715T)) (-RRB- -RRB-))) (VP (VBG introducing) (NP (NP (DT a) (JJ cryptic) (NN splice) (NN site)) (VP (VBG causing) (NP (NP (DT a) (CD 29) (NN bp) (NN truncation)) (PP (IN of) (NP (NN mRNA))) (PP (IN from) (NP (NN exon) (CD 23)))))))))) (: ;) (S (LST (-LRB- -LRB-) (LS iv) (-RRB- -RRB-)) (NP (DT a) (JJ sporadic) (NN case)) (VP (VBD showed) (NP (NP (DT a) (NP (CD 2) (NN bp) (NN deletion))) (PP (IN in) (NP (NN exon) (CD 36)))))) (: ;) (S (LST (-LRB- -LRB-) (LS v) (-RRB- -RRB-)) (NP (DT a) (JJ sporadic) (NN case)) (VP (VBD showed) (NP (NP (NP (DT a) (NP (CD 1) (NN bp) (NN insertion))) (VP (VBG disrupting) (NP (NP (DT the) (NN donor) (NN splice) (NN site)) (PP (IN of) (NP (NN exon) (CD 37)))))) (PRN (-LRB- -LRB-) (NP (NN 5007+2insA)) (-RRB- -RRB-))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT an) (NP (JJ upstream) (JJ exonic) (JJ cryptic) (NN splice) (NN site)))))) (S (VP (TO to) (VP (VB cause) (NP (NP (DT a) (NP (CD 29) (NN bp) (NN truncation))) (PP (IN of) (NP (NN mRNA))) (PP (IN from) (NP (NN exon) (CD 37)))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (CD one) (NN case))) (, ,) (NP (DT the) (NN PTT) (NN shift)) (VP (VBD was) (VP (VBN explained) (PP (IN by) (NP (NP (JJ in-frame) (NN splicing)) (PP (RP out) (PP (IN of) (NP (NN exon) (CD 10)))) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (NP (JJ normal) (NN exon) (CD 10) (JJ genomic) (NN sequence)))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Alternative) (NN splicing)) (PP (IN of) (NP (NN exon) (CD 10))) (PP (IN of) (NP (DT the) (NP (NN TSC2) (NN gene))))) (VP (MD may) (VP (VB be) (NP (DT a) (JJ normal) (NN variant)))) (. .))))
(S1 (S (S (NP (CD Three) (JJ 3rd) (NN base) (NN substitution) (NNS polymorphisms)) (VP (VBD were) (ADVP (RB also)) (VP (VBN detected) (PP (IN during) (NP (NP (JJ direct) (NN sequencing)) (PP (IN of) (NP (NN PCR) (NNS products))))))) (. .))))
(S1 (S (S (S (NP (VBN Confirmed) (NNS mutations)) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (CD 28) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS families)) (VP (VBN studied))))))))) (CC and) (S (PP (IN on) (NP (DT the) (NN assumption) (SBAR (IN that) (S (NP (NP (NN half)) (PP (IN of) (NP (DT the) (JJ sporadic) (NNS cases)))) (VP (MD should) (VP (VB have) (NP (NN TSC2) (NNS mutations)))))))) (, ,) (NP (NP (DT a) (JJ crude) (NN estimate)) (PP (IN of) (NP (DT the) (NN detection) (NN rate)))) (VP (MD would) (VP (VB be) (NP (CD 60) (NN %))))) (. .))))
(S1 (S (S (S (NP (DT This)) (VP (VBZ compares) (ADVP (RB favourably)) (PP (IN with) (NP (NP (JJ other) (NN screening) (NNS methods)) (VP (VBN used) (PP (IN for) (NP (NP (NN TSC2)) (, ,) (ADVP (RB notably)) (NP (NN SSCP))))))))) (, ,) (CC and) (S (SBAR (IN since) (S (NP (NN PTT)) (VP (VBZ involves) (NP (ADJP (RB much) (JJR less)) (NN work))))) (S (NP (PRP it)) (VP (MD may) (VP (VB be) (NP (NP (DT the) (NN method)) (PP (IN of) (NP (NN choice)))))))) (. .))))
(S1 (S (NP (NP (NP (NN Selection)) (PP (IN of) (NP (NP (VBN down-regulated) (NNS sequences)) (PP (IN along) (NP (NP (DT the) (JJ monocytic) (NN differentiation)) (PP (IN of) (NP (JJ leukemic) (NN HL60) (NNS cells))))))) (. .)))))
(S1 (S (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB dissect) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (JJ monocytic) (NN differentiation)))))))) (S (NP (PRP we)) (VP (VBP have) (VP (VBN developed) (NP (DT a) (JJ subtractive) (NN hybridisation) (NN method)) (PP (VBN based) (PP (IN on) (NP (DT a) (JJ simplified) (`` ') (JJ representational) (NN difference) (NN analysis) ('' '))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VP (VBN selected) (NP (CD 16) (NNS sequences))) (CC and) (VP (VBN confirmed) (NP (NP (PRP$ their) (NN down-regulation)) (PP (IN along) (NP (NP (DT the) (JJ TPA-induced) (JJ monocytic) (NN differentiation)) (PP (IN of) (NP (NN HL60) (NNS cells))))))))) (. .))))
(S1 (S (S (PP (IN Among) (NP (DT these) (NNS sequences))) (NP (PRP we)) (VP (VBP have) (VP (VBN identified) (NP (NP (NP (DT the) (NP (NN alpha-tubulin))) (, ,) (NP (DT the) (NP (NN TaxREB) (NN protein)))) (CC and) (NP (NP (CD two) (NP (JJ ribosomal) (NN protein) (NNS sequences))) (SBAR (WHNP (WDT which)) (S (VP (VBD had) (RB not) (VP (VBN been) (ADVP (RB previously)) (VP (VBN described) (PP (IN as) (S (ADVP (RB differentially)) (VP (VBN expressed))))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VP (VBP add) (PP (TO to) (NP (NP (PRP$ our) (NN knowledge)) (PP (IN about) (NP (NP (DT the) (NNS molecules)) (VP (VBN implicated) (PP (IN along) (NP (NP (NP (DT the) (JJ monocytic) (NN differentiation)) (CC and) (NP (NN growth) (NN arrest))) (PP (IN of) (NP (JJ leukemic) (NNS cells))))))))))) (CC and) (VP (VBP provide) (NP (DT a) (JJ first) (NN step)) (PP (IN in) (NP (NP (DT the) (NN study)) (PP (IN of) (NP (PRP$ their) (JJ respective) (NNS roles))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NP (NN Activation)) (PP (IN of) (NP (NP (DT a) (NP (JJ novel) (NN gene))) (PP (IN in) (NP (NN 3q21)))))) (CC and) (NP (NP (NN identification)) (PP (IN of) (NP (NP (JJ intergenic) (NN fusion) (NNS transcripts)) (PP (IN with) (NP (JJ ecotropic) (JJ viral) (NN insertion) (NN site) (CD I))))))) (PP (IN in) (NP (NN leukemia))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN identified) (NP (NP (NP (DT a) (NP (JJ novel) (NN gene))) (, ,) (NP (NN GR6))) (, ,) (ADJP (JJ located) (PP (IN within) (NP (NP (DT the) (NN leukemia) (NN breakpoint) (NN region)) (PP (IN of) (NP (NN 3q21)))))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB normally)) (VP (VBN expressed) (PP (PP (IN in) (NP (JJ early) (JJ fetal) (NN development))) (CC but) (PP (RB not) (IN in) (NP (JJ adult) (JJ peripheral) (NN blood))))))))))) (. .)))))
(S1 (S (S (NP (NN GR6)) (VP (VBZ is) (VP (VBN activated) (PP (PP (IN in) (NP (DT the) (NP (NN UCSD-AML1) (NN cell) (NN line)))) (CC and) (PP (IN in) (NP (DT a) (NP (JJ leukemic) (NN sample))))) (, ,) (SBAR (WHNP (NP (DT both)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP carry) (NP (DT a) (NP (NN t-LRB-3;3-RRB--LRB-q21;q26-RRB-)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN UCSD-AML1))) (, ,) (NP (PRP we)) (VP (VBP have) (ADVP (RB also)) (VP (VBN identified) (NP (NN fusion) (NNS transcripts)) (PP (PP (IN between) (NP (NP (NP (DT the) (NP (JJ ecotropic) (JJ viral) (NN insertion) (NN site) (CD I) (-LRB- -LRB-) (NN EVI1) (-RRB- -RRB-) (NN gene))) (PP (IN in) (NP (NN 3q26)))) (CC and) (NP (NN GR6)))) (CC and) (PP (IN between) (NP (NP (NN EVI1)) (CC and) (NP (NP (NN Ribophorin) (NN I)) (SBAR (WHNP (WDT that)) (S (VP (VBZ maps) (NP (CD 30) (NN kb) (NN telomeric)) (PP (TO to) (NP (NP (NN GR6)) (PP (IN in) (NP (NN 3q21)))))))))))))) (. .))))
(S1 (S (S (S (NP (DT All) (NNS fusions)) (VP (VBP splice) (NP (NP (DT the) (NP (JJ 5') (NNS ends))) (PP (IN of) (NP (DT the) (NP (NN 3q21) (NNS genes))))) (PP (IN into) (NP (NP (NN exon) (CD 2)) (PP (IN of) (NP (DT the) (NP (NN EVI1)) (NN gene))))))) (, ,) (NP (NP (NP (DT an) (NN event)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ similar) (PP (PP (TO to) (NP (NP (DT the) (JJ normal) (JJ intergenic) (NN splicing)) (PP (IN of) (NP (NN MDS1-EVI1))))) (CC and) (PP (TO to) (NP (NP (DT those)) (VP (ADVP (RB previously)) (VBN documented) (PP (IN in) (NP (NP (NNS leukemias)) (PP (IN with) (NP (NP (NN t-LRB-3;21-RRB-)) (CC and) (NP (NN t-LRB-3;12-RRB-))))))))))))))) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (JJ acute) (NP (JJ myelogenous) (NN leukemia) (NN 1-EVI1) (NNS fusions))) (CC and) (NP (JJ ETV6-EVI1) (NNS fusions)) (, ,)) (ADVP (RB respectively)) (, ,) (VP (VBP occur))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN Ribophorin) (NN I-EVI1) (NN fusion))) (PP (IN in) (NP (JJ particular))) (VP (MD may) (VP (VB be) (NP (NP (DT a) (JJ common) (NN occurrence)) (PP (IN in) (NP (NN t-LRB-3;3-RRB-)))))) (. .))))
(S1 (S (NP (NP (NP (NP (JJ Abnormal) (NN apoptosis)) (CC and) (NP (NN cell) (NN cycle) (NN progression))) (PP (IN in) (NP (NP (NNS humans)) (VP (VBN exposed) (PP (TO to) (NP (ADJP (NP (NP (NN methyl) (NN tertiary-butyl) (NN ether)) (CC and) (NP (NN benzene))) (NN contaminating)) (NN water)))))) (. .)))))
(S1 (S (S (S (LST (CD 1) (. .)) (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD hypothesized) (SBAR (IN that) (S (PP (IN in) (NP (NP (NNS individuals)) (PP (IN with) (NP (JJ certain) (JJ genetic) (NN makeup))))) (, ,) (NP (NP (NN MTBE)) (, ,) (NP (NN benzene)) (CC or) (NP (PRP$ their) (NNS metabolites))) (VP (VP (VBP act) (PP (IN as) (NP (NNS adducts)))) (CC and) (VP (MD may) (VP (VB induce) (NP (VBN programmed) (NN cell) (NN death)))))))) (. .)))))
(S1 (S (S (LST (CD 2) (. .)) (NP (PRP$ Our) (NN study)) (VP (VBD involved) (NP (NP (NP (DT a) (NN group)) (PP (IN of) (NP (CD 60) (ADJP (ADJP (NN male)) (CC and) (ADJP (JJ female))) (NNS subjects)))) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (ADJP (ADJP (NN MTBE)) (CC and) (ADJP (JJ benzene-contaminated))) (NN water)) (NP (NP (NNS concentrations)) (NP (NP (NP (QP (IN up) (TO to) (CD 76)) (NN PPB)) (PP (IN for) (NP (NN MTBE)))) (CC and) (NP (NP (QP (CD 14)) (NN PPB)) (PP (IN for) (NP (NN benzene)))))))) (, ,) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (QP (CD 5) (TO to) (CD 8)) (NNS years))))))))))) (. .))))
(S1 (S (S (PP (IN For) (NP (NN comparison))) (, ,) (NP (PRP we)) (VP (VBD recruited) (NP (NP (DT a) (NN control) (NN group)) (VP (VBG consisting) (PP (IN of) (NP (NP (CD 32) (JJ healthy) (NP (NNS males)) (CC and) (NP (NNS females))) (PP (PP (IN with) (NP (JJ similar) (NN age) (NN distribution))) (CC and) (PP (IN without) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NN MTBE)) (CC or) (NP (NN benzene)))))))))))))) (. .))))
(S1 (S (S (LST (CD 3) (. .)) (NP (NP (NP (JJ Peripheral) (NN blood) (NNS lymphocytes)) (PRN (-LRB- -LRB-) (NP (NNS PBL)) (-RRB- -RRB-))) (PP (IN of) (NP (CC both) (NNS groups)))) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (JJ apoptotic) (NNS cells)))) (CC and) (NP (NN cell) (NN cycle) (NN progression))))) (S (VP (VBG using) (NP (NN flow) (NN cytometry))))) (. .))))
(S1 (S (S (LST (LS 4) (. .)) (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ apoptotic) (NNS lymphocytes)) (PP (IN from) (NP (VBN exposed) (NNS individuals)))) (VP (VBD were) (VP (VBN compared) (PP (TO to) (NP (NP (JJ apoptotic) (NNS lymphocytes)) (PP (IN from) (NP (DT the) (JJ control) (NN group))))))))) (, ,) (S (NP (NP (JJ statistically-significant) (NNS differences)) (PP (IN between) (NP (DT each) (NN mean) (NN group)))) (VP (VBD were) (VP (VBN detected)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 26.4) (CC +/-) (CD 1.8)) (CC and) (NP (CD 12.1) (CC +/-) (CD 1.3))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)) (, ,) (VP (VBG indicating) (NP (NP (NP (DT an) (VBN increased) (NN rate)) (PP (IN of) (NP (NN apoptosis))) (PP (IN in) (NP (NP (CD 80.5) (NN %)) (PP (IN of) (NP (VBN exposed) (NNS individuals)))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P)) (ADJP (JJR &lt;) (NP (CD 0.0001)))) (, ,) (NP (JJ Mann-Whitney) (NN U-Test))) (-RRB- -RRB-)))))) (. .))))
(S1 (S (S (NP (ADJP (ADJP (NN MTBE)) (CC and) (ADJP (JJ benzene-induced))) (NN apoptosis)) (VP (VBZ is) (VP (VBN attributed) (PP (TO to) (NP (NP (DT a) (JJ discrete) (NN block)) (PP (IN within) (NP (DT the) (NN cell) (NN cycle) (NN progression))))))) (. .))))
(S1 (S (FRAG (SBAR (IN Because) (S (NP (NN cell) (NN cycle) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (PP (IN in) (NP (NP (NNS PBL)) (PP (IN from) (NP (JJ chemically-exposed) (NNS individuals))))) (, ,) (NP (NP (QP (IN between) (CD 20-50)) (NN %)) (PP (IN of) (NP (NNS cells)))) (VP (VBD were) (VP (VBN accumulated) (PP (IN at) (NP (DT the) (JJ S-G2/M) (NNS boundaries)))))))))) (. .))))
(S1 (S (S (LST (CD 5) (. .)) (NP (NP (CD One)) (PP (IN of) (NP (DT the) (NP (VBG signaling) (NNS molecules)))) (SBAR (WHNP (WDT which)) (S (VP (VBZ mediates) (VP (VBN programmed) (NP (NN cell) (NN death))))))) (VP (VBZ is) (NP (NP (JJ nuclear) (NN factor) (NN Kappa-B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-)))) (. .))))
(S1 (S (S (NP (NN NF-kappa) (NN B)) (VP (VBD was) (VP (VBN examined) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ many) (JJ molecular) (NNS mechanisms)) (PP (IN for) (S (VP (VBG mediating) (NP (NP (NN cell) (NN death)) (PP (IN by) (NP (NP (NN MTBE)) (CC and) (NP (NN benzene)))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Indeed)) (, ,) (NP (NP (NN addition)) (PP (IN of) (NP (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (NN activation)))) (NP (NP (NN pyrrolidine) (NN dithiocarbamate)) (PRN (-LRB- -LRB-) (NP (NN PDTC)) (-RRB- -RRB-))))) (, ,) (PP (TO to) (NP (NP (DT the) (NP (NNS lymphocytes))) (PP (IN of) (NP (DT the) (JJ chemically-exposed) (NN group)))))) (VP (VBD was) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG inhibiting) (NP (VBN programmed) (NN cell) (NN death)) (PP (IN by) (NP (CD 40) (NN %)))))))) (. .))))
(S1 (S (S (NP (NP (DT This) (NN reversal)) (PP (IN of) (NP (NN apoptosis))) (PP (ADVP (RB almost)) (TO to) (NP (DT the) (NN control) (NN level))) (PP (IN by) (NP (NP (NN inhibitor)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (NN activation)))))) (VP (MD may) (VP (VB indicate) (NP (NP (NN involvement)) (PP (IN of) (NP (DT this) (NP (VBG signaling) (NN molecule)))) (PP (IN in) (NP (NP (NP (NN MTBE)) (CC and) (NP (NN benzene)) (NP (NN induction))) (PP (IN of) (NP (VBN programmed) (NN cell) (NN death)))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Alcohol-induced) (NN regulation)) (PP (IN of) (NP (NP (JJ nuclear) (JJ regulatory) (NN factor-kappa) (NN beta)) (PP (IN in) (NP (JJ human) (NNS monocytes))))) (. .)))))
(S1 (S (S (S (NP (JJ Acute) (NN ethanol) (NN exposure)) (VP (VBZ has) (NP (DT the) (NN capacity) (S (VP (VP (TO to) (VP (VB modulate) (NP (JJ immune) (NNS functions)))) (, ,) (VP (ADVP (RB particularly)) (, ,) (TO to) (VP (RP down) (VB regulate) (NP (NP (NN monocyte) (NN production)) (PP (IN of) (NP (JJ inflammatory) (NNS cytokines)))))))))) (. .)))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ intracellular) (NNS mechanisms)) (PP (IN for) (NP (NP (DT these) (NNS effects)) (PP (IN of) (NP (NN ethanol)))))) (VP (VBP are) (ADVP (RB yet)) (S (VP (TO to) (VP (VB be) (VP (VBN understood)))))) (. .))))
(S1 (S (S (PP (VBG Considering) (SBAR (IN that) (S (NP (NP (JJ nuclear) (JJ regulatory) (NN factor-kappa) (NN beta)) (NP (-LRB- -LRB-) (NN NF-kappa) (NN B) (-RRB- -RRB-) (NN /Rel))) (VP (VBZ is) (NP (NP (DT a) (JJ common) (NP (JJ regulatory) (NN element))) (PP (IN of) (NP (NP (DT the) (NP (NN promoter) (NN region))) (PP (IN of) (NP (DT the) (NP (JJ inflammatory) (NN cytokine) (NNS genes))))))))))) (, ,) (ADVP (RB herein)) (, ,) (NP (PRP we)) (VP (VBD tested) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ acute) (NN ethanol)) (VP (VBZ affects) (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (PP (IN in) (NP (JJ human) (NNS monocytes))))))))) (. .))))
(S1 (S (S (NP (JJ Adherence-isolated) (NNS monocytes)) (VP (VBD showed) (NP (NP (JJ constitutive) (NN DNA) (NN binding) (NN activity)) (PP (IN of) (NP (NN NF-kappa) (NN B))))) (. .))))
(S1 (S (S (NP (NP (NP (NP (DT A) (ADJP (RB clinically) (JJ relevant)) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN mM)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ acute) (NN ethanol) (NN treatment)))) (ADVP (FW in) (FW vitro))) (VP (VP (VBD increased) (NP (NP (NP (NN NF-kappa) (NN B)) (NN binding) (NN activity)) (PP (IN in) (NP (NNS monocytes)))) (PP (IN with) (NP (NP (DT a) (JJ preferential) (NN induction)) (PP (IN of) (NP (NP (DT the) (JJ inhibitory)) (, ,) (NP (NN p50/p50)) (, ,) (NP (NN NF-kappa) (NN B/Rel) (NN homodimer))))))) (, ,) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (NN induction)) (PP (IN of) (NP (DT the) (NP (NN p65/p50) (NN heterodimer)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NN lipopolysaccharide) (NN stimulation)) (ADVP (RB primarily)) (VP (VBD induced) (NP (NP (DT the) (NP (NN p65/p50) (NN heterodimer))) (SBAR (WHNP (WDT that)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NN gene) (NN activation))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (ADJP (JJ such) (JJ unique)) (NN activation)) (PP (IN of) (NP (DT the) (NP (JJ inhibitory) (NN p50/p50) (NN homodimer)))) (PP (IN by) (NP (JJ acute) (NN ethanol) (NN treatment)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NP (NN inhibition)) (CONJP (RB rather) (IN than)) (NP (NN activation))) (PP (IN of) (NP (NN NF-kappa) (JJ B-regulated) (JJ inflammatory) (NN cytokine) (NNS genes))))))) (. .))))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (ADJP (RB physiologically) (JJ relevant)) (NNS concentrations)) (PP (IN of) (NP (NN ethanol)))) (VP (MD may) (VP (VB affect) (NP (NP (NN production)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS cytokines)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (, ,) (NP (NN interleukin-1) (NN beta)) (, ,) (CC and) (NP (NN interleukin-6))))))) (PP (IN by) (S (VP (VBG disrupting) (NP (NP (NP (NN NF-kappa) (NN B)) (NN signaling)) (PP (IN in) (NP (NNS monocytes)))))))))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NN BHRF1))) (S (VP (TO to) (VP (VB inhibit) (NP (NN apoptosis)))))) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (NN stimulus)) (CC and) (NP (NN cell) (NN type)))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (NN resistance)) (PP (TO to) (NP (NP (NN host) (NN defense) (NNS mechanisms)) (PP (JJ such) (IN as) (NP (NP (NP (NP (NP (NN tumor) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TNF)) (-RRB- -RRB-))) (: -)) (CC and) (NP (JJ Fas-mediated)) (NP (NN apoptosis))) (PP (IN of) (NP (NP (NP (VBN transformed))) (CC or) (NP (JJ virus-infected) (NNS cells))))))))))) (VP (MD may) (VP (VB be) (NP (DT a) (JJ critical) (NN component)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN disease))))))) (. .)))))
(S1 (S (S (S (VP (TO To) (VP (VB find) (NP (NP (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP protect) (NP (NNS cells)) (PP (IN from) (NP (NN apoptosis)))))))))) (, ,) (S (NP (PRP we)) (VP (VP (VBD used) (NP (DT an) (NN expression) (NN cloning) (NN strategy))) (CC and) (VP (VBD identified) (NP (NP (NN BHRF1)) (, ,) (NP (NP (DT an) (NP (JJ Epstein-Barr) (NN virus) (-LRB- -LRB-) (NN EBV) (-RRB- -RRB-) (JJ early-lytic-cycle) (NN protein))) (PP (IN with) (NP (NP (JJ distant) (NN homology)) (PP (TO to) (NP (NN Bcl-2))))))) (, ,) (PP (IN as) (NP (DT an) (NP (JJ anti-apoptosis) (NN protein))))))) (. .))))
(S1 (S (S (NP (NP (NN Expression)) (PP (IN of) (NP (NN BHRF1))) (PP (IN in) (NP (NN MCF-Fas) (NNS cells)))) (VP (VBD conferred) (NP (NP (ADJP (RB nearly) (JJ complete)) (NN resistance)) (PP (IN against) (NP (CC both) (NP (JJ anti-Fas) (NN antibody)) (CC and) (NP (JJ TNF-mediated) (NN apoptosis)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN BHRF1)) (VP (VP (VBD protected) (NP (DT these) (NNS cells)) (PP (IN from) (NP (JJ monocyte-mediated) (NN killing)))) (CC but) (VP (VBD failed) (S (VP (TO to) (VP (VB protect) (NP (PRP them)) (PP (IN from) (NP (NP (NN killing)) (VP (VBN mediated) (PP (IN by) (NP (JJ lymphokine-activated) (NN killer) (NNS cells))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NN BHRF1))) (S (VP (TO to) (VP (VB protect) (NP (NN MCF-Fas) (NNS cells)) (PP (IN from) (NP (NP (NN apoptosis)) (VP (VBN induced) (PP (IN by) (NP (JJ various) (NNS stimuli)))))))))) (VP (VBD was) (ADJP (JJ identical) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN Bcl-2)) (CC and) (NP (NN Bcl-xL)))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN BHRF1)))))) (VP (VBD resembled) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN Bcl-2)) (CC and) (NP (NN Bcl-xL))))) (SBAR (IN as) (S (NP (PRP it)) (VP (VP (VBD inhibited) (NP (NP (NP (NN TNF-)) (CC and) (NP (JJ anti-Fas-induced)) (NP (NN activation))) (PP (IN of) (NP (NP (CD two) (NNS enzymes)) (VP (VBG participating) (PP (IN in) (NP (DT the) (NN apoptosis) (NN pathway)))) (, ,) (NP (NP (JJ cytosolic) (NN phospholipase) (NN A2)) (CC and) (NP (NN caspase-3/CPP32))))))) (, ,) (CC but) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ NF-kappaB-like) (NN transcription) (NNS factors))))))))))) (. .))))
(S1 (S (S (NP (NP (DT A) (JJ putative) (NN function)) (PP (IN of) (NP (NN BHRF1))) (PP (IN in) (NP (JJ EBV-infected) (JJ epithelial) (NNS cells)))) (VP (MD may) (VP (VB be) (S (VP (TO to) (VP (VB protect) (NP (JJ virus-infected) (NNS cells)) (PP (IN from) (NP (NP (NN TNF-)) (CC and/or) (NP (JJ anti-Fas-induced)) (NP (NN cell) (NN death))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maximize) (NP (NN virus) (NN production)))))))))) (. .))))
(S1 (S (S (ADVP (RB Surprisingly)) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (CC neither) (NP (NN BHRF1)) (CC nor) (NP (NN Bcl-2)))) (PP (IN in) (NP (NP (DT a) (NP (NN B-cell) (NN line))) (, ,) (NP (NN BJAB)))) (, ,)) (VP (VBD protected) (NP (DT the) (NNS cells)) (PP (IN from) (NP (JJ anti-Fas-mediated) (NN apoptosis))) (SBAR (RB even) (IN though) (S (NP (PRP they)) (VP (VBD increased) (NP (NP (DT the) (NN survival)) (PP (IN of) (NP (JJ serum-starved) (NNS cells)))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (JJ protective) (NN role)) (PP (IN of) (NP (NN BHRF1))) (PP (IN against) (NP (NN apoptosis)))) (VP (VBZ resembles) (NP (NP (DT that)) (PP (IN of) (NP (NN Bcl-2)))) (PP (IN in) (S (VP (VBG being) (ADJP (ADJP (NN cell) (NN type) (JJ specific)) (CC and) (ADJP (JJ dependent) (PP (IN on) (NP (DT the) (JJ apoptotic) (NN stimulus))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Expression)) (PP (IN of) (NP (NN bcl-6) (NN protein))) (PP (IN in) (NP (NP (JJ normal) (NN skin)) (CC and) (NP (JJ epidermal) (NNS neoplasms)))) (. .)))))
(S1 (S (S (S (NP (NN Bcl-6) (NN protein)) (VP (VBZ is) (NP (NP (DT a) (ADJP (ADJP (RB recently) (VBN identified)) (ADJP (JJ novel))) (NP (NN transcription) (NN factor))) (SBAR (WHNP (WP$ whose) (VBN deregulated) (NN expression)) (S (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (ADJP (JJ diffuse) (JJ large)) (NN B) (NN cell) (NNS lymphomas))))))))) (. .)))))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN shown) (PP (IN by) (NP (PRP us))) (SBAR (IN that) (S (NP (DT the) (NN protein)) (VP (VBZ is) (ADJP (JJ located) (PP (IN in) (NP (NP (JJ germinal) (NN center) (NN B) (NNS cells)) (CC and) (NP (PRP$ their) (NP (JJ neoplastic) (NNS counterparts))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN bcl-6) (NN protein))) (PP (IN on) (NP (NP (JJ normal) (NN epidermis)) (, ,) (NP (NP (NP (ADJP (JJ benign))) (, ,) (CC and) (NP (ADJP (JJ malignant))) (NP (NNS tumors))) (VP (VBG originating) (PP (IN from) (NP (JJ epidermal) (NNS cells))))) (, ,) (CC and) (NP (JJ squamous) (NN cell) (NN carcinoma) (-LRB- -LRB-) (NN SCC) (-RRB- -RRB-) (NN cell) (NNS lines))))) (VP (VBP are) (VP (VBN investigated))) (. .))))
(S1 (S (S (PP (IN With) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN immunohistochemistry))))) (, ,) (NP (NN bcl-6) (NN protein)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB stain) (ADVP (ADVP (RB intensely)) (PP (IN on) (NP (JJ normal) (NN prickle) (NNS cells))) (, ,) (CC but) (ADVP (NP (NN none)) (PP (TO to) (ADVP (RB only) (RB slightly)))) (PP (IN on) (NP (JJ epidermal) (JJ basal) (NNS cells))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Papillomas)) (CC and) (NP (NNS keratoacanthomas))) (VP (VBD copied) (NP (PRP$ their) (JJ normal) (NNS counterparts)) (PP (IN in) (NP (NP (DT the) (NN mode)) (PP (IN of) (NP (NN expression)))))) (. .))))
(S1 (S (S (NP (NP (JJ Various) (NNS levels)) (PP (IN of) (NP (NN expression)))) (VP (VBD were) (VP (VBN found) (PP (IN on) (NP (JJ seborrheic) (NNS keratoses)))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NN expression) (NN level)) (PP (IN on) (NP (JJ basal) (NN cell) (NNS epitheliomas)))) (VP (VBD was) (ADJP (JJ low)))))) (. .))))
(S1 (S (S (ADVP (RB Peculiarly)) (, ,) (NP (NP (JJ eccrine) (NNS poromas)) (CC and) (NP (ADJP (ADJP (JJ undifferentiated)) (ADJP (JJ spindle-shaped))) (JJ basal) (NN cell) (NNS epitheliomas))) (VP (VBD were) (ADJP (RB totally) (JJ unstained))) (. .))))
(S1 (S (S (NP (JJ Squamous) (NN cell) (NNS carcinomas)) (VP (VBD showed) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN expression) (NNS levels)))) (, ,) (SBAR (IN while) (S (NP (NP (CD two) (ADJP (ADJP (JJ undifferentiated)) (ADJP (JJ spindle-shaped))) (NNS carcinomas)) (CC and) (NP (CD one) (JJ undifferentiated) (NP (NN SCC) (NN cell) (NN line)))) (VP (VBD remained) (ADJP (JJ unstained)))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN bcl-6) (NN protein)))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (JJ morphological) (NN differentiation)) (PP (IN in) (NP (NP (ADJP (JJ normal))) (CC and) (NP (JJ neoplastic) (JJ epidermal) (NNS cells)))))))))))) (. .))))
(S1 (S (NP (NP (NP (ADJP (ADJP (NN Tissue) (JJ transglutaminase-dependent)) (ADJP (JJ posttranslational))) (NN modification)) (PP (IN of) (NP (NP (DT the) (NP (NN retinoblastoma) (NN gene) (NN product))) (PP (IN in) (NP (NP (JJ promonocytic) (NNS cells)) (VP (VBG undergoing) (NP (NN apoptosis))))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NP (NN retinoblastoma) (NN gene) (NN product))) (PRN (-LRB- -LRB-) (NP (NN pRB)) (-RRB- -RRB-))) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG controlling) (NP (CC both) (NP (NP (NN cell) (NN release)) (PP (IN from) (NP (DT the) (NN G1) (NN phase)))) (CC and) (NP (NN apoptosis))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBP show) (ADVP (RB here)) (SBAR (IN that) (S (PP (IN in) (NP (NP (DT the) (JJ early) (NNS phases)) (PP (IN of) (NP (NN apoptosis))))) (, ,) (NP (NN pRB)) (VP (VBZ is) (ADVP (RB posttranslationally)) (VP (VBN modified) (PP (IN by) (NP (DT a) (NN tissue) (NN transglutaminase) (-LRB- -LRB-) (NP (NN tTG)) (-RRB- -RRB-) (JJ -catalyzed) (NN reaction)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN fact))) (, ,) (PP (IN by) (S (VP (VBG employing) (NP (NP (DT a) (JJ novel) (VBN haptenized) (NN lysis) (JJ synthetic) (NN substrate)) (SBAR (WHNP (WDT which)) (S (VP (VBZ allows) (NP (NP (NP (DT the) (NN isolation)) (PP (IN of) (NP (JJ glutaminyl-tTG) (NNS substrates)))) (ADVP (FW in) (FW vivo)))))))))) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (NN pRB)) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN tTG) (NN substrate)) (PP (IN in) (NP (NP (NN U937) (NNS cells)) (VP (VBG undergoing) (NP (NN apoptosis)))))))) (. .))))
(S1 (S (S (PP (IN In) (S (VP (VBG keeping) (PP (IN with) (NP (DT this) (NN finding)))))) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN apoptosis)) (PP (IN of) (NP (NN U937) (NNS cells)))) (VP (VBZ is) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (JJ rapid) (NN disappearance)) (PP (IN of) (NP (DT the) (ADJP (CD 105,000-) (TO to) (JJ 110,000-molecular-weight)) (NP (NN pRB)) (NNS forms))) (ADVP (RB concomitantly) (PP (IN with) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NP (DT a) (NN smear)) (PP (IN of) (NP (NP (JJ immunoreactive) (NNS products)) (PP (IN with) (NP (NP (DT a) (JJ molecular) (NN weight)) (PP (IN of) (NP (QP (JJR greater) (IN than) (CD 250,000)))))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN shift)) (PP (IN in) (NP (NP (NN pRB)) (JJ molecular) (NN weight)))) (VP (VP (VBD was) (VP (VBN reproduced) (PP (IN by) (S (VP (VBG adding) (NP (JJ exogenous) (VBN purified) (NN tTG)) (PP (TO to) (NP (NP (NNS extracts)) (VP (VBN obtained) (PP (IN from) (NP (JJ viable) (NP (NN U937) (NNS cells)))))))))))) (CC and) (VP (VBD was) (VP (VBN prevented) (PP (IN by) (NP (NP (NN dansylcadaverine)) (, ,) (NP (DT a) (JJ potent) (NN enzyme) (NN inhibitor))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (DT the) (NP (NN pRB)) (JJ posttranslational) (NN modification))) (PP (IN during) (NP (NN apoptosis)))) (VP (VBD was) (VP (VBN investigated) (PP (PP (IN by) (S (VP (VBG determining) (NP (DT the) (NP (NN E2F-1)) (NNS levels))))) (CC and) (PP (IN by) (S (VP (VP (VBG isolating)) (CC and) (VP (VBG characterizing)) (NP (NP (JJ pRB-null) (NNS clones)) (PP (IN from) (NP (NN U937) (NNS cells)))))))))) (. .))))
(S1 (S (S (ADVP (RB Notably)) (, ,) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NN pRB))) (PP (IN in) (NP (DT these) (NP (JJ U937-derived) (NNS clones))))) (VP (VBZ renders) (S (NP (DT these) (NP (JJ p53-null) (NNS cells))) (ADJP (RB highly) (JJ resistant) (PP (TO to) (NP (NP (NN apoptosis)) (VP (VBN induced) (PP (IN by) (NP (NP (NN serum) (NN withdrawal)) (, ,) (NP (NN calphostin) (NN C)) (, ,) (CC and) (NP (NN ceramide)))))))))) (. .))))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (NP (DT these) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN tTG)) (, ,) (VP (VBG acting) (PP (IN on) (NP (DT the) (NP (NN pRB) (NN protein))))) (, ,)) (VP (MD might) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN cell) (NN progression)) (PP (IN through) (NP (DT the) (NN death) (NN program))))))))))) (. .))))
(S1 (S (NP (NP (NN Evidence) (SBAR (IN that) (S (NP (NN calcineurin)) (VP (VBZ is) (ADJP (JJ rate-limiting) (PP (IN for) (NP (JJ primary) (JJ human) (NN lymphocyte) (NN activation))))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Cyclosporine)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-))) (VP (VBZ is) (NP (CC both) (NP (DT a) (ADJP (ADJP (JJ clinical)) (ADJP (JJ immunosuppressive))) (NN drug)) (CC and) (NP (NP (DT a) (NN probe)) (SBAR (S (VP (TO to) (VP (VB dissect) (NP (JJ intracellular) (NN signaling) (NNS pathways))))))))) (. .)))))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (NN CsA)) (VP (VBZ inhibits) (NP (NP (NN lymphocyte) (NN gene)) (NN activation)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (DT the) (NP (NN phosphatase)) (NN activity)) (PP (IN of) (NP (NP (NN calcineurin)) (PRN (-LRB- -LRB-) (NP (NN CN)) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NN use))) (, ,) (NP (NN CsA) (NN treatment)) (VP (VBZ inhibits) (NP (NP (CD 50-75) (NN %)) (PP (IN of) (NP (NP (NN CN)) (NN activity))) (PP (IN in) (NP (VBG circulating) (NNS leukocytes))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD modeled) (NP (NP (DT this) (NN degree)) (PP (IN of) (NP (NP (NN CN)) (NN inhibition)) (PP (IN in) (NP (JJ primary) (JJ human) (NNS leukocytes))))) (ADVP (FW in) (FW vitro)) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ partial) (NP (NN CN)) (NN inhibition))) (PP (IN on) (NP (NP (DT the) (JJ downstream) (NN signaling) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP lead) (PP (TO to) (NP (NN gene) (NN activation)))))))))))))) (. .))))
(S1 (S (S (S (PP (IN In) (NP (NP (JJ CsA-treated) (NNS leukocytes)) (VP (VBN stimulated) (PP (IN by) (NP (NN calcium) (NN ionophore)))))) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NN CN)) (NN activity)))))) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ similar) (NN degree)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (DT each) (NN event)) (VP (VBN tested))))))))))) (: :) (NP (NP (NP (NN dephosphorylation)) (PP (IN of) (NP (JJ nuclear) (NN factor) (IN of) (VBN activated) (NN T) (NN cell) (NNS proteins)))) (, ,) (NP (JJ nuclear) (NN DNA) (NN binding)) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (DT a) (NP (VBN transfected) (NN reporter) (NN gene) (NN construct))))) (, ,) (NP (NP (NP (NN IFN-gamma))) (CC and) (NP (NN IL-2) (NN mRNA)) (NP (NN accumulation))) (, ,) (CC and) (NP (NN IFN-gamma) (NN production))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN CN)) (NN inhibition)))) (VP (VBD was) (VP (VBN reflected) (PP (IN by) (NP (NP (DT a) (JJ similar) (NN degree)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NP (NN lymphocyte) (NN proliferation)) (CC and) (NP (NP (NN IFN-gamma)) (NN production))) (PP (IN in) (NP (DT the) (NP (JJ allogeneic) (JJ mixed) (NN lymphocyte) (NNS cultures)))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP support) (NP (DT the) (NN conclusion) (SBAR (IN that) (S (NP (NP (NN CN)) (NN activity)) (VP (VBZ is) (ADJP (JJ rate-limiting) (PP (IN for) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ primary) (JJ human) (NN T) (NNS lymphocytes))))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (NN CN)) (NN activity))) (VP (VBN observed) (PP (IN in) (NP (JJ CsA-treated) (NNS patients))))) (VP (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ similar) (NN degree)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NN lymphocyte) (NN gene)) (NN activation))))))))) (, ,) (CC and) (VP (VBZ accounts) (PP (IN for) (NP (NP (DT the) (NN immunosuppression)) (VP (VBN observed)))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NP (NN DNA) (NN binding) (NN domain))) (PP (IN of) (NP (DT the) (NP (NN A-MYB)) (NP (NN transcription) (NN factor))))) (VP (VP (VBZ is) (ADJP (JJ responsible) (PP (IN for) (NP (PRP$ its) (NN B) (JJ cell-specific) (NN activity))))) (CC and) (VP (VBZ binds) (PP (TO to) (NP (DT a) (NP (NN B) (NN cell) (JJ 110-kDa) (JJ nuclear) (NN protein)))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Expression) (NNS studies)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ transgenic) (NNS animals))))) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (DT the) (NP (NN A-MYB)) (NP (NN transcription) (NN factor))) (VP (VBZ plays) (NP (ADJP (ADJP (JJ central)) (CC and) (ADJP (JJ specific))) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (JJ mature) (NN B) (NN cell)) (NP (NN proliferation)) (CC and/or) (NP (NN differentiation))))))))))) (. .)))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (VP (VBZ is) (ADVP (RB highly)) (VP (VBN expressed) (PP (IN in) (NP (NN Burkitt) (POS 's) (NN lymphoma) (NNS cells))))) (CC and) (VP (MD may) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT this) (NN disease)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VP (VBP have) (ADVP (RB therefore)) (VP (VBN investigated) (NP (NP (NP (NP (DT the) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NN A-MYB)))) (CC and) (NP (PRP$ its) (NN regulation))) (PP (IN in) (NP (JJ several) (NP (JJ human) (JJ lymphoid) (NN cell) (NNS lines)))))) (S (VP (VBG using) (NP (NN co-transfection) (NNS assays))))) (CC and) (VP (VBP show) (SBAR (IN that) (S (NP (NN A-MYB)) (VP (VBZ is) (ADJP (RB transcriptionally) (JJ active) (PP (PP (IN in) (NP (NP (PDT all) (DT the) (NP (NN B) (NN cell) (NNS lines))) (VP (VBN studied)))) (, ,) (CC but) (PP (RB not) (IN in) (NP (NN T) (NNS cells)))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ particular))) (NP (DT the) (JJS best) (NP (NN responder) (NN cell) (NN line))) (VP (VBD was) (NP (DT the) (NP (NN Burkitt) (POS 's) (NN cell) (NN line) (NN Namalwa)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN activity)) (PP (IN of) (NP (NN A-MYB))) (PP (IN in) (NP (NP (NN B)) (CC and) (RB not) (NP (NN T)) (NP (NNS cells))))) (VP (VBD was) (VP (VBN observed)) (SBAR (WHADVP (WRB when)) (S (NP (CC either) (NP (DT an) (JJ artificial) (NN construct)) (CC or) (NP (DT the) (NP (NN c-MYC) (NN promoter)))) (VP (VBD was) (VP (VBN used) (PP (IN as) (NP (DT a) (NN reporter)))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NP (JJ functional) (NNS domains))) (ADJP (JJ responsible) (PP (IN for) (NP (NP (NN DNA) (NN binding)) (, ,) (NP (NN transactivation)) (, ,) (CC and) (NP (JJ negative) (NN regulation))))) (, ,) (VP (ADVP (RB previously)) (VBN characterized) (PP (IN in) (NP (DT a) (NN fibroblast) (NN context)))) (, ,)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB have) (NP (JJ similar) (NN activity)) (PP (IN in) (NP (NN B) (NNS cells)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN region)) (PP (IN of) (NP (NN A-MYB))) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (NN B) (NN cell) (JJ specific) (NN activity))))) (VP (VBD was) (VP (VBN defined) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (NP (JJ N-terminal) (CD 218) (NN amino) (NNS acids))) (VP (VBG containing) (NP (DT the) (NP (NN DNA) (NN binding) (NN domain)))))))))) (. .))))
(S1 (S (S (ADVP (RB Finally)) (, ,) (NP (DT a) (NP (JJ 110-kDa) (NN protein))) (VP (VBZ has) (VP (VBN been) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (NP (PDT all) (DT the) (NP (NN B)) (, ,) (CONJP (CC but) (RB not)) (NP (NN T)) (, ,) (NP (NN cell) (NNS lines)))))))))) (SBAR (WHNP (WDT that)) (S (ADVP (RB specifically)) (VP (VBZ binds) (PP (TO to) (NP (DT this) (NP (NN A-MYB) (JJ N-terminal) (NN domain))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (DT this) (NP (JJ 110-kDa) (NN protein))) (VP (MD may) (VP (VB be) (NP (NP (DT a) (ADJP (RB functionally) (JJ important)) (NP (NN B) (JJ cell-specific) (NN co-activator))) (PP (IN of) (NP (NN A-MYB))))))))) (. .))))
(S1 (S (NP (NP (NP (DT The) (NP (NN A-myb) (NN transcription) (NN factor))) (PP (IN in) (NP (NP (ADJP (JJ neoplastic))) (CC and) (NP (ADJP (JJ normal))) (NP (NN B) (NNS cells)))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NP (NN myb) (NN family))) (PP (IN of) (NP (NN transcription) (NNS factors)))) (VP (VBZ has) (VP (VBN been) (ADVP (RB strongly)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN cell) (NP (NN growth)) (CC and) (NP (NN differentiation)))) (PP (IN in) (NP (DT the) (JJ haematopoietic) (NN system)))))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (NP (NN v-myb) (NN oncogene))) (, ,) (VP (VBN carried) (PP (IN by) (NP (JJ avian) (JJ defective) (NNS retroviruses)))) (, ,)) (VP (VP (VBZ causes) (NP (NNS leukaemias)) (PP (IN in) (NP (DT the) (NN chicken)))) (CC and) (VP (VBZ transforms) (NP (JJ haematopoietic) (NNS cells)) (ADVP (FW in) (FW vitro)))) (. .))))
(S1 (S (S (NP (NP (PRP$ Its) (JJ normal) (JJ cellular) (JJ equivalent)) (NP (NN c-myb)) (, ,)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VP (VB promote) (NP (DT the) (NN proliferation))) (CC and) (VP (VB block) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (JJ haematopoietic) (NNS cells))))) (PP (IN in) (NP (JJ several) (JJ experimental) (NNS models))))))))) (CC and) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (JJ fetal) (NN haematopoiesis)))))) (. .))))
(S1 (S (S (NP (NP (CD Two) (JJ other) (NNS members)) (PP (IN of) (NP (DT the) (NN family)))) (VP (VBP have) (VP (VBN been) (VP (VBN cloned) (ADVP (RBR more) (RB recently))))) (, ,) (NP (NP (NP (NN A-myb)) (CC and) (NP (NN B-myb))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP show) (NP (NP (NN sequence) (NN homology)) (PP (IN with) (NP (NN c-myb)))) (PP (IN in) (NP (NP (JJ several) (NNS domains)) (, ,) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (NP (DT the) (NP (NN DNA) (NN binding) (NN domain))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ other) (NP (JJ regulatory) (NNS domains)))))))))))) (. .))))
(S1 (S (S (NP (DT Both)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP (NN transcription) (NNS factors)))))))) (. .))))
(S1 (S (S (S (NP (NN B-myb)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (NN proliferation)) (CC and) (NP (NN differentiation))))))))) (, ,) (CC but) (, ,) (S (PP (IN unlike) (NP (NN c-myb))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (JJ many) (NN cell) (NNS types)))))) (. .))))
(S1 (S (S (NP (NP (NP (DT The) (JJ third) (NN member)) (PP (IN of) (NP (DT the) (NP (NN family))))) (, ,) (NP (NN A-myb)) (, ,)) (VP (VBZ shows) (NP (NP (DT the) (ADJP (RBS most) (JJ restricted)) (NN pattern)) (PP (IN of) (NP (NN expression)))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (ADJP (RB very) (JJ specific)) (NN role)) (PP (IN for) (NP (DT this) (NP (NN transcription) (NN factor)))))))) (. .))))
(S1 (S (S (NP (NN A-myb)) (VP (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (NP (DT a) (NN subpopulation)) (PP (IN of) (NP (JJ normal) (NN B) (NNS lymphocytes))) (UCP (VP (VBN activated) (ADVP (FW in) (FW vivo))) (CC and) (ADJP (JJ localised) (PP (IN in) (NP (NP (DT the) (JJ germinal) (NN center)) (PP (IN of) (NP (JJ peripheral) (JJ lymphoid) (NNS organs))))))))))) (CC and) (VP (VBZ is) (RB not) (VP (VBN detected) (PP (IN at) (NP (JJ significant) (NNS levels))) (PP (IN in) (NP (NP (NP (NP (DT all) (JJ other) (NP (ADJP (JJ mature))) (CC or) (NP (JJ immature) (JJ haematopoietic) (NNS populations))) (VP (VBN studied))) (, ,) (PP (VBG including) (NP (NP (NN bone) (JJ marrow) (NNS cells)) (, ,) (NP (NN T) (NNS lymphocytes)) (, ,) (NP (NNS granulocytes)) (, ,) (NP (NNS monocytes))))) (, ,) (PP (CC either) (PP (IN at) (NP (NN rest))) (CC or) (PP (RB after) (NP (ADJP (FW in) (FW vitro)) (NN activation))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN A-myb)) (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN during) (NP (NP (DT a) (JJ narrow) (NN window)) (PP (IN of) (NP (NP (JJ normal) (NN B) (NN cell)) (NN differentiation))))))))) (. .))))
(S1 (S (S (NP (NP (NN A-myb)) (NN expression)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (JJ neoplastic) (NN B) (NNS cells)))) (, ,) (VP (VBG representing) (NP (NP (DT the) (JJ whole) (NN spectrum)) (PP (IN of) (NP (NN B) (NN cell) (NN differentiation)))))))))) (. .))))
(S1 (S (S (NP (NN A-myb)) (VP (VBZ is) (ADVP (RB strongly)) (VP (VBN expressed) (PP (PP (IN in) (NP (NP (NP (NN Burkitt) (POS 's) (NNS lymphomas)) (PRN (-LRB- -LRB-) (NP (NNS BL)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ slg+) (JJ B-acute) (JJ lymphoblastic) (NNS leukaemias)) (PRN (-LRB- -LRB-) (NP (NNS B-ALL)) (-RRB- -RRB-))))) (CC and) (PP (RB not) (IN in) (NP (NP (DT all) (JJ other) (NNS leukaemias/lymphomas)) (VP (VBN tested))))) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NN CLL))))) (PRN (-LRB- -LRB-) (NP (NP (QP (RB about) (CD 25)) (NN %)) (PP (IN of) (NP (NNS cases)))) (-RRB- -RRB-)))))) (. .))))
(S1 (S (S (NP (NP (PRP It))) (VP (VBZ is) (ADJP (JJ intriguing)) (SBAR (IN that) (S (NP (DT the) (NP (NN A-myb) (NN genome))) (VP (VBZ has) (VP (VBN been) (ADJP (JJ localised) (PP (ADJP (RB relatively) (RB close)) (TO to) (NP (NP (DT the) (NP (NN c-myc) (NN gene))) (PP (IN on) (NP (NN chromosome) (CD 8)))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT the) (NN c-myc) (NN translocation)) (PP (IN in) (NP (NP (NNS BL)) (CC and) (NP (NNS B-ALL))))) (VP (MD may) (VP (VB affect) (NP (NP (NN A-myb)) (NN transcription))))))))) (. .))))
(S1 (S (S (NP (NNS Studies)) (VP (VBP are) (PP (IN in) (NP (NN progress)))) (SBAR (SBAR (S (VP (TO to) (VP (VB investigate) (NP (NP (NP (DT the) (JJ functional) (NN relationship)) (PP (IN between) (NP (NP (NN A-myb)) (CC and) (NP (NN c-myc))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NNS BL) (NNS cells)))))))))) (CC and) (SBAR (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NN A-myb)) (VP (VBZ is) (VP (VBN deregulated) (PP (IN in) (NP (DT these) (NNS cells)))))))))))) (. .))))
(S1 (S (S (S (NP (JJ Human) (NNS neutrophils)) (VP (VBP express) (NP (NP (NN GH-N) (NN gene) (NNS transcripts)) (CC and) (NP (NP (DT the) (NP (JJ pituitary) (NN transcription) (NN factor))) (NP (NN Pit-1b))))) (. .)))))
(S1 (S (S (S (SBAR (IN Since) (S (NP (NN GH)) (VP (VBZ stimulates) (NP (NP (DT the) (NP (NN development)) (CC and) (NP (NN function))) (PP (IN of) (NP (NNS granulocytes))))))) (, ,) (S (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN GH))) (PP (IN in) (NP (JJ granulocyte) (NNS subsets)))))) (. .)))))
(S1 (S (S (PP (IN By) (NP (NN immunocytochemistry))) (, ,) (NP (NP (QP (CD 25) (CC +/-) (CD 7)) (NN %)) (PP (IN of) (NP (DT the) (NP (JJ human) (NNS neutrophils))))) (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB express) (NP (JJ immunoreactive) (NN GH)))))) (, ,) (SBAR (IN whereas) (S (NP (NNS eosinophils)) (VP (VBD were) (ADJP (JJ negative)))))) (. .))))
(S1 (S (S (NP (VBN Reversed) (NN transcription) (-LRB- -LRB-) (NN RT) (-RRB- -RRB-) (JJ -PCR) (NN analysis)) (VP (VBD demonstrated) (NP (NP (NN GH) (NN mRNA)) (PP (IN in) (NP (NNS neutrophils))))) (. .))))
(S1 (S (S (NP (NN Restriction) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNS neutrophils)) (VP (VBP express) (NP (NP (DT the) (NP (NN GH-N) (NN gene))) (CONJP (CC but) (RB not)) (NP (DT the) (NP (NN GH-V) (NN gene)))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (PP (IN by) (NP (NN western) (NN blot) (NN analysis))) (SBAR (IN that) (S (NP (NNS neutrophils)) (VP (VBP express) (NP (NP (NP (DT an) (ADJP (RB alternatively) (VBN spliced)) (NN variant)) (PP (IN of) (NP (NP (DT the) (NP (JJ pituitary) (NN transcription) (NN factor))) (NP (NN Pit-1))))) (, ,) (VP (VBN designated) (S (NP (NN Pit-1b))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (JJ myeloid-associated) (NNS genes)) (PP (IN in) (NP (JJ human) (JJ hematopoietic) (NN progenitor) (NNS cells))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN distribution)) (PP (IN of) (NP (NP (JJ myeloid) (JJ lineage-associated) (NN cytokine) (NNS receptors)) (CC and) (NP (JJ lysosomal) (NNS proteins))))) (VP (VBD was) (VP (VBN analyzed) (PP (IN in) (NP (JJ human) (JJ CD34+) (NN cord) (NN blood) (NN cell) (-LRB- -LRB-) (NN CB) (-RRB- -RRB-) (NNS subsets))) (PP (IN at) (NP (NP (JJ different) (NNS stages)) (PP (IN of) (NP (JJ myeloid) (NN commitment))))) (PP (IN by) (NP (NP (NN reverse-transcriptase) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-)))))) (. .)))))
(S1 (S (S (NP (NP (NP (DT The) (ADJP (RB highly) (JJ specific)) (NP (JJ granulomonocyte-associated) (JJ lysosomal) (NNS proteins))) (NP (NP (NP (NN myeloperoxidase)) (PRN (-LRB- -LRB-) (NP (NN MPO)) (-RRB- -RRB-))) (CC and) (NP (NP (NN lysozyme)) (PRN (-LRB- -LRB-) (NP (NN LZ)) (-RRB- -RRB-))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NP (NN transcription) (NN factor))) (NP (NN PU.1))) (, ,)) (VP (VBD were) (ADVP (RB already)) (ADJP (JJ detectable) (PP (IN in) (NP (DT the) (ADJP (RBS most) (JJ immature)) (NP (JJ CD34+Thy-1+) (NN subset)))))) (. .))))
(S1 (S (S (NP (NP (NP (NP (NN Messenger) (NN RNA)) (PRN (-LRB- -LRB-) (NP (NN mRNA)) (-RRB- -RRB-))) (NNS levels)) (PP (IN for) (NP (NP (DT the) (NP (NN granulocyte-colony) (NN stimulating) (NN factor) (-LRB- -LRB-) (NN G-CSF) (-RRB- -RRB-) (NN receptor))) (, ,) (NP (JJ granulocyte-macrophage) (-LRB- -LRB-) (NN GM) (-RRB- -RRB-) (NN -CSF) (NN receptor) (NN alpha) (NN subunit)) (CC and) (NP (NP (NP (NP (NN tumor) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TNF)) (-RRB- -RRB-))) (NNS receptors)) (NP (NP (CD I)) (PRN (-LRB- -LRB-) (NP (NN p55)) (-RRB- -RRB-))) (CC and) (NP (NP (CD II)) (PRN (-LRB- -LRB-) (NP (NN p75)) (-RRB- -RRB-))))))) (VP (VBD were) (ADVP (RB also)) (VP (VBN detected) (PP (IN in) (NP (DT this) (NN subset))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (NP (NN c-kit)) (CC and) (NP (NN flt-3))) (, ,) (NP (NP (NNS receptors)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN expressed) (PP (IN on) (NP (NN progenitor) (NNS cells))))))))))))))) (. .))))
(S1 (S (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (DT the) (NP (JJ monocyte-macrophage) (NN colony) (NN stimulating) (NN factor) (-LRB- -LRB-) (NN M-CSF) (-RRB- -RRB-) (NN receptor))) (VP (VBD was) (ADJP (RB largely) (JJ absent) (PP (PP (IN at) (NP (DT this) (NN stage))) (CC and) (PP (IN in) (NP (DT the) (NP (JJ CD34+Thy-1-CD45RA-) (NNS subsets))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN M-CSF) (NN receptor))) (VP (VBD was) (ADVP (RB first)) (ADJP (JJ detectable) (PP (IN in) (NP (DT the) (NP (JJ myeloid-committed) (JJ CD34+Thy-l-CD45RA+) (NN subset)))))) (. .))))
(S1 (S (S (NP (NP (DT All) (JJ other) (NNS molecules)) (VP (VBN studied))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (VBN expressed) (PP (IN at) (NP (NP (DT this) (NN stage)) (PP (IN of) (NP (NN differentiation))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Different) (NNS cocktails)) (PP (IN of) (NP (DT the) (VBN identified) (NNS ligands)))) (VP (VBD were) (VP (VBN added) (PP (TO to) (NP (VBN sorted) (JJ CD34+Thy-1+) (JJ single) (NNS cells))))) (. .))))
(S1 (S (S (NP (ADJP (ADJP (JJ Low)) (ADJP (JJ proliferative))) (NN capacity)) (VP (VBD was) (VP (VBN observed) (PP (IN after) (NP (NP (CD 1) (NN week)) (PP (IN in) (NP (NN culture))))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NP (NN stem) (NN cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN SCF)) (-RRB- -RRB-))) (JJ +) (NP (NP (NN Flt-3) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NN FL)) (-RRB- -RRB-))) (JJ +) (NP (NN G-CSF)))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Addition)) (PP (IN of) (NP (NN GM-CSF))) (PP (TO to) (NP (DT this) (JJ basic) (NN cocktail)))) (ADVP (RB consistently)) (VP (VBD increased) (NP (NP (DT the) (JJ clonogenic) (NN capacity)) (PP (IN of) (NP (JJ single) (JJ CD34+Thy-1+) (NNS cells)))))) (, ,) (CC and) (S (NP (DT this) (NN effect)) (VP (VBD was) (ADVP (RB further)) (VP (VBN enhanced) (PRN (-LRB- -LRB-) (PP (NP (QP (RB up) (TO to) (CD 72.3) (CC +/-) (CD 4.3)) (NN %)) (IN on) (NP (NN day) (CD 7))) (-RRB- -RRB-)) (PP (IN by) (NP (NP (DT the) (NN inclusion)) (PP (IN of) (NP (NN TNF-alpha)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ myeloid-associated) (NN growth) (NN factor) (NN receptor) (NNS transcripts))) (PP (IN in) (NP (JJ CD34+) (NN CB) (NNS subsets)))) (VP (VBZ does) (RB not) (VP (VB discriminate) (NP (NP (DT the) (JJ various) (NNS stages)) (PP (IN of) (NP (NN differentiation)))) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (DT the) (NP (NN M-CSF) (NN receptor)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NN TNF-alpha)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (JJ costimulatory) (NN factor)) (PP (IN of) (NP (DT the) (RB very) (NP (JJ immature) (JJ CD34+Thy-1+) (NN CB) (NN subset))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NP (NNS Glucocorticoids)) (CC and) (NP (DT the) (JJ immune) (NN function))) (PP (IN in) (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus) (NN infection))) (: :)) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (NP (ADJP (JJ hypercortisolemic))) (CC and) (NP (ADJP (JJ cortisol-resistant))) (NP (NNS patients))))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Immunological) (NNS studies)) (PP (IN in) (NP (JJ human) (NN immunodeficiency) (NN virus) (-LRB- -LRB-) (NN HIV) (-RRB- -RRB-) (JJ -positive) (NNS patients)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN disease) (NN progression)) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (DT a) (JJ defective) (NN production)) (PP (IN of) (NP (NP (NN type) (NP (CD 1) (NNS cytokines))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (CC and) (NP (NN IL-12))) (-RRB- -RSB-))))) (, ,) (NP (NP (DT an) (VBN increased) (NN production)) (PP (IN of) (NP (NP (NN type) (CD 2) (NNS cytokines)) (PRN (-LRB- -LRB-) (NP (NP (NN IL-4)) (, ,) (NP (NN IL-6)) (, ,) (CC and) (NP (NN IL-10))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (DT an) (VBN increased) (NN production)) (PP (IN of) (NP (NN IgE))))))))))) (. .)))))
(S1 (S (S (NP (NN HIV) (NN infection)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (JJ hypothalamo-pituitary-adrenal) (NN axis) (NN function)))) (CC and) (NP (VBD increased) (NP (NN plasma)) (CC and) (NP (ADJP (JJ urinary))) (NP (NN cortisol) (NNS concentrations))))))) (. .))))
(S1 (S (S (SBAR (IN As) (S (NP (NN cortisol)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ physiological) (NN regulation)) (PP (IN of) (NP (NNS cytokines))))))))) (, ,) (S (NP (DT a) (NN study)) (VP (VBD was) (VP (VBN conducted))) (SBAR (S (VP (TO to) (VP (VB examine) (NP (NP (NP (NN cytokine)) (NNS patterns)) (PP (IN in) (NP (NP (NP (CD two) (NNS groups)) (PP (IN of) (NP (JJ hypercortisolemic) (NNS patients)))) (, ,) (NP (NP (NP (CD one)) (PP (IN with) (NP (NP (JJ normal) (NN sensitivity)) (PP (TO to) (NP (NNS glucocorticoids)))))) (CC and) (NP (NP (DT the) (JJ other)) (PP (IN with) (NP (NN glucocorticoid) (NN resistance))))))))))))) (. .))))
(S1 (S (S (NP (NP (CD Ten) (NP (NP (NP (JJ HIV-infected) (NNS patients)) (PP (IN with) (NP (NP (JJ normal) (NN receptor) (NN affinity)) (PP (TO to) (NP (NNS glucocorticoids)))))) (PRN (-LRB- -LRB-) (NP (NN AIDS-C)) (-RRB- -RRB-)))) (, ,) (NP (CD 10) (NP (NP (NP (JJ HIV-infected) (NNS patients)) (PP (IN with) (NP (NP (JJ low) (NN receptor) (NN affinity)) (PP (TO to) (NP (NNS glucocorticoids)))))) (PRN (-LRB- -LRB-) (NP (NN AIDS-GR)) (-RRB- -RRB-)))) (, ,) (CC and) (NP (CD 20) (JJ healthy) (NNS subjects))) (VP (VBD were) (VP (VBN studied))) (. .))))
(S1 (S (S (NP (NP (NN Receptor) (NNS characteristics)) (PP (IN of) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)))) (VP (VBD were) (VP (VBN evaluated) (PP (IN by) (NP (NN -LSB-3H-RSB-dexamethasone) (NN binding))))) (. .))))
(S1 (S (S (NP (NP (NN Serum) (NN cortisol)) (CC and) (NP (JJ urinary) (JJ free) (NN cortisol))) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (NN RIA))))) (. .))))
(S1 (S (S (S (NP (NN Serum) (NP (NN ACTH)) (CC and) (NP (NN IgE))) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (JJ immunoradiometric) (NN assay)))))) (, ,) (CC and) (S (NP (NP (NP (NP (NN IL-2))) (, ,) (NP (NP (NN IL-4))) (, ,) (CC and) (NP (NP (NN IL-10))) (NP (NNS cytokines))) (CC and) (NP (NN interferon-gamma))) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (ADJP (ADJP (JJ enzyme-linked)) (ADJP (JJ immunosorbent))) (NN assay)))))) (. .))))
(S1 (S (S (S (NP (NN AIDS-C) (NNS patients)) (VP (VBD showed) (NP (NP (JJ low) (NP (NN IL-2))) (CC and) (NP (JJ high) (NP (NP (NN IL-4))) (, ,) (NP (NP (NN IL-10))) (, ,) (CC and) (NP (NP (NN IgE)))) (NP (NNS concentratios))))) (: ;) (S (ADVP (RB conversely)) (, ,) (NP (NN AIDS-GR) (NNS patients)) (VP (VBD showed) (NP (NP (JJ high) (NP (NN IL-2))) (CC and) (NP (JJ low) (NP (NP (NN IL-4))) (CC and) (NP (NP (NN IgE))) (NP (NNS concentrations)))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (PP (IN in) (NP (NN HIV) (NN infection))) (, ,) (NP (JJ elevated) (NN cortisol) (NNS levels)) (VP (VP (VBP suppress) (NP (JJ cell-mediated) (NN immunity))) (CC and) (VP (VBP stimulate) (NP (JJ humoral) (NN immunity))) (, ,) (SBAR (IN whereas) (S (NP (DT this) (NN response)) (VP (VBZ is) (RB not) (VP (VBN detected) (PP (IN in) (NP (JJ cortisol-resistant) (NNS patients)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN cortisol)) (CC and) (NP (PRP$ its) (NNS receptors))) (VP (VBP are) (ADVP (RB critically)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ immune) (NN function))) (PP (IN in) (NP (NN HIV) (NN infection)))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Dominant) (NP (JJ cytotoxic) (NN T) (NN lymphocyte)) (NN response)) (PP (TO to) (NP (NP (DT the) (NP (JJ immediate-early) (JJ trans-activator) (NN protein))) (, ,) (NP (NN BZLF1)))) (, ,) (PP (IN in) (NP (JJ persistent) (NN type) (NP (NN A)) (CC or) (NP (NN B)) (NP (JJ Epstein-Barr) (NN virus) (NN infection)))) (. .)))))
(S1 (S (S (S (NP (CD Five) (JJ healthy) (JJ human) (NN leukocyte) (NN antigen-B8) (-LRB- -LRB-) (NN HLA-B8) (-RRB- -RRB-) (JJ -positive) (NN virus) (NNS carriers)) (VP (VBD were) (VP (VBN studied)) (S (VP (TO to) (VP (VB investigate) (NP (NP (NP (NP (DT the) (NP (JJ CD8+) (JJ cytotoxic) (NN T) (NN lymphocyte))) (PRN (-LRB- -LRB-) (NP (NN CTL)) (-RRB- -RRB-))) (NN response)) (PP (TO to) (NP (NP (NP (DT an) (JJ HLA-B8-restricted) (NN peptide)) (, ,) (NP (NN RAKFKQLLQ))) (, ,) (ADJP (JJ located) (PP (IN in) (NP (NP (DT the) (NP (JJ Epstein-Barr) (NN virus) (-LRB- -LRB-) (NN EBV) (-RRB- -RRB-) (JJ immediate-early) (NN trans-activator) (NN protein))) (, ,) (NP (NN BZLF1)))))))))))) (. .)))))
(S1 (S (S (PP (IN Of) (NP (DT the) (CD 5) (NN virus) (NNS carriers))) (, ,) (S (S (NP (CD 4)) (VP (VBD were) (VP (VBN infected) (PP (IN with) (NP (NN type) (NN A)))))) (CC and) (S (NP (CD 1)) (PP (IN with) (NP (NN type) (NN B) (NN EBV))))) (. .))))
(S1 (S (S (S (VP (VBG Using) (NP (NP (JJ limiting-dilution) (NN analysis)) (PP (IN of) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)))))) (, ,) (S (NP (DT a) (ADJP (ADJP (JJ high)) (ADJP (JJ RAKFKQLLQ-specific))) (NN CTL) (NN precursor) (NN frequency)) (VP (VBD was) (VP (VBN demonstrated) (PP (IN after) (NP (NP (NP (JJ specific) (NN peptide)) (CC or) (NP (JJ autologous) (JJ lymphoblastoid) (NN cell) (NN line)) (NP (NN stimulation))) (PP (IN in) (NP (CC both) (NP (NN type) (NN A)) (CC and) (NP (NN type) (NN B)) (NP (NN EBV) (NNS carriers))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ RAKFKQLLQ-specific) (NN CTL) (NN precursor) (NNS frequencies)) (PP (IN in) (NP (DT all) (CD 5) (NNS persons)))) (VP (VBD were) (ADJP (ADJP (ADVP (IN at) (JJS least)) (RB as) (JJ dominant)) (PP (IN as) (NP (NP (DT those)) (VP (VBN observed) (PP (IN with) (NP (NP (CD two) (JJ other) (NP (JJ EBV-associated) (, ,) (JJ HLA-B8-restricted) (JJ latent) (NNS epitopes))) (, ,) (NP (NP (NN FLRGRAYGL)) (CC and) (NP (NN QAKWRLQTL)))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (JJ healthy) (NN virus) (NNS carriers)) (VP (VBP maintain) (NP (NP (DT a) (JJ high) (NN frequency)) (PP (IN of) (NP (JJ BZLF1-specific) (NN memory) (NN T) (NNS cells)))) (, ,) (S (ADVP (RB potentially)) (VP (TO to) (VP (VB control) (NP (NP (NN virus) (VBN spread)) (PP (IN from) (NP (RB lytically) (JJ infected) (NNS cells))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (JJ Molecular) (NN characterization)) (CC and) (NP (NP (NN pattern)) (PP (IN of) (NP (NP (NN tissue) (NN expression)) (PP (IN of) (NP (DT the) (NN gene))))))) (PP (IN for) (NP (NP (NN neutrophil) (JJ gelatinase-associated) (NN lipocalin)) (PP (IN from) (NP (NNS humans))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Neutrophil) (JJ gelatinase-associated) (NN lipocalin)) (PRN (-LRB- -LRB-) (NP (NN NGAL)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (NP (JJ 25-kDa) (NN lipocalin))) (VP (ADVP (RB first)) (VBN identified) (PP (IN as) (NP (NP (DT a) (NN protein)) (VP (VBN stored) (PP (IN in) (NP (NP (JJ specific) (NNS granules)) (PP (IN of) (NP (DT the) (NP (JJ human) (NN neutrophil)))))))))))) (. .)))))
(S1 (S (S (NP (DT The) (NN protein)) (VP (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB bind) (NP (NP (JJ small) (JJ lipophilic) (NNS substances)) (PP (JJ such) (IN as) (NP (ADJP (JJ bacterial) (VBN derived)) (NP (NNS formylpeptides)) (CC and) (NP (NP (NNS lipopolysaccharides)) (PRN (-LRB- -LRB-) (NP (NNS LPS)) (-RRB- -RRB-))))))))))) (CC and) (VP (MD might) (NP (NN function) (PP (IN as) (NP (NP (DT a) (NN modulator)) (PP (IN of) (NP (NN inflammation)))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB characterize) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN NGAL)))) (ADVP (RB further))))) (, ,) (S (NP (PRP we)) (VP (VBP have) (VP (VP (VBN cloned)) (CC and) (VP (VBN sequenced)) (NP (NP (DT a) (NP (JJ 5869-bp) (NN region))) (PP (IN of) (NP (DT the) (NP (NN NGAL) (NN gene)))) (PP (VBG including) (NP (NP (NP (CD 1695) (NN bp)) (PP (IN of) (NP (DT the) (NP (JJ 5') (JJ nontranscribed) (NN region))))) (CC and) (NP (NP (DT a) (NP (JJ 3696-bp) (VBG coding) (NN region))) (VP (VBG encompassing) (NP (CD seven) (NNS exons) (CC and) (CD six) (NNS introns)))))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (JJ transcriptional) (NN start) (NNS sites))) (VP (VBD were) (VP (VBN identified) (PP (IN by) (NP (DT an) (NP (NN RNase)) (NN protection) (NN assay))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN NGAL)) (NN gene)) (VP (VBZ is) (ADJP (RB highly) (JJ homologous) (PP (TO to) (NP (DT the) (NP (NN mouse) (NN gene) (NN 24p3)))))) (. .))))
(S1 (S (S (NP (NN NGAL)) (VP (VBD was) (VP (VBN expressed) (PP (PP (IN in) (NP (NN bone) (NN marrow))) (CC and) (PP (IN in) (NP (NP (NNS tissues)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ prone) (PP (TO to) (NP (NP (NN exposure)) (PP (TO to) (NP (NNS microorganisms)))))))))))))) (. .))))
(S1 (S (S (NP (JJ Potential) (NP (JJ cis-acting) (NNS elements))) (VP (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NP (NN promoter) (NN region))) (PP (IN of) (NP (DT the) (NP (NN NGAL) (NN gene)))))) (PP (IN by) (NP (NN computer) (NN analysis))))) (CC and) (VP (VBP include) (NP (NP (VBG binding) (NNS sites)) (PP (IN for) (NP (NP (NN CTF/CBP)) (, ,) (NP (NP (DT the) (NP (JJ hematopoietic) (NN transcription) (NNS factors))) (NP (NP (NN GATA-1)) (CC and) (NP (NN PU.1)))) (, ,) (CC and) (NP (DT the) (NP (JJ LPS-inducible) (NN factor) (NN NF-kappa) (NN B)))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Monocytic) (NN differentiation)) (PP (IN of) (NP (NN HL-60) (JJ promyelocytic) (NN leukemia) (NNS cells)))) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN Bcl-xL)))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Treatment)) (PP (IN of) (NP (JJ human) (JJ promyelocytic) (NN leukemia) (NN HL-60) (NNS cells))) (PP (IN with) (NP (NN phorbol) (NNS esters)))) (ADVP (RB ultimately)) (VP (VBZ induces) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (NP (DT these) (NNS cells)) (PP (IN along) (NP (DT the) (NP (NN monocyte/macrophage) (NN lineage))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ retinoic) (NN acid)) (CC or) (NP (NN DMSO))))) (VP (VBZ induces) (NP (JJ granulocytic/neutrophillic) (NN differentiation)))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (NP (NP (DT the) (JJ disparate) (NNS fates)) (PP (IN of) (NP (NP (NN HL-60) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT the) (NN phorbol) (NN ester) (NN 12,13-phorbol) (JJ dibutyric) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN PDBu)) (-RRB- -RRB-))) (CC or) (NP (NN DMSO))))))))) (. .))))
(S1 (S (S (PP (IN After) (NP (NN DMSO) (NN treatment))) (, ,) (NP (NN HL-60) (NNS cells)) (ADVP (RB eventually)) (VP (VBD died) (PP (IN via) (NP (NN apoptosis))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN viability)) (PP (IN of) (NP (JJ PDBu-treated) (NNS cells)))) (VP (VBD was) (RB not) (VP (VBN affected) (PP (IN during) (NP (DT the) (JJ same) (NN interval)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS levels)) (PP (IN of) (NP (NP (DT the) (NN apoptosis) (NN effector) (NNS proteins)) (NP (NP (NN Bak)) (CC and) (NP (NN Bad)))))) (VP (VBD were) (VP (VBN enhanced)) (, ,) (SBAR (IN whereas) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (JJ slight) (NN down-regulation)) (PP (IN of) (NP (NP (DT the) (NP (NN apoptosis) (NN suppressor) (NN protein))) (NP (NN Bcl-2))))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN of) (NP (DT the) (NNS cells))) (PP (IN with) (NP (NP (NN PDBu)) (CC and) (NP (NN DMSO)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN DMSO)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (NP (DT the) (NP (NN apoptosis) (NN effector))) (NP (NN Bax)))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NN PDBu)))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB alter) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (DT this) (NN protein))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NN treatment)) (PP (IN of) (NP (NN HL-60) (NNS cells))) (PP (IN with) (NP (NN PDBu)))) (VP (VBD induced) (NP (NP (DT the) (JJ rapid) (NN expression)) (PP (IN of) (NP (NP (DT the) (NP (NN apoptosis) (NN suppressor) (NN protein))) (NP (NN Bcl-xL))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT this) (NN protein)))) (VP (VBD remained) (ADJP (JJ unaltered) (PP (IN in) (NP (JJ DMSO-treated) (NNS cells)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN generality)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBD was) (VP (VBN confirmed) (PP (IN by) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN Bcl-xL))) (PP (IN in) (NP (NP (JJ human) (JJ myeloid) (NN U-937) (NNS cells)) (, ,) (NP (NP (JJ human) (JJ peripheral) (NN blood) (NNS monocytes)) (VP (VBN exposed) (PP (TO to) (NP (NN phorbol) (NN ester))))) (, ,) (CC and) (NP (NN mouse) (JJ thioglycollate-activated) (CC and) (JJ resident) (JJ peritoneal) (NNS macrophages)))))))) (. .))))
(S1 (S (S (NP (JJ PDBu-treated) (NN HL-60) (NNS cells)) (VP (VP (VBD remained) (ADJP (JJ viable) (PP (IN for) (NP (CD 7) (NNS days))))) (CC and) (ADVP (RB thereafter)) (VP (VBD began) (S (VP (TO to) (VP (VB die) (PP (IN via) (NP (NN apoptosis))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ concomitant) (NN down-regulation)) (PP (IN of) (NP (NN Bcl-xL)))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP (NP (NN Bcl-xL)) (NN expression)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN differentiation)) (CC and) (NP (NN survival))) (PP (IN of) (NP (NP (JJ hematopoietic) (NNS cells)) (PP (IN along) (NP (DT the) (NP (NN monocyte/macrophage) (NN lineage))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (DT The) (JJ spatial) (NN distribution)) (PP (IN of) (NP (JJ human) (NN immunoglobulin) (NNS genes))) (PP (IN within) (NP (DT the) (NN nucleus))) (: :)) (NP (NP (NN evidence)) (PP (IN for) (NP (NP (NN gene) (NN topography)) (ADJP (JJ independent) (PP (IN of) (NP (NP (NN cell) (NN type)) (CC and) (NP (JJ transcriptional) (NN activity)))))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (JJ three-dimensional) (NN positioning)) (PP (IN of) (NP (NN immunoglobulin) (-LRB- -LRB-) (NN Ig) (-RRB- -RRB-) (NNS genes))) (PP (IN within) (NP (NP (DT the) (NN nucleus)) (PP (IN of) (NP (JJ human) (NNS cells)))))) (VP (VBD was) (VP (VBN investigated)) (S (VP (VBG using) (NP (NP (ADJP (FW in) (FW situ)) (NN hybridization)) (CC and) (NP (JJ confocal) (NN microscopy)))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN visualization)) (PP (IN of) (NP (NP (NP (ADJP (JJ heavy))) (CC and) (NP (ADJP (JJ light))) (NP (NN chain) (NNS genes))) (PP (IN in) (NP (JJ B-lymphoid) (NNS cells)))))) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (CD three) (NP (NN Ig) (NNS genes))) (VP (VBP are) (ADVP (ADVP (RB differentially)) (CC and) (ADVP (RB nonrandomly))) (VP (VBN distributed) (PP (IN in) (NP (JJ different) (JJ nuclear) (NNS subvolumes))))))))) (: :) (S (NP (DT the) (NP (NN kappa) (NNS genes))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADVP (RB preferentially)) (VP (VBN confined) (PP (TO to) (NP (DT an) (JJ outer) (JJ nuclear) (NN volume)))))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NP (NN gamma)) (CC and) (NP (NN lambda)) (NP (NNS genes))) (ADVP (RB consistently)) (VP (VBD occupied) (NP (NP (ADJP (RBR more) (JJ central)) (NNS positions)) (PP (IN within) (NP (DT the) (NN nucleus)))) (, ,) (S (NP (DT the) (NP (NN lambda) (NNS genes))) (VP (VBG being) (ADJP (RBR more) (JJ interior)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (DT the) (NP (NN gamma) (NNS genes)))))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NNS data)) (ADVP (RB further)) (VP (VBP show) (SBAR (IN that) (S (NP (DT these) (ADJP (ADJP (JJ overall)) (ADJP (JJ topographical))) (NNS distributions)) (VP (VP (VBP are) (ADJP (JJ independent) (PP (IN of) (NP (NN gene) (JJ transcriptional) (NN activity))))) (CC and) (VP (VBP are) (VP (VBN conserved) (PP (IN in) (NP (JJ different) (NN cell) (NNS types))))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (JJ subtle) (NN gene) (NNS movements)) (PP (IN within) (NP (DT those) (ADJP (ADJP (VBN defined)) (ADJP (JJ topographical))) (NNS regions)))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN excluded) (PP (IN by) (NP (DT this) (NN study)))))))) (, ,) (S (NP (DT the) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN tissue) (NN specificity)) (PP (IN of) (NP (NN gene) (NN expression)))) (VP (VBZ is) (RB not) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ drastic) (NNS changes)) (PP (IN in) (NP (NN gene) (JJ nuclear) (NN topography))))))))) (, ,) (S (ADVP (RB rather)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (NN gene) (NN organization)) (PP (IN within) (NP (DT the) (NN nucleus)))) (VP (MD may) (VP (VB be) (ADJP (RB primarily) (JJ dependent) (PP (IN on) (NP (NP (JJ structural) (NNS constraints)) (VP (VBN imposed) (PP (IN on) (NP (DT the) (JJ respective) (NP (NNS chromosomes)))))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Epstein-Barr) (NN virus)) (NP (NN EBNA3C))) (VP (VP (VBZ represses) (NP (NP (NN Cp)) (, ,) (NP (NP (DT the) (JJ major) (NN promoter)) (PP (IN for) (NP (NP (NN EBNA)) (NN expression)))))) (, ,) (CC but) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN promoter)) (PP (IN of) (NP (DT the) (NP (NN cell) (NN gene) (NN CD21)))))))) (. .)))))
(S1 (S (S (S (NP (NN EBNA3C)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN repressor)) (PP (IN of) (NP (NN transcription)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN bound) (PP (TO to) (NP (NN DNA))) (PP (IN as) (NP (NP (DT a) (NN fusion)) (PP (IN with) (NP (NP (DT the) (NP (NP (NN DNA) (NN binding) (NN domain)) (PRN (-LRB- -LRB-) (NP (NN DBD)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN GALA))))))))))) (. .)))))
(S1 (S (S (NP (NP (DT A) (NN survey)) (PP (IN of) (NP (NNS promoters)))) (VP (VBZ has) (VP (VBN revealed) (SBAR (IN that) (S (NP (DT the) (NP (JJ wild-type) (, ,) (JJ unfused) (NN EBNA3C))) (VP (MD can) (ADVP (RB specifically)) (VP (VB repress) (NP (NP (NN expression)) (PP (IN from) (NP (NP (NN reporter) (NNS plasmids)) (VP (VBG containing) (NP (DT the) (JJ Epstein-Barr) (NN virus) (NP (NN Cp) (JJ latency-associated) (NN promoter))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Repression)) (PP (IN of) (NP (NP (NN Cp)) (NN activity)))) (VP (VBD required) (NP (NP (NN amino) (NNS acids) (CD 207) (TO to) (CD 368)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encompasses) (NP (NP (NP (DT a) (NN region)) (VP (VBG resembling) (NP (NP (DT a) (NP (JJ basic) (NN DBD))) (ADJP (JJ adjacent) (PP (TO to) (NP (DT a) (NP (NN leucine) (NN zipper) (NN DNA) (NN binding) (NN motif)))))))) (CC and) (NP (NP (DT a) (NN site)) (SBAR (WHNP (WDT which)) (S (VP (VBZ binds) (PP (TO to) (NP (DT the) (NP (JJ cellular) (NN factor) (NN CBF1/RBP-Jkappa)))))))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN amino) (NNS acids) (CD 207) (TO to) (CD 368)) (VP (VBP are) (ADJP (JJ dispensable)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN protein)) (VP (VBZ is) (VP (VBN bound) (PP (TO to) (NP (NN DNA))) (PP (IN as) (NP (NP (DT a) (NN fusion)) (PP (IN with) (NP (DT the) (NN GAL4) (NP (NN DBD)))))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG implicating) (NP (DT this) (NN region)) (PP (IN in) (NP (NN DNA) (NN binding)))))) (. .))))
(S1 (S (S (NP (NP (NN Mutation)) (PP (IN of) (NP (NP (DT the) (NP (NN CBF1/RBP-Jkappa) (NN binding) (NN site))) (PP (IN in) (NP (NN EBNA3C)))))) (VP (VBD abrogated) (NP (NN repression)) (, ,) (S (ADVP (RB strongly)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN CBF1/RBP-Jkappa)) (VP (VBZ is) (ADJP (JJ necessary) (PP (IN for) (S (VP (VBG targeting) (NP (DT the) (JJ viral) (NN protein)) (PP (TO to) (NP (NN Cp))))))))))))) (. .))))
(S1 (S (S (ADVP (JJ Consistent) (PP (IN with) (NP (DT this) (NN result)))) (, ,) (S (NP (NP (NN mutation)) (PP (IN of) (NP (NP (NP (DT the) (NP (NN EBNA2) (NN response) (NN element))) (PRN (-LRB- -LRB-) (NP (DT a) (NP (NN CBF1/RBP-Jkappa) (NN binding) (NN site))) (-RRB- -RRB-))) (PP (IN in) (NP (NN Cp)))))) (ADVP (RB also)) (VP (VBD prevented) (NP (JJ significant) (NN repression)))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN amino) (NNS acids) (CD 346) (TO to) (CD 543)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (ADVP (RB previously)) (VP (VBN defined) (PP (IN as) (S (ADJP (JJ important) (PP (IN for) (NP (NP (DT the) (NN repressor) (NN activity)) (PP (IN of) (NP (DT the) (NP (NN GAL4-EBNA3C) (NN fusion) (NNS proteins))))))))))))) (, ,)) (ADVP (RB also)) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (ADJP (JJ necessary) (PP (IN for) (NP (NP (DT the) (NN repression)) (PP (IN of) (NP (NN Cp)))))))))) (. .))))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NN repression)) (PP (IN by) (NP (DT these) (NNS fusions)))) (VP (VBD was) (RB not) (VP (VBN observed) (PP (IN in) (NP (DT all) (NN cell) (NNS types))))))) (, ,) (S (NP (NP (PRP it))) (VP (VBZ seems) (ADJP (RB likely)) (SBAR (IN that) (S (NP (NN EBNA3C)) (VP (CC either) (VP (VBZ depends) (PP (IN on) (NP (NP (DT a) (NP (NN corepressor))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN amino) (NNS acids) (CD 346) (TO to) (CD 543)))))))))) (CC or) (VP (VBZ is) (VP (VBN modified) (PP (IN in) (NP (DT a) (JJ cell-specific) (NN manner)))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB repress))))))))))) (. .))))
(S1 (S (S (S (NP (DT These) (NNS data)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (NN EBNA3C)) (VP (VBG contributing) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NP (NN EBNA)) (NN expression)) (PP (IN in) (NP (RB latently) (JJ infected) (NN B) (NNS cells))))) (PP (IN through) (NP (NP (NN CBF1/RBP-Jkappa)) (CC and) (NP (DT another) (NN factor)))))))))))) (, ,) (CC but) (S (NP (DT this)) (VP (VBP need) (S (RB not) (ADVP (RB directly)) (VP (VB involve) (NP (NN EBNA2)))))) (. .))))
(S1 (S (S (ADVP (RB Finally)) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NN EBNA3C)) (VP (MD can) (VP (VB upregulate) (NP (NN CD21)) (PP (IN in) (NP (DT some) (NP (NN B) (NNS cells))))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (DT any) (NN effect)) (PP (IN of) (NP (NN EBNA3C))) (PP (IN on) (NP (NP (NN reporter) (NNS plasmids)) (SBAR (WHNP (WDT which)) (S (VP (VBP contain) (NP (DT the) (NP (NN CD21) (NN promoter))))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Late) (NN gene) (NN expression)) (PP (IN from) (NP (DT the) (JJ Epstein-Barr) (NN virus) (NP (NN BcLF1)) (CC and) (NP (NN BFRF3)) (NP (NNS promoters))))) (VP (VBZ does) (RB not) (VP (VB require) (NP (NP (NN DNA) (NN replication)) (PP (IN in) (NP (NN cis)))))) (. .)))))
(S1 (S (S (S (NP (JJ Late) (NN gene) (NN expression)) (VP (VP (VBZ follows)) (CC and) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN upon) (NP (NP (JJ lytic) (NN replication)) (PP (IN of) (NP (DT the) (NP (JJ viral) (NN genome))))))))) (. .)))))
(S1 (S (S (SBAR (IN Although) (S (NP (JJ experimental) (NN evidence)) (VP (VBZ is) (ADJP (JJ lacking))))) (, ,) (S (NP (JJ lytic) (JJ viral) (NN DNA) (NN replication)) (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB remove) (NP (NP (NP (NNS modifications)) (CC or) (NP (VBG binding) (NNS factors))) (PP (IN from) (NP (DT the) (NN genome))))))))) (SBAR (WHNP (WDT which)) (S (VP (VBP serve) (S (VP (TO to) (VP (VB repress) (NP (JJ late) (NN gene) (NN expression)) (PP (IN during) (NP (NP (NN latency)) (CC or) (NP (DT the) (JJ early) (JJ lytic) (NN cycle))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN developed) (NP (DT a) (NN reporter) (NN assay))) (S (VP (TO to) (VP (VB begin) (VP (VBG characterizing) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (NP (JJ late) (NN gene) (NN expression)) (PP (IN in) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-)))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN model) (NN system))) (, ,) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (JJ late) (JJ promoter-reporter) (NNS fusions)))) (VP (VBP are) (VP (VBN measured) (PP (VBG following) (NP (NP (JJ transient) (NN transfection)) (PP (IN into) (NP (NP (NN tissue) (NN culture) (NNS cells)) (VP (VBG expressing) (NP (NN EBV)) (PP (IN during) (NP (NP (JJ different) (NNS stages)) (PP (IN of) (NP (DT the) (JJ lytic) (NN cycle)))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN system)) (ADVP (RB faithfully)) (VP (VBZ recapitulates) (NP (NP (JJ late) (NN expression) (NNS patterns)) (PP (IN from) (NP (DT the) (JJ endogenous) (NN virus)))) (, ,) (S (VP (VBG implicating) (NP (JJ specific) (NP (JJ cis-active) (NNS sequences))) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (JJ late) (NN gene) (NN expression)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT these) (NNS promoters)) (VP (VBP respond) (ADVP (RB only) (RB indirectly)) (PP (TO to) (NP (NP (DT the) (NP (JJ viral) (JJ immediate-early) (NN transactivator))) (, ,) (NP (NN ZEBRA))))) (. .))))
(S1 (S (S (NP (DT This) (JJ indirect) (NN response)) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ other) (NP (ADJP (JJ viral))) (CC or) (NP (ADJP (RB virally) (VBN induced))) (NP (NP (NNS activities)) (ADVP (JJ downstream) (PP (IN of) (NP (NN ZEBRA)))))) (PP (IN in) (NP (DT the) (JJ lytic) (NN cascade))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN system))) (, ,) (NP (JJ late) (NN gene) (NN expression)) (VP (VBZ is) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT the) (NP (JJ viral) (NN DNA) (NN polymerase))))) (PP (JJ such) (IN as) (NP (JJ phosphonoacetic) (NN acid)))))) (, ,) (SBAR (IN although) (S (NP (DT the) (NNS reporters)) (VP (VP (VBP lack) (NP (NP (DT a) (JJ eukaryotic) (NN origin)) (PP (IN of) (NP (NN replication))))) (CC and) (VP (VBP are) (RB not) (VP (VBN replicated) (PP (IN under) (NP (DT the) (NN assay) (NNS conditions))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (S (S (NP (NP (NN replication)) (PP (IN of) (NP (DT the) (NP (JJ transcriptional) (NN template))))) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN prerequisite)) (PP (IN for) (NP (NP (NN expression)) (PP (IN with) (NP (JJ late) (NNS kinetics)))))))) (, ,) (NP (NP (DT a) (NN finding)) (ADJP (JJ inconsistent) (PP (IN with) (NP (NP (DT the) (JJ current) (NNS models)) (SBAR (WHNP (WDT which)) (S (VP (VBP posit) (NP (NP (DT a) (JJ cis-active) (NN relationship)) (PP (IN between) (NP (NP (JJ lytic) (NN EBV) (NN DNA) (NN replication)) (CC and) (NP (JJ late) (NN gene) (NN expression))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Rather)) (, ,) (NP (NP (NN analysis)) (PP (IN of) (NP (DT this) (NN system)))) (VP (VP (VBZ has) (VP (VBN revealed) (NP (NP (DT a) (JJ trans) (NN relationship)) (PP (IN between) (NP (NP (JJ late) (NN gene) (NN expression)) (CC and) (NP (JJ viral) (NN DNA) (NN replication))))))) (CC and) (VP (VBZ highlights) (NP (NP (DT the) (ADJP (ADJP (JJ indirect)) (CC and) (ADJP (JJ complex))) (NN link)) (PP (IN between) (NP (DT these) (CD two) (NNS events)))))) (. .))))
(S1 (S (NP (NP (NP (NP (NN Purification)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (DT the) (NP (JJ human) (NN SR) (JJ 31747A-binding) (NN protein)))) (. .)))))
(S1 (S (NP (NP (DT A) (NP (JJ nuclear) (NN membrane) (NN protein))) (ADJP (JJ related) (PP (TO to) (NP (NN yeast) (NN sterol) (NN isomerase)))) (. .))))
(S1 (S (S (S (NP (NP (NN SR) (NN 31747A)) (, ,) (VP (VBN defined) (PP (IN as) (NP (DT a) (NN sigma) (NN ligand)))) (, ,)) (VP (VBZ is) (NP (NP (DT a) (ADJP (ADJP (JJ novel)) (ADJP (JJ immunosuppressive))) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ blocks) (NP (NP (NN proliferation)) (PP (IN of) (NP (NP (ADJP (JJ human))) (CC and) (NP (NN mouse)) (NP (NNS lymphocytes)))))))))) (. .)))))
(S1 (S (S (S (VP (VBG Using) (NP (DT a) (ADJP (ADJP (JJ radiolabeled)) (ADJP (JJ chemical))) (NN probe)))) (, ,) (S (NP (PRP we)) (ADVP (RB here)) (VP (VP (VBD purified) (NP (NP (DT a) (NN target)) (PP (IN of) (NP (NN SR) (NN 31747A))))) (CC and) (VP (VBD called) (S (NP (PRP it)) (NP (NP (NN SR) (JJ 31747A-binding) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN SR-BP)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (VBN Purified) (NN SR-BP)) (VP (VP (VBD retained) (NP (PRP$ its) (NN binding) (NNS properties))) (CC and) (VP (VBD migrated) (PP (IN on) (NP (JJ SDS-polyacrylamide) (NN gel))) (PP (IN as) (NP (DT a) (NP (NN Mr) (CD 28,000) (NN protein)))))) (. .))))
(S1 (S (S (NP (NP (NN Cloning)) (PP (IN of) (NP (NP (DT the) (NP (NN cDNA))) (VP (VBG encoding) (NP (JJ human) (NN SR-BP)))))) (VP (VBZ shows) (NP (DT an) (NP (JJ open) (NN reading) (NN frame))) (PP (IN for) (NP (NP (DT a) (NP (NN 223-amino) (NN acid) (NN protein))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ homologous) (PP (TO to) (NP (DT the) (ADJP (RB recently) (VBN cloned)) (NP (NN sigma) (CD 1) (NN receptor))))))))))) (. .))))
(S1 (S (S (ADVP (RB Interestingly)) (, ,) (NP (DT the) (VBN deduced) (NN amino) (NN acid) (NN sequence)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ related) (PP (TO to) (NP (NP (JJ fungal) (NN C8-C7) (NN sterol) (NN isomerase)) (, ,) (VP (VBN encoded) (PP (IN by) (NP (DT the) (NP (NN ERG2) (NN gene))))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN ERG2) (NN gene) (NN product))) (VP (VBZ has) (VP (VBN been) (VP (VBN identified) (ADVP (RB recently)) (PP (IN as) (NP (NP (DT the) (JJ molecular) (NN target)) (PP (IN of) (NP (NP (NN SR) (NN 31747A)) (SBAR (WHNP (WDT that)) (S (VP (VBZ mediates) (NP (NP (JJ antiproliferative) (NNS effects)) (PP (IN of) (NP (DT the) (NN drug)))) (PP (IN in) (NP (NN yeast))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Northern) (NN blot) (NN analysis)) (PP (IN of) (NP (NP (NN SR-BP)) (NN gene) (NN expression)))) (VP (VBD revealed) (NP (NP (DT a) (JJ single) (NN transcript)) (PP (IN of) (NP (CD 2) (NNS kilobases))) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (RB widely)) (VP (VBN expressed) (PP (IN among) (NP (NNS organs))) (, ,) (PP (IN with) (NP (NP (NP (DT the) (JJS highest) (NN abundance)) (PP (IN in) (NP (NN liver)))) (CC and) (NP (NP (DT the) (JJS lowest) (NN abundance)) (PP (IN in) (NP (NN brain)))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Subcellular) (NN localization) (NN analysis)) (PP (IN in) (NP (JJ various) (NNS cells))) (, ,) (VP (VBG using) (NP (NP (DT a) (NP (JJ specific) (JJ monoclonal) (NN antibody))) (VP (VBN raised) (PP (IN against) (NP (NN SR-BP)))))) (, ,)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT this) (NN protein)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (DT the) (JJ nuclear) (NN envelope)))))))) (. .))))
(S1 (S (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBG studying) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NP (NN SR) (NN 31747A)) (PP (IN on) (NP (NP (NNS membranes)) (PP (IN from) (NP (NP (NN yeast)) (VP (VBG expressing) (NP (NN SR-BP))))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD found) (NP (NP (DT a) (JJ pharmacological) (NN profile)) (PP (IN of) (NP (NN sigma) (CD 1) (NNS receptors))))))) (: ;) (S (NP (NN binding)) (VP (VBD was) (VP (VBN displaced) (PP (IN by) (NP (NP (NN -LRB-+-RRB--pentazocine)) (, ,) (NP (NN haloperidol)) (, ,) (CC and) (NP (NN -LRB-+-RRB--SKF) (CD 10,047)))) (, ,) (PP (IN with) (S (NP (NN -LRB-+-RRB--SKF) (CD 10,047)) (VP (VBG being) (NP (NP (DT a) (ADJP (RBR more) (JJ potent)) (NN competitor)) (PP (IN than) (NP (NN -LRB---RRB--SKF) (CD 10,047)))))))))) (. .))))
(S1 (S (S (NP (NN Scatchard) (NN plot) (NN analysis)) (VP (VBD revealed) (NP (NP (NN Kd) (NNS values)) (PP (IN of) (NP (NP (CD 7.1) (NN nM)) (CC and) (NP (CD 0.15) (NN nM)))) (PP (IN for) (NP (NP (NN -LRB-+-RRB--pentazocine)) (CC and) (NP (NN SR) (NN 31747A))))) (, ,) (ADVP (RB respectively)) (, ,) (S (VP (VBG indicating) (NP (NP (DT an) (NN affinity)) (PP (IN of) (NP (NN SR-BP))) (ADJP (ADJP (NP (RB 50-fold)) (JJR higher)) (PP (IN for) (NP (NN SR) (NN 31747A))) (PP (IN than) (PP (IN for) (NP (NN pentazocine))))))))) (. .))))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN pentazocine)) (, ,) (NP (NP (DT a) (JJ competitive) (NN inhibitor)) (PP (IN of) (NP (NN SR) (NN 31747A) (NN binding)))) (, ,)) (ADVP (RB also)) (VP (VBZ prevents) (NP (NP (DT the) (JJ immunosuppressive) (NN effect)) (PP (IN of) (NP (NN SR) (NN 31747A)))))))) (. .))))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (NP (DT these) (NNS findings)) (ADVP (RB strongly)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN SR-BP)) (VP (VBZ represents) (NP (NP (DT the) (JJ molecular) (NN target)) (PP (IN for) (NP (NN SR) (NN 31747A)))) (PP (IN in) (NP (JJ mammalian) (NNS tissues))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB be) (ADJP (JJ critical) (PP (IN for) (NP (NN T) (NN cell) (NN proliferation))))))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NP (NN tax) (NN protein))) (PP (IN of) (NP (JJ human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD 1)))) (VP (VBZ mediates) (NP (NP (DT the) (NN transactivation)) (PP (IN of) (NP (DT the) (NP (JJ c-sis/platelet-derived) (NN growth) (NN factor-B) (NN promoter))))) (PP (IN through) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (DT the) (NP (NN zinc) (NN finger) (NN transcription) (NNS factors))) (NP (NP (NN Sp1)) (CC and) (NP (NN NGFI-A/Egr-1)))))))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Transcriptional) (NN up-regulation)) (PP (IN of) (NP (DT the) (NP (JJ c-sis/platelet-derived) (NN growth) (NN factor-B) (-LRB- -LRB-) (NN PDGF-B) (-RRB- -RRB-) (NN proto-oncogene)))) (PP (IN by) (NP (NP (DT the) (NP (NN Tax) (NN protein))) (PP (IN of) (NP (JJ human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD 1)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN as) (NP (NP (CD one) (JJ possible) (NN mechanism)) (PP (IN of) (NP (NP (JJ cellular) (NN transformation)) (PP (IN by) (NP (JJ human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD 1)))))))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (JJ previous) (NN work))) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (NP (NP (DT an) (JJ essential) (NN site)) (PP (IN in) (NP (DT the) (NP (NN c-sis/PDGF-B) (NN promoter))))) (, ,) (NP (NP (JJ Tax-responsive) (NN element) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN TRE1)) (-RRB- -RRB-))) (, ,) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NN transactivation)) (PP (IN by) (NP (NN Tax)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD identified) (NP (NP (NN Sp1)) (, ,) (NP (NN Sp3)) (, ,) (CC and) (NP (NN NGFI-A/Egr-1))) (PP (IN as) (NP (NP (NP (DT the) (NP (JJ primary) (JJ nuclear) (NN transcription) (NNS factors))) (VP (VBG binding) (PP (TO to) (NP (NN TRE1))))) (SBAR (WHNP (WDT which)) (S (VP (VBP mediate) (NP (NP (NN Tax)) (NN responsiveness)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN work))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NN mechanism) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (SBAR (WHADVP (WRB whereby)) (S (NP (NN Tax)) (VP (VBZ transactivates) (NP (DT the) (NP (NN c-sis/PDGF-B) (NN proto-oncogene))))))))) (. .))))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NN transcription) (NNS assays)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN Tax)) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB increase) (NP (NP (DT the) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NP (DT a) (NN template)) (VP (VBG containing) (NP (NP (DT the) (NP (CD -257) (TO to) (CD +74) (NN region))) (PP (IN of) (NP (DT the) (NP (NN c-sis/PDGF-B) (NN promoter))))))))))))))))) (. .))))
(S1 (S (S (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay) (NN analysis)) (VP (VBD showed) (SBAR (DT that) (S (NP (NN Tax)) (VP (VBD increased) (NP (NP (DT the) (NN DNA) (NN binding) (NN activity)) (PP (IN of) (NP (CC both) (NP (NN Sp1)) (CC and) (NP (NN NGFI-A/Egr-1))))) (S (VP (VBG using) (NP (DT a) (NP (NN TRE1) (NN probe))))))))) (. .))))
(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NN Tax) (NNS mutants)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (CD two) (NNS mutants)) (, ,) (NP (NP (NN IEXC29S)) (CC and) (NP (NN IEXL320G))) (, ,)) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB transactivate) (NP (DT the) (NP (NN c-sis/PDGF-B) (NN promoter))))))))))) (. .))))
(S1 (S (S (ADVP (RB Finally)) (, ,) (NP (NN co-immunoprecipitation) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN Tax)) (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (ADVP (RB stably)) (VP (VB bind) (PP (TO to) (NP (CC both) (NP (NN Sp1)) (CC and) (NP (NN NGFI-A/Egr-1)))))))))))) (. .))))
(S1 (S (S (ADVP (RB Interestingly)) (, ,) (NP (NN co-immunoprecipitation) (NN analysis)) (ADVP (RB also)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (NP (NN Tax)) (NN mutant)) (NP (NN IEXC29S))) (VP (VBZ is) (ADJP (JJ unable) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN NGFI-A/Egr-1))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (NN Tax)) (NN mutant)) (NP (NN IEXL320G))) (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN NGFI-A/Egr-1)))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Stable) (NN transfection)) (PP (IN of) (NP (NN U937) (NNS cells))) (PP (IN with) (NP (NP (NN sense)) (CC or) (NP (JJ antisense) (NN RXR-alpha) (NN cDNA))))) (VP (VBZ suggests) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN RXR-alpha))) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (JJ monoblastic) (NN differentiation)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ retinoic) (NN acid)) (CC and) (NP (NN vitamin) (NN D))))))))))) (. .)))))
(S1 (S (S (S (SBAR (IN Although) (S (NP (NP (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN known) (S (PP (IN for) (NP (JJ many) (NNS years))) (VP (TO to) (VP (VB be) (NP (NP (DT a) (VBG modulating) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG generating) (NP (CC both) (NP (NNS granulocytes)) (CC and) (NP (NNS monocytes)))))))))))))))))) (, ,) (S (NP (NP (DT the) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (DT this) (NN role)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN defined) (PP (IN in) (NP (DT the) (NP (NN monoblast) (NN lineage)))))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (DT the) (NN part)) (VP (VBN played) (PP (IN by) (NP (NP (DT the) (NP (NP (JJ retinoid) (NN X) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS RXRs)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NP (NN steroid/thyroid) (NN hormone) (JJ nuclear) (NN receptor) (NN family))))))))))) (, ,)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN explored)))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (ADVP (RB therefore)) (, ,) (NP (DT the) (NP (JJ human) (JJ monoblastic) (NN leukemia) (NN cell) (NN line) (NN U937))) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN model) (NN system)) (SBAR (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NP (NNS RXRs))))) (, ,) (NP (NN RXR-alpha)))) (, ,) (PP (IN in) (NP (NN monoblast) (NN differentiation))))))))))))) (. .))))
(S1 (S (S (S (NP (NN RXR-alpha) (NN mRNA)) (VP (VBD was) (ADJP (JJ present) (PP (IN in) (NP (JJ untreated) (NP (NN U937) (NNS cells))))))) (, ,) (CC and) (S (NP (NNS levels)) (VP (VBD increased) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NN differentiation))) (PP (IN with) (NP (NN phorbol) (NN ester))))))) (. .))))
(S1 (S (S (NP (DT The) (JJ same)) (VP (VBD was) (VP (VBN found) (PP (IN for) (NP (NN RXR-beta) (NN mRNA))))) (. .))))
(S1 (S (S (S (VP (VBG Using) (NP (NP (NNS plasmids)) (VP (VBG containing) (NP (NP (NP (NN sense)) (CC or) (NP (JJ antisense) (NN RXR-alpha) (NNS sequences))) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT an) (JJ inducible) (NN promoter)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD generated) (NP (NP (ADJP (RB stably) (VBN transfected)) (NN cell) (NNS lines)) (SBAR (WHNP (WDT which)) (S (VP (VBD expressed) (NP (CC either) (NP (VBN increased)) (CC or) (NP (VBN decreased)) (NP (NP (NNS levels)) (PP (IN of) (NP (NN RXR-alpha))))) (, ,) (ADVP (RB respectively)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN sense) (NN cell) (NNS lines))) (PRN (-LRB- -LRB-) (NP (NP (NN U) (NN alpha) (NN S)) (CC and) (NP (NP (PRP$ its) (JJ clonal) (JJ derivative)) (NP (NN alpha) (NP (NN G2S))))) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (VBN increased) (NN sensitivity)) (PP (TO to) (NP (NN RA)))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NP (JJ antisense) (NN cell) (NNS lines))) (PRN (-LRB- -LRB-) (NP (NP (NN U) (NN alpha) (NN A)) (CC and) (NP (NP (PRP$ its) (JJ clonal) (JJ derivative)) (NP (NN alpha) (NP (NN B5A))))) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (VBN decreased) (NN sensitivity)) (PP (TO to) (NP (NN RA))))))) (, ,) (SBAR (IN as) (VP (VBN demonstrated) (PP (PP (IN by) (NP (NN growth) (NN inhibition))) (CC and) (PP (IN by) (NP (NP (NN regulation)) (PP (IN of) (NP (DT an) (NP (JJ RA-responsive) (NN reporter) (NN gene)))))))))) (. .))))
(S1 (S (S (S (NP (CC Both) (NP (NN U) (NN alpha) (NN A)) (CC and) (NP (NN alpha) (NP (NN B5A)))) (ADVP (RB also)) (VP (VBD failed) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (DT another) (VBG modulating) (NN agent)) (, ,) (NP (NP (CD 1) (NN alpha,25-dihydroxycholecalciferol)) (PRN (-LRB- -LRB-) (NP (NN DHCC)) (-RRB- -RRB-)))))))))) (, ,) (CC but) (S (NP (NP (ADVP (RB only)) (NP (NN U) (NN alpha) (NN S))) (CC and) (RB not) (NP (NN alpha) (NN G2S))) (VP (VBD showed) (NP (NP (DT an) (VBN enhanced) (NN response)) (PP (TO to) (NP (NN DHCC)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NN RA)) (CC and) (NP (NN DHCC))))) (ADVP (RB together)) (VP (VBD inhibited) (NP (NP (NN growth)) (PP (IN of) (NP (CC both) (NP (NN sense)) (CC and) (NP (JJ antisense) (NN cell) (NNS lines)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN alpha) (NN G2S)) (VP (VBD exhibited) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NP (NN CD11b)) (CC and) (NP (NN CD54))))) (, ,) (SBAR (IN while) (S (NP (NN alpha) (NN B5A) (NNS cells)) (VP (VBD showed) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NN CD102))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN RXR-alpha)) (VP (VBZ has) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (NN expression)) (PP (IN of) (NP (NN cell) (NN adhesion) (NNS molecules)))) (PP (IN in) (NP (NN U937) (NNS cells)))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN RXR-alpha)) (VP (VBZ has) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG mediating) (NP (NP (NN growth) (NN inhibition)) (CC and) (NP (NN cell) (NN adhesion))) (PP (IN during) (NP (JJ myelomonocytic) (NN differentiation)))))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ different) (NNS species)) (PP (IN of) (NP (NNS heterodimers))) (VP (VBG involving) (NP (NN RXR-alpha)))) (VP (MD may) (VP (VB control) (NP (NP (DT the) (NN acquisition)) (PP (IN of) (NP (NP (JJ different) (NNS features)) (PP (IN of) (NP (JJ mature) (NN monocyte/macrophage) (NN function)))))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ B-lymphoblastoid) (NN cell) (NNS lines)) (PP (IN from) (NP (NP (JJ multiple) (NN sclerosis) (NNS patients)) (CC and) (NP (DT a) (JJ healthy) (NN control)))) (VP (VBG producing) (NP (NP (DT a) (ADJP (JJ putative) (JJ new)) (JJ human) (NN retrovirus)) (CC and) (NP (JJ Epstein-Barr) (NN virus)))) (. .)))))
(S1 (S (S (S (PP (IN On) (NP (JJ several) (NNS occasions))) (NP (PRP we)) (VP (VBP have) (VP (VBN observed) (NP (NP (JJ retrovirus-like) (NNS particles)) (PRN (-LRB- -LRB-) (NP (NNS RVLPs)) (-RRB- -RRB-))) (PP (IN by) (NP (NP (NP (NN transmission) (NN electron) (NN microscopy)) (PRN (-LRB- -LRB-) (NP (NN EM)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (VBN cultured) (NN T) (NNS cells)) (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NN MS))))))))))) (. .)))))
(S1 (S (S (ADVP (RB Later)) (NP (PRP we)) (VP (VBD established) (NP (ADJP (RB spontaneously) (VBN formed)) (NP (NP (JJ B-lymphoblastoid) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NNS LCLs)) (-RRB- -RRB-)))) (PP (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (DT an) (JJ MS-like) (NN disease))))) (CC and) (PP (IN from) (NP (NP (DT another) (NN patient)) (PP (IN with) (NP (NN MS))) (SBAR (WHNP (WP who)) (S (VP (VBD had) (NP (DT a) (VBN reactivated) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))) (NN infection))))))))) (. .))))
(S1 (S (S (NP (DT Both) (NP (NNS LCLs))) (VP (VBD were) (VP (VBN found) (S (PP (IN by) (NP (NN EM))) (VP (TO to) (VP (VB produce) (NP (NP (NN RVLP)) (CC and) (NP (NN EBV) (NNS particles)))))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Reverse) (NN transcriptase)) (PRN (-LRB- -LRB-) (NP (NN RT)) (-RRB- -RRB-))) (NNS assays)) (VP (VBD were) (ADJP (JJ positive) (PP (IN in) (NP (NP (VBN purified) (JJ viral) (NN material)) (PP (IN from) (NP (DT both) (NP (NNS LCLs)))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB substantiate) (NP (DT these) (NNS findings))))) (S (NP (PRP we)) (VP (VP (VBD initiated) (NP (DT an) (VBN intensified) (NN culturing) (NN procedure))) (CC and) (VP (VBD were) (ADJP (JJ able) (S (VP (TO to) (VP (VB establish) (NP (NNS LCLs)) (PP (IN from) (NP (NP (QP (CD 5) (RB out) (IN of) (CD 21)) (JJ consecutive) (NN MS) (NNS patients)) (CC and) (NP (QP (CD 1) (RB out) (IN of) (CD 13)) (ADJP (JJ consecutive) (JJ healthy)) (NNS controls))))))))))) (. .))))
(S1 (S (S (NP (DT All) (NP (NNS LCLs))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB produce) (NP (CC both) (NP (NN RVLP)) (CC and) (NP (NN EBV) (NNS particles)))))) (PP (IN by) (NP (NN EM))))) (. .))))
(S1 (S (S (S (SBAR (IN Whether) (S (NP (NP (NP (DT the) (ADJP (JJ putative) (JJ new)) (NN retrovirus)) (PRN (-LRB- -LRB-) (NP (NNS es)) (-RRB- -RRB-))) (CC and) (NP (NN EBV))) (VP (VBP have) (NP (NP (DT any) (JJ causal) (NN relationship)) (PP (TO to) (NP (NN MS))))))) (VP (VBZ is) (ADVP (RB still)) (RB not) (VP (VBN known)))) (, ,) (CC but) (S (NP (DT the) (NNS findings)) (VP (VBP support) (NP (DT this) (NN possibility)))) (. .))))
(S1 (S (NP (NP (NP (NN Involvement)) (PP (IN of) (NP (JJ different) (NN transduction) (NNS pathways))) (PP (IN in) (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (PP (IN by) (NP (JJ several) (NP (NNS inducers)))))) (. .)))))
(S1 (S (S (S (NP (NN Double-stimulation)) (VP (VBD was) (VP (VBN used)) (S (VP (TO to) (VP (VB demonstrate) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (NP (DT a) (NP (NN T) (JJ lymphocytic) (NN cell) (NN line))) (PRN (-LRB- -LRB-) (NP (NN CEM)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN phorbol) (NN myristate) (NN acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-))) (ADVP (RB rapidly)) (VP (VBD induced) (NP (NN NF-kappa) (NN B)) (PP (IN through) (NP (DT a) (NN signaling) (NN pathway))) (SBAR (WHNP (WDT which)) (S (VP (VP (VBD did) (RB not) (VP (VB involve) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNS ROS)) (-RRB- -RRB-))))) (CC and) (VP (VBD was) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (NN activation)) (VP (VBN triggered) (PP (IN by) (NP (CC either) (NP (NN H2O2)) (CC or) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-)))))))))))))))))))) (. .)))))
(S1 (S (S (SBAR (IN Since) (S (NP (DT these) (JJ latter) (NNS compounds)) (VP (VBD were) (VP (VBN known) (S (VP (TO to) (VP (VB activate) (NP (NP (NN NF-kappa) (NN B)) (NN translocation)) (PP (IN in) (NP (DT a) (JJ redox-sensitive) (NN way)))))))))) (, ,) (S (NP (PRP we)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (PP (IN by) (NP (NN PMA)))) (VP (VBD was) (ADJP (ADJP (JJ resistant) (PP (TO to) (NP (NP (JJ antioxidant)) (NP (NP (NN N-acetyl-L-cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-)))))) (CC and) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (NN kinase) (NNS inhibitors)) (NP (NP (NN staurosporine)) (CC and) (NP (NN H7))))))) (SBAR (IN while) (S (NP (NP (NN activation)) (PP (IN by) (NP (NP (NN H2O2)) (CC or) (NP (NN TNF-alpha))))) (VP (VBD were) (RB not)))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Association)) (PP (IN of) (NP (NN glucocorticoid) (NN insensitivity))) (PP (IN with) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NN glucocorticoid) (NN receptor) (NN beta))))) (. .)))))
(S1 (S (S (S (PP (IN In) (NP (JJ many) (JJ chronic) (JJ inflammatory) (NNS disorders))) (, ,) (NP (NP (NP (NN glucocorticoid)) (PRN (-LRB- -LRB-) (NP (NN GC)) (-RRB- -RRB-))) (NN insensitivity)) (VP (VBZ is) (NP (NP (DT a) (ADJP (ADJP (JJ challenging)) (ADJP (JJ clinical))) (NN problem)) (VP (VBN associated) (PP (IN with) (NP (JJ life-threatening) (NN disease) (NN progression)))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (JJ molecular) (NN basis)) (PP (IN of) (NP (NN GC) (NN insensitivity))) (, ,)) (ADVP (RB however)) (, ,) (VP (VBZ is) (ADJP (JJ unknown))) (. .))))
(S1 (S (S (NP (NP (JJ Alternative) (NN splicing)) (PP (IN of) (NP (DT the) (NP (NN GC) (NN receptor) (-LRB- -LRB-) (NN R) (-RRB- -RRB-) (NN pre-messenger) (NN RNA))))) (VP (VBZ generates) (NP (NP (DT a) (JJ second) (NP (NN GCR))) (, ,) (VP (VBN termed) (S (NP (NN GCR-beta)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ does) (RB not) (VP (VB bind) (NP (NNS GCs)))) (CC but) (VP (VBZ antagonizes) (NP (NP (DT the) (NN transactivating) (NN activity)) (PP (IN of) (NP (NP (DT the) (JJ classic) (NP (NN GCR))) (, ,) (VP (VBN termed) (S (NP (NN GCR-alpha))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (JJ GC-insensitive) (NN asthma)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN number)) (PP (IN of) (NP (NP (JJ GCR-beta-immunoreactive) (NNS cells)) (PP (IN in) (NP (JJ peripheral) (NN blood)))))) (SBAR (IN than) (S (NP (NP (JJ GC-sensitive) (NNS asthmatics)) (CC or) (NP (JJ normal) (NNS controls)))))))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NNS patients)) (PP (IN with) (NP (JJ GC-insensitive) (NN asthma)))) (VP (VBP have) (NP (JJ cytokine-induced) (NNS abnormalities)) (PP (IN in) (NP (NP (DT the) (NN DNA) (NN binding) (NN capability)) (PP (IN of) (NP (DT the) (NP (NN GCR)))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS abnormalities)) (VP (MD can) (VP (VB be) (VP (VBN reproduced) (PP (IN by) (NP (NP (NN transfection)) (PP (IN of) (NP (NN cell) (NNS lines))) (PP (IN with) (NP (DT the) (NP (NN GCR-beta)) (NN gene))))))) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ significant) (NN reduction)) (PP (IN of) (NP (PRP$ their) (NP (NN GCR-alpha)) (NN DNA) (NN binding) (NN capacity)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NN GCR-beta)))) (VP (VP (VBZ is) (ADJP (NP (NN cytokine)) (JJ inducible))) (CC and) (VP (MD may) (VP (VB account) (PP (IN for) (NP (NP (NN GC) (NN insensitivity)) (PP (IN in) (NP (DT this) (ADJP (ADJP (JJ common)) (ADJP (JJ inflammatory))) (NN condition))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (NN T) (NN cell))))) (CC and) (NP (NP (NN promotion)) (PP (IN of) (NP (JJ natural) (NN killer) (NN cell) (NN development))))) (PP (IN by) (NP (NP (DT the) (NP (JJ dominant) (JJ negative) (NN helix) (NN loop) (NN helix) (NN factor))) (NP (NN Id3)))) (. .)))))
(S1 (S (S (S (NP (JJ Bipotential) (JJ T/natural) (NN killer) (-LRB- -LRB-) (NN NK) (-RRB- -RRB-) (NN progenitor) (NNS cells)) (VP (VBP are) (ADJP (JJ present) (PP (IN in) (NP (DT the) (JJ human) (NN thymus))))) (. .)))))
(S1 (S (S (PP (IN Despite) (NP (PRP$ their) (JJ bipotential) (NN capacity))) (, ,) (NP (DT these) (NNS progenitors)) (VP (VBP develop) (PP (ADVP (RB predominantly)) (TO to) (NP (NN T) (NNS cells))) (PP (IN in) (NP (DT the) (NN thymus)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS mechanisms)) (VP (VBG controlling) (NP (DT this) (JJ developmental) (NN choice)))) (VP (VBP are) (ADJP (JJ unknown))) (. .))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP present) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (DT a) (NN member) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (NN family)) (PP (IN of) (NP (JJ basic) (NN helix) (NN loop) (NN helix) (-LRB- -LRB-) (JJ bHLH) (-RRB- -RRB-) (NN transcription) (NNS factors)))))) (VP (VBZ determines) (NP (NP (NN lineage) (NN specification)) (PP (IN of) (NP (NN NK/T) (NN cell) (NNS progenitors))))))))) (. .))))
(S1 (S (S (NP (NP (NP (DT The) (JJ natural) (NP (JJ dominant) (JJ negative) (JJ HLH) (NN factor))) (NP (NN Id3))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ blocks) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ known) (NP (JJ bHLH) (NNS factors)))))))))) (, ,)) (VP (VBD was) (VP (VBN expressed) (PP (IN in) (NP (JJ CD34+) (NN progenitor) (NNS cells))) (PP (IN by) (NP (JJ retrovirus-mediated) (NN gene) (NN transfer))))) (. .))))
(S1 (S (S (NP (NP (JJ Constitutive) (NN expression)) (PP (IN of) (NP (NN Id3)))) (ADVP (RB completely)) (VP (VBZ blocks) (NP (NP (NN development)) (PP (IN of) (NP (JJ CD34+) (NNS cells))) (PP (IN into) (NP (NN T) (NNS cells))) (PP (IN in) (NP (DT a) (NP (NP (JJ fetal) (JJ thymic) (NN organ) (NN culture)) (PRN (-LRB- -LRB-) (NP (NN FTOC)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN development)) (PP (IN into) (NP (NN NK) (NNS cells))) (PP (IN in) (NP (DT an) (NN FTOC)))) (VP (VBZ is) (VP (VBN enhanced))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT a) (NP (JJ bHLH) (NN transcription) (NN factor))))) (VP (VBZ is) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NN T) (NN lineage) (NN differentiation)) (PP (IN of) (NP (NP (JJ bipotential) (NNS precursors)) (, ,) (SBAR (WHPP (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (WHNP (WDT which)))))) (S (NP (NP (DT a) (NN default) (NN pathway)) (VP (VBG leading) (PP (TO to) (NP (NN NK) (NN cell) (NN development))))) (VP (VBZ is) (VP (VBN chosen))))))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP identify) (NP (NP (DT a) (JJ molecular) (NN switch)) (PP (IN for) (NP (NP (NN lineage) (NN specification)) (PP (IN in) (NP (NP (JJ early) (JJ lymphoid) (NNS precursors)) (PP (IN of) (NP (NNS humans))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Suppression)) (PP (IN of) (NP (NP (NN MHC) (NN class) (CD II)) (NN expression))) (PP (IN by) (NP (NP (JJ human) (NN class) (CD II) (NN trans-activator) (NNS constructs)) (VP (VBG lacking) (NP (DT the) (NP (JJ N-terminal) (NN domain)))))) (. .)))))
(S1 (S (S (S (NP (DT The) (NP (NP (NN class) (CD II) (NN trans-activator)) (PRN (-LRB- -LRB-) (NP (NN CIITA)) (-RRB- -RRB-)))) (VP (VBZ is) (NP (NP (DT a) (NP (RB bi-) (CC or) (JJ multi-functional) (NN domain) (NN protein))) (SBAR (WHNP (WDT which)) (S (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN MHC) (NN class) (CD II) (NNS genes)))))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBP report) (SBAR (DT that) (S (NP (NP (NP (NN removal)) (PP (IN of) (NP (DT the) (NP (JJ N-terminal) (CD 151) (NN amino) (NNS acids))))) (, ,) (VP (VP (VBG encompassing) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (NP (JJ acidic) (NN domain)))))) (CC but) (VP (VBG leaving) (SINV (ADJP (JJ intact)) (NP (DT the) (NP (JJ proline/serine/threonine-rich) (NN domain)))))) (, ,)) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJ mutant) (NN protein)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ potent)) (ADJP (JJ suppressive))) (NNS properties)) (PP (IN for) (NP (NP (NN MHC) (NN class) (CD II)) (NN expression))))))))))) (. .))))
(S1 (S (S (NP (NP (NN HeLa) (NNS cells)) (VP (ADVP (ADVP (RB stably)) (CC or) (ADVP (RB transiently))) (VBN transfected) (PP (IN with) (NP (JJ mutant) (NN CIITA) (NNS constructs))))) (VP (VBD showed) (NP (NP (NP (ADJP (QP (RB up) (TO to) (CD 99)) (NN %)) (NN suppression)) (PP (IN of) (NP (NP (NP (NN MHC) (NN class) (CD II)) (NN antigen) (NN induction)) (PP (IN by) (NP (NN IFN-gamma)))))) (CC and) (NP (NP (JJ marked) (NN suppression)) (PP (IN of) (NP (NP (NN HLA-DRA) (NN mRNA)) (NN expression)))))) (. .))))
(S1 (S (S (NP (NP (JJ Transient) (NN transfection)) (PP (IN of) (NP (DT a) (NN B) (NN lymphoma) (NN line)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (QP (RB up) (TO to) (CD 89)) (NN %)) (NN reduction)) (PP (IN of) (NP (JJ constitutive) (NP (NN MHC) (NN class) (CD II)) (NN expression))) (PP (IN within) (NP (CD 5) (NNS days)))) (CC and) (NP (NP (NN suppression)) (PP (IN of) (NP (NP (NN HLA-DRA) (NN mRNA)) (NN synthesis))))))) (. .))))
(S1 (S (NP (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (NP (NN proliferation)) (CC and) (NP (NN apoptosis))) (PP (IN of) (NP (NP (ADJP (JJ human))) (CC and) (NP (NN rat)) (NP (NN T) (NNS lymphocytes)))))) (PP (IN by) (NP (NP (NN curcumin)) (, ,) (NP (DT a) (NN curry) (NN pigment)))) (. .)))))
(S1 (S (S (S (NP (NP (NP (NN Curcumin)) (PRN (-LRB- -LRB-) (NP (NN diferuoylmethane)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ yellow) (NN pigment)) (PP (IN in) (NP (NP (DT the) (NN rhizome)) (PP (IN of) (NP (NP (JJ tumeric)) (PRN (-LRB- -LRB-) (NP (FW Curcuma) (FW longa)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT an) (NN ingredient)) (PP (IN of) (NP (NN curry) (NN spice)))) (, ,)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB exhibit) (NP (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ pharmacological) (NNS effects)))) (PP (VBG including) (NP (NP (ADJP (JJ antitumor))) (, ,) (NP (ADJP (JJ antiinflammatory))) (, ,) (CC and) (NP (ADJP (JJ antiinfectious))) (NP (NNS activities)))))))))) (. .)))))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (PRP$ its) (JJ precise) (NN mode)) (PP (IN of) (NP (NN action)))) (VP (VBZ remains) (ADJP (JJ elusive))))) (, ,) (S (NP (NN curcumin)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB suppress) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (NP (NN AP-1)) (NP (NN transcription) (NN factor)))) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN stimulated) (S (VP (TO to) (VP (VB proliferate))))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD observed) (SBAR (IN that) (S (NP (NP (NN curcumin)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN microM)) (-RRB- -RRB-))) (VP (VBD inhibited) (NP (NP (NP (NN proliferation)) (PP (IN of) (NP (NP (NN rat) (NNS thymocytes)) (VP (VBN stimulated) (PP (IN with) (NP (NP (NN concanavalin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN Con) (NN A)) (-RRB- -RRB-)))))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ human) (NN Jurkat) (JJ lymphoblastoid) (NNS cells)) (PP (IN in) (NP (DT the) (JJ logarithmic) (NN growth) (NN phase))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NN pigment)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NN apoptosis)) (PP (PP (IN in) (NP (JJ dexamethasone-treated) (NN rat) (NNS thymocytes))) (CC and) (PP (IN in) (NP (JJ UV-irradiated) (NN Jurkat) (NNS cells))))) (SBAR (IN as) (S (VP (VBN judged) (PP (IN by) (NP (NP (NN DNA) (NN ladder) (NN formation)) (, ,) (NP (JJ cellular) (JJ morphological) (NNS changes)) (, ,) (CC and) (NP (NN flow) (NN cytometry)) (NP (NN analysis)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN inhibition)) (PP (IN of) (NP (NN apoptosis))) (PP (IN by) (NP (NN curcumin))) (PP (IN in) (NP (NN rat) (NNS thymocytes)))) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ partial) (NN suppression)) (PP (IN of) (NP (NP (NN AP-1)) (NN activity))))))) (. .))))
(S1 (S (S (NP (NP (JJ Complete) (NN suppression)) (PP (IN of) (NP (NP (NN AP-1)) (NN activity)))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NN Con) (NN A-treated) (, ,) (VBG proliferating) (NNS thymocytes))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN capacity)) (PP (IN of) (NP (NN curcumin))) (S (VP (TO to) (VP (VB inhibit) (NP (CC both) (NN cell) (NP (NN growth)) (CC and) (NP (NN death))))))) (ADVP (RB strongly)) (VP (VBZ implies) (SBAR (SBAR (IN that) (S (NP (DT these) (CD two) (JJ biological) (NNS processes)) (VP (VBP share) (NP (DT a) (JJ common) (NN pathway)) (PP (IN at) (NP (DT some) (NN point)))))) (CC and) (SBAR (IN that) (S (NP (NN curcumin)) (VP (VBZ affects) (NP (NP (DT a) (JJ common) (NN step)) (, ,) (VP (ADVP (RB presumably)) (VBG involving) (NP (NP (DT a) (NN modulation)) (PP (IN of) (NP (DT the) (NP (NN AP-1)) (NP (NN transcription) (NN factor)))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Nuclear) (NN localization)) (PP (IN of) (NP (NN RelB)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (ADJP (ADJP (JJ effective)) (ADJP (JJ antigen-presenting))) (NN cell) (NN function))))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Dendritic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS DC)) (-RRB- -RRB-))) (VP (VBP are) (NP (NP (JJ potent) (NP (NNS APCs))) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP enter) (NP (VBG resting) (NNS tissues)) (PP (IN as) (NP (NNS precursors)))) (CC and) (, ,) (VP (PP (IN after) (NP (NN Ag) (NN exposure))) (, ,) (VP (VBP differentiate)) (CC and) (VP (VBP migrate) (PP (TO to) (NP (VBG draining) (NN lymph) (NNS nodes)))))))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (NN phenotype)) (PP (IN of) (NP (NP (NN RelB)) (NN knockout) (NNS mice)))) (VP (VBZ implicates) (NP (NP (DT this) (NN member)) (PP (IN of) (NP (DT the) (NP (NN NF) (NN kappa) (NN B/Rel) (NN family))))) (PP (IN in) (NP (NP (NNS DC)) (NN differentiation)))) (. .))))
(S1 (S (S (S (VP (TO To) (ADVP (RB further)) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN RelB))) (PP (IN in) (NP (NP (NNS DC)) (NN differentiation))))))) (, ,) (S (NP (NP (NN mRNA)) (, ,) (NP (JJ intracellular) (NN protein) (NN expression)) (, ,) (CC and) (NP (NP (NN DNA) (NN binding) (NN activity)) (PP (IN of) (NP (NN RelB))))) (VP (VBD were) (VP (VBN examined) (PP (IN in) (NP (NP (NP (ADJP (JJ immature))) (CC and) (NP (VBN differentiated)) (NP (JJ human) (NNS DC))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ other) (NP (NN PB) (JJ mononuclear) (NN cell) (NNS populations)))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN RelB)) (NN protein)) (CC and) (NP (NN mRNA))) (VP (VBD were) (VP (VBN detected) (ADVP (RB constitutively)) (PP (PP (IN in) (NP (NNS lymphocytes))) (CC and) (PP (IN in) (NP (NP (VBN activated) (NNS monocytes)) (, ,) (NP (VBN differentiated) (NNS DC)) (, ,) (CC and) (NP (JJ monocyte-derived) (NNS DC))))))) (. .))))
(S1 (S (S (NP (JJ Immunohistochemical) (NN staining)) (VP (VBD demonstrated) (NP (NN RelB)) (PP (IN within) (NP (NP (NP (DT the) (NP (VBN differentiated) (NN lymph) (NN node) (NN interdigitating) (NNS DC))) (CC and) (NP (JJ follicular) (NNS DC))) (, ,) (CONJP (CC but) (RB not)) (NP (NP (JJ undifferentiated) (NNS DC)) (PP (IN in) (NP (JJ normal) (NN skin))))))) (. .))))
(S1 (S (S (NP (ADJP (JJ Active) (JJ nuclear)) (NP (NN RelB))) (VP (VBD was) (VP (VBN detected) (PP (IN by) (NP (NN supershift) (NN assay))) (PP (PP (ADVP (RB only)) (IN in) (NP (NP (JJ differentiated) (NP (NNS DC))) (VP (VBN derived) (PP (IN from) (NP (CC either) (NP (NN PB) (NNS precursors)) (CC or) (NP (NP (NNS monocytes)))))))) (CC and) (PP (IN in) (NP (VBN activated) (NN B) (NNS cells)))))) (. .))))
(S1 (S (S (NP (DT These) (NP (JJ RelB+) (NN APC))) (VP (VBD were) (NP (NP (JJ potent) (NNS stimulators)) (PP (IN of) (NP (DT the) (NP (NN MLR)))))) (. .))))
(S1 (S (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN RelB)) (NN expression)) (VP (VBZ is) (VP (VBN regulated) (ADVP (CC both) (ADVP (RB transcriptionally)) (CC and) (ADVP (RB post-translationally))) (PP (IN in) (NP (JJ myeloid) (NNS cells)))))))) (. .))))
(S1 (S (S (PP (IN Within) (NP (DT the) (NN nucleus))) (, ,) (NP (NP (NN RelB)) (NN may)) (ADVP (RB specifically)) (VP (VB transactivate) (NP (NP (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN APC)) (NN function))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor-kappa) (NN B)) (CC and) (NP (PRP$ its) (NN inhibitor) (NP (NN I) (NN kappa) (NN B-alpha/MAD-3))))) (PP (IN in) (NP (NNS monocytes))) (PP (PP (IN by) (NP (NN Mycobacterium) (NN tuberculosis))) (CC and) (PP (IN during) (NP (JJ human) (NN tuberculosis)))) (. .)))))
(S1 (S (S (S (NP (NP (NN Blood) (NNS monocytes)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ active) (NN tuberculosis)))))) (VP (VBP are) (VP (VBN activated) (ADVP (FW in) (FW vivo))) (, ,) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (VBN stimulated) (NN release)) (PP (IN of) (NP (NP (JJ proinflammatory) (NNS cytokines)) (, ,) (PP (JJ such) (IN as) (NP (NN TNF-alpha)))))))) (, ,) (CC and) (NP (NP (DT the) (JJ spontaneous) (NN expression)) (PP (IN of) (NP (NN IL-2R)))))))))) (. .)))))
(S1 (S (S (ADVP (RB Further)) (, ,) (NP (NP (NNS monocytes)) (PP (IN from) (NP (NNS patients)))) (VP (VBP demonstrate) (NP (NP (DT an) (JJ augmented) (NN susceptibility)) (PP (TO to) (NP (NP (DT a) (JJ productive) (NN infection)) (PP (IN with) (NP (NN HIV-1)))))) (ADVP (FW in) (FW vitro))) (. .))))
(S1 (S (S (NP (NP (NN Mycobacterium) (NN tuberculosis)) (CC and) (NP (PRP$ its) (NNS components))) (VP (VBP are) (NP (NP (JJ strong) (NNS signals)) (SBAR (S (VP (TO to) (VP (VB activate) (NP (NNS monocytes)) (PP (TO to) (NP (NP (NN production)) (PP (IN of) (NP (NNS cytokines))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NN activation)) (PP (IN of) (NP (NNS monocytes))) (PP (PP (IN during) (NP (JJ active) (NN tuberculosis))) (CC and) (PP (IN by) (NP (NN M.) (NN tuberculosis)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT a) (JJ constitutive) (NN degradation)) (PP (IN of) (NP (NP (NN I) (NN kappa) (NN B-alpha)) (, ,) (NP (NP (DT the) (JJ major) (NP (JJ cytoplasmic) (NN inhibitor))) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))))))) (, ,) (PP (IN in) (NP (NP (ADJP (RB freshly) (VBN isolated)) (NP (NN PBMC)) (CC and) (NP (NNS monocytes))) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NN tuberculosis))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NP (NN I) (NN kappa) (NN B-alpha)) (NNS levels)) (PP (IN in) (NP (NP (NP (NN PBMC)) (CC and) (NP (NNS monocytes))) (PP (PP (IN from) (NP (JJ healthy) (NNS subjects))) (CC or) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (JJ nontuberculous) (JJ pulmonary)) (NNS conditions))))))))) (VP (VBD were) (ADJP (JJ intact))) (. .))))
(S1 (S (S (ADVP (RB Further)) (, ,) (PP (IN by) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))) (, ,) (NP (NN NF-kappa) (NN B)) (VP (VBD was) (VP (VBN activated) (PP (IN in) (NP (NP (NNS monocytes)) (PP (IN from) (NP (JJ tuberculous) (NNS patients))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NP (NN I) (NN kappa) (NN B-alpha)) (NN gene)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ responsive) (PP (TO to) (NP (NP (NN activation)) (PP (IN by) (NP (NN NF-kappa) (NN B))))))))))) (, ,)) (VP (VBD was) (VP (VBN up-regulated) (PP (PP (IN in) (NP (NP (NP (NN PBMC)) (CC and) (NP (NNS monocytes))) (PP (IN from) (NP (NNS patients))))) (, ,) (CC but) (PP (RB not) (IN in) (NP (NP (JJ mononuclear) (NNS cells)) (PP (IN from) (NP (NP (JJ healthy) (NNS subjects)) (CC or) (NP (NP (DT those)) (PP (IN with) (NP (JJ nontuberculous) (NN lung) (NNS diseases))))))))))) (. .))))
(S1 (S (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ other) (NP (JJ adherence-associated) (JJ early) (NNS genes))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN IL-8)) (CC and) (NP (NN IL-1) (NN beta)))))) (, ,)) (VP (VBD was) (RB not) (VP (VBN up-regulated) (PP (IN in) (NP (NP (NN PBMC)) (PP (IN of) (NP (JJ tuberculous) (NNS patients))))))) (. .))))
(S1 (S (S (ADVP (RB Further)) (, ,) (S (S (NP (NP (NN M.) (NN tuberculosis)) (CC and) (NP (NP (PRP$ its) (NP (NN tuberculin))) (, ,) (NP (VBN purified) (NN protein) (NN derivative))) (, ,)) (VP (VBD induced) (NP (NP (NP (DT the) (NN degradation)) (PP (IN of) (NP (NN I) (NN kappa) (NN B-alpha)))) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN I) (NN kappa) (NN B-alpha) (NN mRNA))))))) (, ,) (CC and) (S (NP (VBN purified) (NN protein) (NN derivative)) (VP (VBD induced) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (PP (IN in) (NP (NNS monocytes)))))) (. .))))
(S1 (S (NP (NP (NP (NN Relationship)) (PP (IN between) (NP (NP (NN glucocorticoid) (NN receptor)) (CC and) (NP (NP (NN response)) (PP (TO to) (NP (NP (NN glucocorticoid) (NN therapy)) (PP (IN in) (NP (JJ ulcerative) (NN colitis)))))))) (. .)))))
(S1 (S (NP (NP (NN PURPOSE) (: :)) (S (S (VP (TO To) (VP (VB clarify) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (DT the) (NP (NN glucocorticoid) (NN receptor))) (CC and) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (NN glucocorticoid) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ulcerative) (NN colitis)))))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NP (NN number)) (CC and) (NP (JJ apparent) (NN dissociation) (NN constant))) (PP (IN of) (NP (NP (NN glucocorticoid) (NN receptor)) (PP (IN in) (NP (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS leukocytes)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ulcerative) (NN colitis)))))))))))) (. .)))))
(S1 (S (NP (NP (NP (NNS MATERIALS)) (CC AND) (NP (NNS METHODS)) (: :)) (S (NP (NP (NP (CD Eleven) (NNS patients)) (PP (IN with) (NP (JJ ulcerative) (NN colitis))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 5)) (SBAR (WHNP (WP who)) (S (VP (VBD responded) (PP (TO to) (NP (JJ intravenous) (NNS glucocorticoids))))))) (CC and) (NP (NP (CD 6)) (SBAR (WHNP (WP who)) (S (VP (VBD did) (RB not)))))) (-RRB- -RRB-))) (CC and) (NP (CD ten) (JJ control) (NNS subjects))) (VP (VBD were) (VP (VBN studied)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN number)) (CC and) (NP (JJ apparent) (NN dissociation) (NN constant))) (PP (IN of) (NP (NN glucocorticoid) (NN receptor)))) (VP (VBD were) (VP (VBN measured)) (S (VP (VBG using) (NP (DT a) (JJ whole-cell) (NN binding) (NN assay))))) (. .))))
(S1 (S (S (NP (NNS Results)) (VP (VBD were) (VP (VBN expressed) (PP (IN as) (NP (NP (DT a) (NN median)) (PRN (-LRB- -LRB-) (NP (JJ interquartile) (NN range)) (-RRB- -RRB-)))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS) (: :)) (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NN glucocorticoid) (NNS receptors)) (PP (IN from) (NP (DT the) (NP (CD six) (NNS nonresponders)) (, ,) (NP (CD five) (NNS responders)) (, ,) (CC and) (NP (CD ten) (JJ healthy) (NNS controls))))))) (VP (VBD were) (NP (NP (NP (CD 4922)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 4484-5643))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 3413)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 3183-4450))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (CD 3610)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 2594-3979))) (-RRB- -RRB-))) (NP (VBG binding) (NNS sites/cell))) (, ,) (ADVP (RB respectively)))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ apparent) (NN dissociation) (NN constant)) (PP (IN of) (NP (NP (DT the) (NP (NN glucocorticoid) (NNS receptors))) (PP (IN from) (NP (DT the) (NP (NNS nonresponders)) (, ,) (NP (NNS responders)) (, ,) (CC and) (NP (JJ healthy) (NNS controls))))))) (VP (VBD were) (NP (NP (NP (CD 7.03)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 5.66-10))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 4.27)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 4-5.13))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (CD 6.18)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 5.86-6.74))) (-RRB- -RRB-))) (NP (NN nM))) (, ,) (ADVP (RB respectively))) (. .))))
(S1 (S (S (S (NP (NNS Nonresponders)) (VP (VBD had) (NP (DT a) (JJ significant) (NN increase)) (PP (CC both) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (VBG binding) (NNS sites))))) (CC and) (PP (IN in) (NP (DT the) (JJ apparent) (NN dissociation) (NN constant)))) (PP (VBN compared) (PP (IN with) (NP (NNS responders)))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.045)))) (: ;) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.029))))) (-RRB- -RRB-)) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NP (DT The) (VBN increased) (NP (NN number)) (CC and) (NP (JJ apparent) (NN dissociation) (NN constant))) (PP (IN of) (NP (NN glucocorticoid) (NN receptor)))) (VP (VBP are) (ADVP (RB closely)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NN glucocorticoid) (NN therapy)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN measurement)) (PP (IN of) (NP (NP (DT the) (NP (NN number)) (CC and) (NP (JJ apparent) (NN dissociation) (NN constant))) (PP (IN of) (NP (NN glucocorticoid) (NN receptor)))))) (VP (MD may) (VP (VB be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG predicting) (NP (NP (NN response)) (PP (TO to) (NP (NNS glucocorticoids)))))))))) (. .))))
(S1 (S (UCP (UCP (S (VP (VBG Switching) (NP (NNS gears)) (PP (IN during) (NP (NN T-cell) (NN maturation)))) (: :)) (NP (NP (NN RANTES)) (CC and) (NP (JJ late) (NN transcription))) (. .)))))
(S1 (S (S (S (SBAR (IN Although) (S (NP (JJ much)) (VP (VBZ is) (VP (VBN understood))) (PP (IN about) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN expressed) (PP (ADVP (ADVP (RB early)) (PRN (-LRB- -LRB-) (PP (IN within) (NP (CD 24) (NN h))) (-RRB- -RRB-))) (IN after) (NP (NN T-cell) (NN activation)))))))))) (, ,) (S (NP (JJ little)) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN expressed) (NP (ADVP (`` ') (JJ late) ('' ')) (PRN (-LRB- -LRB-) (NP (NP (CD three)) (CC or) (NP (JJR more)) (NP (NNS days))) (-RRB- -RRB-)) (NP (NN post-stimulation))))))))))))) (. .)))))
(S1 (S (S (NP (NP (DT A) (JJR better) (NN understanding)) (PP (IN of) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN at) (NP (NP (DT this) (JJ important) (NN stage)) (PP (IN of) (NP (NN T-cell) (NN maturation)))))))) (VP (MD may) (VP (VB yield) (NP (NP (NP (JJ new) (NNS insights)) (PP (IN into) (NP (NN T-cell) (NN development)))) (CC and) (NP (ADJP (ADJP (JJ new)) (ADJP (JJ immunotherapeutic))) (NNS targets))))) (. .))))
(S1 (S (NP (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NP (NN huGATA-3)) (NN transcription) (NN factor)) (CC and) (NP (NP (CD three) (NP (NN GATA) (JJ regulatory) (NNS elements))) (PP (IN of) (NP (NN HIV-1) (JJ long) (JJ terminal) (NN repeat)))))))) (, ,) (PP (IN by) (NP (NN surface) (NN plasmon) (NN resonance))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Relative) (NNS affinities)) (PP (IN of) (NP (JJ transcriptional) (JJ regulatory) (NNS elements))) (PP (IN for) (NP (PRP$ their) (JJ respective) (NN factor)))) (VP (VBP have) (VP (VBN been) (ADVP (RB essentially)) (VP (VBN studied) (PP (IN by) (NP (NN bandshift) (NN analysis)))))) (. .)))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (NP (NP (NP (DT a) (JJ real-time) (NN study)) (PP (IN of) (NP (NN factor/DNA) (NNS interactions))) (VP (VBG using) (NP (DT a) (NN surface) (NN plasmon) (NN resonance) (NN approach)))) (CC and) (NP (NP (JJ further) (NN characterization)) (PP (IN of) (NP (NP (VBN recovered) (NNS proteins)) (VP (VBN involved) (PP (IN in) (NP (DT this) (NN interaction))))))))) (. .))))
(S1 (S (S (PP (IN For) (NP (DT this) (NN purpose))) (, ,) (NP (NP (NP (JJ human) (NN GATA-3)) (, ,) (UCP (CC either) (ADJP (JJ recombinant)) (CC or) (PP (IN in) (NP (JJ nuclear) (NNS extracts))))) (, ,) (CC and) (NP (NP (CD three) (NP (JJ natural) (NN GATA) (NNS elements))) (PP (IN of) (NP (DT the) (NP (NN HIV-1) (JJ long) (JJ terminal) (NN repeat)))) (PRN (-LRB- -LRB-) (NP (NNS sites) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (CC and) (NP (CD 3))) (-RRB- -RRB-)))) (VP (VBD were) (VP (VBN chosen))) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ only) (NP (NN site) (CD 2))) (VP (VBZ is) (NP (DT a) (JJ noncanonical) (NP (NN GATA) (NN site)))))) (. .))))
(S1 (S (S (NP (NP (JJ Direct) (NN analysis)) (PP (IN of) (NP (NNS sensorgrams))) (, ,) (PP (IN with) (NP (JJ recombinant) (NN huGATA-3))) (, ,)) (VP (VBD allowed) (NP (NP (NP (DT the) (NN comparison)) (PP (IN of) (NP (NP (NP (NN association)) (CC and) (NP (NN dissociation)) (NP (NNS profiles))) (PP (IN of) (NP (DT the) (CD three) (NP (NN DNA) (NNS regions))))))) (CC and) (NP (NP (PRP$ their) (NN ranking)) (PP (VBG according) (PP (TO to) (NP (PRP$ their) (JJ relative) (NNS affinities))))))) (. .))))
(S1 (S (S (NP (NP (DT This) (NN result)) (, ,) (VP (VBN confirmed) (PP (IN by) (NP (NP (NNS competitions)) (PP (IN with) (NP (DT each) (NP (NN GATA) (NN site))))))) (, ,)) (VP (VBD demonstrated) (NP (NP (NP (DT the) (ADJP (ADJP (JJR higher)) (ADJP (JJ relative))) (NN affinity)) (PRN (-LRB- -LRB-) (NP (ADVP (IN at) (JJS least)) (JJ sevenfold)) (-RRB- -RRB-))) (PP (IN of) (NP (NN site) (CD 3))))) (. .))))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN between) (NP (NP (DT the) (ADJP (ADJP (JJ canonical)) (CC and) (ADJP (JJ unique))) (NP (NN GATA) (NN site) (CD 3))) (CC and) (NP (JJ nuclear) (NNS extracts))))) (VP (VP (VBD were) (ADVP (RB also)) (VP (VBN studied) (PP (IN in) (NP (JJ real) (NN time))))) (CC and) (VP (VBD provided) (NP (NP (NN information)) (PP (IN on) (NP (NP (PRP$ its) (NP (NN association)) (CC and) (NP (NN dissociation)) (NP (NNS rates))) (PP (IN for) (NP (JJ native) (NP (NN huGATA-3))))))))) (. .))))
(S1 (S (S (ADVP (RB Finally)) (, ,) (NP (VBN recovered) (NN protein)) (VP (VBD was) (VP (VBN identified) (PP (IN as) (NP (JJ genuine) (NP (NN huGATA-3)))) (PP (IN by) (NP (NP (NN SDS-PAGE)) (, ,) (NP (NN Western) (NN blotting)) (, ,) (CC and) (NP (NN bandshift)) (NP (NNS assays)))))) (. .))))
(S1 (S (NP (NN Copyright) (CD 1997) (NNP Academic) (NNP Press) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NP (JJ Epstein-Barr) (NN virus) (NN oncogene) (NN product))) (NP (JJ latent) (NN membrane) (NN protein) (CD 1))) (VP (VBZ engages) (NP (DT the) (NN tumor) (NN necrosis) (NN factor) (JJ receptor-associated) (NN death) (NN domain) (NN protein)) (S (VP (TO to) (VP (VP (VB mediate) (NP (NN B) (NN lymphocyte) (NN growth) (NN transformation))) (CC and) (VP (VB activate) (NP (NN NF-kappaB))))))) (. .)))))
(S1 (S (S (S (NP (DT The) (JJ Epstein-Barr) (NN virus) (NP (NP (JJ latent) (NN membrane) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN LMP1)) (-RRB- -RRB-)))) (VP (VBZ is) (ADJP (JJ essential) (PP (IN for) (NP (NP (DT the) (NN transformation)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN into) (NP (JJ lymphoblastoid) (NN cell) (NNS lines))))))) (. .)))))
(S1 (S (S (NP (JJ Previous) (NNS data)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (DT a) (NN model) (SBAR (IN that) (S (NP (NN LMP1)) (VP (VBZ is) (NP (NP (DT a) (NP (RB constitutively) (VBN activated) (NN receptor))) (SBAR (WHNP (WDT that)) (S (VP (VBZ transduces) (NP (NNS signals)) (PP (IN for) (NP (NN transformation))) (PP (IN through) (NP (PRP$ its) (NP (JJ carboxyl-terminal) (JJ cytoplasmic) (NN tail))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NP (CD One) (NP (NN transformation) (NN effector) (NN site))) (PRN (-LRB- -LRB-) (NP (NN TES1)) (-RRB- -RRB-))) (, ,) (ADJP (JJ located) (PP (IN within) (NP (NP (DT the) (NP (NN membrane) (JJ proximal) (CD 45) (NNS residues))) (PP (IN of) (NP (DT the) (JJ cytoplasmic) (NN tail)))))) (, ,)) (ADVP (RB constitutively)) (VP (VBZ engages) (NP (NN tumor) (NN necrosis) (NN factor) (JJ receptor-associated) (NNS factors))) (. .))))
(S1 (S (S (S (NP (NP (NNS Signals)) (PP (IN from) (NP (NN TES1)))) (VP (VBP are) (ADJP (JJ sufficient)) (S (VP (TO to) (VP (VB drive) (NP (NP (JJ initial) (NN proliferation)) (PP (IN of) (NP (ADJP (ADJP (JJ infected)) (ADJP (VBG resting))) (NN B) (NP (NNS lymphocytes)))))))))) (, ,) (CC but) (S (NP (NP (JJS most) (NP (JJ lymphoblastoid) (NNS cells))) (VP (VBN infected) (PP (IN with) (NP (NP (DT a) (NN virus)) (SBAR (WHNP (WDT that)) (S (VP (VBZ does) (RB not) (VP (VB express) (NP (DT the) (NP (CD 155) (NNS residues))) (PP (IN beyond) (NP (NN TES1))))))))))) (VP (VBP fail) (S (VP (TO to) (VP (VB grow) (PP (IN as) (NP (JJ long-term) (NN cell) (NNS lines)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB now)) (VP (VBP find) (SBAR (IN that) (S (S (VP (VBG mutating) (NP (CD two) (NNS tyrosines)) (PP (TO to) (NP (DT an) (NN isoleucine))) (PP (IN at) (NP (NP (DT the) (NP (NN carboxyl) (NN end))) (PP (IN of) (NP (DT the) (NP (JJ cytoplasmic) (NN tail)))))))) (VP (VBZ cripples) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN EBV))) (S (VP (TO to) (VP (VB cause) (NP (JJ lymphoblastoid) (NN cell) (NN outgrowth)))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG marking) (NP (NP (DT a) (JJ second) (NP (NN transformation) (NN effector) (NN site))) (, ,) (NP (NN TES2))))))))) (. .))))
(S1 (S (S (NP (DT A) (NN yeast) (JJ two-hybrid) (NN screen)) (VP (VBD identified) (NP (NP (NN TES2) (NN interacting) (NNS proteins)) (, ,) (PP (VBG including) (NP (NP (DT the) (NP (NN tumor) (NN necrosis) (NN factor) (JJ receptor-associated) (NN death) (NN domain) (NN protein))) (PRN (-LRB- -LRB-) (NP (NN TRADD)) (-RRB- -RRB-)))))) (. .))))
(S1 (S (S (NP (NN TRADD)) (VP (VBD was) (NP (NP (DT the) (JJ only) (NN protein)) (SBAR (WHNP (WDT that)) (S (VP (VBD interacted) (PP (PP (IN with) (NP (JJ wild-type) (NN TES2))) (CC and) (PP (RB not) (IN with) (NP (JJ isoleucine-mutated) (NN TES2))))))))) (. .))))
(S1 (S (S (S (NP (NN TRADD)) (VP (VBD associated) (PP (PP (IN with) (NP (JJ wild-type) (NN LMP1))) (CC but) (PP (RB not) (IN with) (NP (NP (JJ isoleucine-mutated) (NP (NN LMP1))) (PP (IN in) (NP (JJ mammalian) (NNS cells)))))))) (, ,) (CC and) (S (NP (NN TRADD)) (ADVP (RB constitutively)) (VP (VBD associated) (PP (IN with) (NP (NP (NN LMP1)) (PP (IN in) (NP (JJ EBV-transformed) (NNS cells))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN transfection) (NNS assays))) (, ,) (NP (NP (NN TRADD)) (CC and) (NP (NN TES2))) (ADVP (RB synergistically)) (VP (VBD mediated) (NP (JJ high-level) (NP (NN NF-kappaB)) (NN activation))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN LMP1)) (VP (VBZ appropriates) (NP (NN TRADD)) (S (VP (TO to) (VP (VB enable) (NP (ADJP (ADJP (JJ efficient)) (ADJP (JJ long-term))) (JJ lymphoblastoid) (NN cell) (NN outgrowth))))))))) (. .))))
(S1 (S (S (NP (JJ High-level) (NP (NN NF-kappaB)) (NN activation)) (ADVP (RB also)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (JJ critical) (NN component)) (PP (IN of) (NP (JJ long-term) (NN outgrowth)))))))) (. .))))
(S1 (S (NP (NP (NP (NN Modulation)) (PP (IN of) (NP (NP (NN mRNA) (NN expression)) (PP (IN of) (NP (NP (DT a) (NP (JJ novel) (JJ human) (JJ myeloid-selective) (NN CCAAT/enhancer) (NN binding) (NN protein) (NN gene))) (PRN (-LRB- -LRB-) (NP (NN C/EBP) (NN epsilon)) (-RRB- -RRB-)))))) (. .)))))
(S1 (S (S (S (NP (JJ Human) (NP (NN C/EBP) (NN epsilon))) (VP (VBZ is) (NP (NP (NP (DT a) (ADJP (RB newly) (VBN cloned)) (NN gene)) (VP (VBG coding) (PP (IN for) (NP (DT a) (NP (NN CCAAT/enhancer) (NN binding) (NN protein)))))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ myeloid) (NN differentiation)))))))))))) (. .)))))
(S1 (S (S (NP (PRP$ Our) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNS levels)) (PP (IN of) (NP (NN C/EBP) (NN epsilon) (NN mRNA)))) (VP (VBD were) (ADVP (RB markedly)) (VP (VBN increased) (PP (IN in) (NP (NP (NN NB4) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ promyelocytic) (NN leukemia) (NN line)) (-RRB- -RRB-))))) (, ,) (SBAR (IN because) (S (NP (PRP they)) (VP (VBD were) (VP (VBN induced) (S (PP (IN by) (NP (NP (JJ 9-cis) (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (JJ 9-cis) (NN RA)) (-RRB- -RRB-)))) (VP (TO to) (VP (VB differentiate) (PP (IN towards) (NP (NNS granulocytes)))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Accumulation)) (PP (IN of) (NP (NN C/EBP) (NN epsilon) (NN mRNA)))) (VP (VBD occurred) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (PP (NP (CD 1) (NN hour)) (IN after) (NP (NP (NN exposure)) (PP (IN of) (NP (NN NB4) (NNS cells))) (PP (TO to) (NP (NP (JJ 9-cis) (NN RA)) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CC x) (CD 10-LRB--7-RRB-)) (NN mol/L)) (-RRB- -RRB-)))))))))) (: ;) (CC and) (S (PP (IN at) (NP (CD 48) (NNS hours))) (, ,) (NP (NNS levels)) (VP (VBD were) (VP (VBN increased) (PP (IN by) (NP (RB 5.1-fold)))))) (. .))))
(S1 (S (S (S (NP (JJ Dose-response) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (ADJP (QP (CD 10-LRB--7-RRB-) (TO to) (CD 10-LRB--6-RRB-)) (NN mol/L)) (JJ 9-cis) (NN RA)) (PRN (-LRB- -LRB-) (NP (CD 12) (NNS hours)) (-RRB- -RRB-))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN peak) (NNS levels)) (PP (IN of) (NP (NN C/EBP) (NN epsilon) (NN mRNA)))))))))) (: ;) (CC but) (S (NP (ADVP (RB even)) (NP (ADJP (CD 10-LRB--10-RRB-) (NN mol/L)) (JJ 9-cis) (NN RA))) (VP (VBD increased) (NP (NP (NNS levels)) (PP (IN of) (NP (DT these) (NNS transcripts)))))) (. .))))
(S1 (S (S (S (NP (NP (NN NB4) (NNS cells)) (UCP (ADJP (JJ pulse-exposed) (PRN (-LRB- -LRB-) (NP (CD 30) (NNS minutes)) (-RRB- -RRB-)) (PP (TO to) (NP (NP (JJ all-trans) (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN ATRA)) (-RRB- -RRB-))))) (, ,) (VP (VBN washed)) (, ,) (CC and) (VP (VBN cultured) (PRN (-LRB- -LRB-) (NP (CD 3) (NNS days)) (-RRB- -RRB-)) (PP (IN with) (NP (CC either) (NP (NP (NN dimethylsulfoxide)) (PRN (-LRB- -LRB-) (NP (NN DMSO)) (-RRB- -RRB-))) (CC or) (NP (NP (NN hexamethylene) (NN bisacetamide)) (PRN (-LRB- -LRB-) (NP (NN HMBA)) (-RRB- -RRB-)))))))) (VP (VBD had) (NP (NP (NP (DT a) (JJ prominent) (NN increase)) (PP (IN in) (NP (NP (NNS levels)) (PP (IN of) (NP (NN C/EBP) (NN epsilon) (NN mRNA)))))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ granulocytic) (NN differentiation))))))) (, ,) (CC but) (S (NP (NP (NN exposure)) (PP (TO to) (NP (CC either) (NP (NN DMSO)) (CC or) (NP (NN HMBA)) (ADVP (RB alone))))) (VP (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN base) (NNS levels)) (PP (IN of) (NP (NN C/EBP) (NN epsilon)))))) (CC and) (VP (VBD did) (RB not) (VP (VB induce) (NP (NN differentiation)))))) (. .))))
(S1 (S (S (NP (NP (NN Macrophage-differentiation)) (PP (IN of) (NP (NN NB4)))) (VP (VBD reduced) (NP (NP (NNS levels)) (PP (IN of) (NP (NN C/EBP) (NN epsilon) (NN mRNA))))) (. .))))
(S1 (S (S (NP (NP (JJ Nuclear) (JJ run-off) (NNS assays)) (CC and) (NP (JJ half-life) (NNS studies))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN accumulation)) (PP (IN of) (NP (NN C/EBP) (NN epsilon) (NN mRNA))) (PP (IN by) (NP (JJ 9-cis) (NN RA)))) (VP (VBD was) (ADJP (JJ due) (PP (TO to) (NP (VBN enhanced) (NN transcription)))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (DT this) (NP (NN C/EBP) (NN epsilon) (NN mRNA)) (NN accumulation)) (VP (VBD did) (RB not) (VP (VB require) (NP (NP (NN synthesis)) (PP (IN of) (NP (JJ new) (NP (NN protein) (NNS factors)))))) (SBAR (IN because) (S (NP (JJ 9-cis) (NN RA)) (VP (VBD induced) (NP (NP (NN C/EBP) (NN epsilon) (NN mRNA)) (NN accumulation)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ new) (NN protein) (NN synthesis))))))))) (. .))))
(S1 (S (S (NP (NN ATRA)) (ADVP (RB also)) (VP (VBD induced) (NP (NP (NN expression)) (PP (IN of) (NP (NN C/EBP) (NN epsilon) (NN protein)))) (PP (IN in) (NP (NN NB4) (NNS cells))) (, ,) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NN Western) (NN blotting))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NN C/EBP) (NN epsilon))) (PP (IN in) (NP (ADJP (JJ 9-cis) (JJ RA-mediated)) (JJ granulocytic) (NN differentiation))))))) (, ,) (NP (NP (DT the) (JJ DMSO-induced) (NN differentiation)) (PP (IN of) (NP (NN HL-60) (NNS cells))) (ADVP (IN down) (NP (DT the) (JJ granulocytic) (NN pathway)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ initial) (NN reduction)) (PP (IN of) (NP (NP (NN C/EBP) (NN epsilon) (NN mRNA)) (NNS levels))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN summary))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN discovered) (SBAR (IN that) (S (NP (NP (NN expression)) (PP (IN of) (NP (NN C/EBP) (NN epsilon) (NN mRNA)))) (VP (VBZ is) (ADVP (RB markedly)) (VP (VBN enhanced)) (SBAR (IN as) (S (NP (DT the) (NP (NN NB4) (NNS promyelocytes))) (VP (VBP are) (VP (VBN induced) (S (PP (IN by) (NP (NNS retinoids))) (VP (TO to) (VP (VB differentiate) (PP (IN towards) (NP (NNS granulocytes))))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT This) (NN induction)) (PP (IN of) (NP (NP (NN C/EBP) (NN epsilon) (NN mRNA)) (NN expression)))) (VP (VP (VBZ is) (ADVP (RB transcriptionally)) (VP (VBN mediated))) (CC and) (VP (VBZ occurs) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NN synthesis)) (PP (IN of) (NP (JJ additional) (NP (NN protein) (NNS factors)))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP suspect) (SBAR (IN that) (S (NP (DT the) (NP (NN C/EBP) (NN epsilon) (NN promoter/enhancer))) (VP (VBZ contains) (NP (NP (DT a) (NP (JJ retinoic) (JJ acid-response) (NN element))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB directly)) (VP (VBN stimulated) (PP (IN by) (NP (NNS retinoids)))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Expression)) (PP (IN of) (NP (NN c-fos)))) (VP (VBZ correlates) (PP (IN with) (NP (NP (NP (NN IFN-alpha)) (NN responsiveness)) (PP (IN in) (NP (NN Philadelphia) (NN chromosome) (JJ positive) (JJ chronic) (JJ myelogenous) (NN leukemia)))))) (. .)))))
(S1 (S (S (S (NP (DT This) (NN study)) (VP (VBZ evaluates) (NP (NP (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (NP (JJ constitutive) (NNS levels)) (PP (IN of) (NP (NP (NN oncogene)) (CC and) (NP (NN p53) (NNS transcripts)))) (PP (IN in) (NP (JJ chronic) (NN phase) (NN CML) (NNS patients))))) (CC and) (NP (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (NP (PRP$ their) (NNS modulations)) (ADJP (JJ subsequent) (PP (TO to) (NP (NP (ADJP (FW in) (FW vivo)) (NN therapy)) (PP (IN with) (NP (NN rIFN-alpha) (NN 2c)))))))))) (. .)))))
(S1 (S (S (NP (NP (NP (NP (JJ Peripheral) (NN blood) (JJ mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN pbmc)) (-RRB- -RRB-))) (CC and) (NP (NN bone) (NN marrow) (NNS cells))) (PP (IN of) (NP (CD 26) (NNS patients)))) (VP (VBD were) (VP (VBN examined) (PP (IN for) (NP (NP (NN c-fos)) (, ,) (NP (NN c-myc)) (, ,) (NP (NN p53)) (CC and) (NP (DT the) (NN hybrid) (NN bcr/abl)) (NP (NN mRNA) (NNS levels)))))) (. .))))
(S1 (S (S (NP (NNS Results)) (VP (VBD indicated) (SBAR (IN that) (S (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (JJ constitutive) (NP (NN c-fos) (NN transcript)) (NNS levels)) (VP (VBP are) (UCP (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB subsequently)) (VBG responding) (PP (TO to) (NP (NP (NN IFN-alpha)) (NN therapy))))))) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR &lt;) (NP (CD 0.01)))) (-RRB- -RRB-)) (CC and) (VP (VP (ADVP (RB positively)) (VBN correlated) (PP (IN with) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NNS lymphocytes))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN r)) (ADJP (JJ =) (NP (CD 0.6895)))) (, ,) (NP (NP (NN p)) (ADJP (JJR &lt;) (NP (CD 0.01))))) (-RRB- -RRB-))) (CC and) (VP (ADVP (RB negatively)) (PP (IN with) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NP (JJ immature) (NNS cells)))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN r)) (ADJP (JJ =) (NP (CD -0.568)))) (, ,) (NP (NP (NN p)) (ADJP (JJR &lt;) (NP (CD 0.01))))) (-RRB- -RRB-)) (VP (VBN contained) (PP (IN in) (NP (NP (DT the) (NP (NN pbmc)) (NNS preparations)) (VP (VBN tested)))))))))) (, ,) (S (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (NP (NP (JJ constitutive) (NN mRNA)) (NNS levels)) (PP (IN of) (NP (NP (DT the) (NP (NN hybrid) (NN bcr/abl))) (, ,) (NP (NN c-myc)) (CC and) (NP (NN p53))))) (VP (VP (VBP are) (ADVP (RB positively)) (VP (VBN correlated) (PP (IN with) (NP (DT each) (JJ other))))) (, ,) (CC but) (VP (VBD failed) (S (VP (TO to) (VP (VB relate) (PP (TO to) (NP (NN disease) (NNS parameters))))))))) (, ,) (CC and) (S (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (NP (NP (NP (ADJP (JJ acute))) (CC and) (NP (ADJP (JJ chronic))) (NP (ADJP (FW in) (FW vivo)) (NN exposure))) (PP (TO to) (NP (NN IFN-alpha)))) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (NP (NN upregulation)) (PP (IN of) (NP (NP (NN c-fos))))) (CC and) (NP (NP (NN downregulation)) (PP (IN of) (NP (NP (NN c-myc) (NN mRNA)) (NNS levels))))) (PP (IN in) (NP (NN responder) (NNS patients))))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Paternal) (NN expression)) (PP (IN of) (NP (NN WT1))) (PP (IN in) (NP (NP (JJ human) (NNS fibroblasts)) (CC and) (NP (NNS lymphocytes)))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NP (NN Wilms) (POS ') (NN tumor) (NN suppressor) (NN gene))) (PRN (-LRB- -LRB-) (NP (NN WT1)) (-RRB- -RRB-))) (VP (VBD was) (ADVP (RB previously)) (VP (VBN identified) (PP (IN as) (S (VP (VBG being) (VP (VBN imprinted) (, ,) (PP (IN with) (NP (NP (JJ frequent) (JJ maternal) (NN expression)) (PP (IN in) (NP (NP (JJ human) (NN placentae)) (CC and) (NP (JJ fetal) (NNS brains)))))))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (JJ allele-specific) (NN expression)) (PP (IN of) (NP (NN WT1))) (PP (IN in) (NP (NP (VBN cultured) (NP (JJ human) (NNS fibroblasts))) (PP (IN from) (NP (CD 15) (NNS individuals))))))) (. .))))
(S1 (S (S (S (NP (QP (CD Seven) (IN of) (CD 15)) (NP (NN fibroblast) (NNS lines))) (VP (VBD were) (ADJP (JJ heterozygous) (PP (IN for) (NP (JJ polymorphic) (NNS alleles)))))) (, ,) (CC and) (S (NP (DT the) (NN expression) (NNS patterns)) (VP (VBD were) (ADJP (ADJP (ADJP (JJ variable)) (, ,) (PP (FW i.e.)) (, ,) (NP (NP (ADJP (JJ equal))) (, ,) (NP (ADJP (JJ unequal))) (CC or) (NP (ADJP (JJ monoallelic) (JJ paternal))) (NP (NN expression)))) (PP (IN in) (NP (NP (CD three)) (, ,) (NP (CD two)) (CC and) (NP (CD two)) (NP (NNS cases)))) (, ,) (ADVP (RB respectively))))) (. .))))
(S1 (S (S (NP (NP (JJ Exclusive) (JJ paternal) (NN expression)) (PP (IN of) (NP (NN WT1)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN shown) (PP (IN in) (NP (NP (JJ non-cultured) (JJ peripheral) (NNS lymphocytes)) (PP (IN from) (NP (DT the) (JJ latter) (CD two) (NNS individuals))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ allele-specific) (NN expression) (NNS profiles)) (PP (IN of) (NP (NP (NP (JJ other) (NP (JJ imprinted) (NNS genes))) (, ,) (NP (NP (NN IGF2)) (CC and) (NP (NN H19)))) (, ,) (PP (IN on) (NP (JJ human) (NN chromosome) (CD 11)))))) (VP (VBD were) (ADJP (ADJP (JJ constant)) (CC and) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (JJ other) (NNS tissues)))))))) (. .))))
(S1 (S (S (NP (NP (PRP$ Our) (JJ unexpected) (NNS observations)) (PP (IN of) (NP (NP (NP (ADJP (JJ paternal))) (CC or) (NP (ADJP (JJ biallelic))) (NP (NN expression))) (PP (IN of) (NP (NN WT1))) (PP (IN in) (NP (NP (NNS fibroblasts)) (CC and) (NP (NNS lymphocytes)))))) (, ,)) (PP (ADVP (RB together)) (IN with) (NP (NP (DT the) (JJ previous) (NNS findings)) (PP (IN of) (NP (NP (NP (ADJP (JJ maternal))) (CC or) (NP (ADJP (JJ biallelic))) (NP (NN expression))) (PP (IN in) (NP (NP (NN placentae)) (CC and) (NP (NNS brains)))))))) (, ,) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ allele-specific) (JJ regulatory) (NN system)) (PP (IN of) (NP (NN WT1)))) (VP (VP (VBZ is) (ADJP (JJ unique))) (CC and) (VP (MD may) (VP (VB be) (VP (VBN controlled) (PP (IN by) (NP (DT a) (ADJP (ADJP (JJ putative)) (ADJP (ADJP (NN tissue-)) (CC and) (ADJP (JJ individual-specific)))) (NN modifier)))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Aberrant) (NN splicing)) (PP (IN of) (NP (DT the) (NP (NN TSG101)) (CC and) (NP (NN FHIT)) (NP (NNS genes))))) (VP (VP (VBZ occurs) (ADVP (RB frequently)) (PP (PP (IN in) (NP (JJ multiple) (NNS malignancies))) (CC and) (PP (IN in) (NP (JJ normal) (NNS tissues))))) (CC and) (VP (VBZ mimics) (NP (NP (NNS alterations)) (VP (ADVP (RB previously)) (VBN described) (PP (IN in) (NP (NNS tumours))))))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Intragenic) (NNS deletions)) (PP (IN of) (NP (NP (NN TSG101)) (, ,) (NP (NP (DT the) (JJ human) (NN homolog)) (PP (IN of) (NP (NP (DT a) (NP (NN mouse) (NN gene))) (PRN (-LRB- -LRB-) (NP (NN tsg101)) (-RRB- -RRB-)))) (SBAR (WHNP (WDT that)) (S (VP (VBZ acts) (S (VP (TO to) (VP (VB suppress) (NP (JJ malignant) (NN cell) (NN growth))))))))))) (, ,)) (VP (VBD were) (VP (VBN reported) (PP (IN in) (NP (JJ human) (NN breast) (NNS tumours))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBD screened) (NP (NN TSG101)) (PP (IN for) (NP (NP (JJ somatic) (NNS mutations)) (PP (IN in) (NP (NP (NP (NN DNA)) (CC and) (NP (NN RNA)) (NP (NNS samples))) (VP (VBN isolated) (PP (IN from) (NP (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ common) (JJ human) (NNS malignancies)))) (, ,) (NP (JJ EBV-immortalised) (NNS B-cells)) (, ,) (CC and) (NP (JJ normal) (NN lung) (NN parenchyma)))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Intragenic) (NP (NN TSG101)) (NNS deletions)) (PP (IN in) (NP (NN RNA) (NNS transcripts)))) (VP (VBD were) (ADVP (RB frequently)) (VP (VBN found) (PP (IN in) (NP (NP (DT all) (NNS types)) (PP (IN of) (NP (NNS samples))))))) (. .))))
(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NN DNA)))) (VP (VBD failed) (S (VP (TO to) (VP (VB show) (NP (NP (JJ genomic) (NNS rearrangements)) (VP (VBG corresponding) (PP (TO to) (NP (NP (NNS transcripts)) (VP (VBG containing) (NP (NP (NNS deletions)) (PP (IN in) (NP (DT the) (JJ same) (NNS samples))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS breakpoints)) (PP (IN of) (NP (JJS most) (NN transcript) (NNS deletions)))) (VP (VBP coincide) (PP (IN with) (NP (NP (ADJP (JJ genuine))) (CC or) (NP (ADJP (JJ cryptic))) (NP (NN splice) (NN site) (NNS sequences)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (PRP they)) (VP (VBP result) (PP (IN from) (NP (NP (ADJP (JJ alternative))) (CC or) (NP (ADJP (JJ aberrant))) (NP (NN splicing)))))))))) (. .))))
(S1 (S (S (NP (NP (DT A) (JJ similar) (NN spectrum)) (PP (IN of) (NP (NN transcript) (NNS deletions)))) (VP (VBZ has) (ADVP (RB previously)) (VP (VBN been) (VP (VBN described) (PP (IN in) (NP (NP (DT the) (NP (JJ putative) (NN tumour) (NN suppressor) (NN gene))) (NP (NN FHIT))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VP (VBD analysed) (NP (NP (NN FHIT)) (PP (IN in) (NP (NP (DT the) (JJ same) (NN series)) (PP (IN of) (NP (NN RNA) (NNS samples))))))) (CC and) (VP (VBD detected) (NP (VBN truncated) (NP (NN FHIT) (NNS transcripts))) (ADVP (RB frequently)) (PP (IN in) (NP (CC both) (NP (NN tumour)) (CC and) (NP (ADJP (JJ normal))) (NP (NNS tissues)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS transcripts)) (PP (IN from) (NP (NP (NN TSG101)) (, ,) (NP (NN FHIT)) (CC and) (NP (CD seven) (JJ other) (NNS genes))))) (VP (VBD were) (VP (VBN analysed) (PP (IN in) (NP (NP (NN RNA)) (VP (VBN isolated) (PP (IN from) (NP (JJ normal) (JJ peripheral) (NN blood) (NNS lymphocytes)))))))) (. .))))
(S1 (S (S (S (NP (JJ Large) (NP (NP (NN TSG101))) (CC and) (NP (NP (NN FHIT))) (NP (JJ intragenic) (NN transcript) (NNS deletions))) (VP (VBD were) (VP (VBN detected)))) (CC and) (S (NP (DT these)) (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (JJ predominant) (NN transcript)) (PP (IN in) (NP (`` ') (JJ aged) ('' ') (NNS lymphocytes))))))))) (. .))))
(S1 (S (S (NP (JJ Similar) (NNS alterations)) (VP (VBD were) (RB not) (VP (VBN detected) (PP (IN in) (NP (NP (NNS transcripts)) (PP (IN of) (NP (DT the) (JJ other) (NNS genes))) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (VP (VBN analysed))))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS findings)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (VBN truncated) (NP (NN TSG101)) (CC and) (NP (NN FHIT)) (NP (NNS transcripts))) (VP (VBP are) (ADVP (RB commonly)) (VP (VBN detected) (PP (IN in) (NP (CC both) (NP (ADJP (JJ normal))) (CC and) (NP (ADJP (JJ malignant))) (NP (NNS tissues)))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT a) (JJ significant) (NN fraction)) (PP (IN of) (NP (DT these)))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (JJ aberrant) (NN splicing))))))))))))) (. .))))
(S1 (S (S (SBAR (IN While) (S (NP (PRP we)) (VP (MD can) (RB not) (VP (VB exclude) (SBAR (IN that) (S (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (NN TSG101)) (CC and) (NP (NN FHIT))))) (VP (VBP occur) (PP (IN during) (NP (NN cancer) (NN development)))))))))) (, ,) (S (NP (PRP$ our) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN in) (NP (DT this) (NN context))) (NP (DT the) (ADJP (RB commonly) (VBN observed)) (NN transcript) (NNS abnormalities)) (VP (VBP are) (ADJP (JJ misleading))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Impaired) (NN cortisol) (NN binding)) (PP (TO to) (NP (NN glucocorticoid) (NNS receptors))) (PP (IN in) (NP (JJ hypertensive) (NNS patients))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBD compared) (NP (NP (NN glucocorticoid) (NN receptor) (NN binding) (NNS characteristics)) (CC and) (NP (NP (NN glucocorticoid) (NN responsiveness)) (PP (IN of) (NP (NP (NP (JJ human) (JJ mononuclear) (NNS leukocytes)) (PRN (-LRB- -LRB-) (NP (NN HML)) (-RRB- -RRB-))) (PP (IN from) (NP (NP (JJ hypertensive) (NNS patients)) (CC and) (NP (VBD matched) (JJ normotensive) (NNS volunteers))))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD considered) (NP (NP (NNS associations)) (PP (IN of) (NP (DT these) (NNS variables))) (PP (IN with) (NP (NP (NN plasma) (NP (NN renin)) (NN activity)) (, ,) (NP (NP (NN aldosterone)) (, ,) (NP (NN cortisol)) (, ,) (NP (NN corticotropin)) (, ,) (CC and) (NP (NN electrolyte)) (NP (NNS concentrations))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD calculated) (NP (NP (NN binding) (NP (NP (NN affinity)) (PRN (-LRB- -LRB-) (NP (NP (NN Kd)) (: ;) (NP (NN nmol/L))) (-RRB- -RRB-))) (CC and) (NP (NP (NN capacity)) (PRN (-LRB- -LRB-) (NP (NP (NN Bmax)) (: ;) (NP (NNS sites/cell))) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN dexamethasone)) (CC and) (NP (NN cortisol))))) (PP (IN from) (NP (NP (NP (ADJP (JJ homologous))) (CC and) (NP (ADJP (JJ heterologous))) (NP (NN competition) (NNS curves))) (PP (IN for) (NP (NP (JJ specific) (NN -LSB-3H-RSB-dexamethasone) (NN binding) (NNS sites)) (PP (IN on) (NP (NP (NN HML)) (VP (VBN isolated) (PP (IN from) (NP (NP (DT the) (NN blood)) (PP (IN of) (NP (NP (JJ normotensive) (NNS volunteers)) (CC and) (NP (NP (NNS subjects)) (PP (IN with) (NP (JJ essential) (NN hypertension)))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Glucocorticoid) (NN responsiveness)) (PP (IN of) (NP (NN HML)))) (VP (VBD was) (VP (VBN evaluated) (PP (IN as) (NP (NP (NP (NN IC50) (NNS values)) (PRN (-LRB- -LRB-) (NP (NN nmol/L)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NP (NN dexamethasone)) (CC and) (NP (NN cortisol))) (PP (IN for) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (NN lysozyme)) (NN release))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD measured) (NP (NN plasma) (NNS hormones)) (PP (IN by) (NP (NN radioimmunoassay)))) (. .))))
(S1 (S (S (S (NP (NP (NP (NN Kd) (NNS values)) (PRN (-LRB- -LRB-) (NP (NN mean+/-SE)) (-RRB- -RRB-))) (PP (IN for) (NP (NN cortisol))) (PP (IN in) (NP (NP (NN HML)) (PP (IN of) (NP (JJ hypertensive) (NNS patients)))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (PP (IN than) (PP (IN in) (NP (NN control) (NNS subjects))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 24.6+/-2.4))) (CC versus) (NP (QP (CD 17.5+/-1.7))) (NP (NN nmol/L))) (, ,) (NP (NP (NN P)) (ADJP (JJR &lt;) (NP (CD .04))))) (-RRB- -RRB-)) (. .))))
(S1 (S (S (NP (NP (NP (NN Binding) (NN capacity)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 4978+/-391))) (CC versus) (NP (QP (CD 4131+/-321))) (NP (NNS sites/cell))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN Kd) (NNS values)) (PP (IN for) (NP (NN dexamethasone)))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 6.7+/-0.5))) (CC versus) (NP (QP (CD 5.7+/-0.3))) (NP (NN nmol/L))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN IC50) (NNS values)) (PP (IN for) (NP (NP (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 3.4+/-0.3))) (CC versus) (NP (QP (CD 3.1+/-0.2))) (NP (NN nmol/L))) (-RRB- -RRB-))) (CC and) (NP (NP (NN cortisol)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 12.2+/-1.6))) (CC versus) (NP (QP (CD 9.5+/-0.3))) (NP (NN nmol/L))) (-RRB- -RRB-))))))) (VP (VBD were) (RB not) (ADJP (RB significantly) (JJ different))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NP (NN renin)) (NNS values)) (ADJP (JJR less) (PP (IN than) (NP (NP (ADJP (CD 0.13) (NN ng)) (NN angiotensin) (NN I/L)) (PP (IN per) (NP (NN second))))))))) (VP (VBD were) (ADJP (ADJP (ADVP (RB markedly) (RBR less)) (JJ sensitive)) (PP (TO to) (NP (NN cortisol))) (PP (IN than) (NP (NP (DT those)) (PP (IN with) (NP (JJR higher) (NNS values))))))) (. .))))
(S1 (S (S (NP (NP (CC Both) (NP (NP (NN Kd)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 30.3+/-2.5))) (CC versus) (NP (QP (CD 19.2+/-2.4))) (NP (NN nmol/L))) (-RRB- -RRB-))) (CC and) (NP (NP (NN IC50) (NNS values)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 15.5+/-1.8))) (CC versus) (NP (QP (CD 8.9+/-1.2))) (NP (NN nmol/L))) (-RRB- -RRB-)))) (PP (IN for) (NP (NN cortisol)))) (VP (VBD were) (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJR lower) (NP (NN renin)) (NNS values)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR &lt;) (NP (CD .03)))) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Other) (NNS variables)) (, ,) (PP (VBG including) (NP (NP (NP (NN plasma) (NN hormone)) (CC and) (NP (NN electrolyte)) (NP (NNS values))) (CC and) (NP (NP (NN binding) (NNS characteristics)) (PP (IN for) (NP (NN dexamethasone)))))) (, ,)) (VP (VBD were) (RB not) (ADJP (JJ different))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN cortisol) (NN binding)) (PP (TO to) (NP (NN glucocorticoid) (NN receptor)))) (VP (VBZ is) (ADJP (RB slightly) (JJ impaired) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ essential) (NN hypertension)))))))))) (. .))))
(S1 (S (S (ADVP (FW In) (FW vivo)) (, ,) (NP (DT this)) (VP (MD could) (VP (VB lead) (PP (TO to) (NP (NP (JJ inappropriate) (NN binding)) (PP (IN of) (NP (NN cortisol))) (PP (TO to) (NP (NN mineralocorticoid) (NNS receptors))))))) (. .))))
(S1 (S (S (ADVP (RB Hence)) (, ,) (NP (NP (VBN decreased) (NN sensitivity)) (PP (TO to) (NP (NN cortisol)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN renin)) (NN suppression))))) (. .))))
(S1 (S (S (NP (DT This) (NN hypothesis)) (VP (VBZ is) (VP (VBN supported) (PP (IN by) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (NN hypertension)) (CC and) (NP (JJ low) (NP (NN renin)) (NN activity))) (, ,) (SBAR (WHNP (WDT which)) (S (NP (NNS others)) (VP (VBP have) (VP (VBN described) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ primary) (NN glucocorticoid) (NN resistance)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS mutations)) (PP (IN of) (NP (DT the) (NP (NN glucocorticoid) (NN receptor))))))))))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NN Repression)) (PP (IN of) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1))) (PP (IN through) (NP (NP (DT the) (JJ novel) (NN cooperation)) (PP (IN of) (NP (NP (JJ human) (NNS factors)) (NP (NP (NN YY1)) (CC and) (NP (NN LSF)))))))) (S (-LRB- -LSB-) (NP (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP J) (NNP Virol)) (NP (CD 1998) (NNP Feb)) (: ;) (NP (CD 72) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (: :) (NP (CD 1709))))) (-RRB- -RSB-))))))
(S1 (S (S (S (S (NP (NP (DT A) (NN subpopulation)) (PP (IN of) (NP (RB stably) (JJ infected) (JJ CD4+) (NNS cells))) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG producing) (NP (NN virus)) (PP (IN upon) (NP (NN stimulation)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN identified) (PP (IN in) (NP (JJ human) (NN immunodeficiency) (NN virus) (-LRB- -LRB-) (NN HIV) (-RRB- -RRB-) (JJ -positive) (NNS individuals))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP T.-W.Chun)) (, ,) (NP (NNP D.Finzi)) (, ,) (NP (NNP J.Margolick)) (, ,) (NP (NNP K.Chadwick)) (, ,) (NP (NNP D.Schwartz)) (, ,) (CC and) (NP (NNP R.F.Siliciano))) (, ,) (NP (NNP Nat.Med.1)) (: :) (NP (CD 1284-1290)) (, ,) (NP (CD 1995))) (-RRB- -RRB-)) (. .)))))
(S1 (S (S (NP (NP (JJ Few) (NN host) (NNS factors)) (SBAR (WHNP (WDT that)) (S (ADVP (RB directly)) (VP (VP (VBP limit) (NP (NN HIV-1) (NN transcription))) (CC and) (VP (MD could) (VP (VB support) (NP (NP (DT this) (NN state)) (PP (IN of) (NP (JJ nonproductive) (NN HIV-1) (NN infection)))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN described)))) (. .))))
(S1 (S (S (NP (NP (NN YY1)) (, ,) (NP (DT a) (ADJP (RB widely) (VBN distributed)) (NP (JJ human) (NN transcription) (NN factor))) (, ,)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NP (NP (NN HIV-1) (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-))) (NN transcription)) (CC and) (NP (NN virus) (NN production)))))))) (. .))))
(S1 (S (S (S (NP (NP (NN LSF)) (PRN (-LRB- -LRB-) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP (NP (NN LBP-1)) (, ,) (NP (NN UBP)) (, ,) (CC and) (NP (NN CP-2))))) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB repress) (NP (NN LTR) (NN transcription)) (ADVP (FW in) (FW vitro))))))))) (, ,) (CC but) (S (NP (NP (JJ transient) (NN expression)) (PP (IN of) (NP (NN LSF)))) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN LTR)) (NN activity))) (ADVP (FW in) (FW vivo)))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP report) (SBAR (IN that) (S (NP (CC both) (NP (NN YY1)) (CC and) (NP (NN LSF))) (VP (VBP participate) (PP (IN in) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (DT a) (NN complex)) (SBAR (WHNP (WDT that)) (S (VP (VBZ recognizes) (NP (NP (DT the) (NN initiation) (NN region)) (PP (IN of) (NP (DT the) (NP (NN HIV-1) (NN LTR)))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Further)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN found) (SBAR (IN that) (S (NP (DT these) (NNS factors)) (VP (VBP cooperate) (PP (IN in) (NP (NP (DT the) (NN repression)) (PP (IN of) (NP (NP (NP (NN LTR)) (NN expression)) (CC and) (NP (JJ viral) (NN replication))))))))))) (. .))))
(S1 (S (S (NP (DT This) (JJ cooperative) (NN function)) (VP (MD may) (VP (VB account) (PP (IN for) (NP (NP (DT the) (JJ divergent) (NNS effects)) (PP (IN of) (NP (NN LSF))) (VP (ADVP (RB previously)) (VBN observed) (ADVP (ADVP (FW in) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo)))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN cooperation)) (PP (IN of) (NP (CD two) (JJ general) (JJ cellular) (NN transcription) (NNS factors)))) (VP (MD may) (VP (VB allow) (PP (IN for) (NP (NP (DT the) (JJ selective) (NN downregulation)) (PP (IN of) (NP (NN HIV) (NN transcription))))))) (. .))))
(S1 (S (S (PP (IN Through) (NP (NP (DT this) (NN mechanism)) (PP (IN of) (NP (NN gene) (NN regulation))))) (, ,) (NP (NP (NN YY1)) (CC and) (NP (NN LSF))) (VP (MD could) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NP (NN establishment)) (CC and) (NP (NN maintenance))) (PP (IN of) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (NNS cells))) (VP (ADVP (ADVP (RB stably)) (CC but) (ADVP (RB nonproductively))) (VBN infected) (PP (IN with) (NP (NN HIV-1)))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Ras-related) (JJ GTP-binding) (NNS proteins)) (CC and) (NP (NP (NN leukocyte)) (NN signal) (NN transduction)) (. .)))))
(S1 (S (S (S (S (NP (NP (JJ Many) (NNS aspects)) (PP (IN of) (NP (NP (NN leukocyte)) (NN function)))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP (CC both) (NP (NP (JJ heterotrimeric))) (CC and) (NP (JJ Ras-related) (JJ GTP-binding) (NNS proteins))))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBZ is) (NP (NP (ADJP (ADJP (JJ little)) (ADJP (JJ definite))) (NN information)) (PP (IN about) (NP (NP (PRP$ their) (NNS roles)) (PP (IN in) (NP (DT the) (JJ specialized) (NNS processes))) (VP (VBN utilized) (PP (IN by) (NP (NNS leukocytes))) (PP (IN for) (NP (NN cell) (NN killing))))))))) (. .)))))
(S1 (S (S (NP (NP (JJ Recent) (NN progress)) (PP (IN in) (S (VP (VBG understanding) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (NP (NN phagocyte) (NN NADPH) (NN oxidase)))) (PP (IN by) (NP (DT the) (NP (NN Rac) (JJ GTP-binding) (NNS proteins))))))))) (VP (VBZ provides) (NP (NP (DT a) (NN basis)) (PP (IN for) (S (VP (VBG defining) (NP (NP (DT the) (JJ operational) (NNS characteristics)) (PP (IN of) (NP (CD one) (JJ such) (NN phagocyte) (NN system))))))))) (. .))))
(S1 (S (S (NP (NP (PRP It))) (VP (VBZ is) (ADJP (JJ clear)) (PP (IN from) (NP (JJ various) (NNS studies))) (SBAR (IN that) (S (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (NP (NN NADPH) (NN oxidase))))) (VP (MD can) (VP (VB be) (VP (VBN modulated) (PP (IN through) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT the) (JJ GTP-GDP) (NN state)) (PP (IN of) (NP (NN Rac))))))))))))) (. .))))
(S1 (S (S (S (NP (NNS Proteins)) (VP (VBP exist) (PP (IN in) (NP (NNS leukocytes)))) (ADJP (JJ able) (VP (TO to) (S (VP (VB modify) (NP (NP (JJ GTP-binding) (NN protein)) (NN function)) (PP (IN in) (NP (DT this) (NN manner)))))))) (, ,) (CC and) (S (NP (PRP$ their) (NN activity)) (VP (MD may) (VP (VB be) (VP (VBN regulated) (PP (IN by) (NP (NP (NNS signals)) (VP (VBN generated) (PP (IN on) (NP (NN phagocyte) (NN stimulation)))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Proteins)) (PP (IN of) (NP (DT the) (NP (NN Ras) (NN superfamily))))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ normal) (NN phagocyte) (NNS functions))))) (PP (IN through) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB modulate) (UCP (NP (NP (DT the) (NN assembly)) (PP (IN of) (NP (NN actin) (NNS filaments)))) (, ,) (NP (JJ direct) (NN vesicle) (NP (NN trafficking)) (CC and) (NP (NN fusion))) (, ,) (CC and) (ADVP (RB so) (RB forth)))))))))))))) (. .))))
(S1 (S (S (S (S (NP (NN OCA-B)) (VP (VP (VBZ is) (NP (NP (DT a) (JJ functional) (NN analog)) (PP (IN of) (NP (NN VP16))))) (CC but) (VP (VBZ targets) (NP (NP (DT a) (JJ separate) (NN surface)) (PP (IN of) (NP (DT the) (NP (NN Oct-1) (NN POU) (NN domain)))))))) (S (-LRB- -LSB-) (NP (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP Mol) (NNP Cell) (NNP Biol)) (NP (CD 1998) (NNP Apr)) (: ;) (NP (CD 18) (-LRB- -LRB-) (CD 4) (-RRB- -RRB-)) (: :) (NP (CD 2430))))) (-RRB- -RSB-))))))
(S1 (S (S (S (NP (NN OCA-B)) (VP (VBZ is) (NP (NP (DT a) (NP (JJ B-cell-specific) (NN coregulator))) (PP (IN of) (NP (NP (DT the) (ADJP (RB broadly) (VBN expressed)) (NP (NN POU) (NN domain) (NN transcription) (NN factor))) (NP (NN Oct-1)))))) (. .)))))
(S1 (S (S (NP (NN OCA-B)) (VP (VBZ associates) (PP (IN with) (NP (NP (DT the) (NP (NN Oct-1) (NN POU) (NN domain))) (, ,) (NP (NP (DT a) (ADJP (ADJP (JJ bipartite)) (ADJP (JJ DNA-binding))) (NN structure)) (VP (VBG containing) (NP (NP (DT a) (NP (JJ POU-specific) (-LRB- -LRB-) (JJ POU-LSB-S-RSB-) (-RRB- -RRB-) (NN domain))) (VP (VBN joined) (PP (IN by) (NP (NP (DT a) (JJ flexible) (NN linker)) (PP (TO to) (NP (NP (DT a) (NP (NN POU) (NN homeodomain))) (PRN (-LRB- -LRB-) (NP (NN POU-LSB-H-RSB-)) (-RRB- -RRB-))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NN OCA-B)) (VP (VBZ alters) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN Oct-1)))) (PP (IN in) (NP (CD two) (NNS ways))))))) (. .))))
(S1 (S (S (S (NP (PRP It)) (VP (VBZ provides) (NP (NP (DT a) (JJ transcriptional) (NN activation) (NN domain)) (SBAR (WHNP (WDT which)) (S (, ,) (PP (IN unlike) (NP (NN Oct-1))) (, ,) (VP (VBZ activates) (NP (DT an) (NP (JJ mRNA-type) (NN promoter))) (ADVP (RB effectively)))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ stabilizes) (NP (NN Oct-1)) (PP (IN on) (NP (NP (DT the) (NP (JJ Oct-1-responsive) (NN octamer) (NN sequence))) (NP (NN ATGCAAAT)))))) (. .))))
(S1 (S (S (NP (NP (DT These) (NNS properties)) (PP (IN of) (NP (NN OCA-B)))) (VP (VBP parallel) (NP (NP (DT those)) (VP (VBN displayed) (PP (IN by) (NP (NP (DT the) (NP (NN herpes) (JJ simplex) (NN virus) (NN Oct-1) (NN coregulator))) (NP (NN VP16))))))) (. .))))
(S1 (S (S (NP (NP (NN OCA-B)) (, ,)) (ADVP (RB however)) (, ,) (VP (VBZ interacts) (PP (IN with) (NP (NP (DT a) (JJ different) (NN surface)) (PP (IN of) (NP (DT the) (JJ DNA-bound) (NP (NN Oct-1) (NN POU) (NN domain)))))) (, ,) (S (VP (VBG interacting) (PP (IN with) (NP (CC both) (NP (DT the) (NP (JJ POU-LRB-S-RRB-) (CC and) (NN POU-LRB-H-RRB-) (NNS domains))) (CC and) (NP (NP (DT the) (NN center)) (PP (IN of) (NP (DT the) (NP (NN ATGCAAAT) (NN octamer) (NN sequence)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN OCA-B)) (CC and) (NP (NP (NN VP16))) (NP (NNS interactions))) (PP (IN with) (NP (DT the) (NP (NN Oct-1) (NN POU) (NN domain))))) (VP (VBP are) (ADJP (RB sufficiently) (JJ different)) (S (VP (TO to) (VP (VB permit) (S (NP (NP (NN OCA-B)) (CC and) (NP (NN VP16))) (VP (TO to) (VP (VB bind) (NP (DT the) (NP (NN Oct-1) (NN POU) (NN domain))) (ADVP (RB simultaneously))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP emphasize) (NP (NP (DT the) (JJ structural) (NN versatility)) (PP (IN of) (NP (DT the) (NP (NN Oct-1) (NN POU) (NN domain)))) (PP (IN in) (NP (NP (PRP$ its) (NN interaction)) (PP (IN with) (NP (NNS coregulators))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Extinction)) (PP (IN of) (NP (NP (NP (NN immunoglobulin) (NN gene)) (NN expression)) (PP (IN in) (NP (NN B) (NNS cells))))) (PP (IN upon) (NP (NP (NN fusion)) (PP (IN with) (NP (NN HeLa) (NNS cells)))))) (VP (VP (VBZ is) (VP (VBN preceded) (PP (IN by) (NP (NP (JJ rapid) (JJ nuclear) (NN depletion)) (PP (IN of) (NP (JJ essential) (NN transcription) (NNS factors))))))) (CC and) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ widespread) (NN inactivation)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN expressed) (PP (IN in) (NP (DT a) (NN B) (JJ cell-specific) (NN manner))))))))))) (. .)))))
(S1 (S (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN immunoglobulin) (-LRB- -LRB-) (NN Ig) (-RRB- -RRB-) (NN expressing) (NN B) (NNS cells)) (VP (VBP are) (VP (VBN fused) (PP (IN with) (NP (JJ non-B) (NNS cells))))))) (, ,) (S (S (NP (NN Ig) (NN expression)) (VP (VBZ is) (ADVP (RB rapidly)) (VP (VBN suppressed) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN transcription)))))))) (, ,) (NP (NP (DT a) (NN phenomenon)) (VP (VBN termed) (S (NP (NN extinction)))))) (. .)))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN fusion)) (PP (IN of) (NP (NN HeLa) (NNS cells))) (PP (IN with) (NP (CC either) (NP (ADJP (JJ diploid))) (CC or) (NP (ADJP (JJ tetraploid))) (NP (NN B) (NNS cells))) (PRN (-LRB- -LRB-) (NP (NN Daudi)) (-RRB- -RRB-)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJ widespread) (NN extinction)) (PP (IN of) (NP (NP (ADJP (JJ several) (JJ other)) (NP (NN B) (JJ cell-encoded) (NNS genes))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN expressed) (PP (IN in) (NP (DT a) (NN B) (JJ cell-specific) (NN manner))))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NN B) (JJ cell-expressed) (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (ADJP (JJ dependent) (PP (IN on) (NP (JJ cell-specific) (NNS controls)))))))))) (VP (VBZ is) (ADJP (JJ unaffected))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ molecular) (NN mechanism) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (VP (VBG underlying) (NP (NP (NN Ig) (NN gene)) (NN extinction)))) (VP (MD can) (VP (VB be) (VP (VBN explained) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (IN by) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ essential) (PP (IN for) (NP (NP (NN Ig) (NN gene)) (NN transcription))))))))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NP (NN transcription) (NNS factors))) (VP (VP (VBP are) (CC either) (VP (RB not) (VBN produced) (ADJP (JJ due) (PP (TO to) (NP (NP (NN block)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (PRP$ their) (JJ respective) (NNS genes)) (PRN (-LRB- -LRB-) (NP (NP (NN Oct-2)) (, ,) (NP (NN OBF-1)) (, ,) (NP (NN PU.1))) (-RRB- -RRB-))))))))))) (, ,) (CC or) (VP (VBP are) (VP (VBN rendered) (S (ADJP (JJ inactive) (ADVP (ADVP (RB posttranslationally)) (PRN (-LRB- -LRB-) (NP (NP (NN NF-kappa) (NN B)) (, ,) (NP (NN E47))) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (S (PP (IN By) (S (VP (VBG isolating) (NP (JJ Daudi) (NN x) (NN HeLa) (NNS heterokaryons)) (PP (NP (DT a) (JJ few) (NNS hours)) (IN after) (NP (NN fusion)))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN studied) (NP (NP (DT the) (JJ initial) (NN fate)) (PP (IN of) (NP (NP (CD two) (NP (NN B) (JJ cell-specific) (NN transcription) (NNS factors))) (VP (VBN involved) (PP (IN in) (NP (NP (NN Ig) (NN gene)) (NN transcription)))) (, ,) (NP (NP (NN Oct-2)) (CC and) (NP (NN NF-kappa) (NN B)))))))) (. .))))
(S1 (S (S (NP (DT This) (NN report)) (VP (VBZ provides) (NP (DT the) (JJ first) (NN demonstration) (SBAR (IN that) (S (PP (IN upon) (NP (NP (NN fusion)) (PP (IN with) (NP (NN HeLa) (NNS cells))))) (, ,) (NP (NP (DT the) (JJ nuclear) (NNS contents)) (PP (IN of) (NP (NN B) (JJ cell-expressed) (NN transcription) (NNS factors)))) (VP (VBP are) (VP (VBN depleted) (PP (IN within) (NP (DT a) (JJ few) (NNS hours))) (PP (IN with) (NP (NP (NNS kinetics)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (IN as) (ADJP (ADJP (JJ fast)) (CC or) (ADJP (JJR faster))) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN Ig) (NN gene)) (NN extinction))))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (DT the) (NN extinguishing) (NN mechanism)) (VP (VBZ is) (ADJP (JJ effective) (PP (ADVP (RB very) (RB early)) (IN after) (NP (NN fusion))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN extinction)) (PP (IN of) (NP (NN Ig) (NNS genes)))) (VP (VBZ is) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJ global) (NN mechanism)) (SBAR (WHNP (WDT that)) (S (VP (VBZ suppresses) (NP (NP (DT the) (NN differentiation) (NN program)) (ADJP (JJ foreign) (PP (TO to) (NP (DT the) (NP (NN HeLa) (NN phenotype)))))))))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Nuclear) (NN accumulation)) (PP (IN of) (NP (NN NFAT4))) (VP (VBN opposed) (PP (IN by) (NP (DT the) (NP (NN JNK)) (NN signal) (NN transduction) (NN pathway)))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NP (JJ nuclear) (NN factor) (IN of) (VBN activated) (NN T) (NNS cells) (-LRB- -LRB-) (NN NFAT) (-RRB- -RRB-) (NN group))) (PP (IN of) (NP (NN transcription) (NNS factors)))) (VP (VBZ is) (VP (VBN retained) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (JJ quiescent) (NNS cells))))))) (. .)))))
(S1 (S (S (NP (NP (NN NFAT)) (NN activation)) (VP (VBZ is) (VP (VBN mediated) (PP (IN in) (NP (NN part))) (PP (IN by) (NP (VBN induced) (JJ nuclear) (NN import))))) (. .))))
(S1 (S (S (NP (DT This) (NN process)) (VP (VBZ requires) (NP (NP (JJ calcium-dependent) (NN dephosphorylation)) (PP (IN of) (NP (NN NFAT))) (VP (VBN caused) (PP (IN by) (NP (DT the) (NP (NN phosphatase)) (NP (NN calcineurin))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN c-Jun) (JJ amino-terminal) (NN kinase))) (PRN (-LRB- -LRB-) (NP (NN JNK)) (-RRB- -RRB-))) (VP (VBZ phosphorylates) (NP (NN NFAT4)) (PP (IN on) (NP (CD two) (NNS sites)))) (. .))))
(S1 (S (S (NP (NP (JJ Mutational) (NN removal)) (PP (IN of) (NP (DT the) (NP (NN JNK) (NN phosphorylation) (NNS sites))))) (VP (VBD caused) (NP (NP (JJ constitutive) (JJ nuclear) (NN localization)) (PP (IN of) (NP (NN NFAT4))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NP (NN JNK)) (NN activation)) (PP (IN in) (NP (JJ calcineurin-stimulated) (NNS cells)))) (VP (VBD caused) (NP (NP (JJ nuclear) (NN exclusion)) (PP (IN of) (NP (NN NFAT4))))) (. .))))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ nuclear) (NN accumulation)) (PP (IN of) (NP (NN NFAT4))) (VP (VBN promoted) (PP (IN by) (NP (NN calcineurin))))) (VP (VBZ is) (VP (VBN opposed) (PP (IN by) (NP (DT the) (NP (NN JNK)) (NN signal) (NN transduction) (NN pathway)))))))) (. .))))
(S1 (S (NP (NP (NN Pathogenesis) (. .)))))
(S1 (S (S (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ many) (NNS hypotheses)) (VP (VBG concerning) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN endometriosis)))))) (, ,) (SBAR (IN though) (S (NP (DT no) (JJ single) (NN theory)) (VP (MD can) (VP (VB explain) (NP (DT all) (NNS cases))))))) (. .)))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ likely) (SBAR (IN that) (S (NP (JJ several) (NNS mechanisms)) (VP (VBP are) (VP (VBN involved))))))) (. .))))
(S1 (S (S (NP (JJ Early) (NNS studies)) (VP (VBD concentrated) (PP (IN on) (NP (NP (DT the) (NN histogenesis)) (PP (IN of) (NP (DT the) (JJ endometriotic) (NN lesion)))))) (. .))))
(S1 (S (S (NP (JJ Recent) (NN evidence)) (VP (VBZ has) (VP (VBN implicated) (NP (NP (NNS components)) (PP (IN of) (NP (DT the) (JJ immune) (NN system)))) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN endometriosis))))))) (. .))))
(S1 (S (S (NP (DT This) (NN review)) (VP (VP (VBZ considers) (NP (NP (DT the) (NN evidence)) (PP (IN for) (NP (NP (JJ different) (NNS theories)) (PP (IN of) (NP (NP (DT the) (NN histogenesis)) (PP (IN of) (NP (NN endometriosis))))))))) (CC and) (VP (VBZ discusses) (NP (NP (JJ possible) (JJ immune) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (DT the) (NN disease))))))))))))) (. .))))
(S1 (S (NP (-LRB- -LSB-) (NP (DT The) (NN value)) (PP (IN of) (NP (NP (DT the) (JJ clinical) (NN test)) (PP (IN of) (NP (NP (NN glucocorticoid) (NNS receptors)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ pulmonary) (NN heart) (NN disease))))))))))) (-RRB- -RSB-))))
(S1 (S (S (SBAR (IN In) (NN order) (TO to) (S (VP (VB inquire) (PP (IN into) (NP (NP (DT the) (JJ functional) (NN state)) (PP (IN of) (NP (NP (JJ adrenal) (NN cortex)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pulmonary) (NN heart) (NN disease)))))))))))) (, ,) (S (S (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NP (NN glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN GCR)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ pulmonary) (NN heart) (NN disease)))))))))) (VP (VBD was) (VP (VBN determined) (PP (IN with) (NP (JJ radioligand-binding) (NN assay)))))) (CC and) (S (NP (DT the) (JJ corresponding) (NN plasma) (NN cortisol) (NNS levels)) (VP (VBD were) (VP (VBN assessed) (PP (IN with) (NP (JJ radioimmune) (NNS assays))))))) (. .))))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (S (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (DT the) (NNS patients)))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN reduced) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-))))) (CC and) (S (NP (PRP it)) (VP (VBD was) (VP (VBN increased) (SBAR (WHADVP (WRB when)) (S (NP (PRP$ their) (NN health) (NN state)) (VP (VBD was) (VP (VBN improved))))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (VBD was) (ADVP (RB still)) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (DT the) (NNS patients)))))) (VP (VBD was) (ADVP (RB greatly)) (VP (VBN increased) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS patients)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NN oxygen))))))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-)))) (. .))))
(S1 (S (S (NP (NP (DT No) (NN difference)) (PP (IN in) (NP (NN plasma) (NN cortisol)))) (VP (VBD was) (VP (VBN found) (PP (IN between) (NP (NP (DT the) (NNS patients)) (CC and) (NP (DT the) (JJ healthy) (NNS subjects)))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (QP (JJR &gt;) (CD 0.05)))) (-RRB- -RRB-)))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NP (DT the) (NN function)) (PP (IN of) (NP (JJ adrenal) (NN cortex)))) (VP (MD may) (VP (VB be) (VP (VBN improved) (PP (IN by) (NP (NP (DT the) (NN compensation) (NN mechanism)) (PP (IN of) (NP (DT the) (NNS patients))))))))) (, ,) (CC but) (S (NP (DT the) (JJR lower) (NN GCR) (NN number)) (VP (VBD was) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (NN lacking)) (PP (IN of) (NP (NN oxygen))) (PP (IN in) (NP (DT the) (NNS patients))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NN GCR)))) (VP (MD may) (VP (VB be) (VP (VBN improved) (PP (IN by) (NP (NP (NN inhalation)) (PP (IN of) (NP (NN oxygen)))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (NP (NN oxygen) (NN therapy)) (VP (VBZ is) (ADJP (JJ helpful)) (PP (IN in) (S (VP (VP (VBG raising) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN glucocorticoid) (NNS receptors))))) (CC and) (VP (VBG controlling) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (NN disease))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (JJ Molecular) (NN cloning)) (CC and) (NP (JJ functional) (NN characterization))) (PP (IN of) (NP (NP (JJ murine) (NN cDNA) (NN encoding) (NN transcription) (NN factor)) (NP (NN NFATc)))) (. .)))))
(S1 (S (S (S (NP (NP (NN Transcription) (NNS factors)) (PP (IN of) (NP (DT the) (NP (NN NFAT) (-LRB- -LRB-) (JJ nuclear) (NN factor) (IN of) (VBN activated) (NN T) (NNS cells) (-RRB- -RRB-) (NN family))))) (VP (VBP play) (NP (JJ important) (NNS roles)) (PP (IN in) (NP (NP (ADJP (JJ immune))) (CC and) (NP (ADJP (JJ inflammatory))) (NP (NNS responses)))) (PP (IN by) (S (VP (VBG regulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBG encoding) (NP (NP (NNS cytokines)) (CC and) (NP (JJ immunoregulatory) (NNS proteins))))))))))) (. .)))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP describe) (NP (NP (NP (NN cloning)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (JJ full-length) (NP (NN cDNA) (NN encoding) (JJ murine) (-LRB- -LRB-) (JJ m) (-RRB- -RRB-) (NN NFATc)))) (SBAR (WHNP (WDT which)) (S (VP (VBZ predicts) (SBAR (IN that) (S (NP (DT the) (NN protein)) (VP (VBZ has) (NP (NP (PDT all) (DT the) (NP (VBN conserved) (JJ structural) (NNS motifs))) (PP (IN of) (NP (NN NFAT) (NN family) (NNS members))) (, ,) (PP (VBG including) (NP (NP (DT the) (NN rel) (NN homology) (NN domain)) (, ,) (NP (DT the) (NP (NN NFAT) (NN homology) (NN domain))) (CC and) (NP (DT the) (JJ nuclear) (NN translocation) (NNS signals))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN mNFATc)) (VP (VBN complexed) (PP (IN with) (NP (NN AP-1))))) (VP (VP (VBD bound) (ADVP (RB specifically)) (PP (TO to) (NP (DT the) (NP (JJ murine) (NN IL-2) (NN NFAT) (NN recognition) (NN sequence))))) (CC and) (VP (VBD activated) (NP (NN transcription)) (PP (IN from) (NP (NP (DT the) (NP (JJ co-transfected) (NN IL-2) (NN promoter))) (PP (IN in) (NP (NN COS-7) (NNS cells))))))) (. .))))
(S1 (S (S (NP (NN Northern) (NN blot) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (NP (NN cDNA) (NN probe))) (VP (VBD hybridized) (PP (IN with) (NP (NP (DT a) (ADJP (CD 4.5) (NN kb)) (NN transcript)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (RB highly) (JJ inducible) (PP (IN in) (NP (JJ murine) (NN T) (NNS cells))))))))))))) (. .))))
(S1 (S (S (PP (IN By) (NP (NP (NN Northern)) (CC and) (NP (ADJP (FW in) (FW situ))) (NP (NN hybridization)))) (, ,) (NP (NN mNFATc) (NN transcript)) (VP (VBD was) (VP (VBN detected) (PP (IN from) (NP (NP (DT the) (JJ early) (NN stage)) (PP (IN of) (NP (NN development))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (NN mouse) (NN embryo))) (, ,) (NP (NN mNFATc) (NN transcript)) (VP (VP (VBD was) (ADVP (RB strongly)) (VP (VBN expressed) (PP (IN in) (NP (NP (NN thymus)) (, ,) (NP (NN lung)) (CC and) (NP (JJ submandibular) (NN gland)))))) (CC and) (VP (ADVP (RB weakly)) (PP (IN in) (NP (NP (JJ skeletal) (NN muscle)) (CC and) (NP (NN heart))))) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN mNFATc)) (VP (MD may) (VP (VB have) (NP (DT a) (NN role)) (PP (CC both) (PP (IN in) (NP (NN embryogenesis))) (CC and) (PP (IN in) (NP (JJ mature) (NN T) (NNS cells))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Differanisole) (NN A)) (, ,) (NP (DT a) (ADJP (ADJP (JJ novel)) (ADJP (JJ antitumor))) (NN antibiotic)) (, ,)) (VP (VBZ enhances) (NP (NP (NP (NN growth) (NN inhibition)) (CC and) (NP (NN differentiation))) (PP (IN of) (NP (JJ human) (JJ myeloid) (NN leukemia) (NNS cells))) (VP (VBN induced) (PP (IN by) (NP (JJ 9-cis) (JJ retinoic) (NN acid)))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Differanisole) (NN A)) (, ,) (NP (JJ 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic) (NN acid)) (, ,)) (VP (VBD inhibited) (NP (NP (NN growth)) (PP (IN of) (NP (JJ human) (JJ myeloid) (NN leukemia) (NNS cells))))) (. .)))))
(S1 (S (S (NP (DT The) (NN compound)) (VP (VBD induced) (NP (NP (NP (NN G1) (NN arrest)) (CC and) (NP (JJ granulocytic) (NN differentiation))) (PP (IN of) (NP (NN HL-60) (NNS cells)))) (, ,) (SBAR (IN although) (S (NP (DT the) (JJ differentiation-inducing) (NN effect)) (VP (VBD was) (ADJP (JJ modest)))))) (. .))))
(S1 (S (S (NP (NP (NN Differanisole) (DT A)) (CC and) (NP (NP (JJ 9-cis) (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN 9cisRA)) (-RRB- -RRB-)))) (ADVP (RB synergistically)) (VP (VBD inhibited) (NP (NP (NP (DT the) (NN growth)) (CC and) (NP (VBD induced) (NP (ADJP (JJ functional))) (CC and) (NP (ADJP (JJ morphologic))) (NP (NN differentiation)))) (PP (IN of) (NP (NP (NN HL-60)) (CC and) (NP (NN NB4)) (NP (NNS cells))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ combined) (NN treatment)) (PP (IN with) (NP (NP (NN differanisole) (NN A)) (CC and) (NP (NP (JJ all-trans) (JJ retinoic) (NN acid)) (CC or) (NP (NN 1alpha,25-dihydroxyvitamin) (NN D3)))))) (VP (VBD was) (ADJP (RBR less) (JJ effective)))))) (. .))))
(S1 (S (S (NP (JJ Similar) (NNS results)) (VP (VBD were) (VP (VBN obtained) (PP (IN in) (NP (NP (JJ primary) (NN culture)) (PP (IN of) (NP (NP (NN leukemia) (NNS cells)) (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ acute) (JJ promyelocytic) (NN leukemia))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ synergistic) (NN effect)) (PP (IN on) (NP (NP (NN growth) (NN inhibition)) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NN differentiation))))))) (VP (VBD required) (NP (NP (JJ simultaneous) (NN treatment)) (PP (IN with) (NP (NP (NN differanisole) (NN A)) (CC and) (NP (NN 9cisRA)))))) (. .))))
(S1 (S (S (NP (NP (NN Differanisole) (NN A)) (CC and) (NP (NP (DT an) (JJ RXR-specific) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NN Ro47-5944)) (-RRB- -RRB-)))) (ADVP (RB cooperatively)) (VP (VBD inhibited) (NP (DT the) (NN cell) (NN growth)) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (JJ combined) (NN effect)) (PP (IN of) (NP (NP (NN differanisole) (NN A)) (CC and) (NP (NP (DT an) (JJ RAR-specific) (NN ligand)) (NP (NN Am80)))))) (VP (VBD was) (ADJP (RB just) (JJ additive)))))) (. .))))
(S1 (S (S (NP (NP (NN Differanisole) (NN A)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN 9cisRA)))))) (VP (MD may) (VP (VB have) (NP (NNS implications)) (PP (IN for) (NP (NP (NN therapy)) (PP (IN of) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (NNS patients))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Molecular) (NNS mechanisms)) (PP (IN of) (NP (NP (JJ anoxia/reoxygenation-induced) (NN neutrophil) (NN adherence)) (PP (TO to) (NP (VBN cultured) (JJ endothelial) (NNS cells))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NNS objectives)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD were) (S (VP (TO to) (VP (VP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (VB determine) (NP (NP (DT the) (NN time) (NN course)) (PP (IN of) (NP (NP (NN neutrophil) (NN adhesion)) (PP (TO to) (NP (NP (NNS monolayers)) (PP (IN of) (NP (NP (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS HUVECs)) (-RRB- -RRB-)))) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (CD 60) (NNS minutes)) (PP (IN of) (NP (NN anoxia))) (VP (VBN followed) (PP (IN by) (NP (NP (QP (CD 30) (TO to) (CD 600)) (NNS minutes)) (PP (IN of) (NP (NN reoxygenation)))))))))))))))))) (CC and) (VP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (VB define) (NP (NP (DT the) (NNS mechanisms)) (ADJP (JJ responsible) (PP (IN for) (NP (CC both) (DT the) (NP (ADJP (ADJP (JJ early)) (PRN (-LRB- -LRB-) (NP (NNS minutes)) (-RRB- -RRB-)))) (CC and) (NP (ADJP (ADJP (JJ late)) (PRN (-LRB- -LRB-) (NP (NNS hours)) (-RRB- -RRB-)))) (NP (NP (NN hyperadhesivity)) (PP (IN of) (NP (JJ postanoxic) (NNS HUVECs))) (PP (TO to) (NP (JJ human) (NNS neutrophils))))))))))))) (. .)))))
(S1 (S (S (NP (DT The) (NNS results)) (ADVP (RB clearly)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN anoxia/reoxygenation)) (PRN (-LRB- -LRB-) (NP (NN A/R)) (-RRB- -RRB-))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (JJ biphasic) (NN increase)) (PP (IN in) (NP (NP (NN neutrophil) (NN adhesion)) (PP (TO to) (NP (NNS HUVECs))))))) (, ,) (PP (IN with) (S (NP (NN peak) (NNS responses)) (VP (VBG occurring) (PP (IN at) (NP (NP (NP (NP (CD 30) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (NN phase) (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 240) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (NN phase) (CD 2)) (-RRB- -RRB-)))) (PP (IN after) (NP (NN reoxygenation)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Oxypurinol)) (CC and) (NP (NN catalase))) (VP (VBD inhibited) (NP (JJ phase-1) (NN adhesion)) (, ,) (S (VP (VBG suggesting) (NP (DT a) (NN role)) (PP (IN for) (NP (NP (NN xanthine) (NN oxidase)) (CC and) (NP (NN H2O2))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN comparison))) (, ,) (NP (NP (NN platelet) (NN activating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN PAF)) (-RRB- -RRB-))) (VP (VBD contributed) (PP (TO to) (NP (NP (CC both) (NNS phases)) (PP (IN of) (NP (NN neutrophil) (NN adhesion)))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Anti-intercellular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN ICAM-1)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ anti-P-selectin) (NNS antibodies)) (PRN (-LRB- -LRB-) (NP (NP (JJ monoclonal) (NNS antibodies)) (PRN (-LRB- -LSB-) (NP (NNS mAbs)) (-RRB- -RSB-))) (-RRB- -RRB-)))) (VP (VBD attenuated) (NP (JJ phase-1) (NN neutrophil) (NN adhesion)) (, ,) (ADVP (JJ consistent) (PP (IN with) (NP (NP (NNS roles)) (PP (IN for) (NP (NP (ADJP (RB constitutively) (VBN expressed)) (NP (NN ICAM-1))) (CC and) (NP (NP (VBN enhanced) (NN surface) (NN expression)) (PP (IN of) (NP (JJ preformed) (NP (NN P-selectin))))))))))) (. .))))
(S1 (S (S (NP (NN Phase-2) (NN neutrophil) (NN adhesion)) (VP (VBD was) (VP (VBN attenuated) (PP (IN by) (NP (DT an) (NP (JJ anti-E-selectin) (NN mAb))))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (JJ dominant) (NN role)) (PP (IN of) (NP (DT this) (NN adhesion) (NN molecule))) (PP (IN in) (NP (DT the) (JJ late) (NN phase) (NN response))))))) (. .))))
(S1 (S (S (NP (NP (NN Pretreatment)) (PP (PP (IN with) (NP (NP (NN actinomycin) (NN D)) (CC and) (NP (NN cycloheximide)))) (CC or) (PP (IN with) (NP (NP (VBG competing) (NNS ds-oligonucleotides)) (VP (VBG containing) (NP (NP (DT the) (NP (JJ nuclear) (NN factor-kappa) (NN B))) (CC or) (NP (NP (NN activator) (NN protein-1)) (NP (NN cognate) (NN DNA) (NNS sequences))))))))) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (NN phase-2) (NN response)) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (ADJP (FW de) (FW novo)) (NN macromolecule) (NN synthesis))))))) (. .))))
(S1 (S (S (NP (NP (NN Surface) (NN expression)) (PP (IN of) (NP (NP (NN ICAM-1)) (, ,) (NP (NN P-selectin)) (, ,) (CC and) (NP (NN E-selectin)))) (PP (IN on) (NP (NNS HUVECs)))) (VP (VBD correlated) (PP (IN with) (NP (DT the) (NP (JJ phase-1)) (CC and) (NP (CD -2)) (NP (NN neutrophil) (NN adhesion) (NNS responses))))) (. .))))
(S1 (S (S (ADVP (RB Collectively)) (, ,) (NP (DT these) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN A/R)) (VP (VBZ elicits) (NP (NP (DT a) (JJ two-phase) (JJ neutrophil-endothelial) (NN cell) (NN adhesion) (NN response)) (SBAR (WHNP (WDT that)) (S (VP (VBZ involves) (NP (NP (ADJP (JJ transcription-independent))) (CC and) (NP (ADJP (JJ transcription-dependent))) (NP (NP (NN surface) (NN expression)) (PP (IN of) (NP (JJ different) (NP (JJ endothelial) (NN cell) (NN adhesion) (NNS molecules)))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN B) (NNS lymphocytes)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ lymphocytic) (NN leukemia)))))) (VP (VBP contain) (NP (NP (NP (NN signal) (NN transducer) (CC and) (NN activator) (IN of) (NN transcription) (-LRB- -LRB-) (NN STAT) (-RRB- -RRB-) (CD 1)) (CC and) (NP (NN STAT3))) (VP (ADVP (RB constitutively)) (VBN phosphorylated) (PP (IN on) (NP (NN serine) (NNS residues)))))) (. .)))))
(S1 (S (S (S (S (VP (TO To) (VP (VB explore) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (JJ chronic) (JJ lymphocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN CLL)) (-RRB- -RRB-)))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NP (CD one)) (CC or) (NP (JJR more)) (NP (NN signal) (NN transducer) (CC and) (NN activator) (IN of) (NN transcription) (-LRB- -LRB-) (NN STAT) (-RRB- -RRB-) (NNS factors))))) (VP (VBD was) (ADJP (JJ abnormal) (PP (IN in) (NP (NP (NNS cells)) (PP (IN from) (NP (NN CLL) (NNS patients))))))))))) (. .)))))
(S1 (S (S (NP (DT No) (JJ constitutive) (NN tyrosine) (NN phosphorylation)) (VP (VBD was) (VP (VBN detected) (PP (IN on) (NP (NP (DT any) (NP (NN STAT))) (PP (IN in) (NP (NN CLL) (NNS cells))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NP (NN serine) (NNS residues)) (PP (IN of) (NP (NP (NP (NN STAT1)) (CC and) (NP (NN STAT3))) (PP (IN in) (NP (NN CLL) (NNS cells))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD raised) (NP (NP (NNS antibodies)) (SBAR (WHNP (WDT that)) (S (ADVP (RB specifically)) (VP (VBP recognize) (NP (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NP (NN STAT1)) (VP (VBN phosphorylated) (PP (IN on) (NP (NN ser-727))))))) (CC and) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NP (NN STAT3)) (VP (VBN phosphorylated) (PP (IN on) (NP (NN ser-727)))))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (PP (IN in) (NP (NP (CD 100) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN CLL))) (PRN (-LRB- -LRB-) (NP (NP (NN n)) (ADJP (JJ =) (NP (CD 32)))) (-RRB- -RRB-)))))) (, ,) (NP (NP (NN STAT1)) (CC and) (NP (NN STAT3))) (VP (VBD were) (ADVP (RB constitutively)) (VP (VBN phosphorylated) (PP (IN on) (NP (NN serine)))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBD was) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (JJ normal) (NP (JJ peripheral) (NN blood) (NP (NN B) (NNS lymphocytes))) (CC or) (NP (JJ CD5+-RRB-) (NN B) (NNS cells))) (VP (VBN isolated) (PP (IN from) (NP (NNS tonsils)))) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT this) (NN phosphorylation)) (VP (VBD was) (ADJP (JJ absent)))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Serine) (NN phosphorylation)) (PP (IN of) (NP (NP (NN STAT1)) (CC and) (NP (NN STAT3))))) (VP (VBD was) (VP (VBN seen) (ADVP (RB occasionally)) (PP (IN in) (NP (JJ other) (NNS leukemias)))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBD was) (NP (NP (DT a) (JJ universal) (NN finding)) (PP (ADVP (RB only)) (IN in) (NP (NN CLL)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN serine) (NN phosphorylation)) (PP (IN of) (NP (DT these) (NP (NNS STATs))))) (VP (VBD was) (NP (DT a) (JJ continuous) (NN process)) (, ,) (SBAR (IN as) (S (NP (NP (NN incubation)) (PP (IN of) (NP (NN CLL) (NNS cells))) (PP (IN with) (NP (DT the) (NP (NN kinase) (NN inhibitor) (NN H7))))) (VP (VBD led) (PP (TO to) (NP (NP (DT the) (NN dephosphorylation)) (PP (IN of) (NP (DT these) (NN serine) (NNS residues))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN STAT) (NN serine) (NN kinase)) (PP (IN in) (NP (NN CLL) (NNS cells)))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN identified)))) (, ,) (CC and) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP (DT neither) (NP (JJ mitogen-activated) (NN protein) (NN kinase)) (CC nor) (NP (NN pp70-LRB-s6k-RRB-)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NP (DT the) (JJ constitutive) (NN serine) (NN phosphorylation)) (PP (IN of) (NP (NP (NN STAT1)) (CC and) (NP (NN STAT3))))) (VP (VBZ is) (ADJP (JJ present) (PP (IN in) (NP (NP (DT all) (NN CLL) (NNS samples)) (VP (VBN tested) (PP (TO to) (NP (NN date))))))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (JJ physiologic) (NN significance)) (PP (IN of) (NP (DT this) (NN modification)))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN determined))))))))) (. .))))
(S1 (S (S (S (NP (NN C/EBP)) (VP (VBZ activates) (NP (DT the) (NP (JJ human) (JJ corticotropin-releasing) (NN hormone) (NN gene) (NN promoter)))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBD was) (S (VP (TO to) (VP (VB identify) (SBAR (IN whether) (S (NP (NP (NN transcription) (NNS factors)) (, ,) (VP (VBN associated) (PP (IN with) (NP (NN cytokine) (NN signalling)))) (, ,)) (VP (VBD affected) (NP (NP (NN promoter) (NN activity)) (PP (IN of) (NP (DT the) (NP (NN corticotropin) (NN releasing) (NN hormone) (-LRB- -LRB-) (NN CRH) (-RRB- -RRB-) (NN gene)))))))))))) (. .)))))
(S1 (S (S (NP (NP (NNS Fragments)) (PP (IN of) (NP (NP (DT a) (ADJP (CD 3.6) (NN kb)) (NN sequence)) (PP (IN of) (NP (DT the) (NP (JJ human) (NN CRH) (NN gene) (NN promoter))))))) (VP (VBD were) (VP (VP (VBN amplified) (PP (IN by) (NP (NN PCR)))) (CC and) (VP (VBN ligated) (ADVP (RB upstream) (PP (IN of) (NP (DT a) (NP (NN CAT) (NN reporter)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS constructs)) (VP (VBD were) (VP (VBN transfected) (PP (IN into) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN cell) (NNS lines))))) (, ,) (ADVP (CC either) (ADVP (RB alone)) (CC or) (ADVP (RB together))) (, ,) (PP (IN with) (NP (NP (NN transcription) (NN factor)) (NN expression) (NNS vectors))))) (. .))))
(S1 (S (S (NP (NP (JJ Basal) (NN activity)) (PP (IN of) (NP (DT a) (NP (CD 3070) (NN bp) (NN CRH) (NN promoter) (NN fragment))))) (VP (VBD was) (ADVP (RB only)) (VP (VBN seen) (PP (IN in) (NP (NP (ADJP (JJ neuronal))) (CC and) (NP (JJ lymphoblastoid) (NN cell) (NNS lines)))))) (. .))))
(S1 (S (S (NP (NN Promoter) (NN activity)) (VP (VBD was) (VP (VBN increased) (PP (PP (IN by) (NP (NP (DT the) (NP (NN transcription) (NNS factors)) (NP (NN C/EBPbeta))) (PRN (-LRB- -LRB-) (NP (NN NF-IL6)) (-RRB- -RRB-)))) (CC and) (ADVP (RBR more) (RB strongly)) (, ,) (PP (IN by) (NP (NP (NN C/EBPdelta)) (PRN (-LRB- -LRB-) (NP (NN NF-IL6beta)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (NP (VBN Increased) (NP (NN CRH)) (NN promoter) (NN activity)) (PP (VBG following) (NP (NN phorbol) (NN ester) (NN treatment)))) (VP (VBD was) (VP (VBN inhibited) (PP (IN by) (NP (DT a) (JJ dominant) (JJ negative) (NP (NN NF-IL6) (NN mutant))))) (, ,) (S (VP (VBG showing) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN phorbol) (NN ester)))) (VP (VBD were) (ADVP (RB principally)) (VP (VBN mediated) (PP (IN by) (NP (NN C/EBP)))))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (JJ inverse) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN CRH))) (PP (IN in) (NP (NP (DT the) (NP (NN hypothalamus)) (CC and) (NP (NNS spleens))) (PP (IN of) (NP (JJ arthritic) (NNS rats)))))))) (VP (VBD were) (VP (VBN paralleled) (PP (IN by) (NP (NP (JJ similar) (NN inverse) (NNS changes)) (PP (IN in) (NP (NP (NP (NN NF-IL6beta)) (NN expression)) (PP (IN in) (NP (DT these) (NNS organs))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT some) (NP (NN transcription) (NNS factors))) (VP (VBN associated) (PP (IN with) (NP (NP (NN cytokine)) (NN signalling))))) (VP (MD can) (ADVP (RB also)) (VP (VB activate) (NP (DT the) (NP (NN CRH) (NN promoter)))))))) (. .))))
(S1 (S (NP (NP (NP (NP (DT A) (JJ novel) (NN form)) (PP (IN of) (NP (DT the) (NP (JJ myeloid-specific) (NN zinc) (NN finger) (NN protein))))) (PRN (-LRB- -LRB-) (NP (NN MZF-2)) (-RRB- -RRB-)) (. .)))))
(S1 (S (NP (NP (NN BACKGROUND) (: :)) (S (NP (JJ Myeloid) (NN cell) (NN development)) (VP (VBZ is) (VP (VBN controlled) (PP (IN by) (NP (JJ tissue-specific) (NP (NN transcription) (NNS factors)))))) (. .)))))
(S1 (S (S (NP (NP (JJ Human) (JJ myeloid) (NN zinc) (NN finger) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN MZF-1)) (-RRB- -RRB-))) (VP (VP (VBZ is) (NP (NP (DT a) (JJ putative) (NN transcription) (NN factor)) (VP (VBG containing) (NP (CD 13) (NN zinc) (NNS fingers))))) (, ,) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ regulates) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ neutrophilic) (NNS granulocytes))))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS) (: :)) (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN isolated) (NP (NP (DT the) (NP (ADJP (JJ murine))) (CC and) (NP (ADJP (JJ human))) (NP (NNS cDNAs))) (SBAR (WHNP (WDT which)) (S (VP (VBP encode) (NP (NP (NP (DT a) (JJ novel) (NN form)) (PP (IN of) (NP (NN MZF) (NN protein)))) (PRN (-LRB- -LRB-) (NP (NN MZF-2)) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (NP (NP (ADJP (JJ Murine))) (CC and) (NP (ADJP (JJ human))) (NP (NN MZF-2) (NNS proteins))) (VP (VP (VBD consisted) (PP (IN of) (NP (NP (CD 814)) (CC and) (NP (CD 775)) (NP (NN amino) (NNS acids)))) (, ,) (ADVP (RB respectively))) (, ,) (CC and) (VP (VBP have) (NP (NP (NN identity)) (PP (IN of) (NP (CD 75.3) (NN %)))) (PP (IN between) (NP (PRP them))))) (. .))))
(S1 (S (S (NP (NP (NP (DT The) (NP (JJ C-terminal) (NN half))) (PP (IN of) (NP (JJ human) (NN MZF-2)))) (, ,) (VP (VBG carrying) (NP (DT the) (NP (NN zinc) (NN finger) (NNS domains)))) (, ,)) (VP (VBD was) (ADJP (RB completely) (JJ identical) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (JJ human) (NN MZF-1)))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NP (JJ N-terminal) (NN half))) (PP (IN of) (NP (NN MZF-2)))) (VP (VP (VBD was) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (JJ corresponding) (NN region)) (PP (IN of) (NP (JJ human) (NP (NN MZF-1)))))))) (, ,) (CC and) (VP (VBD was) (VP (VBN coded) (PP (IN by) (NP (JJ distinct) (NP (NNS exons)))))))))) (. .))))
(S1 (S (S (NP (NN MZF-2) (NN mRNA)) (VP (VBD was) (VP (VP (VBN expressed) (PP (PP (IN in) (NP (JJ myeloid) (NNS cells))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT the) (NNS cells)) (VP (VBN committed) (PP (TO to) (NP (DT the) (NP (JJ neutrophilic) (NN lineage))))))))) (, ,) (CC and) (VP (VBN down-regulated) (PP (IN by) (NP (NN G-CSF)))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NP (NN MZF-1)) (CC and) (NP (NN MZF-2)) (NP (NNS mRNAs))) (VP (VBP seem) (S (VP (TO to) (VP (VB be) (VP (VBN produced) (PP (IN by) (NP (NP (DT the) (JJ alternative) (NN use)) (PP (IN of) (NP (CD two) (JJ different) (NP (NN transcription) (NN initiation) (NNS sites)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ distinct) (NP (JJ N-terminal) (NN half))) (PP (IN of) (NP (NN MZF-2)))) (VP (VBZ carries) (NP (NP (CD two) (JJ characteristic) (NNS domains)) (, ,) (NP (NP (NP (DT a) (NP (JJ leucine-rich) (NN domain))) (VP (VBN called) (S (NP (NN LeR))))) (CC and) (NP (DT an) (NP (JJ acidic) (NN domain))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ suggests) (NP (NP (DT a) (JJ unique) (NN function)) (PP (IN of) (NP (NN MZF-2))) (PP (IN in) (NP (NN neutrophil) (NN development)))))))) (. .))))
(S1 (S (S (S (NP (NP (NN c-Rel)) (CC and) (NP (NN p65)) (NP (NNS subunits))) (VP (VBP bind) (PP (TO to) (NP (NP (DT an) (NP (JJ upstream) (NN NF-kappaB) (NN site))) (PP (IN in) (NP (NP (JJ human) (NN granulocyte) (NN macrophage-colony) (NN stimulating) (NN factor) (NN promoter)) (VP (VBN involved) (PP (IN in) (NP (NP (NN phorbol) (NN ester) (NN response)) (PP (IN in) (NP (CD 5637) (NNS cells))))))))))) (. .)))))
(S1 (S (S (S (S (VP (TO To) (ADVP (RB further)) (VP (VB clarify) (NP (NP (NP (DT the) (JJ complex) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NP (JJ human) (NN GM-CSF) (NN gene))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (RB extensively)) (VP (VBN investigated) (PP (IN in) (NP (VBN activated) (NN T) (NNS cells))))))))))) (, ,) (S (NP (PRP we)) (VP (VBP have) (VP (VBN studied) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (DT an) (JJ upstream) (NP (NN NF-kappaB) (JJ like) (NN site))) (PP (IN in) (NP (NP (DT the) (NP (CD 5637) (JJ non-lymphoid) (NN cell) (NN line))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ derives) (PP (IN from) (NP (DT a) (NN bladder) (NN carcinoma)))) (CC and) (VP (ADVP (RB constitutively)) (VBZ produces) (NP (NN GM-CSF)))))))))))))) (. .)))))
(S1 (S (S (NP (NP (DT This) (NN sequence)) (, ,) (VP (VBN named) (S (NP (DT the) (NN A) (NN element)))) (, ,)) (VP (VP (VBZ has) (NP (DT an) (JJ active) (NN role)) (PP (IN on) (NP (NP (NN GM-CSF)) (NN transcription)))) (CC and) (VP (VBZ is) (ADJP (JJ responsive) (PP (TO to) (NP (DT the) (NP (NN tumor) (NN promoter) (NN PMA)))) (PP (IN in) (NP (JJ transient) (NN transfection) (NNS experiments)))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP describe) (ADVP (RB here)) (NP (NP (DT a) (NP (JJ heterodimeric) (NN binding) (NN complex))) (PP (IN of) (NP (NP (NN NF-kappaB) (NNS subunits)) (PRN (-LRB- -LRB-) (NP (NP (NN c-Rel)) (CC and) (NP (NN p65))) (-RRB- -RRB-))))) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (ADJP (JJ identical) (PP (TO to) (NP (NP (DT the) (CD one)) (VP (VBN obtained) (S (VP (VBG using) (NP (DT the) (NP (NN HIV-LTR-kappaB) (NN site))) (PP (IN as) (NP (NN recognition) (NN sequence))))))))) (CC and) (ADJP (JJ different) (PP (IN from) (NP (NP (NP (DT the) (CD one)) (PRN (-LRB- -LRB-) (NP (NP (NN c-Rel)) (CC and) (NP (NN p50))) (-RRB- -RRB-))) (VP (VBN observed) (PP (IN with) (NP (NP (JJ nuclear) (NNS extracts)) (PP (IN from) (NP (NN Mo) (NN T-lymphoid) (NN HTLV-II) (JJ infected) (NNS cells)))))))))))))) (. .))))
(S1 (S (S (S (NP (NN Cyclosporin) (NN A)) (VP (VBZ inhibits) (NP (NP (NN monocyte) (NP (NN tissue) (NN factor)) (NN activation)) (PP (IN in) (NP (JJ cardiac) (NN transplant) (NNS recipients))))) (. .)))))
(S1 (S (NP (NP (NN BACKGROUND) (: :)) (S (NP (NP (NN Fibrin) (NN deposition)) (CC and) (NP (NN thrombosis))) (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (CC both) (NP (NN allograft) (NN rejection)) (CC and) (NP (NN vasculopathy)))) (PP (IN after) (NP (JJ cardiac) (NN transplantation)))))) (. .)))))
(S1 (S (S (SBAR (IN Because) (S (NP (NNS monocytes)) (VP (VBP play) (NP (DT a) (JJ pivotal) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (JJ intravascular) (NN coagulation) (NN activation))))) (PP (IN through) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB synthesize) (NP (NP (NN tissue) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TF)) (-RRB- -RRB-))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD asked) (SBAR (SBAR (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (IN whether) (S (NP (NN monocyte) (NP (NN TF)) (NN activation)) (VP (VBZ occurs) (PP (IN in) (NP (JJ cardiac) (NN transplant) (NNS recipients)))))) (CC and) (SBAR (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (IN whether) (S (NP (NN monocyte) (NP (NN TF)) (NN expression)) (VP (VBZ is) (VP (VBN affected) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NNS METHODS)) (CC AND) (NP (NNS RESULTS)) (: :)) (S (NP (PRP We)) (VP (VBD measured) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NP (NN TF)) (NN activity)) (PP (IN in) (NP (NP (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)) (CC and) (NP (RB highly) (VBN purified) (NNS monocytes/macrophages))) (PP (IN from) (NP (NP (CD 10) (JJ consecutive) (JJ cardiac) (NN transplant) (NNS recipients)) (CC and) (NP (CD 10) (JJ healthy) (JJ control) (NNS subjects))))))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN TF)) (NN activity)) (VP (VBN generated) (PP (IN by) (NP (CC both) (NP (ADJP (NP (JJ unstimulated)))) (CC and) (NP (JJ endotoxin-stimulated) (NNS cells)))))) (VP (VBD was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NN transplant) (NNS recipients))) (PP (IN than) (PP (IN in) (NP (NP (JJ control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR &lt;) (NP (CD .05)))) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (S (NP (NP (VBN Increased) (NN monocyte) (NP (NN TF)) (NN expression)) (PP (IN in) (NP (NN transplant) (NNS recipients)))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADVP (RB adversely)) (VP (VBN affected) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NN CsA)))))))))))) (: :) (S (NP (NP (NN TF)) (NN induction)) (VP (VBD was) (ADVP (RB markedly)) (VP (VBN reduced) (PP (IN by) (NP (NP (NN CsA) (NN serum) (NNS concentrations)) (VP (VBG reaching) (NP (JJ peak) (NN CsA) (NN drug) (NNS levels)))))))) (. .))))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (NN TF)) (NN induction))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ high) (NN CsA) (NN blood) (NNS concentrations)))))) (VP (VBD was) (ADVP (RB also)) (VP (VBN observed)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN stimulation)) (PP (IN of) (NP (NNS cells)))) (VP (VBD was) (VP (VBN performed) (PP (IN with) (NP (NP (NN interferon-gamma)) (CC or) (NP (NN interleukin-1beta))))))))) (. .))))
(S1 (S (S (SBAR (IN As) (S (VP (VBN shown) (PP (IN by) (NP (NP (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction)) (CC and) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)))) (, ,) (ADVP (RB respectively))))) (, ,) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NN CsA)))) (VP (VBZ leads) (PP (TO to) (NP (NP (VBN decreased) (NP (NN TF) (NN mRNA)) (NN expression)) (CC and) (NP (NP (VBN reduced) (NN activation)) (PP (IN of) (NP (NP (DT the) (NP (NN NF-kappaB) (NN transcription) (NN factor))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (DT the) (NP (NN TF) (NN promotor)))) (PP (IN in) (NP (JJ human) (NNS monocytes))))))))))))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (NP (NN TF)) (NN activation)) (, ,) (VP (VBG occurring) (PP (IN in) (NP (NP (JJ mononuclear) (NNS cells)) (PP (IN of) (NP (JJ cardiac) (NN transplant) (NNS recipients)))))) (, ,)) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NN CsA))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN monocyte) (NP (NN TF)) (NN induction))) (PP (IN by) (NP (NN CsA)))) (VP (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (PRP$ its) (JJ successful) (NN use)) (PP (IN in) (NP (JJ cardiac) (NN transplant) (NN medicine))))))) (CC and) (VP (MD might) (VP (VB be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG managing) (NP (NP (JJ further) (NNS settings)) (PP (IN of) (NP (NP (JJ vascular) (NN pathology)) (ADVP (RB also)) (VP (VBN known) (S (VP (TO to) (VP (VB involve) (NP (NP (NP (NN TF)) (NN expression)) (CC and) (NP (NP (NN NF-kappaB)) (NN activation))))))))))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Agonistic) (NN activity)) (PP (IN of) (NP (NP (DT a) (NP (JJ CD40-specific) (JJ single-chain) (NN Fv))) (VP (VBN constructed) (PP (IN from) (NP (NP (DT the) (NP (JJ variable) (NNS regions))) (PP (IN of) (NP (NN mAb) (NN G28-5)))))))) (. .)))))
(S1 (S (S (S (NP (DT A) (NP (NP (JJ single-chain) (NN Fv)) (PRN (-LRB- -LRB-) (NP (NN sFv)) (-RRB- -RRB-)))) (VP (VBD was) (VP (VBN expressed) (PP (IN from) (NP (NP (DT the) (NP (JJ variable) (NNS regions))) (PP (IN of) (NP (DT the) (JJ CD40-specific) (NP (NN mAb) (NN G28-5)))))))) (. .)))))
(S1 (S (S (NP (DT The) (NN molecule)) (VP (VP (VBD bound) (NP (NN CD40)) (PP (IN with) (NP (NP (DT a) (JJ high) (NN affinity)) (PRN (-LRB- -LRB-) (NP (CD 2.2) (NN nM)) (-RRB- -RRB-))))) (CC and) (VP (VBD was) (NP (DT a) (NN monomer)) (PP (IN in) (NP (NN solution))))) (. .))))
(S1 (S (S (ADVP (RB Surprisingly)) (, ,) (NP (NN G28-5) (NN sFv)) (VP (VBD was) (NP (NP (DT a) (JJ potent) (NP (NN CD40) (NN agonist))) (SBAR (WHNP (WDT that)) (S (VP (VP (ADVP (RB rapidly)) (VBD crosslinked) (NP (NP (NN CD40)) (PP (IN on) (NP (DT the) (NN cell) (NN surface))))) (CC but) (VP (VBD did) (RB not) (VP (VB crosslink) (NP (NP (NN CD40-Ig)) (PP (IN in) (NP (NN solution))))))))))) (. .))))
(S1 (S (S (NP (NN G28-5) (NN sFv)) (VP (VP (VBD was) (NP (NP (DT a) (ADJP (RBR more) (JJ potent)) (NN agonist)) (PP (IN than) (NP (NN G28-5) (NN IgG))))) (CC and) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (VP (VB stimulate) (NP (NP (NP (NN CD40)) (NNS responses)) (PP (IN by) (NP (NP (NN B) (NNS cells)) (CC and) (NP (NNS monocytes))))))))))) (. .))))
(S1 (S (S (NP (NN G28-5) (NN IgG)) (ADVP (RB partially)) (VP (VBD blocked) (, ,) (SBAR (IN whereas) (S (NP (NN G28-5) (NN sFv)) (VP (VBD augmented) (NP (NP (NN CD40)) (NNS responses)) (PP (IN during) (NP (NP (NN stimulation)) (PP (IN with) (NP (NP (JJ natural) (NN ligand)) (PRN (-LRB- -LRB-) (NP (JJ gp39-CD8) (NN fusion) (NN protein)) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ functional) (NN activity)) (PP (IN of) (NP (NP (NNS ligands)) (VP (VBN built) (PP (IN from) (NP (NP (DT the) (NP (VBG binding) (NN site))) (PP (IN of) (NP (NN G28-5))))))))) (VP (VBZ is) (ADJP (RB highly) (JJ dependent) (PP (IN upon) (NP (NP (DT the) (NP (NN size)) (CC and) (NP (JJ physical) (NNS properties))) (PP (IN of) (NP (DT the) (NN molecule))))) (PP (CC both) (PP (IN in) (NP (NN solution))) (CC and) (PP (IN on) (NP (DT the) (NN cell) (NNS surfaces))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Competent) (NN transcription) (NN initiation)) (PP (IN by) (NP (NN RNA) (NN polymerase) (CD II))) (PP (IN in) (NP (NP (JJ cell-free) (NNS extracts)) (PP (IN from) (NP (NN xeroderma) (NN pigmentosum) (NNS groups) (NP (NN B)) (CC and) (NP (NN D)))))) (PP (IN in) (NP (DT an) (VBN optimized) (NN RNA) (NN transcription) (NN assay))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (JJ human) (JJ autosomal) (JJ recessive) (NN disease)) (, ,) (NP (NP (NN xeroderma) (NN pigmentosum)) (PRN (-LRB- -LRB-) (NP (NN XP)) (-RRB- -RRB-))) (, ,)) (VP (MD can) (VP (VB result) (PP (IN from) (NP (NP (NNS mutations)) (PP (IN in) (NP (NP (DT any) (CD one)) (PP (IN of) (NP (NP (CD seven) (NNS genes)) (, ,) (VP (VBN designated) (S (NP (NP (NN XPA)) (PP (IN through) (NP (NN XPG)))))))))))))) (. .)))))
(S1 (S (S (PP (IN Of) (NP (DT these))) (, ,) (NP (DT the) (NP (NN XPB)) (CC and) (NP (NN XPD)) (NP (NNS genes))) (VP (VBP encode) (NP (NP (NNS proteins)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NP (NNS subunits)) (PP (IN of) (NP (NP (DT a) (NP (JJ general) (NN transcription) (NN factor))) (, ,) (NP (NN TFIIH))))) (, ,) (VP (VBN involved) (PP (IN in) (NP (NP (CC both) (NP (NP (NN nucleotide) (NN excision) (NN repair)) (PRN (-LRB- -LRB-) (NP (NN NER)) (-RRB- -RRB-))) (CC and) (NP (NP (NN initiation)) (PP (IN of) (NP (NN mRNA) (NN transcription))))) (PP (IN by) (NP (NN RNA) (NN polymerase) (CD II)))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NNS humans))) (, ,) (NP (NP (NN mutation)) (PP (IN of) (NP (DT the) (NP (NN XPB)) (CC or) (NP (NN XPD)) (NP (NN gene))))) (VP (VBZ impairs) (NP (NN NER)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NP (NN hyper-sensitivity)) (PP (TO to) (NP (NN sunlight)))) (CC and) (NP (ADJP (RB greatly) (VBN increased)) (NN skin) (NN tumor) (NN formation))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT no) (NN transcription) (NN deficiency)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (CC either) (NP (NN XP-B)) (CC or) (NP (NN XP-D))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN employed) (NP (DT an) (VBN optimized) (JJ cell-free) (NN RNA) (NN transcription) (NN assay))) (S (VP (TO to) (VP (VB analyze) (NP (NP (NN transcription) (NN activity)) (PP (IN of) (NP (NP (NN XP-B)) (CC and) (NP (NN XP-D))))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (DT the) (NN growth) (NN rate)) (VP (VBD was) (ADJP (JJ normal))))) (, ,) (S (NP (DT the) (NP (NN XP-B)) (CC and) (NP (NN XP-D)) (NP (NNS cells))) (VP (VBD contained) (NP (NP (VBN reduced) (NNS amounts)) (PP (IN of) (NP (NN TFIIH)))))) (. .))))
(S1 (S (S (NP (NP (NNS Extracts)) (VP (VBN prepared) (PP (IN from) (NP (NP (NN XP-B)) (CC and) (NP (NN XP-D)) (NP (JJ lymphoblastoid) (NNS cells)))))) (VP (VBD exhibited) (NP (NP (JJ similar) (NN transcription) (NN activity)) (PP (IN from) (NP (DT the) (NP (NN adenovirus) (JJ major) (JJ late) (NN promoter))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (NP (NNS extracts)) (PP (IN from) (NP (JJ normal) (NNS cells))))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (NP (NN XP-B)) (CC and) (NP (NN XP-D)) (NP (JJ lymphoblastoid) (NNS cells))) (VP (VBP do) (RB not) (VP (VB have) (NP (JJ impaired) (NN RNA) (NN transcription) (NN activity))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VP (VBP consider) (NP (NP (DT the) (JJ possible) (NNS consequences)) (PP (IN of) (NP (NP (DT the) (VBN reduced) (JJ cellular) (NN content)) (PP (IN of) (NP (NN TFIIH)))))) (PP (IN for) (NP (NP (DT the) (JJ clinical) (NNS symptoms)) (PP (IN in) (NP (NP (NN XP-B)) (CC or) (NP (NN XP-D)) (NP (NNS patients))))))) (, ,) (CC and) (VP (VBP discuss) (NP (NP (DT a) (`` ') (JJ conditional) (NN phenotype) ('' ')) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB involve) (NP (NP (DT an) (NN impairment)) (PP (IN of) (NP (JJ cellular) (NN function)))) (PP (ADVP (RB only)) (IN under) (NP (JJ certain) (NN growth) (NNS conditions)))))))))) (. .))))
(S1 (S (S (S (NP (NN Cyclosporin) (NN A)) (VP (VBZ inhibits) (NP (NP (JJ early) (NN mRNA) (NN expression)) (PP (IN of) (NP (NP (NN G0/G1) (NN switch) (NN gene) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN G0S2)) (-RRB- -RRB-)))) (PP (IN in) (NP (VBN cultured) (JJ human) (NN blood) (JJ mononuclear) (NNS cells))))) (. .)))))
(S1 (S (S (S (NP (NP (NN Cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-))) (VP (MD may) (VP (VB achieve) (NP (PRP$ its) (JJ immunosuppressive) (NNS effects)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (NP (DT the) (NP (NN calcium-) (CC and) (JJ calmodulin-dependent) (NN phosphatase))) (NP (NN calcineurin))) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (NN activation)) (PP (IN of) (NP (NN target) (NNS genes))) (PP (IN by) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NP (NN NFAT) (-LRB- -LRB-) (JJ nuclear) (NN factor) (IN of) (VBN activated) (NN T) (NNS cells) (-RRB- -RRB-) (NN transcription) (NN factor) (NN family)))))))))))))))))) (. .)))))
(S1 (S (S (PP (IN Among) (NP (DT these) (NP (NN target) (NNS genes)))) (VP (VBZ is)) (NP (NP (DT the) (NN gene)) (VP (VBG encoding) (NP (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL2)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NP (NN cytokine))) (VP (VBG facilitating) (NP (NP (NN progression)) (PP (IN through) (NP (NP (DT the) (NN G1) (NN phase)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle))))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN IL2)) (VP (VBZ does) (RB not) (VP (VB reverse) (NP (NN CsA) (NN inhibition))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (QP (IN at) (JJS least) (CD one)) (JJ other) (NP (JJ NFAT-sensitive) (NN gene))) (VP (MD may) (VP (VB be) (VP (VBN involved))))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NP (JJ human) (NN G0/G1) (NN switch) (NN gene)) (, ,) (NP (NN G0S2))) (, ,)) (VP (VP (VBZ has) (NP (JJ potential) (NP (JJ NFAT-binding) (NNS sites))) (PP (IN in) (NP (DT the) (NP (JJ 5') (NN flank))))) (CC and) (VP (VBZ encodes) (NP (NP (DT a) (NP (JJ small) (JJ basic) (JJ potential) (NN phosphoprotein))) (PP (IN of) (NP (JJ unknown) (NN function)))))) (. .))))
(S1 (S (S (S (VP (VBG Using) (NP (DT a) (JJ sensitive) (, ,) (NP (NP (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (NN assay)))) (, ,) (S (NP (NP (NN G0S2)) (NN mRNA) (NNS levels)) (VP (VBD were) (VP (VBN assayed) (PP (IN in) (NP (VBN cultured) (NN blood) (JJ mononuclear) (NNS cells)))))) (. .))))
(S1 (S (S (NP (ADJP (RB Freshly) (VBN isolated)) (NNS cells)) (VP (VBP contain) (NP (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN G0S2) (NN mRNA)))) (SBAR (WHNP (WDT which)) (S (ADVP (RB rapidly)) (VP (VBP decline)))))) (. .))))
(S1 (S (S (NP (DT This) (`` ``) (JJ spontaneous) (NN stimulation)) (VP (VP (VBZ is) (ADVP (RB also)) (VP (VBN noted) (PP (IN with) (NP (DT some) (JJ other) (NP (NN G0S) (NNS genes)))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (DT some) (NN aspect)) (PP (IN of) (NP (DT the) (NN isolation) (NN procedure))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN preincubated) (VP (TO to) (VP (VB lower) (NP (NN mRNA) (NNS levels))))))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ transient) (NN increase)) (PP (IN in) (NP (NN G0S2) (NN mRNA))) (, ,) (VP (VBG peaking) (PP (IN between) (NP (CD 1-2) (NN h)))) (, ,) (PP (IN in) (NP (NP (NN response)) (PP (PP (TO to) (NP (NP (NN Concanavalin-A)) (PRN (-LRB- -LRB-) (NP (NN ConA)) (-RRB- -RRB-)))) (, ,) (CC or) (PP (TO to) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NP (NN phorbol) (NN ester)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (DT the) (NN calcium) (NN ionophore)) (, ,) (NP (NN ionomycin)))))))))))) (. .))))
(S1 (S (S (NP (PDT Both) (DT these) (NNS responses)) (VP (VBP are) (VP (VBN inhibited) (PP (IN by) (NP (NN CsA))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NP (NN G0S2)) (NN expression)) (VP (VBZ is) (VP (VBN required)) (S (VP (TO to) (VP (VB commit) (S (NP (NNS cells)) (VP (TO to) (VP (VB enter) (NP (NP (DT the) (NN G1) (NN phase)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle))))))))))))) (, ,) (CC and) (SBAR (IN that) (S (, ,) (SBAR (IN while) (S (RB not) (VP (VBG excluding) (NP (DT other) (JJ possible) (NNS targets))))) (, ,) (S (NP (NP (JJ early) (NN inhibition)) (PP (IN of) (NP (NP (NN G0S2)) (NN expression))) (PP (IN by) (NP (NN CsA)))) (VP (MD may) (VP (VB be) (ADJP (JJ important) (PP (IN in) (S (VP (VBG achieving) (NP (NN immunosuppression))))))))))))) (. .))))
(S1 (S (S (NP (NN G0S2)) (VP (MD may) (VP (VB be) (PP (IN of) (NP (NN value))) (PP (IN as) (NP (NP (DT a) (NN reporter) (NN gene)) (PP (IN for) (S (VP (VBG analyzing) (NP (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN CsA)))))) (CC and) (NP (NP (PRP$ its) (NN influence)) (PP (IN on) (NP (NP (NP (DT the) (NP (ADJP (JJ positive))) (CC and) (NP (ADJP (JJ negative))) (NP (NN selection))) (PP (IN of) (NP (NNS lymphocytes)))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (NN self)) (CC and) (NP (JJ not-self)) (NP (NNS antigens))))))))))))))))) (. .))))
(S1 (S (S (S (NP (NN Estrogen) (NN receptor)) (VP (VBZ diminishes) (NP (NP (JJ DNA-binding) (NNS activities)) (PP (IN of) (NP (NP (NN chicken) (NN GATA-1)) (CC and) (NP (NP (JJ CACCC-binding) (NNS proteins))))))) (. .)))))
(S1 (S (S (S (NP (DT The) (NP (NP (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-)))) (VP (VBD repressed) (NP (NP (JJ erythroid) (NN differentiation)) (CC and) (NP (NP (JJ erythroid-specific) (NN gene)) (NN expression)))) (. .)))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN ER) (NN alpha)) (PRN (-LRB- -LRB-) (VP (VBN referred) (PP (TO to)) (ADVP (RB throughout)) (PP (IN as) (NP (NN ER)))) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ DNA-binding) (NNS activities)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (VP (VBN involved) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ erythroid-specific) (NNS genes)) (, ,) (CC and) (, ,) (PP (IN in) (NP (JJ particular))) (, ,) (NP (DT the) (NP (NN histone) (NN H5) (NN gene)))))))))))))))) (. .))))
(S1 (S (S (S (VP (VBG Using) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)))) (, ,) (S (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN rabbit) (NN reticulocyte) (NN lysate))))) (, ,) (NP (JJ human) (NN ER)) (VP (VBD reduced) (NP (NP (DT the) (NN binding) (NNS activities)) (PP (IN of) (NP (NN chicken) (JJ immature) (NN erythrocyte) (JJ nuclear) (JJ extracted) (NNS proteins))) (PP (TO to) (NP (NP (NP (NN GATA)) (CC and) (NP (NN CACCC)) (NP (NNS sites))) (PP (IN in) (NP (DT the) (NN H5) (NP (NN promoter)) (CC and) (NP (NN enhancer)))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN binding) (NNS activities)) (PP (IN of) (NP (NP (NN NF1)) (CC and) (NP (NN Sp1))))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NN ER))))) (. .))))
(S1 (S (S (NP (NP (NN Binding)) (PP (IN of) (NP (NN ER))) (PP (TO to) (NP (DT an) (NP (NN estrogen) (NN response) (NN element))))) (VP (VBD was) (VP (VBN enhanced) (PP (IN by) (NP (NP (NN addition)) (PP (IN of) (NP (NN rabbit) (NN reticulocyte) (NN lysate))))))) (. .))))
(S1 (S (S (NP (DT This) (NN lysate)) (VP (VBD was) (ADVP (RB also)) (ADJP (JJ necessary) (SBAR (IN for) (S (NP (NN ER)) (VP (TO to) (VP (VB diminish) (NP (NP (DT the) (JJ DNA-binding) (NN activity)) (PP (IN of) (NP (NN GATA-1)))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ additional) (NN factor) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (VP (VBP are) (ADJP (JJ necessary) (PP (IN for) (NP (JJ full) (NP (NN ER)) (NN function)))))))) (. .))))
(S1 (S (S (NP (CC Both) (NP (NP (NN GATA-1))) (CC and) (NP (JJ CACCC-binding) (NNS proteins))) (VP (VBP are) (ADJP (JJ critical) (PP (IN for) (NP (NP (DT the) (ADJP (RB developmentally) (VBN regulated)) (NN expression)) (PP (IN of) (NP (JJ erythroid-specific) (NNS genes))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (NP (NN interference)) (PP (IN in) (NP (NP (JJ DNA-binding) (NNS activities)) (PP (IN of) (NP (NP (NP (NN GATA-1))) (CC and) (NP (JJ CACCC-binding) (NNS proteins))))))) (VP (VBZ is) (NP (NP (DT the) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (DT the) (NP (NN ER))) (VP (VBZ inhibits) (NP (NP (NN regulation)) (PP (IN of) (NP (DT these) (NNS genes)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN HLA) (NN binding) (NNS characteristics)) (CC and) (NP (NP (NN generation)) (PP (IN of) (NP (NP (JJ cytotoxic) (NNS lymphocytes)) (PP (IN against) (NP (NP (NNS peptides)) (VP (VBN derived) (PP (IN from) (NP (JJ oncogenic) (NNS proteins))))))))) (. .)))))
(S1 (S (NP (S (NP (NP (NNS AIMS)) (CC AND) (NP (NN BACKGROUND)) (: :)) (NP (NP (ADJP (RB Structurally) (VBN altered)) (NNS proteins)) (PRN (-LRB- -LRB-) (VP (VBN derived) (PP (IN from) (NP (NP (JJ chromosomal) (NNS translocations)) (CC or) (NP (NN gene) (NNS mutations))))) (-RRB- -RRB-))) (VP (MD can) (VP (VP (VB be) (VP (VBN considered) (S (NP (NN tumor) (JJ specific) (NNS antigens))))) (CC and) (VP (VB represent) (NP (NP (DT an) (JJ attractive) (NN target)) (PP (IN for) (NP (DT a) (NN T-cell) (JJ mediated) (NN response))))))) (. .)))))
(S1 (S (S (NP (NN T) (NNS lymphocytes)) (VP (VBP recognize) (NP (NP (NNS antigens)) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NP (NNS peptides)) (VP (VBN bound) (PP (TO to) (NP (NNS HLA-molecules)))))))))) (. .))))
(S1 (S (NP (NP (NP (NNS MATERIALS)) (CC AND) (NP (NNS METHODS)) (: :)) (S (S (NP (NP (NNS Peptides)) (VP (VBN derived) (PP (IN from) (NP (JJ oncogenic) (NNS proteins))))) (VP (VBD were) (VP (VBN screened) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN HLA) (NN binding) (NNS motifs)))))))) (: ;) (S (NP (JJ actual) (NN binding)) (VP (VBD were) (VP (VBN evaluated) (PP (IN by) (NP (NN HLA) (NN stabilization) (NNS experiments)))) (S (VP (VBG using) (NP (NP (NNS transfectants)) (CC and) (NP (JJ specific) (NP (JJ anti-HLA) (NNS antibodies))))))))) (. .))))
(S1 (S (S (NP (JJ Specific) (NP (NNS lymphocytes))) (VP (VBD were) (VP (VP (VBN induced) (PP (IN by) (NP (ADJP (FW in) (FW vitro)) (NN peptide) (NN sensitization)))) (CC and) (VP (VBN screened) (PP (IN by) (NP (NP (NN thymidine) (NN uptake)) (CC or) (NP (JJ cellular) (JJ cytotoxic) (NNS assays))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS) (: :)) (S (NP (PRP We)) (VP (VBD identified) (NP (NP (NNS peptides)) (VP (VBN derived) (PP (PP (PP (IN from) (NP (NN EWS/FLI-1) (NN fusion) (NN protein))) (CC and) (PP (IN from) (NP (VBN mutated) (NN K-RAS) (NN protein)))) (PRN (-LRB- -LRB-) (VP (VBG encompassing) (ADVP (RB respectively)) (NP (NP (DT the) (NP (NN fusion) (NN point))) (CC and) (NP (NP (DT the) (NN mutation)) (PP (IN at) (NP (NN position) (CD 12)))))) (-RRB- -RRB-)))) (SBAR (WHNP (WDT that)) (S (VP (VBD showed) (NP (NP (VBG binding) (NN motif)) (PP (IN for) (NP (NP (NN HLA-Cw*0702)) (CC and) (NP (NN HLA-A3))))) (ADVP (RB respectively)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ actual) (NN binding)) (PP (IN of) (NP (DT these) (NNS peptides)))) (VP (VBD was) (VP (VBN analysed) (PP (IN in) (NP (DT a) (NN stabilization) (NN assay))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD detected) (NP (NP (NN binding)) (PP (PP (IN for) (NP (DT the) (NN EWS/FLI-1) (NN peptide))) (CC and) (PP (IN for) (NP (NP (CD 5) (NN RAS) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (JJ wild) (NN type)) (CC and) (NP (CD 4) (VBN mutated))) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NN temperature)) (, ,) (NP (NP (NN beta) (NN 2-microglobulin)) (PRN (-LRB- -LRB-) (NP (NN beta) (NN 2-m)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ fetal) (NN calf) (NN serum)) (PRN (-LRB- -LRB-) (NP (NN FCS)) (-RRB- -RRB-))))) (PP (IN on) (NP (NP (NP (DT the) (NN binding)) (CC and) (NP (DT the) (NN stability))) (PP (IN of) (NP (DT the) (NP (NN HLA/peptide) (NN complex))))))) (VP (VBD was) (VP (VBN studied))) (. .))))
(S1 (S (S (NP (NP (DT A) (JJ low) (NN temperature)) (PRN (-LRB- -LRB-) (NP (CD 26) (NNS degrees) (NN C)) (-RRB- -RRB-))) (VP (VBD increased) (NP (NP (DT the) (NN binding)) (PP (CC both) (IN in) (NP (NP (NN HLA-A3)) (CC and) (NP (NN HLA-Cw*0702))))) (, ,) (SBAR (IN while) (S (NP (NN FCS)) (VP (VBD reduced) (NP (PRP it)))))) (. .))))
(S1 (S (S (NP (NN beta) (NN 2-m)) (VP (VP (VBD increased) (NP (NP (DT the) (NN binding)) (PP (TO to) (NP (DT the) (NP (NN HLA-A3) (NN molecule)))))) (CC but) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (NN binding)) (PP (TO to) (NP (DT the) (NP (NN HLA-Cw*0702)))))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NN stability)) (PP (IN of) (NP (RB already) (VBN formed) (VBN complexed)))) (VP (VBD was) (ADJP (RB somewhat) (JJ different) (PP (IN in) (NP (DT the) (NP (NP (NN HLA-A3))) (CC and) (NP (NP (NN HLA-Cw*0702))) (NP (NN system))))))) (: :) (S (S (NP (DT both)) (VP (VBD were) (ADJP (ADJP (RBR more) (JJ stable)) (PP (IN at) (NP (CD 26) (NNS degrees) (NN C))) (PP (IN than) (PP (IN at) (NP (CD 37) (NNS degrees) (NN C))))))) (CC but) (S (SBAR (IN while) (S (NP (DT the) (NP (NP (NN beta) (NN 2-m))) (CC and) (NP (NN FCS))) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (NN stability)) (PP (IN of) (NP (DT the) (NP (NN HLA-A3/peptide) (NN complex))))))))) (, ,) (S (S (NP (PRP they)) (VP (VBD seemed) (S (VP (TO to) (VP (VB cause) (NP (JJ opposite) (NNS effects)) (PP (IN in) (NP (DT the) (NP (NN HLA-Cw*0702)) (NN system)))))))) (PRN (-LRB- -LRB-) (S (S (NP (NN beta) (NN 2-m)) (VP (VBD stabilized))) (CC and) (S (NP (NN FCS)) (VP (VBD destabilized) (NP (DT the) (NN complex))))) (-RRB- -RRB-))))) (. .))))
(S1 (S (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBD were) (ADJP (JJ able) (S (VP (TO to) (VP (VB generate) (NP (DT a) (JJ specific) (NP (JJ CD8+) (NN CTL) (NN line))) (PP (IN against) (NP (DT a) (NN K-RAS) (JJ mutated) (NN peptide)))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (SBAR (IN Although) (S (NP (NP (VBG binding) (NNS motifs)) (CC and) (NP (JJ actual) (NN HLA) (NN binding))) (VP (MD can) (VP (VB be) (VP (VBN detected) (PP (IN in) (NP (JJ several) (NNS cases)))))))) (, ,) (S (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (DT a) (JJ cellular) (NN response)))) (VP (VBZ is) (ADJP (JJ infrequent)) (, ,) (S (VP (VBG confirming) (SBAR (IN that) (S (NP (NN HLA) (NN binding)) (VP (VBZ is) (ADJP (ADJP (JJ necessary)) (CC but) (ADJP (RB not) (JJ sufficient)) (S (VP (TO to) (VP (VB obtain) (NP (DT an) (ADJP (FW in) (FW vitro)) (NN response)))))))))))))) (. .))))
(S1 (S (S (NP (NP (RB Further) (NN optimization)) (PP (IN of) (NP (NP (NN culture) (NNS conditions)) (, ,) (NP (NP (NN type)) (PP (IN of) (NP (NP (NP (NN Antigen) (NN Presenting) (NNS Cells)) (PRN (-LRB- -LRB-) (NP (NNS APC)) (-RRB- -RRB-))) (, ,) (NP (NNS peptides))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NNS stabilizers)) (PP (IN like) (NP (NN beta) (NN 2-m))))))))) (VP (VBP are) (ADVP (RB still)) (VP (VBN needed))) (. .))))
(S1 (S (NP (NP (NP (NN Control)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (NN activity))) (PP (IN by) (NP (DT the) (NP (NN I) (NN kappa) (NN B) (NN beta) (NN inhibitor)))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NP (NN transcription) (NN factor))) (NP (NN NF-kappa) (NN B))) (VP (VBZ is) (VP (JJ maintained) (PP (IN in) (NP (DT an) (ADJP (ADJP (JJ inactive)) (ADJP (JJ cytoplasmic))) (NN state))) (PP (IN by) (NP (NN I) (NN kappa) (NN B) (NNS inhibitors))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (JJ mammalian) (NNS cells))) (, ,) (NP (NP (NP (NN I) (NN kappa) (NN B) (NN alpha))) (CC and) (NP (NN I) (NN kappa) (NN B) (NN beta) (NNS proteins))) (VP (VBP have) (VP (VBN been) (VP (VP (VBN purified)) (CC and) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (NNS inhibitors)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (PP (IN through) (NP (NP (PRP$ their) (NN association)) (PP (IN with) (NP (DT the) (NP (NN p65)) (CC or) (NP (NN c-Rel)) (NP (NNS subunits))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN isolated) (NP (NP (DT a) (JJ third) (NP (NN NF-kappa) (NN B) (NN inhibitor))) (, ,) (NP (NP (NN I) (NN kappa) (NN B) (NN epsilon)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-))))) (. .))))
(S1 (S (S (PP (IN Upon) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (DT a) (JJ large) (NN variety)) (PP (IN of) (NP (NNS inducers))))))) (, ,) (NP (NP (NN I) (NN kappa) (NN B) (NN alpha)) (, ,) (NP (NN I) (NN kappa) (NN B) (NN beta))) (VP (VBP are) (ADVP (RB proteolytically)) (VP (VBN degraded)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NP (NN NF-kappa) (NN B)) (NN translocation)) (PP (IN into) (NP (DT the) (NN nucleus)))))))) (. .))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (SBAR (IN that) (S (PP (IN in) (NP (NN E29.1) (NN T) (NN cell) (NN hybridoma))) (NP (NP (NN I) (NN kappa) (NN B) (NN alpha)) (CC and) (NP (NN I) (NN kappa) (NN B) (NN beta))) (VP (VBP are) (ADVP (RB equally)) (VP (VBN associated) (PP (IN with) (NP (NN p65))))))) (CC and) (SBAR (IN that) (S (NP (NN I) (NN kappa) (NN B) (NN beta)) (VP (VBZ is) (VP (VBN degraded) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NN TNF) (NN alpha))))) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (SBAR (WHNP (WP what)) (S (VP (VBZ has) (VP (VBN been) (ADVP (RB originally)) (VP (VBN published))))))))))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (, ,) (PP (IN unlike) (NP (NN I) (NN kappa) (NN B) (NN alpha))) (, ,) (NP (NN I) (NN kappa) (NN B) (NN beta)) (VP (VBZ is) (VP (ADVP (RB constitutively)) (VP (VBN phosphorylated)) (CC and) (VP (VBN resynthesized) (PP (IN as) (NP (DT a) (NP (VBN hypophosphorylated) (NN form)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN absence)) (PP (IN of) (NP (NP (ADJP (JJ slow) (JJ migrating)) (NNS forms)) (PP (IN of) (NP (NN I) (NN kappa) (NN B) (NN beta))))) (VP (VBG following) (NP (NN stimulation)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT the) (NN phosphorylation)) (VP (VBZ does) (RB not) (ADVP (RB necessarily)) (VP (VB constitute) (NP (NP (DT the) (JJ signal-induced) (NN event)) (SBAR (WHNP (WDT which)) (S (VP (VBZ targets) (NP (NP (DT the) (NN molecule)) (PP (IN for) (NP (NN proteolysis))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NN LPS) (NN tolerance)) (PP (IN in) (NP (NNS monocytes/macrophages))) (: :)) (S (NP (CD three) (JJ 3') (NNS cytosins)) (VP (VBP are) (VP (VBN required) (PP (IN in) (NP (DT the) (NP (NN DNA) (NN binding) (NN motif)))) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (VBN upregulated) (NP (NN NF-kappa) (NN B) (NN p50) (NNS homodimers))))))))) (. .)))))
(S1 (S (S (S (S (SBAR (WHADVP (WRB When)) (S (NP (NNS monocytes)) (VP (VBP are) (VP (VBN stimulated) (PP (IN with) (NP (NP (NN LPS)) (PRN (-LRB- -LRB-) (NP (NN lipopolysaccharide)) (-RRB- -RRB-)))) (ADVP (RB repeatedly)))))) (S (ADVP (RB then)) (NP (NP (DT the) (ADJP (RB initially) (JJ high)) (NN expression)) (PP (IN of) (NP (DT the) (NP (NN TNF) (-LRB- -LRB-) (NN tumor) (NN necrosis) (NN factor) (-RRB- -RRB-) (NN gene))))) (VP (VBZ is) (ADJP (ADVP (RB only)) (RB very) (JJ low))))) (, ,) (PP (FW i.e.)) (S (NP (DT the) (NNS cells)) (VP (VBP are) (ADJP (JJ tolerant) (PP (TO to) (NP (NN LPS)))))) (. .)))))
(S1 (S (S (S (NP (JJ Tolerant) (NNS cells)) (ADVP (RB still)) (VP (VBP express) (NP (DT the) (NP (NN CD14) (NN receptor))))) (CC and) (S (NP (PRP they)) (VP (MD can) (ADVP (RB still)) (VP (VB be) (VP (VBN activated))) (S (VP (TO to) (VP (VB mobilize) (NP (NN NF-kappa) (NN B)) (PP (IN into) (NP (NN nucleus)))))))) (. .))))
(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (VBG binding) (NNS proteins)) (VP (VBG employing) (NP (NP (NP (DT the) (CD -605) (NN motif)) (PP (IN of) (NP (DT the) (NP (JJ human) (NN TNF) (NN promoter))))) (PRN (-LRB- -LRB-) (NP (NN GGGGCTGTCCC)) (-RRB- -RRB-))))))) (VP (VBD revealed) (SBAR (IN that) (S (PP (IN in) (NP (NP (JJ tolerant) (NNS cells)) (PP (IN of) (NP (NP (DT the) (NP (JJ human) (JJ monocytic) (NN cell) (NN line))) (NP (NN Mono) (NN Mac) (CD 6)))))) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN predominance)) (PP (IN of) (NP (NP (NN p50p50)) (PP (IN of) (NP (NN NF-kappa) (NN B)))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB now)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT a) (NP (JJ mutant) (NN motif))) (SBAR (WHNP (WDT that)) (S (VP (VBZ exchanges) (NP (DT the) (JJ terminal) (JJ 3') (NN C)) (PP (IN for) (NP (DT a) (NN G))))))) (VP (VBZ fails) (S (VP (TO to) (VP (VB bind) (NP (NP (DT the) (NP (NN p50) (NN homodimer))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN upregulated) (PP (IN in) (NP (ADJP (NN LPS) (NN toler) (JJ ant)) (NP (JJ human) (NN Mono) (NN Mac) (CD 6) (NNS cells)))))))))))))))) (. .))))
(S1 (S (S (NP (DT The) (JJ same)) (VP (VBZ is) (ADJP (JJ true) (PP (IN for) (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN taken) (PP (IN from) (NP (DT the) (NP (JJ murine) (NN P388D1) (NN macrophage) (NN cell) (NN line)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN tested) (PP (IN with) (NP (NP (NP (DT the) (NP (CD -516) (NN motif))) (PP (IN of) (NP (DT the) (NP (JJ murine) (NN TNF) (NN promoter))))) (PRN (-LRB- -LRB-) (NP (NN GGGGGCTTTCCC)) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (S (ADVP (RB Here)) (NP (DT the) (NP (JJ wild) (NN type) (NN motif))) (VP (VBZ gives) (NP (NP (JJ efficient) (NN binding)) (PP (IN of) (NP (NP (NN p50p50)) (SBAR (WHNP (WDT that)) (S (ADVP (RB again)) (VP (VBZ is) (VP (VBN upregulated) (PP (IN in) (NP (JJ tolerant) (NNS cells)))))))))) (SBAR (IN whereas) (S (NP (NP (DT a) (NN mutant)) (PP (IN with) (NP (DT a) (JJ 3') (NN G)))) (VP (VBZ shows) (NP (NP (ADJP (RB hardly) (DT any)) (NN binding)) (PP (IN of) (NP (NN p50p50)))))))) (. .))))
(S1 (S (S (ADVP (RB Conversely)) (, ,) (NP (NP (DT the) (NP (JJ murine) (NN kappa) (JJ light) (NN chain) (NN enhancer) (NN motif))) (PRN (-LRB- -LRB-) (NP (NN GGGGACTTTCCG)) (-RRB- -RRB-))) (VP (VBZ does) (RB not) (ADVP (RB efficiently)) (VP (VB bind) (NP (NP (DT the) (JJ nuclear) (NP (NN p50p50))) (PP (IN from) (NP (JJ tolerant) (JJ murine) (NN P388) (NNS macrophages)))))) (. .))))
(S1 (S (S (NP (NN Binding)) (VP (VBZ is) (, ,) (ADVP (RB however)) (, ,) (ADVP (RB readily)) (VP (VBN detected)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ 3') (NN G)) (VP (VBZ is) (VP (VBN replaced) (PP (IN by) (NP (DT a) (NN C)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (NP (VBN upregulated) (NP (NN p50) (NNS homodimers))) (PP (IN in) (NP (NN LPS) (NP (JJ tolerant) (NNS cells))))))) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (JJ subtle) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN sequence)) (PP (IN of) (NP (DT the) (NP (NN DNA) (NN binding) (NN motif))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NP (JJ winged-helix) (NN transcription) (NN factor))) (NP (NN Trident))) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (RB actively) (NP (VBG dividing) (NNS lymphocytes)))))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (ADVP (RB recently)) (VP (VP (VBD identified) (NP (NP (DT the) (NP (JJ winged-helix) (NN transcription) (NN factor))) (NP (NN Trident)))) (CC and) (VP (VBD described) (NP (NP (PRP$ its) (NN expression) (NN pattern)) (PP (IN in) (NP (VBN synchronized) (NNS fibroblasts)))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB now)) (VP (VBN studied) (NP (NP (NP (NN Trident)) (NN expression)) (PP (PP (IN in) (NP (NP (NN cell) (NNS lines)) (, ,) (NP (VBG differentiating) (NNS thymocytes)))) (CC and) (PP (IN in) (NP (NP (NNS lymphocytes)) (VP (VBN derived) (PP (IN from) (NP (JJ peripheral) (NN blood)))))))))) (. .))))
(S1 (S (S (PP (IN During) (NP (NN T) (NN cell) (NN differentiation))) (, ,) (NP (NN expression)) (VP (VBD peaked) (PP (IN in) (NP (DT the) (NP (RB actively) (VBG dividing) (JJ immature) (JJ single) (JJ positive) (NNS cells))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ peripheral) (NN blood) (NNS lymphocytes))) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (NN Trident) (NN mRNA)))) (VP (VP (VBD was) (ADJP (JJ absent))) (, ,) (CC but) (VP (MD could) (VP (VB be) (VP (VBN induced) (PP (IN upon) (NP (NP (NP (NN stimulation)) (PP (IN with) (NP (NNS mitogens)))) (ADVP (FW in) (FW vitro)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS observations)) (VP (VBP imply) (NP (NP (DT a) (NN function)) (PP (IN for) (NP (NP (NN Trident)) (PP (IN in) (NP (VBG dividing) (NNS lymphocytes))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Temporal) (NN control)) (PP (IN of) (NP (NP (NP (JJ IgH) (NN gene)) (NN expression)) (PP (IN in) (NP (VBG developing) (NN B) (NNS cells))))) (PP (IN by) (NP (DT the) (NP (JJ 3') (NN locus) (NN control) (NN region)))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (VBN suggested) (NNS roles)) (PP (IN of) (NP (NP (DT the) (NP (JJ downstream) (JJ 3') (NNS regions))) (VP (VBG acting) (PP (IN as) (NP (DT a) (NP (NP (NN Locus) (NN Control) (NN Region)) (PRN (-LRB- -LRB-) (NP (NN LCR)) (-RRB- -RRB-)))))))) (, ,)) (VP (VBP have) (VP (VBN allowed) (S (NP (NNS comparisons)) (VP (TO to) (VP (VB be) (VP (VBN made))))))) (PP (IN between) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (NP (JJ IgH) (NN locus)))))) (PP (IN with) (NP (NP (JJ other) (NN model) (NNS systems)) (SBAR (WHNP (WP$ whose) (NN gene) (NN expression)) (S (VP (VBZ is) (VP (VBN governed) (PP (IN by) (NP (NP (NN LCR)) (NN activity))))))))) (. .)))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VP (VBP summarize) (NP (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT the) (NP (JJ IgH) (NN 3'LCR))))) (CC and) (NP (NP (PRP$ its) (JJ putative) (JJ functional) (NN role)) (PP (IN in) (NP (NP (JJ IgH) (NN gene)) (NN expression)))))) (CC and) (VP (VBP compare) (NP (PRP it)) (PP (IN with) (NP (NP (DT the) (NP (NN 5'LCR) (JJ regulatory) (NN region))) (PP (IN of) (NP (DT the) (NP (JJ human) (NN beta-globin) (NN locus)))))))) (. .))))
(S1 (S (NP (NP (NP (NN Expression)) (PP (IN of) (NP (NN transcription) (NN factor) (NNS genes))) (PP (IN after) (NP (NN influenza) (NN A) (NN virus) (NN infection))) (. .)))))
(S1 (S (S (S (NP (NP (NN Infection)) (PP (IN of) (NP (JJ human) (NP (NNS monocytes)))) (PP (IN with) (NP (NN influenza) (NN A) (NN virus)))) (VP (VBZ induces) (NP (NP (DT a) (JJ broad) (NN range)) (PP (IN of) (NP (NP (JJ proinflammatory) (NNS cytokines)) (CC and) (NP (NP (JJ mononuclear) (NN cell)) (VP (NN attracting) (NP (NNS chemokines))))))) (SBAR (IN before) (S (NP (DT the) (NP (JJ infected) (NNS cells))) (VP (VBP undergo) (NP (NN apoptosis)))))) (. .)))))
(S1 (S (S (NP (NP (DT The) (VBG underlying) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (DT the) (JJ corresponding) (NNS genes)) (VP (VBP are) (ADVP (RB transcriptionally)) (VP (VBN initiated) (PP (IN after) (NP (NN virus) (NN infection)))))))) (VP (VBP are) (ADVP (RB still)) (ADVP (RB poorly)) (VP (VBN understood))) (. .))))
(S1 (S (S (NP (NP (NN Activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VP (VBZ seems) (S (VP (TO to) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ many) (NP (JJ proinflammatory) (NN cytokine) (NNS genes)))))))))) (, ,) (CC but) (VP (MD can) (RB not) (VP (VB be) (NP (DT the) (JJ only) (NN mechanism))) (, ,) (SBAR (IN since) (S (NP (JJ several) (NP (NN cytokine) (NNS genes))) (VP (VBP lack) (NP (JJ respective) (NP (VBG binding) (NNS sites))) (PP (IN in) (NP (PRP$ their) (NP (NN promoter) (NNS regions))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (ADVP (RB additionally)) (VP (VBD investigated) (NP (NP (JJ other) (NP (NN transcription) (NNS factors))) (PP (IN of) (NP (JJ possible) (NN importance))) (PP (JJ such) (IN as) (NP (NP (NN CREB)) (, ,) (NP (NN CTF)) (, ,) (NP (NN OTF-1)) (, ,) (CC and) (NP (NN OTF-2)))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB explore) (NP (JJ long-term) (JJ regulatory) (NNS mechanisms))))) (, ,) (S (NP (PRP we)) (VP (VBD investigated) (NP (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN transcription) (NNS factors))) (PP (IN on) (NP (DT the) (NN gene) (NN expression) (NN level)))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (ADJP (JJ important))) (S (VP (TO to) (VP (VB substitute) (PP (IN for) (NP (VBN metabolized) (NN transcription) (NN factor) (NNS proteins))) (PP (IN after) (NP (PRP$ their) (NN activation)))))))))))) (. .))))
(S1 (S (S (S (NP (PRP We)) (VP (VBD identified) (NP (DT a) (ADJP (ADJP (JJ cell-type-specific)) (ADJP (JJ differential))) (NN response)))) (: :) (S (NP (NP (NN CREB)) (, ,) (NP (NN CTF)) (, ,) (NP (NN OTF-1)) (, ,) (NP (NN OFT-2)) (, ,) (CC and) (NP (NN NF-kappa) (NN B)) (NP (NNS genes))) (VP (VBD were) (ADVP (RB strongly)) (VP (VBN induced) (PP (NP (QP (CD 1) (TO to) (CD 4)) (NNS hours)) (IN after) (NP (NN influenza) (NN A) (NN virus) (NN infection))) (PP (IN in) (NP (NP (DT the) (NP (JJ monocytic) (NN cell) (NN line))) (NP (NN Mono) (NN Mac) (CD 6))))) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (ADJP (RB freshly) (VBN prepared)) (JJ human) (NP (NNS monocytes)))) (NP (DT no) (JJ significant) (NNS changes)) (VP (VBD were) (VP (VBN detected))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (JJ infected) (NP (NNS monocytes))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP die) (PP (IN by) (NP (NN apoptosis)))))))) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN CREB)) (, ,) (NP (NN CTF)) (, ,) (CC and) (NP (NN OTF-2))))) (VP (VBD was) (ADVP (RB rather)) (VP (VBN suppressed) (PP (NP (CD 8) (NNS hours)) (IN after) (NP (NN infection))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (JJ long-term) (NN regulation)) (PP (IN of) (NP (NP (NP (NN transcription) (NN factor)) (NN gene) (NN expression)) (PP (IN in) (NP (JJ non-proliferating) (NNS cells)))))) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ minor) (NN importance))) (PP (IN after) (NP (NN influenza) (NN infection)))))) (SBAR (IN since) (S (PP (IN in) (NP (JJ apoptosisprone) (NNS cells))) (NP (NP (DT an) (JJ immediate) (NN availability)) (PP (IN of) (NP (NN transcription) (NN factor) (NNS proteins)))) (VP (VBZ is) (VP (VBN required)))))) (. .))))
(S1 (S (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NP (NN interleukin-12)) (NP (NN p40) (NN transcript)))) (PP (IN by) (NP (NP (NP (NN CD40)) (NN ligation)) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (JJ nuclear) (NN factor-kappaB))))))) (. .)))))
(S1 (S (S (S (NP (NN Interleukin-12)) (VP (VBZ is) (VP (VP (VBN produced) (PP (IN in) (NP (NP (NN response)) (PP (PP (TO to) (NP (NP (NN infection)) (PP (IN with) (NP (NP (NNS bacteria)) (CC or) (NP (NNS parasites)))))) (CC or) (PP (TO to) (NP (NP (JJ bacterial) (NNS constituents)) (PP (JJ such) (IN as) (NP (NP (NN LPS)) (PP (IN in) (NP (NP (NNS monocytes/macrophages)) (CC and) (NP (JJ dendritic) (NNS cells)))))))))))) (, ,) (CC and) (ADVP (RB also)) (VP (VBN generated) (PP (IN by) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NP (VBN activated) (NN T) (NNS cells)) (CC and) (NP (JJ antigen-presenting) (NNS cells))) (PP (IN via) (NP (NP (NN CD40-CD40) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NN CD40L)) (-RRB- -RRB-))))))))))) (. .)))))
(S1 (S (S (ADVP (RB So) (RB far)) (, ,) (NP (NP (JJ transcriptional) (NNS analyses)) (PP (IN of) (NP (NN p40)))) (VP (VBP have) (VP (VBN been) (VP (VBN carried) (PRT (RP out)))) (S (ADVP (RB only)) (VP (VBG using) (NP (NP (JJ bacterial) (NNS constituents)) (PP (JJ such) (IN as) (NP (NN LPS)))) (PP (IN as) (NP (NNS stimuli)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN characterized) (NP (NP (DT the) (JJ transcriptional) (NN induction)) (PP (IN of) (NP (NN p40))) (PP (IN by) (NP (NP (NP (NN CD40)) (NN ligation)) (PP (IN in) (NP (NP (NP (DT a) (NP (JJ human) (NN B) (JJ lymphoblastoid) (NN cell) (NN line))) (, ,) (NP (NN Daudi))) (, ,) (CC and) (NP (NP (DT a) (NP (JJ human) (JJ acute) (JJ monocytic) (NN leukemia) (NN cell) (NN line))) (, ,) (NP (NN THP-1)))))))))) (. .))))
(S1 (S (S (NP (NP (DT These) (NNS cells)) (, ,) (VP (VBN stimulated) (PP (PP (IN by) (NP (NP (DT an) (JJ agonistic) (JJ monoclonal) (NN antibody)) (PP (IN against) (NP (NN CD40))))) (CC or) (PP (IN by) (NP (NP (NN transfection)) (PP (IN with) (NP (DT a) (NP (NN CD40L) (NN expression) (NN vector)))))))) (, ,)) (VP (VP (VBD secreted) (NP (NN p40))) (CC and) (VP (VBD showed) (NP (VBN enhanced) (NP (NN p40) (NN mRNA)) (NN expression)))) (. .))))
(S1 (S (S (NP (NP (NN Sequence) (NN analysis)) (PP (IN of) (NP (DT the) (NP (NN p40) (NN promoter) (NN region))))) (VP (VBD identified) (NP (NP (CD two) (NP (JJ potential) (JJ nuclear) (NN factor) (-LRB- -LRB-) (NN NF) (-RRB- -RRB-) (NN -kappaB) (NN binding) (NNS sites))) (VP (VBN conserved) (PP (IN between) (NP (NP (NN mouse)) (CC and) (NP (NN human))))))) (. .))))
(S1 (S (S (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (JJ potential) (NP (NN NF-kappaB) (NN binding) (NN sequence))) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ located) (PP (IN around) (NP (NP (CD 120) (NN bp) (RB upstream)) (PP (IN of) (NP (NP (DT the) (NP (NN transcription) (NN initiation) (NN site))) (PP (IN in) (NP (NP (ADJP (JJ murine))) (CC and) (NP (JJ human)) (NP (NN p40) (NNS genes))))))))))))) (VP (VBD formed) (NP (NP (DT an) (NP (NN NF-kappaB) (NN complex))) (PP (IN with) (NP (NP (JJ nuclear) (NN extract)) (PP (IN from) (NP (NP (NN Daudi) (NNS cells)) (VP (VBN stimulated) (PP (IN by) (NP (NP (NN CD40)) (NN ligation))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (S (S (NP (NP (NN transfection)) (PP (IN of) (NP (NN Daudi) (NNS cells))) (PP (IN with) (NP (NP (DT the) (JJ polymerized) (NP (NN NF-kappaB) (NN binding) (NN sequence))) (VP (VBN ligated) (PP (TO to) (NP (DT a) (NP (NN thymidine) (NN kinase/chloramphenicol) (NN acetyltransferase) (-LRB- -LRB-) (NN CAT) (-RRB- -RRB-) (NN reporter) (NN plasmid)))))))) (ADVP (RB greatly)) (VP (VBD induced) (NP (NP (NN CAT)) (NN activity)))) (, ,) (CC but) (S (NP (NP (NN transfection)) (PP (IN with) (NP (DT the) (NP (JJ polymerized) (VBN mutated) (NN NF-kappaB) (NN binding) (NN sequence))))) (VP (VBD did) (RB not)))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NP (NN NF-kappaB) (NN binding) (NN site))) (ADJP (JJ located) (PP (IN around) (NP (NP (CD 120) (NN bp) (RB upstream)) (PP (IN of) (NP (NP (DT the) (NP (NN transcription) (NN initiation) (NN site))) (PP (IN in) (NP (NP (ADJP (JJ murine))) (CC and) (NP (JJ human)) (NP (NP (NN p40)) (NN promoter) (NNS regions)))))))))) (VP (MD could) (VP (VB be) (ADJP (JJ important) (PP (IN for) (NP (NP (DT the) (NN p40) (NN induction)) (PP (IN by) (NP (NP (NP (NN CD40)) (NN ligation)) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))))))))))))))) (. .))))
(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B) (NN subunit) (NN p65) (NN mRNA) (NN accumulation)) (PP (IN in) (NP (NP (JJ lipopolysaccharide-stimulated) (JJ human) (JJ monocytic) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NN sodium) (NN salicylate)))))))) (. .))))
(S1 (S (S (NP (NN Lipopolysaccharide)) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN trigger) (NNS substances))))) (PP (IN for) (NP (NP (NNS monocytes)) (CC and) (NP (NNS macrophages)))) (VP (VBG causing) (NP (NP (NN secretion)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS mediators)) (PP (JJ such) (IN as) (NP (NP (NN tumor) (NN necrosis) (NN factor)) (CC and) (NP (NN interleukin-1))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN nature)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (NP (NN regulation)) (PP (IN of) (NP (DT these) (NN cytokine) (NNS genes))))))))) (VP (VBZ is) (ADVP (RB still)) (ADJP (JJ unknown))) (. .))))
(S1 (S (S (NP (JJ Nuclear) (NN factor) (NN kappa) (NN B) (PRN (-LRB- -LRB-) (NP (NP (NN NF-kappa) (NN B)) (: ;) (NP (NP (NN heterodimer)) (PP (IN of) (NP (NP (NN p50)) (CC and) (NP (NN p65)))))) (-RRB- -RRB-)) (NNS proteins)) (VP (VBP have) (VP (VBN been) (VP (VBN suggested) (S (VP (TO to) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NN gene) (NN transcription)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators))))) (SBAR (WRB when) (S (NP (NNS monocytes)) (VP (VBP are) (VP (VBN stimulated) (PP (IN with) (NP (NN lipopolysaccharide))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PP (JJ such) (IN as) (NP (NNS salicylates)))) (VP (VBP have) (VP (VBN been) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN inflammation))))))))))) (, ,) (CC and) (S (NP (NP (DT a) (JJ new) (NN mechanism)) (PP (IN of) (NP (NN drug) (NN action)))) (VP (VBD was) (VP (VBN suggested) (ADVP (RB recently))))) (. .))))
(S1 (S (S (NP (NNS Salicylates)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (JJ lipopolysaccharide-induced) (NN gene) (NN transcription)) (PP (IN via) (NP (NP (NP (NN inhibition)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN activation)))) (PP (IN by) (S (VP (VP (VBG preventing) (NP (NP (DT the) (NN degradation)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B) (NN inhibitor)) (NP (`` ``) (NN I) (NN kappa) (NN B)))))) (, ,) (VP (VBG blocking) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN into) (NP (DT the) (JJ nuclear) (NN compartment)))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN nature)) (PP (IN of) (NP (NP (DT the) (NN subunit)) (VP (VBN involved) (PP (IN in) (NP (DT this) (NN mechanism))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN defined)))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNS salicylates)) (VP (VBP affect) (NP (NN cytokine) (NN gene) (NN transcription))))))))) (, ,) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (ADJP (ADJP (JJ active)) (CC and) (ADJP (JJ inactive))) (NP (NP (NN NF-kappa) (NN B)) (CC and) (NP (NN NF-kappa) (NN B) (NN mRNA))))) (, ,) (PP (IN in) (NP (NN Porphyromonas) (NN gingivalis) (JJ lipopolysaccharide-stimulated) (JJ human) (JJ monocytic) (NNS cells)))) (VP (VBD was) (VP (VBN assessed))) (. .))))
(S1 (S (S (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NN sodium) (NN salicylate)))) (VP (VBD suppressed) (NP (NN NF-kappa) (NN B) (NN p65) (NN mRNA) (NN accumulation)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ total) (NN NF-kappa) (NN B))))))))) (, ,) (S (NP (NP (NN p50)) (PP (IN on) (NP (NN tissue) (NN oligonucleotide)))) (VP (VBD had) (NP (DT no) (NNS effects)) (PP (IN on) (NP (JJ lipopolysaccharide-induced) (NN NF-kappa) (NN B) (NN activation))))) (. .))))
(S1 (S (S (NP (DT The) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT the) (NN p65) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NN salicylate) (NN treatment))))) (CC and) (VP (VBP highlight) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN salicylate)))) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (NN gene) (NN expression)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Glucocorticoid) (NNS receptors)) (PP (IN in) (NP (NP (NN cord) (NN blood) (NNS lymphocytes)) (PP (PP (IN of) (NP (JJ healthy) (NNS neonates))) (CC and) (PP (IN of) (NP (NP (NNS preterms)) (VP (VBG suffering) (PP (IN from) (NP (JJ respiratory) (NN distress) (NN syndrome))))))))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBD measured) (NP (NP (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NP (NN glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (PP (IN in) (NP (NN cord) (NN blood) (NNS lymphocytes)))))) (CC and) (NP (NP (DT the) (NN binding) (NN affinity)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-)))) (PP (PP (IN in) (NP (CD 15) (NN term))) (CC and) (PP (IN in) (NP (CD 20) (JJ preterm) (NNS babies)))))) (. .)))))
(S1 (S (S (NP (NP (CD Thirteen) (NNS preterms)) (PP (IN of) (NP (DT the) (JJ latter) (NN group)))) (VP (VBD received) (NP (JJ prenatal) (NN steroid) (NN treatment))) (. .))))
(S1 (S (S (NP (CD Seven) (NNS preterms)) (VP (VBD developed) (NP (NP (JJ neonatal) (JJ respiratory) (NN distress) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN NRDS)) (-RRB- -RRB-)))) (. .))))
(S1 (S (S (NP (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NN GR)))) (CC and) (NP (DT the) (NN Kd))) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT the) (NP (NN term)) (CC and) (NP (NP (ADJP (JJ preterm))) (PRN (-LRB- -LRB-) (PP (PP (IN with)) (CC and) (PP (IN without)) (NP (NN NRDS))) (-RRB- -RRB-))) (NP (NNS babies)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN maximum) (NN -LRB-3H-RRB--thymidine) (NN incorporation)) (PP (IN into) (NP (NP (NN DNA)) (PP (IN of) (NP (NP (NN cord) (NN blood) (NNS lymphocytes)) (PP (IN from) (NP (NP (DT all) (NNS preterms)) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without)) (NP (NN NRDS)))))))))) (VP (VBD was) (VP (VBN suppressed)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN from) (NP (NP (NN term) (NNS babies)) (CC or) (NP (NNS adults)))))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (MD could) (ADVP (RB partly)) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP (DT the) (JJ antenatal) (NN steroid) (NN treatment)))))) (. .))))
(S1 (S (S (NP (NP (NP (NN Sensitivity)) (PRN (-LRB- -LRB-) (NP (NN ID50)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NP (NNS lymphocytes)))) (PP (IN for) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN dexamethasone)))))) (VP (VBD was) (NP (DT the) (JJ same)) (PP (IN in) (NP (DT all) (NNS groups)))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (DT this) (NN study)) (PP (IN on) (NP (NP (DT the) (NP (NN number)) (CC and) (NP (NN function))) (PP (IN of) (NP (NP (NN GR)) (PP (IN in) (NP (NNS lymphocytes))))))))) (, ,) (NP (PRP we)) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (VP (VB find) (NP (NP (DT a) (NN relation)) (PP (IN between) (NP (NP (NP (DT the) (NN functionality)) (PP (IN of) (NP (DT the) (NP (NN GR))))) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN NRDS)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NNS Oxidants)) (, ,) (NP (NN transcription) (NNS factors)) (, ,) (CC and) (NP (JJ intestinal) (NN inflammation)) (. .)))))
(S1 (S (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB now)) (ADVP (RB well)) (VP (VBN appreciated) (SBAR (IN that) (S (NP (JJ chronic) (NN gut) (NN inflammation)) (VP (VBZ is) (VP (VBN characterized) (PP (IN by) (NP (NP (VBN enhanced) (NN production)) (PP (IN of) (NP (NP (JJ reactive) (NNS metabolites)) (PP (IN of) (NP (NP (NN oxygen)) (CC and) (NP (NN nitrogen)))))))))))))) (. .)))))
(S1 (S (S (NP (NP (DT Some)) (PP (IN of) (NP (DT these) (NNS oxidants)))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB modulate) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS genes)))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (DT the) (NP (ADJP (JJ immune))) (CC and) (NP (ADJP (JJ inflammatory))) (NP (NNS responses)))))))))))))))) (. .))))
(S1 (S (S (PP (IN For) (NP (NN example))) (, ,) (NP (JJ certain) (NNS oxidants)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB activate) (NP (NP (DT the) (NP (JJ nuclear) (NN transcription) (NN factor) (NN kappa) (NN B))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ regulates) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ different) (NP (NN adhesion) (NNS molecules)) (, ,) (NP (NNS cytokines)) (, ,) (CC and) (NP (NNS enzymes)))))))))))))))) (. .))))
(S1 (S (S (NP (NNS Oxidants)) (VP (VBP are) (ADVP (RB also)) (VP (VBN known) (S (VP (TO to) (VP (VB activate) (NP (NP (DT another) (NP (NN transcription) (NN factor))) (, ,) (NP (NN activator) (NN protein-1)))))))) (. .))))
(S1 (S (S (NP (DT This) (NP (NN transcription) (NN factor))) (VP (VP (VBZ is) (VP (VBN composed) (PP (IN of) (NP (NP (NNS products)) (PP (IN from) (NP (DT the) (NP (NN fos) (CC and) (NN jun) (NN proto-oncogene) (NN family)))))))) (CC and) (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB be) (ADJP (JJ important) (PP (IN in) (S (VP (VBG regulating) (NP (NN cell) (NP (NN growth)) (CC and) (NP (NN proliferation))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Finally)) (, ,) (S (S (NP (NNS oxidants)) (VP (VBP are) (VP (VBN believed) (S (VP (TO to) (VP (VB promote) (NP (NP (JJ intestinal) (JJ epithelial) (NN cell)) (NN apoptosis)))))))) (, ,) (CC and) (S (NP (DT the) (NP (NN B-cell) (NN lymphoma/leukemia-2) (NN gene) (NN product))) (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB inhibit) (NP (DT this) (NN phenomenon)) (PP (IN in) (NP (DT an) (JJ antioxidant-dependent) (NN manner)))))))))) (. .))))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (NP (DT these) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ nontoxic) (NNS concentrations)) (PP (IN of) (NP (NP (JJ reactive) (NNS metabolites)) (PP (IN of) (NP (NP (NN oxygen)) (CC and) (NP (NN nitrogen))))))) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (DT the) (JJ inflammatory) (NN response)))))))))) (CC and) (PP (IN in) (S (VP (VBG modulating) (NP (NN apoptosis))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Glucocorticoid) (NNS receptors)) (, ,) (NP (NP (NN fibromyalgia)) (CC and) (NP (JJ low) (JJ back) (NN pain))) (. .)))))
(S1 (S (S (S (ADVP (RB Recently)) (, ,) (NP (NP (NN fibromyalgia)) (PRN (-LRB- -LRB-) (NP (NN FMS)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (NN disorder)) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ altered) (NN functioning)) (PP (IN of) (NP (DT the) (NN stress) (NN response) (NN system)))))))))))) (. .)))))
(S1 (S (S (NP (NN FMS) (NNS patients)) (VP (VBP display) (NP (DT a) (ADJP (ADJP (JJ hyperreactive)) (ADJP (JJ pituitary))) (NP (NP (JJ adrenocorticotropic) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN ACTH)) (-RRB- -RRB-))) (NN release) (PP (IN in) (NP (NP (NN response)) (PP (PP (TO to) (NP (NP (JJ corticotropin-releasing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN CRH)) (-RRB- -RRB-)))) (CC and) (PP (TO to) (NP (JJ insulin-induced) (NN hypoglycemia)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (JJ negative) (NN feedback)) (PP (IN of) (NP (NN cortisol)))) (VP (MD could) (VP (VB be) (VP (VBN deranged))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (NP (PRP we)) (VP (VP (VBD investigated) (NP (NP (DT the) (NP (NNS properties)) (CC and) (NP (NN function))) (PP (IN of) (NP (NP (NP (DT the) (NP (NN glucocorticoid) (NNS receptors))) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (PP (IN in) (NP (NN FMS) (NNS patients))))))) (CC and) (VP (VBD compared) (NP (DT the) (NNS results)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (JJ healthy) (NNS persons)) (CC and) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NP (NP (JJ low) (JJ back) (NN pain)) (PRN (-LRB- -LRB-) (NP (NP (NN LBP)) (NP (DT a) (JJ localized) (NN pain) (NN condition))) (-RRB- -RRB-)))))))))))) (. .))))
(S1 (S (S (NP (NP (NP (CD Forty) (JJ primary) (NN FMS) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN F) (: :) (NN M)) (ADJP (JJ =) (NP (CD 36) (: :) (CD 4)))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 28) (NN LBP) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 25) (: :) (CD 3)) (-RRB- -RRB-))) (CC and) (NP (QP (CD 14) (PRN (-LRB- -LRB-) (NP (CD 12) (: :) (CD 2)) (-RRB- -RRB-))) (ADJP (ADJP (JJ healthy)) (, ,) (ADJP (JJ sedentary))) (JJ control) (NNS persons))) (VP (VBD were) (VP (VBN recruited) (PP (IN for) (NP (DT the) (NN study))))) (. .))))
(S1 (S (S (NP (NP (JJ Urinary) (JJ free) (NN cortisol) (NN excretion)) (PP (IN in) (NP (NP (NN FMS)) (CC and) (NP (NN LBP)) (NP (NNS patients))))) (VP (VBD was) (ADJP (JJR lower) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))))) (. .))))
(S1 (S (S (NP (RB Only) (NN FMS) (NNS patients)) (VP (VBD displayed) (NP (NP (JJR lower) (NN CBG)) (CC and) (NP (JJ basal) (NN serum) (NN cortisol) (NNS concentrations))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NNS controls))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN plasma) (JJ free) (NN cortisol) (NNS concentrations)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT the) (CD three) (NNS groups))))) (. .))))
(S1 (S (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN GR))) (PP (IN per) (NP (NN cell))))) (PP (IN among) (NP (DT the) (CD three) (NNS groups))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN FMS)) (: :) (NP (CD 6498) (CC +/-) (CD 252))) (, ,) (NP (NP (NN LBP)) (: :) (NP (CD 6625) (CC +/-) (CD 284))) (, ,) (NP (NP (NNS controls)) (: :) (NP (CD 6576) (CC +/-) (CD 304)))) (-RRB- -RRB-))))) (, ,) (CC but) (S (NP (NP (NP (DT the) (NN dissociation) (NN constant)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NP (NP (NN FMS)) (PRN (-LRB- -LRB-) (NP (QP (CD 14.5) (CC +/-) (CD 0.9)) (NN nmol/l)) (-RRB- -RRB-))) (CC and) (NP (NP (NN LBP)) (PRN (-LRB- -LRB-) (NP (QP (CD 14.7) (CC +/-) (CD 1.3)) (NN nmol/l)) (-RRB- -RRB-))) (NP (NNS subjects))))) (VP (VBD was) (ADJP (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NNS controls)))) (PRN (-LRB- -LRB-) (NP (QP (CD 10.9) (CC +/-) (CD 0.8)) (NN nmol/l)) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR &lt;) (NP (CD .05)))) (-RRB- -RRB-))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ maximal) (NN stimulation)) (PP (IN of) (NP (DT the) (NP (NNS lymphocytes)))) (, ,)) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (DT the) (JJ maximal) (NN thymidine) (NN incorporation)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN cortisol))))) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NN FMS) (NN group)))))) (VP (VBD was) (ADJP (ADJP (ADJP (QP (RB approximately) (CD 1.5) (NNS times)) (JJR higher)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR &lt;) (NP (CD .05)))) (-RRB- -RRB-))) (PP (IN than) (PP (IN in) (NP (DT the) (NP (JJ control)) (CC or) (NP (NN LBP) (NN group))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN ED50)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (NN cortisol) (NN concentration)) (VP (VBG giving) (NP (NP (ADJP (CD 50) (NN %)) (NN inhibition)) (PP (IN of) (NP (DT the) (JJ thymidine) (NN incorporation)))))) (-RRB- -RRB-)) (, ,)) (ADVP (RB however)) (, ,) (VP (VBD was) (ADJP (JJ identical) (PP (IN in) (NP (DT all) (CD three) (NNS groups))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NN FMS) (NNS patients)) (VP (VBP have) (NP (NP (NP (DT a) (JJ mild) (NN hypocortisolemia)) (, ,) (NP (VBN increased) (NN cortisol) (NN feedback) (NN resistance))) (PP (IN in) (NP (NP (NN combination)) (PP (ADVP (RB probably)) (IN with) (NP (NP (DT a) (VBN reduced) (NN CRH) (NP (NN synthesis)) (CC or) (NP (NN release))) (PP (IN in) (NP (DT the) (NN hypothalamus)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (DT the) (NP (NN GR)) (CC and) (NP (NP (NN mineralocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN MR)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NN CRH) (NN regulation)) (PP (IN in) (NP (DT the) (NN FMS) (NNS patients)))))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN solved)))))) (. .))))
(S1 (S (NP (NP (NP (NN Transcription) (NNS factors)) (VP (VBN required) (PP (IN for) (NP (JJ lymphoid) (NN lineage) (NN commitment)))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Intimate) (NNS interactions)) (PP (IN between) (NP (NP (JJ multipotential) (NP (JJ hemopoietic) (NN stem) (NNS cells))) (CC and) (NP (PRP$ their) (NN microenvironment))))) (VP (VBP work) (PP (IN towards) (S (VP (VBG redefining) (NP (NP (NP (DT the) (NN identity)) (CC and) (NP (DT the) (JJ differentiative) (NN fate))) (PP (IN of) (NP (DT these) (NP (JJ primitive) (NNS cells))))))))) (. .)))))
(S1 (S (S (NP (NP (JJ Molecular) (NNS cues)) (VP (VBN delivered) (PP (IN by) (NP (DT the) (NN microenvironment))))) (ADVP (RB frequently)) (VP (VBP act) (PP (IN in) (NP (DT an) (JJ instructive) (NN fashion))) (PP (IN by) (S (VP (VBG initiating) (NP (NP (JJ intracellular) (NN signaling) (NNS pathways)) (SBAR (WHNP (WDT that)) (S (ADVP (RB ultimately)) (VP (VBP target) (NP (NP (DT a) (JJ select) (NN group)) (PP (IN of) (NP (NN transcription) (NNS factors)))))))))))) (. .))))
(S1 (S (S (NP (DT These) (JJ transcriptional) (NNS regulators)) (PP (IN in) (NP (NN turn))) (VP (VBP trigger) (NP (NP (DT a) (NN cascade)) (PP (IN of) (NP (NP (JJ genetic) (NNS changes)) (SBAR (WHNP (WDT that)) (S (ADVP (RB ultimately)) (VP (VBP determine) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (NNS cells)))) (PP (IN during) (NP (NN differentiation)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Gene) (NN inactivation) (NNS studies)) (PP (IN on) (NP (DT the) (NP (NN PU.1)) (, ,) (NP (NN Ikaros)) (CC and) (NP (NN GATA-3)) (NP (NNS genes))))) (VP (VBP have) (VP (VBN revealed) (SBAR (IN that) (S (NP (PRP$ their) (VBN encoded) (NNS factors)) (VP (VBP are) (ADJP (JJ essential) (PP (IN for) (NP (NP (DT the) (JJS earliest) (NN commitment) (NN step)) (PP (IN into) (NP (DT the) (NP (NN B)) (CC and) (NP (NN T)) (NP (JJ lymphoid) (NNS lineages)))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NP (NN Cytokine)) (NN rescue)) (PP (IN from) (NP (NP (ADJP (NN glucocorticoid) (JJ induced)) (NN apoptosis)) (PP (IN in) (NP (NN T) (NNS cells)))))) (VP (VBZ is) (VP (VBN mediated) (PP (IN through) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN IkappaBalpha))))))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (SBAR (IN that) (S (NP (NP (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (NN DEX)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ synthetic) (NN glucocorticoid)) (, ,)) (VP (VBZ causes) (NP (NN apoptosis)) (PP (IN in) (NP (JJ mature) (NN Th) (NN cell) (NNS lines)))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (DT this) (NN induction)) (PP (IN of) (NP (NN cell) (NN death)))) (VP (VBZ is) (VP (VBN prevented) (PP (PP (IN by) (NP (JJ specific) (NP (NNS cytokines)))) (, ,) (ADVP (RB namely)) (, ,) (PP (PP (IN by) (NP (NP (NN IL-2)) (PP (IN in) (NP (NN Th1) (NNS cells))))) (CC and) (PP (IN by) (NP (NP (NN IL-4)) (PP (IN in) (NP (NN Th2) (NNS cells))))))))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (ADVP (RB now)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT this) (JJ differential) (NN rescue)) (PP (IN by) (NP (NP (JJ specific) (NP (NNS cytokines))) (PP (IN in) (NP (NN Th) (NNS cells)))))) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN IkappaBalpha)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP (NP (NN DEX)) (CC and) (NP (NNS cytokines)))))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT both) (NN cell) (NNS types))) (NP (NP (DT the) (JJ cellular) (NNS levels)) (PP (IN of) (NP (NP (NN IkappaBalpha) (NN mRNA)) (CC and) (NP (NN protein))))) (VP (VBD were) (VP (VBN evaluated) (PP (IN by) (NP (NN DEX) (NN treatment))))) (. .))))
(S1 (S (S (ADVP (RB Interestingly)) (, ,) (NP (DT the) (JJ DEX-mediated) (NP (NN IkappaBalpha)) (NN induction)) (VP (VBD was) (ADVP (RB completely)) (VP (VBN inhibited) (PP (IN by) (NP (NP (NP (NP (NN IL-2))) (, ,) (CONJP (CC but) (RB not)) (NP (NN IL-4))) (, ,) (PP (IN in) (NP (NN Th1) (NNS cells)))))) (, ,) (SBAR (IN while) (S (NP (DT the) (NN reverse) (NN profile)) (VP (VBD was) (VP (VBN seen) (PP (IN in) (NP (NN Th2) (NNS cells)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT both) (NN cell) (NNS types))) (, ,) (NP (NP (DT the) (NP (NN cytokine))) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN IkappaBalpha))) (PP (IN by) (NP (NN DEX))))))) (, ,)) (ADVP (RB also)) (VP (VBZ rescues) (NP (DT these) (NNS cells)) (PP (IN from) (NP (JJ DEX-induced) (NN apoptosis))) (, ,) (SBAR (IN although) (S (NP (DT the) (NN rescue) (NN cytokine)) (VP (VBZ is) (ADJP (JJ different) (PP (IN in) (NP (NP (NN Th1)) (CC and) (NP (NN Th2)) (NP (NNS cells))))))))) (. .))))
(S1 (S (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP imply) (SBAR (IN that) (S (NP (NN T) (NNS cells)) (VP (VBP need) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT a) (JJ certain) (NN level)) (PP (IN of) (NP (NP (NN NF-kappaB)) (JJ transcriptional) (NN activity))))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB survive)))))))))) (: ;) (S (NP (NP (NP (JJ up-)) (CC or) (NP (NN down-regulation))) (PP (IN of) (NP (JJ nuclear) (NN NF) (NN kappaB))) (PP (IN through) (NP (NP (NN modulation)) (PP (IN of) (NP (NP (NP (NN IkappaBalpha)) (NN expression)) (PP (IN by) (NP (NP (NNS cytokines)) (CC or) (NP (NN DEX))))))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN cell) (NN survival)) (CC or) (NP (NN cell) (NN death)))) (, ,) (ADVP (RB respectively))))) (. .))))
(S1 (S (NP (NP (NP (NNS Genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (NP (NP (NN interleukin-4)) (NN expression)) (PP (IN in) (NP (NN T) (NNS cells))))))) (. .)))))
(S1 (S (S (S (NP (NN Interleukin-4)) (VP (VBZ is) (NP (NP (DT an) (NP (JJ immunomodulatory) (NN cytokine))) (SBAR (WHNP (WDT which)) (S (VP (VBZ plays) (NP (DT a) (JJ central) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (ADJP (JJ allergic))) (CC and) (NP (ADJP (JJ atopic))) (NP (JJ immune) (NNS responses))))))))))) (. .)))))
(S1 (S (S (NP (JJ Significant) (NN progress)) (VP (VBZ has) (VP (VBN been) (VP (VBN made)))) (PP (IN in) (S (VP (VBG gaining) (NP (NP (DT a) (JJ detailed) (NN understanding)) (PP (IN of) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NP (NN interleukin-4) (NN gene)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ recent) (NP (NN identification)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (JJ several) (JJ key) (NP (NN transcription) (NNS factors))))) (VP (VBZ has) (VP (VBN helped) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NP (NN T) (NN helper) (NN cell) (NN cytokine) (NN gene)) (NN expression))))))))) (. .))))
(S1 (S (S (S (NP (JJ Xenogeneic) (JJ human) (NN serum)) (VP (VBZ promotes) (NP (NP (NN leukocyte) (NN adhesion)) (PP (TO to) (NP (NN porcine) (NN endothelium)))) (PP (IN under) (NP (NN flow) (NNS conditions))) (, ,) (PP (ADVP (RB possibly)) (IN through) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT the) (NP (NN transcription) (NN factor) (NN NF-kappa) (NN B))))))) (. .)))))
(S1 (S (S (S (NP (NP (JJ Endothelial) (NN cell) (NN activation)) (CC and) (NP (NN leukocyte) (NN infiltration))) (VP (VBP are) (NP (NP (DT a) (JJ consistent) (NN feature)) (PP (IN of) (NP (JJ discordant) (NN xenograft) (NN rejection))))) (. .)))))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBD evaluated) (SBAR (IN whether) (S (NP (JJ xenogeneic) (NN serum) (, ,)) (PP (IN as) (NP (NP (DT a) (NN source)) (PP (IN of) (NP (NP (JJ xenoreactive) (JJ natural) (NNS antibodies)) (CC and) (NP (NN complement)))))) (, ,) (VP (VBD induced) (NP (JJ endothelial) (NN cell) (NN activation)) (PP (IN with) (NP (JJ consequent) (NN leukocyte) (NN adhesion))) (PP (IN under) (NP (NN flow) (NNS conditions))))))) (. .))))
(S1 (S (S (NP (NP (JJ Porcine) (JJ aortic) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS PAEC)) (-RRB- -RRB-))) (VP (VBD were) (VP (VP (VBN incubated) (PP (IN for) (NP (NP (CD 1) (NN hr) (CD 30) (NN min)) (CC or) (NP (CD 5) (NN hr)))) (PP (IN with) (NP (NP (NP (ADJP (CD 10) (NN %)) (JJ homologous) (JJ porcine) (NN serum)) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-))) (CC or) (NP (ADJP (CD 10) (NN %)) (JJ xenogeneic) (JJ human) (NN serum))))) (CC and) (ADVP (RB then)) (VP (VBN perfused) (PP (IN with) (NP (JJ total) (NP (JJ human) (NNS leukocytes)))) (PP (IN in) (NP (DT a) (NN parallel) (NN plate) (NN flow) (NN chamber))) (PP (IN under) (NP (NP (JJ laminar) (NN flow)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NNS dynes/cm2)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (JJ Adherent) (NNS cells)) (VP (VBD were) (VP (VBN counted) (PP (IN by) (NP (JJ digital) (NN image) (NN analysis))))) (. .))))
(S1 (S (S (NP (JJ Xenogeneic) (JJ human) (NN serum)) (ADVP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR &lt;) (NP (CD 0.01)))) (-RRB- -RRB-))) (VP (VBD increased) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ adherent) (NNS leukocytes)))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (JJ porcine) (NN serum))))))) (. .))))
(S1 (S (S (NP (DT A) (ADJP (ADJP (JJ similar)) (ADJP (JJ adhesive))) (NN response)) (VP (VBD was) (VP (VBN elicited) (PP (IN by) (NP (NP (NP (NN TNF) (NN alpha)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN U/ml)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NNS inducers)) (PP (IN of) (NP (NP (JJ endothelial) (NN cell)) (JJ adhesive) (NNS properties)))))) (, ,) (VP (ADVP (RB here)) (VBN used) (PP (IN as) (NP (JJ positive) (NN control))))))))) (. .))))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (NP (JJ possible) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (NP (JJ endothelial) (NN cell)) (NN activation)) (PP (IN by) (NP (JJ xenogeneic) (NN serum)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD focussed) (PP (IN on) (NP (NP (NN transcription) (NN factor) (NN NF-kappa) (NN B)) (, ,) (NP (NP (DT a) (JJ central) (NN regulator)) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (JJ different) (NNS genes)) (, ,) (PP (VBG including) (NP (NP (JJ adhesive) (NNS molecules)) (CC and) (NP (NNS chemoattractants))))))))))))) (. .))))
(S1 (S (S (PP (IN By) (NP (JJ confocal) (NN fluorescence) (NN microscopy))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT a) (JJ positive) (NN staining)) (PP (IN for) (NP (NP (NN NF-kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN p65) (NN subunit)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (NP (NNS PAEC)) (VP (VBN exposed) (PP (IN for) (NP (CD 1) (NN hr) (CD 30) (NN min))) (PP (TO to) (NP (JJ human) (NN serum)))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD indicated) (NP (NP (NN NF-kappa) (NN B)) (NN activation)) (PP (IN in) (NP (DT this) (NN setting))))))) (. .))))
(S1 (S (S (PP (IN At) (NP (NN variance))) (, ,) (PP (IN in) (NP (NP (NNS PAEC)) (VP (VBN incubated) (PP (IN with) (NP (DT the) (JJ homologous) (NN serum)))))) (, ,) (NP (NN NF-kappa) (NN B)) (VP (VBD was) (ADJP (RB strictly) (JJ localized) (PP (IN in) (NP (DT the) (NN cell) (NN cytoplasm))))) (. .))))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN of) (NP (NP (NNS PAEC)) (VP (VBN exposed) (PP (TO to) (NP (JJ xenogeneic) (NN serum)))))) (PP (IN with) (NP (NP (DT the) (NP (NN NF-kappa) (NN B)) (NNS inhibitors)) (NP (NP (NP (NN pyrrolidinedithiocarbamate)) (PRN (-LRB- -LRB-) (NP (NP (NN PDTC)) (, ,) (NP (CD 25) (NN microM))) (-RRB- -RRB-))) (CC and) (NP (NP (NN tosyl-phechloromethylketone)) (PRN (-LRB- -LRB-) (NP (NP (NN TPCK)) (, ,) (NP (CD 25) (NN microM))) (-RRB- -RRB-))))))) (ADVP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR &lt;) (NP (CD 0.01)))) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NN leukocyte) (NN adhesion)) (PP (IN in) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NNS PAEC)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ human) (NN serum)) (ADVP (RB alone)))))))))) (. .))))
(S1 (S (S (NP (NNS Findings) (SBAR (IN that) (S (NP (JJ xenogeneic) (NN serum)) (VP (VBZ promotes) (NP (JJ leukocyte-endothelium) (NN interaction)) (PP (ADVP (RB possibly)) (IN through) (NP (NP (NN NF-kappa) (NN B)) (NN activation))))))) (VP (MD might) (VP (VB be) (ADJP (JJ relevant) (PP (IN for) (S (VP (VBG designing) (NP (NP (ADJP (ADJP (JJ future)) (ADJP (JJ therapeutic))) (NNS strategies)) (VP (VBN aimed) (PP (IN at) (S (VP (VBG prolonging) (NP (NN xenograft) (NN survival))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Delta-opioid) (NNS receptors)) (VP (VBN expressed) (PP (IN by) (NP (NN Jurkat) (NN T) (NNS cells))))) (VP (VBP enhance) (NP (NP (NP (NP (NN IL-2)) (NN secretion)) (PP (IN by) (S (VP (VBG increasing) (NP (NN AP-1) (NNS complexes)))))) (CC and) (NP (NP (NN activity)) (PP (IN of) (NP (DT the) (NP (JJ NF-AT/AP-1-binding) (NN promoter) (NN element))))))) (. .)))))
(S1 (S (S (S (NP (ADJP (ADJP (JJ Recent)) (ADJP (JJ molecular))) (NN evidence)) (VP (VBZ points) (PP (TO to) (NP (NP (NP (NP (ADJP (JJ transient))) (CC and/or) (NP (ADJP (JJ stage-specific))) (NP (NN expression))) (PP (IN of) (NP (NP (NN delta-)) (CC and) (NP (JJ kappa-opioid)) (NP (NNS receptors))))) (PP (IN by) (NP (NP (ADJP (JJ thymic))) (CC and) (NP (JJ peripheral) (NN T)) (NP (NNS lymphocytes))))))) (. .)))))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (JJ medical) (NNS treatments)) (CC or) (NP (NN stress))) (ADVP (RB commonly)) (VP (VBP increase) (NP (JJ opioid) (NNS levels))))) (, ,) (S (NP (NP (PRP it))) (VP (VBZ is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB understand) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNS opioids)) (VP (VBP affect) (NP (NN T) (NN lymphocyte) (NNS functions))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VP (VBD created)) (CC and) (VP (VBD studied)) (NP (NP (DT a) (NP (NN T) (NN cell) (NN line))) (VP (VBG expressing) (NP (NP (DT the) (NP (VBN cloned) (JJ delta-opioid) (NN receptor))) (PRN (-LRB- -LRB-) (NP (NN DOR1)) (-RRB- -RRB-)))))) (. .))))
(S1 (S (S (NP (NP (NP (NN DOR1)) (NN ligation)) (PP (IN by) (NP (NP (DT a) (JJ specific) (NP (NN DOR1)) (NN agonist)) (, ,) (NP (NN deltorphin)))) (, ,)) (VP (VBD augmented) (NP (NP (NN IL-2)) (NN secretion)) (PP (IN by) (S (VP (VBG synergizing) (PP (IN with) (NP (NP (NNS signals)) (PP (IN from) (NP (NP (NN TCR-CD3)) (CC and) (NP (NN CD28)))))))))) (. .))))
(S1 (S (S (NP (NN Reporter) (NN gene) (NNS constructs)) (VP (VBD were) (VP (VBN used)) (S (VP (TO to) (VP (VB map) (NP (NP (DT this) (NN effect)) (PP (IN of) (NP (NN deltorphin)))) (PP (TO to) (NP (NP (DT the) (NP (NN AP-1-)) (CC and) (NP (JJ NF-AT/AP-1-binding)) (NP (NNS sites))) (PP (IN of) (NP (DT the) (NP (NN IL-2) (NN promoter)))))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NN DOR1)) (NN signaling)) (VP (VBD increased) (NP (NN -LSB-Ca2+-RSB-i))))) (, ,) (S (NP (NN deltorphin)) (VP (VBD enhanced) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN of) (NP (DT the) (NP (JJ NF-AT/AP-1-binding) (NN site))))) (PP (IN via) (NP (NP (DT a) (NN mechanism)) (ADJP (ADJP (JJ independent) (PP (IN of) (NP (NN calcineurin)))) (CC and) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ elevated) (NN -LSB-Ca2+-RSB-i))))))))))) (. .))))
(S1 (S (S (NP (NN Deltorphin)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN accumulation)) (PP (IN of) (NP (NN AP-1) (NN transcription) (NN factor) (NNS complexes)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN DOR1)) (VP (VBZ augments) (NP (NP (NN IL-2)) (NN secretion)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (NP (NN AP-1) (NN component))) (PP (IN of) (NP (DT the) (NP (NN NF-AT/AP-1) (NN transcription) (NN factor)))))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VP (VBP advance) (NP (NP (DT the) (JJ molecular) (NN understanding)) (PP (IN of) (NP (NP (JJ opioid) (NNS effects)) (PP (IN on) (NP (NNS lymphocytes))))))) (, ,) (CC and) (PP (IN in) (NP (NN addition))) (, ,) (VP (VBP demonstrate) (NP (NP (NN regulation)) (PP (IN of) (NP (NP (NN IL-2)) (NP (NN synthesis)) (CC and) (NP (NN secretion)))) (PP (IN by) (NP (NP (DT the) (JJ novel) (NN mechanism)) (PP (IN of) (NP (JJ receptor-mediated) (NP (NN AP-1)) (NN induction)))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Pharmacological) (NN control)) (PP (IN of) (NP (NN antigen) (NN responsiveness))) (PP (IN in) (NP (RB genetically) (VBN modified) (NN T) (NNS lymphocytes))) (. .)))))
(S1 (S (S (S (NP (NP (DT A) (NP (JJ chimeric) (NN TCR) (NN gene))) (, ,) (VP (VBG comprising) (NP (NP (DT an) (NP (JJ anti-hapten) (JJ single-chain) (NN Ab) (JJ variable) (NN fragment))) (VP (VBN fused) (PP (TO to) (NP (NP (DT the) (NP (JJ transmembrane) (CC and) (JJ cytoplasmic) (NNS regions))) (PP (IN of) (NP (DT the) (NP (JJ human) (NN TCR) (NN zeta-chain))))))))) (, ,)) (VP (VBD was) (VP (VBN used)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (DT the) (JJ tetracycline-regulatable) (NN system)) (VP (MD could) (VP (VB be) (VP (VBN used))) (S (VP (TO to) (VP (VB regulate) (NP (NP (NN gene) (NN expression)) (PP (IN in) (NP (NN T) (NNS cells)))))))))))))) (. .)))))
(S1 (S (S (NP (NN Jurkat) (NN T) (NNS cells)) (VP (VBD were) (ADVP (RB stably)) (VP (VBN transfected) (PP (IN with) (NP (NP (NP (DT a) (JJ single) (NN vector)) (VP (VBG encoding) (NP (NP (DT the) (NP (NN tetracycline) (JJ trans-activator) (NN protein))) (, ,) (VP (VBN controlled) (PP (IN by) (NP (DT a) (NP (JJ constitutive) (NN promoter)))))))) (, ,) (CC and) (NP (DT the) (NP (JJ chimeric) (NN TCR))))) (, ,) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT a) (NP (JJ trans-activator) (JJ protein-responsive) (NN promoter)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNS tetracyclines))))) (, ,) (NP (DT the) (VBN transfected) (NP (NN T) (NNS cells))) (VP (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB express) (NP (DT the) (NP (JJ chimeric) (NN receptor))) (PP (IN on) (NP (DT the) (NN cell) (NN surface)))))))) (CC and) (VP (MD could) (VP (VB be) (VP (VBN activated) (PP (IN by) (NP (PRP$ its) (NP (JJ cognate) (NN Ag))))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NN IL-2)))))))) (. .))))
(S1 (S (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNS cells)) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (VBG increasing) (NNS concentrations)) (PP (IN of) (NP (NNS tetracyclines))))))))) (, ,) (S (NP (NP (NN surface) (NN expression)) (PP (IN of) (NP (DT the) (NP (JJ chimeric) (NN receptor))))) (VP (VBD was) (VP (VBN suppressed) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))))))) (, ,) (CC and) (S (NP (DT this) (NN suppression)) (VP (VBD was) (ADJP (JJ sufficient)) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NP (JJ complete) (NN loss)) (PP (IN of) (NP (NP (NN responsiveness)) (PP (TO to) (NP (DT the) (NP (VBN targeted) (NN Ag))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Prolonged) (NN suppression)) (PP (IN of) (NP (JJ trans-gene) (NN expression))) (PP (IN for) (NP (QP (RB up) (TO to) (CD 7)) (NNS days)))) (VP (VBD was) (VP (VBN observed)) (SBAR (IN after) (S (NP (NN doxycycline)) (VP (VBD was) (VP (VBN removed) (PP (IN from) (NP (DT the) (NNS cultures))))))))) (, ,) (CC but) (S (S (NP (NP (JJ eventual) (NN recovery)) (PP (IN of) (NP (NN surface) (NN expression)))) (VP (VBD was) (ADJP (JJ complete)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ absolute) (NN time)) (PP (TO to) (NP (NN recovery)))) (VP (VBD was) (ADJP (RB directly) (JJ proportional) (PP (TO to) (NP (NP (DT the) (JJ initial) (NN concentration)) (PP (IN of) (NP (DT the) (NN drug))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Pharmacologic) (NN control)) (PP (IN of) (NP (NP (JJ trans-gene) (NN expression)) (PP (IN in) (NP (JJ gene-modified) (NN T) (NNS cells)))))) (VP (VP (MD will) (CONJP (RB not) (RB only)) (VP (VB facilitate) (NP (NP (JJ new) (NNS approaches)) (PP (TO to) (NP (NP (DT the) (NN study)) (PP (IN of) (NP (NP (JJ different) (NNS aspects)) (PP (IN of) (NP (NN T) (NN cell) (NN biology)))))))))) (, ,) (CC but) (VP (MD will) (ADVP (RB also)) (VP (VB provide) (NP (NP (DT the) (NN basis)) (PP (IN for) (NP (JJ new) (NN gene) (NN therapy) (NNS strategies))))))) (. .))))
(S1 (S (S (S (NP (JJ Human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (JJ long) (JJ terminal) (NN repeat) (NNS quasispecies)) (VP (VBP differ) (PP (IN in) (NP (NP (NP (JJ basal) (NN transcription)) (CC and) (NP (NP (JJ nuclear) (NN factor)) (NN recruitment))) (PP (IN in) (NP (JJ human) (NP (JJ glial) (NNS cells)) (CC and) (NP (NNS lymphocytes))))))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN generation)) (PP (IN of) (NP (JJ genomic) (NN diversity))) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NN infection)))))) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB affect) (NP (NP (NP (DT all) (NNS aspects)) (PP (IN of) (NP (NN HIV-1) (NN replication)))) (, ,) (PP (VBG including) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NP (JJ proviral) (NN genome)))))))))))) (. .)))))
(S1 (S (S (S (VP (TO To) (VP (VB gain) (NP (NP (DT a) (JJR better) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (NP (NP (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-))) (NN sequence) (NN diversity))) (PP (IN on) (NP (NP (NP (JJ LTR-directed) (NN gene)) (NN expression)) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (NP (NP (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (NN CNS)) (-RRB- -RRB-))) (CC and) (NP (JJ immune) (NN system)))))))))))))) (, ,) (S (NP (PRP we)) (VP (VP (VBD amplified)) (CC and) (VP (VBN cloned)) (NP (NP (NNS LTRs)) (PP (IN from) (NP (NP (JJ proviral) (NN DNA)) (PP (IN in) (NP (JJ HIV-1-infected) (JJ peripheral) (NN blood)))))))) (. .))))
(S1 (S (S (NP (NP (NN Sequence) (NN analysis)) (PP (IN of) (NP (NP (CD nineteen) (NP (NNS LTRs))) (VP (VBN cloned) (PP (IN from) (NP (NP (CD 2) (JJ adult)) (CC and) (NP (CD 3) (JJ pediatric)) (NP (NNS patients)))))))) (VP (VBD revealed) (NP (NP (NP (NP (DT an) (NN average)) (PP (IN of) (NP (CD 33) (NN nucleotide) (NNS changes)))) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN sequence)) (PP (IN of) (NP (DT the) (NP (NN LAI) (NN LTR)))))))) (-RRB- -RRB-))) (PP (IN within) (NP (DT the) (NP (JJ 455-bp) (NN U3) (NN region)))))) (. .))))
(S1 (S (S (NP (NP (JJ Transient) (NN expression) (NNS analyses)) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (NP (ADJP (JJ neuroglial))) (CC and) (NP (ADJP (JJ lymphocytic))) (NP (NN origin))))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT some)) (PP (IN of) (NP (DT these) (NP (NNS LTRs))))) (VP (VBD had) (NP (NP (NNS activities)) (SBAR (WHNP (WDT which)) (S (VP (VBD varied) (ADVP (RB significantly)) (PP (IN from) (NP (NP (DT the) (NP (NN LAI) (NN LTR))) (PP (PP (IN in) (NP (NP (NN U-373) (NN MG) (NNS cells)) (PRN (-LRB- -LRB-) (NP (DT an) (NP (NN astrocytoma) (NN cell) (NN line))) (-RRB- -RRB-)))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (NN Jurkat) (NNS cells)) (PRN (-LRB- -LRB-) (NP (DT a) (NP (JJ CD4-) (JJ positive) (NN lymphocyte) (NN cell) (NN line))) (-RRB- -RRB-))))))))))))))) (. .))))
(S1 (S (S (SBAR (IN While) (S (NP (NP (NNS LTRs)) (SBAR (WHNP (WDT which)) (S (VP (VBD demonstrated) (NP (DT the) (JJS highest) (NNS activities)) (PP (IN in) (NP (NN U-373) (NN MG) (NNS cells))))))) (ADVP (RB also)) (VP (VBD yielded) (NP (JJ high) (NNS activities)) (PP (IN in) (NP (NN Jurkat) (NNS cells)))))) (, ,) (S (NP (DT the) (NP (NNS LTRs))) (VP (VBD were) (ADVP (RB generally)) (ADJP (RBR more) (JJ active) (PP (IN in) (NP (NN Jurkat) (NNS cells)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (DT the) (NP (NN LAI) (NN LTR))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Differences)) (PP (IN in) (NP (NN LTR) (NN sequence)))) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (NN transcription) (NN factor) (NN recruitment)) (PP (TO to) (NP (NP (JJ cis-acting) (NNS sites)) (PP (IN within) (NP (NP (DT the) (NP (NN U3) (NN region))) (PP (IN of) (NP (DT the) (NP (NN LTR)))))))))))) (, ,) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (ADJP (RB naturally) (VBG occurring)) (NN sequence) (NN variation)) (VP (JJ impacted) (NP (NP (NN transcription) (NN factor)) (VP (VBG binding) (PP (TO to) (NP (NP (NP (DT an) (NP (VBG activating) (NN transcription) (NN factor/cAMP) (NN response) (NN element) (NN binding) (-LRB- -LRB-) (NN ATF/CREB) (-RRB- -RRB-) (NN binding) (NN site))) (PRN (-LRB- -LRB-) (ADJP (JJ located) (PP (IN between) (NP (DT the) (NP (NN LEF-1)) (CC and) (NP (JJ distal) (NN NF-kappaB) (NN transcription) (NN factor)) (NP (NN binding) (NNS sites))))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (NP (PRP we)) (VP (VBN identified) (PP (IN in) (NP (NP (JJ previous) (NNS studies)) (PP (IN of) (NP (DT the) (NP (NN HIV-1) (NN LTR)))))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN LTR) (NN sequence)) (NNS changes)) (VP (MD can) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (JJ basal) (NP (NN LTR)) (NN function)) (CC and) (NP (NP (NN transcription) (NN factor)) (NN recruitment)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (, ,) (PP (IN in) (NP (NN turn))) (, ,) (VP (VB alter) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NP (JJ viral) (NN replication)) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (NP (NN CNS)) (CC and) (NP (JJ immune) (NN system) (NN origin))))))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappaB)) (NN activation)))) (VP (VBZ attenuates) (NP (NP (NN apoptosis) (NN resistance)) (PP (IN in) (NP (JJ lymphoid) (NNS cells))))) (. .)))))
(S1 (S (S (S (NP (NP (NP (NN Death-inducing) (NNS ligands)) (PRN (-LRB- -LRB-) (NP (NNS DILs)) (-RRB- -RRB-))) (PP (JJ such) (IN as) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNFalpha)) (-RRB- -RRB-))) (CC or) (NP (NP (DT the) (JJ cytotoxic) (NN drug)) (NP (NN doxorubicin)))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB activate) (NP (NP (DT a) (NP (JJ nuclear) (NN factor) (NN kappaB)) (-LRB- -LRB-) (NP (NN NFkappaB)) (-RRB- -RRB-) (JJ -dependent) (NN program)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB rescue) (NP (NNS cells)) (PP (IN from) (NP (NN apoptosis) (NN induction)))))))))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBP demonstrate) (ADVP (RB here)) (SBAR (IN that) (S (NP (NP (NP (NN TRAIL)) (PRN (-LRB- -LRB-) (NP (JJ TNF-related) (NN apoptosis-inducing) (NN ligand)) (-RRB- -RRB-))) (, ,) (NP (DT a) (ADJP (RB recently) (VBN identified)) (NP (NN DIL))) (, ,)) (ADVP (RB also)) (VP (VBZ activates) (NP (NP (NN NFkappaB)) (PP (IN in) (NP (JJ lymphoid) (NN cell) (NNS lines)))) (PP (IN in) (NP (NP (DT a) (JJ kinetic)) (ADJP (JJ similar) (PP (TO to) (NP (NN TNFalpha)))))))))) (. .))))
(S1 (S (S (NP (NP (NN NFkappaB)) (NN activity)) (VP (VBZ is) (ADJP (JJ independent) (PP (IN from) (NP (NP (NN FADD)) (, ,) (NP (NNS caspases)) (, ,) (CC and) (NP (NN apoptosis) (NN induction)))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (NN NFkappaB)) (NN activity))) (PP (IN on) (NP (NP (NN apoptosis)) (VP (VBN mediated) (PP (IN by) (NP (NP (NN TRAIL)) (, ,) (NP (NN CD95)) (, ,) (NP (NN TNFalpha)) (, ,) (CC or) (NP (NN doxorubicin))))))))))) (, ,) (S (NP (NP (NN NFkappaB)) (NN activation)) (VP (VBD was) (VP (VBN inhibited)) (S (VP (VBG using) (NP (NP (NP (DT the) (NP (NN proteasome)) (NN inhibitor)) (NP (NN N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal))) (CC or) (NP (NP (JJ transient) (NN overexpression)) (PP (IN of) (NP (JJ mutant) (NN IkappaBalpha))))))))) (. .))))
(S1 (S (S (NP (NP (NN Sensitivity)) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN apoptosis)))))) (VP (VBD was) (ADVP (RB markedly)) (VP (VBN increased) (PP (IN by) (NP (NP (DT these) (NNS treatments)) (PP (IN in) (NP (ADJP (NN apoptosis) (JJ sensitive)) (NP (NN cell) (NNS lines)))))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (PP (CC both) (PP (IN in) (NP (NN cell) (NNS lines))) (CC and) (PP (IN in) (NP (JJ primary) (NN leukemia) (NNS cells))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ resistant) (PP (IN towards) (NP (NP (NN induction)) (PP (IN of) (NP (NP (NN apoptosis)) (PP (IN by) (NP (NP (NN DILs)) (CC and) (NP (NN doxorubicin))))))))))))) (, ,) (NP (NP (NN antagonization)) (PP (IN of) (NP (NP (NN NFkappaB)) (NN activity)))) (ADVP (RB partially)) (VP (VBD restored) (NP (NN apoptosis) (NN sensitivity))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN NFkappaB)) (NN activation)))) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ molecular) (NN approach)) (SBAR (S (VP (TO to) (VP (VB increase) (NP (NN apoptosis) (NN sensitivity)) (PP (IN in) (NP (JJ anticancer) (NN treatment))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN HMG) (NN box)) (VP (VBG containing) (NP (NN transcription) (NNS factors))) (PP (IN in) (NP (NP (NN lymphocyte)) (NN differentiation))) (. .)))))
(S1 (S (S (S (NP (NP (DT The) (NN identification)) (PP (IN of) (NP (DT the) (NP (JJ mammalian) (JJ sex-determining) (NN gene) (NN Sry))))) (VP (VBZ has) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN discovery)) (PP (IN of) (NP (NP (DT a) (JJ large) (NN family)) (PP (IN of) (NP (ADJP (ADJP (JJ related)) (PRN (-LRB- -LRB-) (`` ') (NP (NN HMG) (NN box)) ('' ') (-RRB- -RRB-))) (NP (NN transcription) (NNS factors)))) (SBAR (WHNP (WDT that)) (S (VP (VBP control) (NP (JJ developmental) (NNS events)) (PP (IN in) (NP (NP (NN yeast)) (, ,) (NP (FW C.) (FW elegans)) (, ,) (NP (FW Drosophila)) (CC and) (NP (NNS vertebrates))))))))))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (NP (NN lymphocyte)) (NN differentiation))) (, ,) (NP (JJ several) (NP (NN HMG) (NN box) (NNS proteins))) (VP (VBP play) (NP (DT a) (JJ decisive) (NN role))) (. .))))
(S1 (S (S (NP (NN Sox-4)) (VP (VBZ is) (ADJP (JJ important) (PP (IN for) (NP (ADJP (RB very) (JJ early)) (NN B-cell) (NN differentiation)))) (, ,) (SBAR (IN while) (S (NP (NN TCF-1/LEF-1)) (VP (VBP play) (NP (DT a) (JJ crucial) (NN role)) (PP (IN in) (NP (JJ early) (NN thymocyte) (NN development))))))) (. .))))
(S1 (S (S (NP (NN TCF/LEF) (NNS proteins)) (VP (VBP have) (ADVP (RB recently)) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB constitute) (NP (NP (DT a) (JJ downstream) (NN component)) (PP (IN of) (NP (DT the) (NN Wingless/Wnt) (NN signal) (NN transduction) (NN pathway)))))))))) (. .))))
(S1 (S (S (S (PP (IN In) (NP (NNS flies))) (, ,) (NP (DT this) (NN pathway)) (VP (VBZ controls) (NP (NN segment) (NN polarity)))) (: ;) (S (PP (IN in) (NP (FW Xenopus))) (NP (PRP it)) (VP (VBZ controls) (NP (NP (DT the) (NN definition)) (PP (IN of) (NP (DT the) (NN body) (NN axis)))))) (. .))))
(S1 (S (S (NP (NP (NN Deregulation)) (PP (IN of) (NP (DT the) (NN pathway)))) (VP (VBZ occurs) (PP (IN in) (NP (JJ several) (JJ human) (NNS tumors)))) (. .))))
(S1 (S (S (NP (NP (DT These) (VBZ insights)) (PP (IN in) (NP (NP (DT the) (JJ molecular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (NP (NN TCF/LEF)) (NN function)) (PP (IN in) (NP (DT these) (NNS organisms)))))))))))) (VP (MD may) (ADVP (RB eventually)) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT these) (NP (NN HMG) (NN box) (NNS proteins)))) (PP (IN in) (NP (JJ lymphoid) (NN development))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Loss-)) (CC and) (NP (NN gain-of-function)) (NP (NNS mutations))) (VP (VBP reveal) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN of) (NP (NP (NN BSAP)) (PRN (-LRB- -LRB-) (NP (NN Pax-5)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (DT the) (NP (NN start)) (CC and) (NP (NN end))) (PP (IN of) (NP (NN B) (NN cell) (NN differentiation))))))) (. .)))))
(S1 (S (S (S (NP (NN Pax-5)) (VP (VBZ codes) (PP (IN for) (NP (NP (NP (DT the) (NP (NN transcription) (NN factor))) (NP (NN BSAP))) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN expressed) (PP (IN throughout) (NP (NN B) (NN cell) (NN development))) (PP (NN except) (PP (IN in) (NP (RB terminally) (VBN differentiated) (NN plasma) (NNS cells))))))))))) (. .)))))
(S1 (S (S (NP (NP (NN Gene) (NN targeting) (NNS experiments)) (PP (IN in) (NP (DT the) (NN mouse)))) (VP (VBD revealed) (NP (NP (DT a) (JJ differential) (NN dependency)) (PP (IN of) (NP (NP (ADJP (JJ fetal))) (CC and) (NP (ADJP (JJ adult))) (NP (NN B-lymphopoiesis)))) (PP (IN on) (NP (DT this) (NP (NN transcription) (NN factor)))))) (. .))))
(S1 (S (S (NP (NN BSAP)) (VP (VBZ is) (VP (VBN required) (PP (PP (IN for) (NP (NP (NN B-lineage) (NN commitment)) (PP (IN in) (NP (DT the) (JJ fetal) (NN liver))))) (CC and) (PP (IN for) (NP (NP (NN progression)) (PP (IN beyond) (NP (DT an) (JJ early) (NN pro-B) (NN cell) (NN stage))) (PP (IN in) (NP (JJ adult) (NN bone) (NN marrow)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN characterization)) (PP (IN of) (NP (JJ Pax-5-deficient) (NN pro-B) (NNS cells)))) (VP (VBD demonstrated) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN of) (NP (NN BSAP))) (PP (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (NP (NP (NN CD19))) (, ,) (NP (NP (NN mb-1)) (PRN (-LRB- -LRB-) (NP (NN Ig) (NN alpha)) (-RRB- -RRB-))) (CC and) (NP (NN N-myc) (NNS genes)))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT the) (JJ developmental) (NN pathway)) (VP (VBG controlling) (NP (NP (JJ VH-to-DHJH) (NN recombination)) (PP (IN at) (NP (DT the) (NP (NN immunoglobulin) (JJ heavy-chain) (-LRB- -LRB-) (NN IgH) (-RRB- -RRB-) (NN locus))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (JJ human) (NN PAX-5) (NN gene))) (VP (VBD was) (ADVP (RB recently)) (VP (VBN shown) (S (VP (TO to) (VP (VB participate) (PP (ADVP (RB together)) (IN with) (NP (DT the) (NP (NN IgH) (NN locus)))) (PP (IN in) (NP (DT the) (JJ chromosomal) (NN translocation) (NP (NN t-LRB-9;14-RRB--LRB-p13;q32-RRB-))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN translocation)) (VP (VBZ is) (ADJP (JJ characteristic) (PP (IN of) (NP (NP (NP (DT a) (JJ small) (NN subset)) (PP (IN of) (NP (JJ non-Hodgkin) (NNS lymphomas)))) (VP (VBG exhibiting) (NP (JJ plasmacytoid) (NN differentiation))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (JJ translocated) (NN PAX-5) (NN gene))) (VP (VBZ is) (VP (VBN deregulated) (PP (IN by) (NP (NP (DT the) (NN insertion)) (PP (IN of) (NP (NN IgH) (JJ regulatory) (NNS elements))) (PP (IN into) (NP (PRP$ its) (NP (JJ 5') (NN region))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NN tumorigenesis))) (PP (IN by) (S (VP (VBG interfering) (PP (PP (IN with) (NP (NP (DT the) (NN shut-down)) (PP (IN of) (NP (NP (NN PAX-5)) (NN transcription))))) (CC and) (ADVP (RB thus)) (PP (IN with) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NP (NN plasma) (NN cell)) (NN differentiation)))))))))))))) (. .))))
(S1 (S (NP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNS E-proteins))) (PP (IN in) (NP (NP (NN B-)) (CC and) (NP (NN T-lymphocyte)) (NP (NN development)))) (. .)))))
(S1 (S (S (S (NP (NP (NN Department)) (PP (IN of) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ hematopoietic) (NN stem) (NNS cells)))))) (VP (VBZ is) (VP (VBN controlled) (, ,) (PP (IN in) (NP (NN part))) (, ,) (PP (IN by) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ transcriptional) (JJ regulatory) (NNS proteins))))))) (. .)))))
(S1 (S (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (NP (CD one) (NN class)) (PP (IN of) (NP (JJ helix-loop-helix) (NNS proteins)))) (, ,) (VP (VBN termed) (S (NP (NNS E-proteins)))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN gene) (NN expression))))) (PP (IN during) (NP (NN B-cell) (NN development)))))) (. .))))
(S1 (S (S (NP (NP (JJ Recent) (NN analysis)) (PP (IN of) (NP (JJ gene-targeted) (NNS mice)))) (VP (VBZ has) (VP (VBN allowed) (NP (NP (DT a) (JJ direct) (NN assessment)) (PP (IN of) (NP (NP (DT the) (JJ functional) (NNS roles)) (PP (IN of) (NP (JJ several) (NN E-protein) (NN family) (NNS members))) (PP (IN in) (NP (NN hematopoiesis)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT this) (NN review))) (NP (PRP we)) (VP (VP (VBP describe) (NP (NP (DT the) (NNS defects)) (PP (IN in) (NP (NP (NN B-)) (CC and) (NP (NN T-lymphocyte)) (NP (NN development))))) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG carrying) (NP (NP (VBN targeted) (NNS mutations)) (PP (IN in) (NP (DT the) (NP (NN E-protein) (NNS genes))))))))) (CC and) (VP (VBP discuss) (NP (NP (PRP$ our) (JJ current) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT these) (NNS proteins))) (PP (IN in) (NP (JJ lymphoid) (NN development)))))))) (. .))))
(S1 (S (S (S (NP (JJ Oxidative) (NN stress)) (VP (VBZ suppresses) (NP (NP (NP (NN transcription) (NN factor)) (NNS activities)) (PP (IN in) (NP (VBN stimulated) (NNS lymphocytes))))) (. .)))))
(S1 (S (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ oxidative) (NN stress))) (PP (IN on) (NP (NP (JJ stimulation-dependent) (NN signal) (NN transduction)) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (NN IL-2)) (NN expression)))))) (, ,)) (VP (VBD were) (VP (VBN studied))) (. .)))))
(S1 (S (S (S (NP (VBN Purified) (JJ quiescent) (JJ human) (NN blood) (NN T) (NNS lymphocytes)) (VP (VBD were) (VP (VBN subjected) (PP (TO to))))) (: :) (NP (NP (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (JJ acute) (NN exposure)) (PP (TO to) (NP (NN hydrogen) (NN peroxide)))) (: ;) (NP (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (JJ chronic) (NN exposure)) (PP (TO to) (NP (NN hydrogen) (NN peroxide)))) (: ;) (CC and) (NP (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (NP (JJ acute) (NN exposure)) (PP (TO to) (NP (VBG ionizing) (NN radiation))))) (. .))))
(S1 (S (S (NP (DT The) (NNS cells)) (VP (VBD were) (ADVP (RB then)) (VP (VBN stimulated) (PP (IN for) (NP (CD 6) (NN h))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ DNA-binding) (NNS activities)) (PRN (-LRB- -LRB-) (VP (VBN determined) (PP (IN by) (NP (DT the) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (CD three) (NP (NN transcription) (NNS factors)) (: :)) (NP (NP (NN NFkappaB)) (, ,) (NP (NN AP-1)) (CC and) (NP (NN NFAT))))) (, ,)) (VP (VBD were) (VP (VBN abolished) (PP (IN in) (NP (DT the) (NP (NNS lymphocytes)))) (PP (IN by) (NP (NP (DT all) (CD three) (NNS modes)) (PP (IN of) (NP (JJ oxidative) (NN stress))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NNS lymphocytes))) (VP (VBD exhibited) (NP (NN lipid) (NN peroxidation)) (PP (ADVP (RB only)) (IN upon) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NP (DT the) (JJS lowest) (NN level)) (PP (IN of) (NP (NP (NN hydrogen) (NN peroxide)) (VP (VBN used))))) (PRN (-LRB- -LRB-) (NP (CD 20) (NN microM)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (NP (DT All) (CD three) (NNS modes)) (PP (IN of) (NP (JJ oxidative) (NN stress)))) (VP (VBD induced) (NP (NP (NN catalase)) (NN activity)) (PP (IN in) (NP (DT the) (NP (NNS lymphocytes))))) (. .))))
(S1 (S (S (NP (DT The) (RB only) (NN exception)) (VP (VBD was) (NP (NP (NP (NN hydrogen) (NN peroxide)) (PP (IN at) (NP (CD 20) (NN microM)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD did) (RB not) (VP (VB induce) (NP (NP (NN catalase)) (NN activity)))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (: :) (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ specific) (NP (NN transcription) (NN factor)) (NNS functions)))) (VP (MD can) (ADVP (RB potentially)) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NP (NP (NN exposure)) (PP (TO to) (NP (JJ oxidative) (NN stress)))) (CC and) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (JJ human) (NNS lymphocytes))))))))))) (: ;) (S (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (NN lipid) (NN peroxidation)) (VP (VBZ is) (ADJP (RB only) (JJ detectable) (PP (IN in) (NP (JJ human) (NNS lymphocytes))) (PP (IN upon) (NP (NP (NN exposure)) (PP (TO to) (NP (ADJP (JJ weak) (JJ oxidative)) (NN stress))) (SBAR (WHNP (WDT which)) (S (VP (VBZ does) (RB not) (VP (VB induce) (NP (NP (NN catalase)) (NN activity))))))))))) (: ;) (S (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (ADVP (RB therefore)) (, ,) (NP (NP (NN transcription) (NN factor)) (JJ DNA-binding) (NNS activities)) (VP (VBP are) (ADJP (ADJP (RBR more) (JJ sensitive)) (PP (TO to) (NP (JJ oxidative) (NN stress))) (SBAR (IN than) (S (NP (NN lipid) (NN peroxidation)))))))))) (. .))))
(S1 (S (S (S (NP (NN Ro) (CD 09-2210)) (VP (VBZ exhibits) (NP (NP (ADJP (ADJP (JJ potent)) (ADJP (JJ anti-proliferative))) (NNS effects)) (PP (IN on) (NP (VBN activated) (NP (NN T) (NNS cells))))) (PP (IN by) (S (ADVP (RB selectively)) (VP (VBG blocking) (NP (NP (NN MKK)) (NN activity)))))) (. .)))))
(S1 (S (S (S (PP (IN By) (S (VP (VBG using) (NP (NP (JJ high) (NN throughput) (NN screening)) (PP (IN of) (NP (JJ microbial) (NNS broths))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN identified) (NP (NP (NP (DT a) (NN compound)) (, ,) (VP (VBN designated) (S (NP (NN Ro) (CD 09-2210))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB block) (NP (ADJP (NP (JJ anti-CD3)) (JJ induced)) (JJ peripheral) (NN blood) (NN T) (NN cell) (NN activation)) (PP (IN with) (NP (NP (DT an) (NN IC50)) (ADJP (JJ =) (NP (CD 40) (NN nM))))))))))))))) (. .)))))
(S1 (S (S (NP (NN Ro) (CD 09-2210)) (VP (VP (VBD was) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB block) (NP (JJ antigen-induced) (NP (NN IL-2)) (NN secretion)) (PP (IN with) (NP (NP (DT an) (NN IC50)) (ADJP (JJ =) (NP (CD 30) (NN nM)))))))))) (, ,) (CC but) (VP (VBD was) (ADJP (ADVP (RB considerably) (RBR less)) (JJ potent) (PP (IN at) (S (VP (VBG blocking) (NP (NP (NN Ca2+) (NN flux)) (VP (VBN stimulated) (PP (IN by) (NP (NP (JJ anti-CD3)) (NN treatment))))))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN Ro) (CD 09-2210))))))))) (, ,) (S (NP (PRP we)) (VP (VP (VBD set) (PRT (IN up)) (NP (DT a) (JJ transient) (NN expression) (NN system)) (PP (IN in) (NP (NN Jurkat) (NN T) (NNS cells))) (S (VP (VBG using) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN reporter) (NN gene) (NNS constructs))))))) (CC and) (VP (VBD showed) (NP (NP (JJ effective) (NN inhibition)) (PP (IN of) (NP (NP (ADJP (NN phorbol) (JJ ester/ionomycin-induced)) (NP (NN NF-AT)) (NN activation)) (CC and) (NP (ADJP (NN anti-CD3) (VBD induced)) (NP (NN NF-AT))))) (PP (IN with) (NP (NP (NN IC50)) (ADJP (JJ =) (NP (NP (CD 7.7)) (CC and) (NP (CD 10)) (NP (NN nM)))))) (, ,) (ADVP (RB respectively)))))) (. .))))
(S1 (S (S (NP (NN Ro) (CD 09-2210)) (VP (VBD was) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB inhibit) (NP (NP (ADJP (NN phorbol) (JJ ester/ionomycin-induced)) (NN activation)) (PP (IN of) (NP (NN AP1)))) (PP (IN with) (NP (NP (NN IC50)) (ADJP (JJ =) (JJR &lt;) (NP (CD 10) (NN nM)))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB further)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN Ro) (CD 09-2210)) (VP (VP (VBD was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB inhibit) (NP (NP (ADJP (NP (NN c-jun)) (JJ induced)) (NN expression)) (PP (IN of) (NP (JJ AP1-dependent) (NN reporter) (NNS constructs)))) (PRN (-LRB- -LRB-) (NP (NP (NN IC50)) (ADJP (JJR &gt;) (NP (CD 500) (NN nM)))) (-RRB- -RRB-))))))) (, ,) (CC but) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (ADVP (RB potently)) (VP (VB inhibit) (NP (JJ ras-induced) (NP (NN AP1)) (NN activation)) (PRN (-LRB- -LRB-) (NP (NP (NN IC50)) (ADJP (JJ =) (NP (CD 20) (NN nM)))) (-RRB- -RRB-))))))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NN Ro) (CD 09-2210)) (VP (VBD was) (VP (VBG inhibiting) (NP (NP (DT an) (NN activator)) (PP (IN of) (NP (NP (NN AP-1)) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (ADVP (JJ upstream) (PP (IN of) (NP (NN c-jun)))) (CC and) (ADVP (RB downstream) (PP (IN of) (NP (NP (NN ras)) (NN signaling)))))))))))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB investigate) (ADVP (RB further))))) (, ,) (S (NP (PRP we)) (ADVP (RB then)) (VP (VP (VBN purified) (NP (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ different) (NNS kinases)))) (, ,) (PP (VBG including) (NP (NP (NN PKC)) (, ,) (NP (NN PhK)) (, ,) (NP (NN ZAP-70)) (, ,) (NP (NN ERK)) (, ,) (CC and) (NP (NP (NN MEK) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN a) (NP (NN MKK))) (-RRB- -RRB-))))))) (, ,) (CC and) (VP (VBD showed) (SBAR (IN that) (S (NP (NN Ro) (CD 09-2210)) (VP (VBD was) (NP (NP (NP (DT a) (JJ selective) (NN inhibitor)) (PP (IN of) (NP (NN MEK1)))) (ADVP (FW in) (FW vitro)) (PRN (-LRB- -LRB-) (NP (NP (NN IC50)) (ADJP (JJ =) (NP (CD 59) (NN nM)))) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (NP (NP (NP (NN Role)) (PP (IN of) (NP (NN GATA-1))) (PP (IN in) (NP (NP (NP (NN proliferation)) (CC and) (NP (NN differentiation))) (PP (IN of) (NP (JJ definitive) (NP (JJ erythroid)) (CC and) (NP (JJ megakaryocytic)) (NP (NNS cells)))) (ADVP (FW in) (FW vivo)))) (. .)))))
(S1 (S (S (S (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (NNS contributions)) (PP (IN of) (NP (NN GATA-1))) (PP (TO to) (NP (NP (JJ definitive) (NN hematopoiesis)) (ADVP (FW in) (FW vivo)))))))) (, ,) (S (NP (PRP we)) (VP (VBP have) (VP (VBN examined) (NP (NP (JJ adult) (NNS mice)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (VP (VBN rendered) (S (ADJP (RB genetically) (JJ defective) (PP (IN in) (NP (NP (NN GATA-1)) (NN synthesis)))))))))))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Takahashi) (FW et) (FW al)) (, ,) (NP (NNP J) (NNP Biol) (NNP Chem) (CD 272)) (: :) (NP (CD 12611)) (, ,) (NP (CD 1997))) (-RRB- -RRB-)) (. .)))))
(S1 (S (S (SBAR (IN Because) (S (NP (DT the) (NP (NN GATA-1) (NN gene))) (VP (VBZ is) (ADJP (JJ located) (PP (IN on) (NP (NP (DT the) (NP (NN X) (NN chromosome))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADVP (RB randomly)) (VP (VBN inactivated) (PP (IN in) (NP (JJ every) (NN cell))))))))))))) (, ,) (S (NP (JJ heterozygous) (NNS females)) (VP (MD can) (VP (VB bear) (NP (CC either) (DT an) (NP (ADJP (JJ active) (JJ wild-type))) (CC or) (NP (NP (JJ mutant)) (PRN (-LRB- -LRB-) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (NN GATA-1.05)))) (-RRB- -RRB-))) (NP (NP (NN GATA-1)) (NN allele)))) (, ,) (S (ADVP (RB consequently)) (VP (VBG leading) (PP (TO to) (NP (ADJP (ADJP (JJ variable)) (ADJP (JJ anemic))) (NN severity))))))) (. .))))
(S1 (S (S (S (NP (DT These) (JJ heterozygous) (JJ mutant) (NNS mice)) (ADVP (RB usually)) (VP (VBN developed) (ADVP (RB normally)))) (, ,) (CC but) (S (NP (PRP they)) (VP (VBD began) (S (VP (TO to) (VP (VB die) (PP (IN after) (NP (CD 5) (NNS months)))))))) (. .))))
(S1 (S (S (NP (DT These) (VBN affected) (NNS animals)) (VP (VBD displayed) (NP (JJ marked) (NP (NN splenomegaly)) (, ,) (NP (NN anemia)) (, ,) (CC and) (NP (NN thrombocytopenia)))) (. .))))
(S1 (S (S (S (NP (NP (NNS Proerythroblasts)) (CC and) (NP (NNS megakaryocytes))) (ADVP (RB massively)) (VP (VBN accumulated) (PP (IN in) (NP (NP (DT the) (NNS spleens)) (PP (IN of) (NP (DT the) (NNS heterozygotes))))))) (, ,) (CC and) (S (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NP (NN neomycin) (NN resistance) (NN gene))) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (DT the) (JJ positive) (NN selection) (NN marker)) (PP (IN in) (NP (NN ES) (NNS cells))))))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN expressed) (ADVP (RB profusely)) (PP (IN in) (NP (NP (DT the) (ADJP (RB abnormally) (JJ abundant)) (NNS cells)) (VP (VBN generated) (PP (IN in) (NP (DT the) (NP (NN GATA-1.05)) (JJ mutant) (NNS females)))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD observed) (NP (NP (NN hematopoiesis)) (PP (NN outside) (PP (IN of) (NP (NP (DT the) (NN bone) (NN marrow)) (PP (IN in) (NP (DT the) (VBN affected) (JJ mutant) (NNS mice)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (DT a) (JJ small) (NN number)) (PP (IN of) (NP (NN GATA-1.05) (JJ mutant) (JJ hematopoietic) (NN progenitor) (NNS cells)))) (VP (VBP begin) (S (VP (TO to) (VP (VB proliferate) (ADVP (RB vigorously)) (PP (IN during) (NP (JJ early) (NN adulthood)))))))) (, ,) (CC but) (S (SBAR (IN because) (S (NP (DT the) (NNS cells)) (VP (VBP are) (ADJP (JJ unable) (S (VP (TO to) (ADVP (RB terminally)) (VP (VB differentiate)))))))) (, ,) (S (NP (DT this)) (VP (VBZ leads) (PP (TO to) (NP (NP (NP (NN progenitor) (NN proliferation)) (PP (IN in) (NP (DT the) (NN spleen)))) (CC and) (ADVP (RB consequently)) (NP (NN death)))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN GATA-1)) (VP (VBZ plays) (NP (ADJP (ADJP (JJ important)) (ADJP (FW in) (FW vivo))) (NNS roles)) (PP (IN for) (S (VP (VBG directing) (S (NP (JJ definitive) (NP (JJ hematopoietic) (NNS progenitors))) (VP (TO to) (VP (VB differentiate) (PP (IN along) (NP (CC both) (DT the) (NP (ADJP (JJ erythroid))) (CC and) (NP (ADJP (JJ megakaryocytic))) (NP (NNS pathways))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NP (NN GATA-1)) (JJ heterozygous) (JJ mutant) (NN mouse)) (VP (VP (VBZ shows) (NP (NP (DT a) (NN phenotype)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ analogous) (PP (TO to) (NP (JJ human) (JJ myelodysplastic) (NN syndrome))))))))) (CC and) (ADVP (RB thus)) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (JJ useful) (NN model)) (PP (IN for) (NP (DT this) (NN disorder)))))))) (. .))))
(S1 (S (S (S (NP (NN Erythropoietin)) (VP (VBZ induces) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NP (NN Jak2)) (, ,) (NP (NN STAT5A)) (, ,) (CC and) (NP (NN STAT5B))))) (PP (IN in) (NP (JJ primary) (VBN cultured) (JJ human) (JJ erythroid) (NNS precursors)))) (. .)))))
(S1 (S (S (S (NP (PRP We)) (VP (VBD examined) (NP (NP (NN signaling)) (PP (IN by) (NP (NP (NN erythropoietin)) (PP (IN in) (NP (NP (RB highly) (VBN purified) (JJ human) (NN colony) (NN forming) (JJ unit-erythroid) (NNS cells)) (, ,) (VP (VBN generated) (ADVP (FW in) (FW vitro)) (PP (IN from) (NP (JJ CD34-LRB-+-RRB-) (NNS cells)))))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NN erythropoietin)) (VP (VBZ induces) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NP (NN Jak2)) (, ,) (NP (NN STAT5A)) (, ,) (CC and) (NP (NN STAT5B))))))))) (. .))))
(S1 (S (S (NP (NP (NN Tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN Jak2)))) (VP (VP (VBZ reaches) (NP (DT a) (NN peak)) (PP (IN around) (NP (NP (CD 10) (NNS minutes)) (PP (IN after) (NP (NN stimulation)))))) (CC and) (VP (VBZ is) (ADJP (JJ maximum) (PP (IN at) (NP (NP (CD 5) (NN U/mL)) (PP (IN of) (NP (NN erythropoietin)))))))) (. .))))
(S1 (S (S (NP (NP (NN Tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN STAT5)))) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (VBN activated) (NP (NN STAT5)))) (PP (TO to) (NP (DT the) (NN nucleus)))))) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NP (NP (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)) (PRN (-LRB- -LRB-) (NP (NN EMSA)) (-RRB- -RRB-))) (VP (VBG using) (NP (NP (JJ 32Pi-labeled) (NP (NN STAT5) (NN binding) (NN site))) (PP (IN in) (NP (DT the) (NP (NN beta-casein) (NN promoter)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Tyrosine) (NN phosphorylation)) (NP (NP (NN STAT1)) (CC or) (NP (NN STAT3)))) (VP (VBD was) (RB not) (VP (VBN detected) (PP (IN in) (NP (JJ human) (JJ erythroid) (NNS precursors))) (PP (IN after) (NP (NP (NN stimulation)) (PP (IN with) (NP (NN erythropoietin))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Crkl)) (, ,) (NP (DT an) (NP (NN SH2/SH3) (NN adapter) (NN protein))) (, ,)) (VP (VBZ becomes) (VP (VBN coimmunoprecipitated) (PP (ADVP (RB specifically)) (IN with) (NP (NP (NN STAT5)) (PP (IN from) (NP (JJ erythropoietin-stimulated) (JJ erythroid) (NNS cells)))))))) (: ;) (SBAR (IN although) (S (NP (PRP it)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB become) (VP (VBN associated) (PP (IN with) (NP (NN c-Cbl))))))) (PP (IN in) (NP (NP (DT the) (NNS studies)) (VP (VBG using) (NP (NN cell) (NNS lines))))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (JJ human) (JJ erythroid) (NNS precursors)) (VP (MD can) (VP (VB be) (VP (VBN expanded) (ADVP (FW in) (FW vitro)) (PP (IN in) (NP (JJ sufficient) (NP (NNS numbers)) (CC and) (NP (NN purity)))))) (S (VP (TO to) (VP (VB allow) (NP (NP (PRP$ its) (NN usage)) (PP (IN in) (NP (NN signal) (NN transduction) (NNS studies)))))))) (. .))))
(S1 (S (S (NP (DT This) (NN report)) (VP (VBZ sets) (NP (NP (DT a) (NN basis)) (PP (IN for) (NP (NP (JJ further) (NNS studies)) (PP (IN on) (NP (NP (NN signaling)) (PP (IN in) (NP (JJ primary) (VBN cultured) (JJ human) (JJ erythroid) (NNS precursors)))))))) (, ,) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBP contribute) (PP (TO to) (NP (NP (PRP$ our) (JJR better) (NN understanding)) (PP (IN in) (NP (NP (DT the) (NN differentiation) (NNS processes)) (PP (IN of) (NP (NP (NNS erythrocytes)) (CC and) (NP (PRP$ their) (NNS precursors)))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (DT A) (ADJP (ADJP (JJ small)) (, ,) (ADJP (JJ nonpeptidyl))) (NN mimic)) (PP (IN of) (NP (JJ granulocyte-colony-stimulating) (NN factor)))) (PRN (-LRB- -LSB-) (S (VP (VB see) (NP (NNS commetns)))) (-RRB- -RSB-))))))
(S1 (S (S (S (NP (NP (NP (DT A) (ADJP (ADJP (JJ nonpeptidyl)) (ADJP (JJ small))) (NN molecule)) (NP (NN SB) (CD 247464))) (, ,) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG activating) (NP (NP (NP (JJ granulocyte-colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN G-CSF)) (-RRB- -RRB-))) (NN signal) (NN transduction) (NNS pathways)))))) (, ,)) (VP (VBD was) (VP (VBN identified) (PP (IN in) (NP (DT a) (JJ high-throughput) (NN assay))) (PP (IN in) (NP (VBN cultured) (NNS cells))))) (. .)))))
(S1 (S (S (PP (IN Like) (NP (NN G-CSF))) (, ,) (NP (NN SB) (CD 247464)) (VP (VP (VBD induced) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (JJ multiple) (NN signaling) (NNS proteins))))) (CC and) (VP (VBN stimulated) (NP (JJ primary) (JJ murine) (NN bone) (NN marrow) (NNS cells)) (S (VP (TO to) (VP (VB form) (NP (JJ granulocytic) (NNS colonies)) (ADVP (FW in) (FW vitro))))))) (. .))))
(S1 (S (S (NP (PRP It)) (ADVP (RB also)) (VP (JJ elevated) (NP (NP (JJ peripheral) (NN blood) (NN neutrophil)) (NNS counts)) (PP (IN in) (NP (NNS mice)))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ extracellular) (NN domain)) (PP (IN of) (NP (DT the) (NP (JJ murine) (NN G-CSF) (NN receptor))))) (VP (VBD was) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN SB) (CD 247464)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT the) (NN compound)) (VP (VBZ acts) (PP (IN by) (S (VP (VBG oligomerizing) (NP (NN receptor) (NNS chains))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT a) (JJ small) (NN molecule)) (VP (MD can) (VP (VB activate) (NP (NP (DT a) (NN receptor)) (SBAR (WHNP (WDT that)) (S (ADVP (RB normally)) (VP (VBZ binds) (NP (DT a) (ADJP (RB relatively) (JJ large)) (NN protein) (NN ligand))))))))))) (. .))))
(S1 (S (S (NP (NN Thrombopoietin)) (VP (VBZ supports) (NP (ADJP (FW in) (FW vitro)) (JJ erythroid) (NN differentiation)) (PP (IN via) (NP (NP (PRP$ its) (JJ specific) (NN receptor) (NN c-Mpl)) (PP (IN in) (NP (DT a) (JJ human) (NN leukemia) (NN cell) (NN line)))))) (. .))))
(S1 (S (S (NP (NP (NN Thrombopoietin)) (PRN (-LRB- -LRB-) (NP (NN TPO)) (-RRB- -RRB-))) (VP (VBZ acts) (PP (IN on) (NP (NP (NN megakaryopoiesis)) (CC and) (NP (NN erythropoiesis)))) (ADVP (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo)))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD isolated) (NP (NP (DT a) (JJ novel) (NN subline)) (, ,) (NP (NN UT-7/GMT)) (, ,)) (PP (IN from) (NP (DT the) (JJ human) (NN leukemia) (NN cell) (NN line) (NN UT-7/GM))) (PRN (-LRB- -LRB-) (NP (NP (NN N.) (NN Komatsu)) (, ,) (FW et) (NP (FW al.))) (, ,) (NP (NN Blood)) (, ,) (NP (CD 89) (: :) (CD 4021-4033)) (, ,) (NP (CD 1997)) (-RRB- -RRB-))) (. .))))
(S1 (S (S (NP (NP (DT A) (JJ small) (NN population)) (PP (IN of) (NP (NN UT-7/GM) (NNS cells)))) (VP (ADVP (RB positively)) (VBN stained) (PP (IN for) (NP (NP (NN hemoglobin)) (PRN (-LRB- -LRB-) (NP (NN Hb)) (-RRB- -RRB-)))) (PP (IN after) (NP (NP (DT a) (JJ 7-day) (NN exposure)) (PP (TO to) (NP (NN TPO)))))) (. .))))
(S1 (S (S (NP (NP (QP (JJR More) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (JJ TPO-treated) (NN UT-7/GMT) (NNS cells)))) (VP (ADVP (RB positively)) (VBN stained) (PP (IN for) (NP (NN Hb)))) (. .))))
(S1 (S (S (S (VP (VBG Using) (NP (NN UT-7/GMT) (NNS cells)))) (, ,) (NP (PRP we)) (VP (VBD examined) (SBAR (WHADVP (WRB how)) (S (NP (NN TPO)) (VP (VBZ promotes) (NP (NN hemoglobinization)))))) (. .))))
(S1 (S (S (NP (NN TPO)) (VP (VBD induced) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NP (DT the) (NN TPO) (NN receptor)) (CONJP (CC but) (RB not)) (NP (DT the) (NN erythropoietin) (-LRB- -LRB-) (NN EPO) (-RRB- -RRB-) (NN receptor)))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN competition)) (PP (IN between) (NP (NP (NN TPO)) (CC and) (NP (NN EPO)))) (PP (IN for) (NP (NP (NN binding)) (PP (TO to) (NP (NN EPO) (NN receptor))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN TPO)) (VP (VBZ has) (NP (DT a) (JJ direct) (NN effect)) (PP (IN on) (NP (NN hemoglobinization))) (PP (IN via) (NP (NP (DT a) (JJ specific) (NN receptor)) (PP (IN on) (NP (NN UT-7/GMT) (NNS cells))))))))) (. .))))
(S1 (S (S (NP (JJ Isoelectric) (NN focusing)) (VP (VBD demonstrated) (SBAR (IN that) (S (S (NP (NN TPO)) (VP (VBD induced) (NP (ADJP (ADJP (JJ fetal)) (CC and) (ADJP (JJ adult))) (NN Hb) (NN synthesis)))) (, ,) (IN whereas) (S (NP (NN EPO)) (VP (VBD induced) (NP (ADJP (ADJP (JJ embryonic)) (, ,) (ADJP (JJ fetal)) (, ,) (CC and) (ADJP (JJ adult))) (NN Hb) (NN synthesis))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (PRP$ our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN TPO)) (VP (VBZ has) (NP (DT a) (JJ distinct) (NN action)) (PP (IN on) (NP (NN erythropoiesis))))))) (. .))))
(S1 (S (S (S (S (NP (NP (NNS Macrophages)) (PP (IN in) (NP (JJ human) (NN atheroma)))) (VP (VBP contain) (NP (NN PPARgamma)))) (: :) (NP (NP (NP (NP (JJ differentiation-dependent) (JJ peroxisomal) (JJ proliferator-activated) (NN receptor) (NN gamma)) (PRN (-LRB- -LRB-) (NP (NN PPARgamma)) (-RRB- -RRB-))) (NP (NP (NN expression)) (CC and) (NP (NN reduction)))) (PP (IN of) (NP (NP (NN MMP-9) (NN activity)) (PP (IN through) (NP (NP (NN PPARgamma) (NN activation)) (PP (IN in) (NP (JJ mononuclear) (NNS phagocytes))) (ADVP (FW in) (FW vitro))))))) (. .)))))
(S1 (S (S (NP (JJ Mononuclear) (NNS phagocytes)) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NN atherosclerosis)) (CC and) (NP (PRP$ its) (NN sequela) (NN plaque) (NN rupture)))) (PP (IN in) (NP (NN part))) (PP (IN by) (NP (NP (PRP$ their) (NN secretion)) (PP (IN of) (NP (NP (NP (NN matrix) (NNS metalloproteinases)) (PRN (-LRB- -LRB-) (NP (NNS MMPs)) (-RRB- -RRB-))) (, ,) (PP (VBG including) (NP (NN MMP-9)))))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Peroxisomal) (JJ proliferator-activated) (NN receptor) (NN gamma)) (PRN (-LRB- -LRB-) (NP (NN PPARgamma)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN transcription) (NN factor)) (PP (IN in) (NP (DT the) (JJ nuclear) (NN receptor) (NN superfamily)))) (, ,)) (VP (VBZ regulates) (NP (NN gene) (NN expression)) (PP (IN in) (NN response) (TO to) (NP (NP (JJ various) (NNS activators)) (, ,) (PP (VBG including) (NP (NP (NN 15-deoxy-delta12,14-prostaglandin) (NN J2)) (CC and) (NP (DT the) (JJ antidiabetic) (NN agent) (NN troglitazone))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NN PPARgamma))) (PP (IN in) (NP (JJ human) (NN atherosclerosis)))) (VP (VBZ is) (ADJP (JJ unexplored))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP report) (ADVP (RB here)) (SBAR (IN that) (S (NP (NP (NNS monocytes/macrophages)) (PP (IN in) (NP (JJ human) (JJ atherosclerotic) (NNS lesions) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 12)))) (-RRB- -RRB-))))) (VP (VBP express) (NP (JJ immunostainable) (NN PPARgamma)))))) (. .))))
(S1 (S (S (NP (JJ Normal) (NN artery) (NNS specimens) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 6)))) (-RRB- -RRB-))) (VP (VBP reveal) (NP (JJ minimal) (JJ immunoreactive) (NN PPARgamma))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Human) (NNS monocytes)) (CC and) (NP (JJ monocyte-derived) (NNS macrophages))) (VP (VBN cultured) (PP (IN for) (NP (CD 6) (NNS days))) (PP (IN in) (NP (NP (CD 5) (NN %)) (NP (JJ human) (NN serum)))))) (VP (VBD expressed) (NP (NP (NN PPARgamma) (NN mRNA)) (CC and) (NP (NN protein))) (PP (IN by) (NP (NP (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction)) (CC and) (NP (NN Western) (NN blotting)))) (, ,) (ADVP (RB respectively))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN PPARgamma) (NN mRNA) (NN expression)) (PP (IN in) (NP (NN U937) (NNS cells)))) (VP (VBN increased) (PP (IN during) (NP (ADJP (NN phorbol) (NN 12-myristate) (CD 13) (JJ acetate-induced)) (NN differentiation)))) (. .))))
(S1 (S (S (NP (NP (NN Stimulation)) (PP (IN of) (NP (NN PPARgamma))) (PP (IN with) (NP (NP (NP (NN troglitazone)) (CC or) (NP (NN 15-deoxy-delta12,14-prostaglandin) (NN J2))) (PP (IN in) (NP (ADJP (JJ human) (JJ monocyte-derived)) (NNS macrophages)))))) (VP (VBD inhibited) (NP (NN MMP-9) (JJ gelatinolytic) (NN activity)) (PP (IN in) (NP (DT a) (JJ concentration-dependent) (NN fashion))) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN by) (NP (NN zymography))))))) (. .))))
(S1 (S (S (NP (DT This) (NN inhibition)) (VP (VBZ correlates) (PP (IN with) (NP (VBN decreased) (NN MMP-9) (NN secretion))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN Western) (NN blotting))))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN PPARgamma)) (VP (VP (VBZ is) (ADJP (JJ present) (PP (IN in) (NP (NP (NNS macrophages)) (PP (IN in) (NP (JJ human) (JJ atherosclerotic) (NNS lesions))))))) (CC and) (VP (MD may) (VP (VB regulate) (NP (NP (NP (NN expression)) (CC and) (NP (NN activity))) (PP (IN of) (NP (NP (NN MMP-9)) (, ,) (NP (NP (DT an) (NN enzyme)) (VP (VBN implicated) (PP (IN in) (NP (NN plaque) (NN rupture))))))))))) (. .))))
(S1 (S (S (NP (NN PPARgamma)) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (JJ important) (NN regulator)) (PP (IN of) (NP (NP (NN monocyte/macrophage) (NN function)) (PP (IN with) (NP (NP (NN relevance)) (PP (IN for) (NP (JJ human) (JJ atherosclerotic) (NN disease))))))))))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Peripheral) (NN blood) (NN T) (NNS cells)) (CC and) (NP (NNS monocytes)) (CC and) (NP (NN B) (NN cell) (NNS lines))) (VP (VBN derived) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NN lupus))))))) (VP (VBP express) (NP (NP (NN estrogen) (NN receptor) (NNS transcripts)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (JJ normal) (NNS cells)))))))) (. .))))
(S1 (S (NP (NP (NP (NN OBJECTIVE)) (: :) (S (VP (TO To) (VP (VP (VB identify)) (CC and) (VP (VB characterize)) (NP (NP (NN estrogen) (NN receptor) (-LRB- -LRB-) (NN ER) (-RRB- -RRB-) (NNS transcripts)) (VP (VBN expressed) (PP (IN in) (NP (NP (JJ immune) (NNS cells)) (PP (IN of) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ systemic) (NN lupus) (NN erythematosus)) (PRN (-LRB- -LRB-) (NP (NN SLE)) (-RRB- -RRB-))))) (CC and) (NP (JJ healthy) (NNS donors))))))))))) (. .)))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (JJ Peripheral) (NN blood) (NNS monocytes)) (CC and) (NP (NN T) (NNS cells))) (VP (VBD were) (VP (VBN prepared) (PP (IN from) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NN SLE))) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 6)))) (-RRB- -RRB-))) (CC and) (NP (JJ healthy) (NNS donors) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 8)))) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (S (NP (NN T) (NNS cells)) (VP (VBD were) (VP (VBN separated) (PP (IN into) (NP (NP (NN CD4)) (CC and) (NP (NN CD8)))))) (. .))))
(S1 (S (S (NP (DT Some) (NP (NP (NNS monocytes)) (CC and) (NP (NN T) (NNS cells)))) (VP (VBD were) (VP (VBN stimulated) (PP (IN with) (NP (NP (NN estradiol)) (, ,) (NP (NN PMA)) (, ,) (CC and) (NP (NN ionomycin)))))) (. .))))
(S1 (S (S (NP (NP (NP (ADJP (JJ Epstein-Barr) (JJ virus-transformed)) (NN B) (NN cell) (NNS lines) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 7)))) (-RRB- -RRB-))) (CC and) (NP (NN B) (NN cell) (NNS hybridomas) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (LS 2)))) (-RRB- -RRB-)))) (VP (VBN established) (PP (IN from) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NN SLE)))) (CC and) (NP (DT a) (JJ healthy) (JJ individual)))))) (VP (VBD were) (VP (VBN used) (PP (IN as) (NP (DT a) (NN B) (NN cell) (RB source))))) (. .))))
(S1 (S (S (NP (DT These) (NNS cells)) (VP (VBD were) (VP (VBN examined) (PP (IN for) (NP (NN ER) (NN mRNA))) (PP (IN by) (NP (ADJP (JJ reverse) (NN transcription) (JJ nested)) (NN polymerase) (NN chain) (NN reaction))))) (. .))))
(S1 (S (S (NP (JJ Amplified) (NN cDNA)) (VP (VBD were) (VP (VBN sequenced) (PP (IN by) (NP (JJ standard) (NNS methods))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (PP (IN In) (NP (NP (DT all) (NNS cells)) (VP (VBN tested)))) (, ,) (NP (NN ER) (NN mRNA)) (VP (VBD was) (VP (VBN expressed) (PP (IN without) (NP (JJ prior) (ADJP (FW in) (FW vitro)) (NN stimulation)))))) (. .))))
(S1 (S (S (NP (NP (JJ Partial) (NNS sequences)) (PP (IN from) (NP (NNS exons) (CD 1-8)))) (VP (VBD were) (ADJP (RB nearly) (JJ identical) (PP (TO to) (NP (NP (DT the) (VBN published) (NN sequence)) (PP (IN of) (NP (DT the) (JJ human) (NN ER) (NN mRNA))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (DT no) (JJ notable) (NNS differences)) (PP (IN in) (NP (DT the) (NN ER) (NNS transcripts))) (PP (IN between) (NP (NP (NNS patients)) (CC and) (NP (JJ healthy) (NNS controls))))) (. .))))
(S1 (S (S (NP (NP (JJ Variant) (NN receptor) (NNS transcripts)) (VP (VBG lacking) (NP (NP (NP (NN exon) (CD 5)) (CC or) (NP (NN exon) (CD 7))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (DT the) (NN hormone) (NN binding) (NN domain))))) (, ,)))) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (DT the) (NNS cells))))))) (. .))))
(S1 (S (S (NP (NP (JJ Precise) (NN deletion)) (PP (IN of) (NP (DT the) (NNS exons)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (PRP they)) (VP (VBP are) (NP (ADJP (RB alternatively) (VBN spliced)) (NNS transcripts)))))) (. .))))
(S1 (S (S (SBAR (IN Whether) (S (NP (DT the) (JJ detected) (NNS transcripts)) (VP (VBP are) (VP (VBN translated) (PP (IN into) (NP (JJ functional) (NN receptor) (NNS proteins))))))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN determined)))))) (. .))))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NN stimulation)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NN ER) (NN mRNA) (NN expression)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NNS variants)))) (VP (VBD did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (NN disease) (NN activity)) (CC or) (NP (NN medication)))))) (. .))))
(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (NP (NNS Monocytes)) (, ,) (NP (NN T) (NNS cells)) (, ,) (CC and) (NP (NN B) (NNS cells))) (PP (IN in) (NP (NNS patients)))) (VP (VBP express) (NP (NP (NNS transcripts)) (PP (IN of) (NP (NP (DT the) (JJ normal) (JJ wild) (NN type) (NN ER)) (CC and) (NP (DT the) (NN hormone) (NN binding) (NN domain) (NNS variants))))) (ADVP (FW in) (FW vivo)))) (. .))))
(S1 (S (NP (NP (NN Suppression)) (PP (IN of) (NP (JJ human) (JJ anti-porcine) (NN T-cell) (JJ immune) (NNS responses))) (PP (IN by) (NP (NP (JJ major) (NN histocompatibility) (NN complex) (NN class) (CD II) (NN transactivator) (NNS constructs)) (VP (VBG lacking) (NP (DT the) (NN amino) (JJ terminal) (NN domain))))) (. .))))
(S1 (S (NP (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (DT The) (NN class) (CD II) (NN transactivator)) (PRN (-LRB- -LRB-) (NP (NN CIITA)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (ADJP (ADJP (JJ bi-)) (CC or) (ADJP (JJ multifunctional))) (NN domain) (NN protein)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ acts) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN activator)))) (CC and) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN MHC) (NN class) (CD II) (NNS genes)))))))))))) (. .)))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (DT a) (VBN mutated) (NN form)) (PP (IN of) (NP (NP (DT the) (JJ human) (NN CIITA) (NN gene)) (, ,) (VP (VBG coding) (PP (IN for) (NP (NP (DT a) (NN protein)) (VP (VBG lacking) (NP (DT the) (NN amino) (JJ terminal) (CD 151) (NN amino) (NNS acids)))))) (, ,)))) (VP (VBZ acts) (PP (IN as) (NP (NP (DT a) (JJ potent) (JJ dominant-negative) (NN suppressor)) (PP (IN of) (NP (NN HLA) (NN class) (CD II) (NN expression)))))))))) (. .))))
(S1 (S (S (NP (NN Porcine) (NN MHC) (NN class) (CD II) (NNS antigens)) (VP (VP (VBP are) (NP (NP (JJ potent) (NNS stimulators)) (PP (IN of) (NP (NP (JJ direct) (NN T-cell) (NN recognition)) (PP (IN by) (NP (JJ human) (JJ CD4+) (NN T) (NNS cells))))))) (CC and) (VP (VBP are) (, ,) (ADVP (RB therefore)) (, ,) (ADJP (JJ likely) (S (VP (TO to) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN rejection) (NNS responses)) (PP (TO to) (NP (JJ transgenic) (NN pig) (NNS donors))) (PP (IN in) (NP (JJ clinical) (NN xenotransplantation))))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD were) (, ,) (ADVP (RB therefore)) (, ,) (ADJP (VBD interested) (PP (IN in) (S (VP (VBG examining) (NP (VBN mutated) (NN CIITA) (NNS constructs)) (PP (IN for) (NP (NP (PRP$ their) (NN effect)) (PP (IN on) (NP (NN porcine) (NN MHC) (NN class) (CD II) (NN expression)))))))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (JJ Stable) (NNS transfectants)) (PP (IN of) (NP (DT the) (NN porcine) (JJ vascular) (JJ endothelial) (NN cell) (NN line) (NN PIEC))) (PP (IN with) (NP (VBN mutated) (NN CIITA) (NNS constructs)))) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (NN SLA-DR) (CC and) (NN SLA-DQ) (NN induction)) (PP (IN by) (NP (JJ recombinant) (NN porcine) (NN interferon-gamma)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Transient) (NNS transfectants)) (PP (IN of) (NP (DT the) (NN porcine) (NN B-cell) (NN line) (NN L23))) (PP (IN with) (NP (DT the) (VBN mutated) (NN CIITA) (NNS constructs)))) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP (JJ constitutive) (NN SLA-DR) (CC and) (NN SLA-DQ) (NN expression))))))) (. .))))
(S1 (S (S (NP (NN T-cell) (NN proliferation) (NNS studies)) (VP (VBD were) (VP (VBN performed) (S (VP (VBG using) (NP (ADJP (RB highly) (VBN purified)) (JJ human) (JJ CD4+) (NN T) (NNS cells)))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (PP (FW In) (NP (JJ preliminary) (NNS studies))) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NN transfection)) (PP (IN of) (NP (DT the) (NN PIEC) (NN line))) (PP (IN with) (NP (JJ full-length) (JJ human) (NN CIITA) (NNS constructs)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ strong) (NN expression)) (PP (IN of) (NP (NN SLA-DR) (CC and) (NN SLA-DQ) (NNS antigens))))) (, ,) (S (ADVP (RB thus)) (VP (VBG establishing) (NP (NP (DT the) (JJ cross-species) (NN effectiveness)) (PP (IN of) (NP (JJ human) (NN CIITA))) (PP (IN in) (NP (DT the) (NN pig))))))))))) (. .))))
(S1 (S (S (NP (DT The) (VBN mutated) (JJ human) (NN CIITA) (NNS constructs)) (VP (VBD were) (, ,) (ADVP (RB therefore)) (, ,) (VP (VBN tested) (PP (IN in) (NP (DT the) (NN pig))))) (. .))))
(S1 (S (S (NP (NP (NN PIEC) (NNS clones)) (VP (ADVP (RB stably)) (VBN transfected) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS constructs))))))) (VP (VP (VBD showed) (NP (NP (ADJP (QP (RB up) (TO to) (CD 99)) (NN %)) (NN suppression)) (PP (IN of) (NP (NN SLA-DR) (CC and) (NN SLA-DQ) (NN antigen) (NN induction))))) (CC and) (VP (JJ marked) (NP (NP (NN suppression)) (PP (IN of) (NP (NN SLA-DRA) (NN mRNA) (NN induction)))))) (. .))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ transient) (NN transfection)) (PP (IN of) (NP (DT the) (NN porcine) (NN B-cell) (NN line) (NN L23)))) (VP (VBD showed) (NP (NP (ADJP (QP (RB up) (TO to) (CD 90)) (NN %)) (NN suppression)) (PP (IN of) (NP (JJ constitutive) (NN SLA-DR) (CC and) (NN SLA-DQ) (NN antigen) (NN expression))) (PP (IN in) (NP (CD 5-8) (NNS days))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ functional) (NNS studies))) (, ,) (NP (NP (JJ interferon-gamma-stimulated) (NN PIEC) (NNS clones)) (VP (VBN transfected) (PP (IN with) (NP (DT this) (VBN mutated) (NN CIITA) (NN construct))))) (VP (VBD failed) (S (VP (TO to) (VP (VB stimulate) (NP (VBN purified) (JJ human) (JJ CD4+) (NN T) (NNS lymphocytes)))))) (. .))))
(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (JJ Mutated) (JJ human) (NN CIITA) (NNS constructs)) (VP (VBP are) (NP (NP (JJ potent) (NNS suppressors)) (PP (IN of) (NP (NN porcine) (NN MHC) (NN class) (CD II) (NN expression)))))) (. .))))
(S1 (S (NP (NP (NP (NN Redox) (NNS signals)) (CC and) (NP (NN NF-kappaB) (NN activation))) (PP (IN in) (NP (NN T) (NNS cells))) (. .))))
(S1 (S (S (NP (NP (JJ Accumulating) (NNS data)) (PP (IN from) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS laboratories)))))) (VP (VBP have) (ADVP (RB recently)) (VP (VBN indicated) (SBAR (IN that) (S (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NN transcription) (NN factor) (NN NF-kappaB))) (PP (TO to) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NN redox) (NN homeostasis)) (PP (IN of) (NP (NNS cells)))))))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG modulating) (NP (JJ immune) (NN function))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN activation)) (PP (IN of) (NP (NN NF-kappaB)))) (VP (VBZ has) (VP (VBN been) (VP (VBN recognized) (S (VP (TO to) (VP (VB regulate) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS genes))) (ADJP (JJ necessary) (PP (IN for) (NP (NP (JJ normal) (NN T) (NN cell) (NNS responses)) (PP (VBG including) (NP (NP (NN IL-2)) (, ,) (NP (NN IL-6)) (, ,) (NP (NN IL-8)) (, ,) (CC and) (NP (JJ several) (NN T) (NN cell) (NN surface) (NNS receptors)))))))))))))) (. .))))
(S1 (S (S (NP (JJ Diminished) (NN NF-kappaB) (NN activity)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB occur) (PP (IN in) (NP (NP (NN T) (NNS cells)) (PP (IN with) (NP (NN aging))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (JJ impaired) (NN activation)) (PP (IN of) (NP (NN NF-kappaB)))) (VP (MD might) (VP (VB occur) (PP (IN during) (NP (JJ cellular) (NN senescence))))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS aberrancies)) (PP (IN in) (NP (NN NF-kappaB) (NN activity)))) (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN immunopathogenesis)) (PP (IN of) (NP (NP (NNS diseases)) (VP (VBG involving) (NP (NP (ADJP (ADJP (JJ immune)) (CC or) (ADJP (JJ inflammatory))) (NNS processes)) (PP (JJ such) (IN as) (NP (NP (NN atherosclerosis)) (CC and) (NP (NN HIV-1) (NN infection))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (NN H2O2)) (CC and) (NP (JJ other) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-)))))) (PP (IN as) (NP (NP (DT an) (JJ integratory) (JJ secondary) (NN messenger)) (PP (IN for) (NP (JJ divergent) (NN T) (NN cell) (NNS signals)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN complicated) (PP (IN by) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (JJ various) (NP (NP (NN T) (NN cell) (NNS lines)) (CC and) (NP (JJ peripheral) (NN blood) (NN T) (NNS cells)))) (VP (VBP differ) (ADVP (RB markedly)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NN NF-kappaB) (NN activation)) (VP (VBN induced) (PP (IN by) (NP (JJ oxidant) (NN stress)))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (NP (NP (JJ proposed) (NNS pathways)) (PP (IN of) (NP (NN NF-kappaB) (NN activation)))) (VP (VBP have) (VP (VBN been) (VP (VBN based) (PP (IN on) (NP (NP (JJ indirect) (NN evidence)) (VP (VBN provided) (PP (IN by) (NP (NP (NNS experiments)) (SBAR (WHNP (WDT which)) (S (VP (VBD used) (NP (NNS antioxidants)) (S (VP (TO to) (VP (VB inhibit) (NP (JJ active) (NN NF-kappaB) (NN formation)))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Further)) (, ,) (NP (NP (JJ complete) (NN activation)) (PP (IN of) (NP (NN T) (NNS cells)))) (VP (VBZ requires) (NP (NP (QP (IN at) (JJS least) (CD two)) (NNS signals)) (, ,) (NP (NP (NP (CD one)) (SBAR (WHNP (IN that)) (S (VP (VBZ stimulates) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ intracellular) (NN calcium)))))))) (CC and) (NP (NP (CD one)) (SBAR (WHNP (WDT that)) (S (VP (VBZ stimulates) (NP (NP (JJ enzymatic) (NNS processes)) (PP (VBG including) (NP (NNS kinases))))))))))) (. .))))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (JJ substantial) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (JJ full) (NN activation)) (PP (IN of) (NP (NN NF-kappaB)))) (VP (VBZ requires) (NP (JJ dual) (NNS signals)))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NP (NN H2O2)) (CC or) (NP (JJ other) (NN ROS)))) (S (VP (TO to) (VP (VB induce) (NP (NP (NN T) (NN cell) (NNS signals)) (CC and) (NP (JJ functional) (NNS responses))) (PP (IN by) (NP (DT these) (CD two) (NNS mechanisms))))))) (VP (VBZ is) (VP (VBN reviewed)))) (CC and) (S (NP (NP (DT the) (JJ specific) (NN response)) (PP (IN of) (NP (NN NF-kappaB))) (PP (TO to) (NP (NP (NN redox) (NNS changes)) (PP (IN in) (NP (NN T) (NNS cells)))))) (VP (VBZ is) (VP (VBN examined)))) (. .))))
(S1 (S (S (NP (NNS Data)) (VP (VBP are) (ADVP (RB also)) (VP (VBN presented) (S (VP (TO to) (VP (VB suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN redox) (NN regulation)) (PP (IN in) (NP (NN NF-kappaB) (NN activation)))) (VP (MD may) (VP (VB be) (ADJP (JJ relevant) (PP (PP (TO to) (NP (JJ immune-related) (NNS diseases))) (CC and) (PP (TO to) (NP (NN aging)))))))))))))) (. .))))
(S1 (S (S (NP (NN Ciprofloxacin)) (VP (VBZ induces) (NP (DT an) (JJ immunomodulatory) (NN stress) (NN response)) (PP (IN in) (NP (JJ human) (NN T) (NNS lymphocytes)))) (. .))))
(S1 (S (S (NP (NP (NN Exposure)) (PP (IN of) (NP (NNS cells))) (PP (TO to) (NP (JJ adverse) (JJ environmental) (NNS conditions)))) (VP (VBZ invokes) (NP (NP (DT a) (ADJP (RB genetically) (VBN programmed)) (NNS series)) (PP (IN of) (NP (NNS events))) (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ specific) (NNS genes)))))))) (. .))))
(S1 (S (S (NP (DT The) (NN fluoroquinolone) (JJ antibiotic) (NN ciprofloxacin)) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB upregulate) (NP (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (NN gene) (NN induction)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN investigation))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN ciprofloxacin))) (PP (IN at) (NP (JJ supratherapeutic) (NNS concentrations))) (PP (IN on) (NP (NP (JJ immediate-early) (PRN (-LRB- -LRB-) (ADJP (QP (JJR &lt;) (CD 2)) (NN h)) (-RRB- -RRB-)) (NN gene) (NN expression)) (PP (IN in) (NP (JJ primary) (JJ human) (JJ peripheral) (NN blood) (NNS lymphocytes)))))) (VP (VBD was) (VP (VBN studied) (PP (IN with) (NP (NN Northern) (NNS blots))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NP (NN IL-2) (CC and) (NN metallothionein) (NN enhancer) (CC and) (NN promoter) (NNS regions)) (CC and) (NP (NN transcription) (NNS factors) (NP (NP (NN AP-1)) (, ,) (NP (NN NF-kappaB)) (, ,) (CC and) (NP (NN NF-AT))))))) (VP (VBD were) (VP (VBN analyzed) (PP (IN by) (NP (NP (NP (NN chloramphenicol) (NN acetyltransferase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (CC and) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)))) (, ,) (ADVP (RB respectively)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN concentration)) (PP (IN of) (NP (NN c-fos) (, ,) (NN c-jun) (, ,) (NN c-myc) (, ,) (NN junB) (, ,) (CC and) (NN fra-1) (NNS mRNAs)))) (VP (VBD was) (VP (VBN increased) (PP (IN in) (NP (NP (VBN activated) (JJ peripheral) (NN blood) (NNS lymphocytes)) (VP (VBN incubated) (PP (IN with) (NP (NN ciprofloxacin)))))) (PP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (JJ untreated) (NNS controls)))))))) (. .))))
(S1 (S (S (NP (NN Ciprofloxacin)) (VP (VBD increased) (NP (NN CAT) (NN activity)) (PP (IN in) (NP (NP (VBN stimulated) (NNS lymphocytes)) (VP (VBN transfected) (PP (IN with) (NP (NP (NNS plasmids)) (VP (VBG containing) (NP (CC either) (DT the) (NP (NP (NN IL-2)) (CC or) (NP (NN metallothionein) (NN enhancer))))))))))) (. .))))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (PP (IN among) (NP (NP (DT the) (NN transcription) (NNS factors)) (VP (VBN tested)))) (, ,) (NP (NN AP-1) (NN activity)) (VP (VBD was) (VP (VBN increased) (PP (IN in) (NP (NP (VBN stimulated) (VBN purified) (NN T) (NN helper) (NNS lymphocytes)) (VP (VBN incubated) (PP (IN with) (NP (NN ciprofloxacin)))))) (PP (VBN compared) (PP (TO to) (NP (JJ drug-free) (NNS controls)))))) (. .))))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NN ciprofloxacin)) (VP (VP (VP (VBD increased) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (JJ immediate-early) (NNS transcripts))))) (, ,) (VP (VBD enhanced) (NP (NN IL-2) (CC and) (NN metallothionein) (NN promoter) (NN induction))) (, ,) (CC and) (VP (VBD upregulated) (NP (NN AP-1) (NNS concentrations)))) (PP (IN in) (NP (JJ primary) (NNS lymphocytes))) (, ,) (S (VP (VBG reflecting) (NP (NP (DT a) (NN program)) (VP (ADVP (RB commonly)) (VBN observed) (PP (IN in) (NP (JJ mammalian) (NN stress) (NNS responses)))))))) (. .))))
(S1 (S (NP (NP (NN Recognition)) (PP (IN of) (NP (NN herpes) (NN simplex) (NN virus) (NN type) (CD 2) (NN tegument) (NNS proteins))) (PP (IN by) (NP (NP (NN CD4) (NN T) (NNS cells)) (VP (VBG infiltrating) (NP (JJ human) (JJ genital) (NN herpes) (NNS lesions))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ local) (JJ cellular) (JJ immune) (NN response)) (PP (TO to) (NP (NP (NN herpes) (NN simplex) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HSV)) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP (JJ important)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (JJ recurrent) (NN HSV) (NN infection)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ antiviral) (NNS functions)) (PP (IN of) (NP (VBG infiltrating) (JJ CD4-bearing) (NN T) (NNS cells)))) (VP (MD may) (VP (VBP include) (NP (NP (NN cytotoxicity)) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ viral) (NN growth)))) (, ,) (NP (NN lymphokine) (NN secretion)) (, ,) (CC and) (NP (NP (NN support)) (PP (IN of) (NP (UCP (ADJP (JJ humoral)) (CC and) (NP (NN CD8))) (NNS responses))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS antigens)) (VP (VBN recognized) (PP (IN by) (S (NP (JJ many) (JJ HSV-specific) (NN CD4) (NN T) (NNS cells)) (VP (VBG localizing) (PP (TO to) (NP (JJ genital) (NN HSV-2) (NNS lesions)))))))) (VP (VBP are) (ADJP (JJ unknown))) (. .))))
(S1 (S (S (NP (NP (NN T) (NNS cells)) (VP (VBG recognizing) (NP (NP (NNS antigens)) (VP (VBN encoded) (PP (IN within) (NP (NP (NN map) (NNS units) (NP (NP (CD 0.67)) (TO to) (NP (CD 0.73)))) (PP (IN of) (NP (NN HSV) (NN DNA))))))))) (VP (VBP are) (VP (ADVP (RB frequently)) (VBN recovered) (PP (IN from) (NP (JJ herpetic) (NNS lesions))))) (. .))))
(S1 (S (S (NP (NP (NN Expression) (NN cloning)) (PP (IN with) (NP (NP (DT this) (NN region)) (PP (IN of) (NP (NN DNA)))))) (ADVP (RB now)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (NP (NN tegument) (NN protein) (NN VP22)) (CC and) (NP (DT the) (JJ viral) (NN dUTPase))) (, ,) (VP (VBN encoded) (PP (IN by) (NP (NNS genes) (NP (NP (NN UL49)) (CC and) (NP (NN UL50))))) (, ,) (ADVP (RB respectively))) (, ,)) (VP (VBP are) (NP (NN T-cell) (NNS antigens)))))) (. .))))
(S1 (S (S (NP (NP (JJ Separate) (NNS epitopes)) (PP (IN in) (NP (NN VP22)))) (VP (VBD were) (VP (VBN defined) (PP (IN for) (NP (NP (NN T-cell) (NNS clones)) (PP (IN from) (NP (NP (DT each)) (PP (IN of) (NP (CD three) (NNS patients))))))))) (. .))))
(S1 (S (S (NP (NP (NN Reactivity)) (PP (IN with) (NP (NP (DT the) (JJ tegument) (NN protein)) (VP (VBN encoded) (PP (IN by) (NP (NN UL21))))))) (VP (VBD was) (VP (VBN identified) (PP (IN for) (NP (DT an) (JJ additional) (NN patient))))) (. .))))
(S1 (S (S (NP (CD Three) (JJ new) (NNS epitopes)) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (NN VP16)) (, ,) (NP (NP (DT a) (JJ tegument) (NN protein)) (VP (VBN associated) (PP (IN with) (NP (NN VP22))))))))) (. .))))
(S1 (S (S (NP (DT Some) (JJ tegument-specific) (NN CD4) (NN T-cell) (NNS clones)) (VP (VBD exhibited) (NP (JJ cytotoxic) (NN activity)) (PP (IN against) (NP (JJ HSV-infected) (NNS cells)))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN herpes) (NN simplex) (NN tegument) (NNS proteins)) (VP (VP (VBP are) (VP (VBN processed) (PP (IN for) (NP (NN antigen) (NN presentation))) (ADVP (FW in) (FW vivo)))) (CC and) (VP (VBP are) (NP (NP (JJ possible) (NN candidate) (NNS compounds)) (PP (IN for) (NP (NN herpes) (NN simplex) (NNS vaccines))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Human) (NN 15-lipoxygenase) (NN gene) (NN promoter)) (: :) (NP (NP (NP (NN analysis)) (CC and) (NP (NN identification))) (PP (IN of) (NP (NP (NN DNA) (NN binding) (NNS sites)) (PP (IN for) (NP (NP (JJ IL-13-induced) (JJ regulatory) (NNS factors)) (PP (IN in) (NP (NNS monocytes)))))))) (. .)))))
(S1 (S (S (SBAR (IN In) (NN order) (TO to) (S (VP (VB study) (NP (NP (DT the) (JJ transcriptional) (NN control)) (PP (IN of) (NP (NN 15-LO) (NN expression))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VP (VP (VBN cloned)) (CC and) (VP (VBD sequenced))) (NP (DT the) (JJ human) (NN 15-LO) (NN promoter) (NN region)))) (. .))))
(S1 (S (S (S (NP (DT The) (NN 15-LO) (NN promoter)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN CpG) (NN island)) (PP (IN at) (NP (NP (DT the) (NN 5'-end)) (PP (IN of) (NP (DT the) (NN gene)))))))))) (, ,) (CC and) (S (NP (NN sequence) (NN analysis)) (VP (VBZ reveals) (NP (NP (JJ putative) (NN Sp1) (CC and) (NN Ap2) (NN binding) (NNS site/s)) (CC and) (NP (NP (NN absence)) (PP (IN of) (NP (NN TATA) (CC or) (NN CAAT) (NNS motifs))))))) (. .))))
(S1 (S (S (NP (NN Transcription)) (VP (VBZ is) (VP (VBN initiated) (PP (IN at) (NP (CD one) (JJ major) (NN site))))) (. .))))
(S1 (S (S (S (VP (VBG Using) (NP (NN deletion) (NNS constructs)))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN defined) (NP (NP (DT an) (JJ active) (NN promoter) (NN region)) (PP (IN of) (NP (NP (CD 1056)) (NP (NN bp))))))) (. .))))
(S1 (S (S (NP (NN Gel-shift) (NNS assays)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (JJ transcriptional) (NN factor) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (VP (VBN induced) (PP (ADVP (RB only)) (IN in) (NN response) (TO to) (NP (NP (NN IL-13) (NN treatment)) (PP (IN of) (NP (JJ human) (JJ peripheral) (NN blood) (NNS monocytes))))))) (VP (VBP bind) (PP (TO to) (NP (DT the) (NN 15-LO) (NN promoter) (NN DNA))))))) (. .))))
(S1 (S (S (NP (NP (CD Two) (NNS regions)) (, ,) (NP (NP (NP (NP (NN DP1)) (PRN (-LRB- -LRB-) (NP (CD -140) (TO to) (CD -92) (NN bp)) (-RRB- -RRB-))) (CC and) (NP (NP (NN DP2)) (PRN (-LRB- -LRB-) (NP (CD -353) (TO to) (CD -304) (NN bp)) (-RRB- -RRB-)))) (PP (IN of) (NP (DT the) (NN promoter))))) (VP (VBD were) (ADJP (JJ essential) (PP (IN for) (NP (NP (NN transcription)) (PP (IN in) (NP (NP (NN HeLa) (NNS cells)) (CC and) (NP (JJ human) (JJ peripheral) (NNS monocytes)))))))) (. .))))
(S1 (S (S (NP (NN Hela) (JJ nuclear) (NNS extracts)) (VP (VBD contained) (NP (NP (DT a) (JJ specific) (JJ nuclear) (NN factor) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (VP (VBG binding) (PP (TO to) (NP (NP (NN 15-LO) (NN promoter) (NN DNA)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT those)) (VP (VBN derived) (PP (IN from) (NP (JJ IL-13-treated) (JJ human) (JJ peripheral) (NN monocyte) (JJ nuclear) (NNS extracts))))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (JJ fluorescent) (ADJP (FW in) (FW situ)) (NN hybridization)) (PRN (-LRB- -LRB-) (NP (NN FISH)) (-RRB- -RRB-))) (VBZ results)) (VP (VBD refined) (NP (NP (DT the) (JJ previous) (NN localization)) (PP (IN of) (NP (NN 15-LO)))) (PP (TO to) (NP (JJ human) (NN chromosome) (NN 17p13.3)))) (. .))))
(S1 (S (NP (NP (NN Lack)) (PP (IN of) (NP (NP (JJ T-cell-mediated) (NN recognition)) (PP (IN of) (NP (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (NN pml/RAR-alpha) (NN hybrid) (NN protein))))) (PP (IN by) (NP (NP (NNS lymphocytes)) (PP (IN of) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (NNS patients))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ previous) (NNS studies))) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (NN pml/RAR-alpha) (NN protein))) (, ,) (VP (VBN expressed) (PP (IN by) (NP (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))) (NNS cells)))) (, ,)) (VP (MD can) (VP (VB be) (VP (ADVP (RB specifically)) (VBN recognized) (ADVP (FW in) (FW vitro)) (PP (IN by) (NP (NP (NP (NN donor)) (PRN (-LRB- -LRB-) (NP (NNP D.) (NNP E.)) (-RRB- -RRB-))) (NN CD4) (NN T) (NNS cells))) (PP (IN in) (NP (DT a) (ADJP (NN HLA) (NN class) (CD II) (JJ DR11-restricted)) (NN fashion)))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP present) (ADVP (RB here)) (NP (NP (DT the) (NNS results)) (PP (IN on) (NP (NP (DT the) (NN recognition)) (PP (IN of) (NP (JJ several) (NN pml/RAR-alpha) (NNS peptides))) (PP (IN by) (NP (NP (NN APL) (NNS patients)) (VP (VBG expressing) (NP (NN HLA) (NN DR11))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (ADJP (FW in) (FW vitro)) (NN immunization)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS lymphocytes)) (PP (IN from) (NP (NP (NP (CD four) (NNS patients)) (PP (IN in) (NP (NN remission)))) (PRN (-LRB- -LRB-) (NP (NP (NNP S.R.)) (, ,) (NP (NNP F.R.)) (, ,) (NP (NNP M.M.)) (, ,) (NP (NNP P.) (NNP G.))) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (NN BCR1/25)) (, ,) (NP (DT a) (NN 25-mer) (NN pml/RAR-alpha)) (, ,)))) (VP (VBD did) (RB not) (VP (VB elicit) (NP (NP (NP (CC either) (NP (DT a) (JJ polyclonal)) (CC or) (NP (DT a) (JJ clonal))) (NP (JJ immune) (NN response))) (ADJP (JJ specific) (PP (TO to) (NP (DT the) (NN peptide))))))) (. .))))
(S1 (S (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD generated) (NP (JJ new) (NN donor) (JJ anti-pml/RAR-alpha) (JJ CD4-LRB-+-RRB-) (NN T-cell) (NNS clones))) (. .))))
(S1 (S (S (NP (DT These) (NNS clones)) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (PRP$ their) (NN recognition)) (PP (IN of) (NP (NN BCR1/25))))))) (. .))))
(S1 (S (S (NP (NP (CD One) (NN clone)) (PRN (-LRB- -LRB-) (NP (NP (NN C3/5)) (, ,) (ADJP (ADJP (JJ CD3-LRB-+-RRB-)) (, ,) (ADJP (JJ CD4-LRB-+-RRB-)) (, ,) (ADJP (JJ CD8-LRB---RRB-)))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN selected) (PP (IN for) (NP (JJ further) (NN analysis))))) (. .))))
(S1 (S (S (NP (NN Clone) (NN C3/5)) (VP (VBD showed) (NP (JJ specific) (NP (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NP (NP (NN cytokine)) (PRN (-LRB- -LRB-) (NP (UCP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (, ,) (ADJP (JJ granulocyte-macrophage) (JJ colony-stimulating))) (NN factor)) (-RRB- -RRB-))) (NN production)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN challenged) (PP (IN with) (NP (NP (JJ autologous) (JJ lymphoblastic) (NN cell) (NNS lines)) (VP (VBN pulsed) (PP (IN with) (NP (NN peptide) (NN BCR1/25)))))))))) (. .))))
(S1 (S (S (NP (NN C3/5) (NNS cells)) (VP (VBD developed) (NP (JJ specific) (NP (NP (NN proliferation)) (CC and) (NP (NN cytotoxicity)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN challenged) (PP (IN with) (NP (NP (JJ peptide-pulsed) (NP (NP (JJ lymphoblastic) (NN cell) (NNS lines)) (CC and) (NP (JJ peripheral) (NN blood) (NNS lymphocytes)))) (PP (IN from) (NP (DT the) (CD four) (JJ DR11-LRB-+-RRB-) (NN APL) (NNS patients))))))))) (. .))))
(S1 (S (S (NP (NP (NN APL) (NNS blasts)) (, ,) (ADJP (JJ available) (PP (RB only) (IN from) (NP (NNS patients) (NP (NP (NNP F.R.)) (CC and) (NP (NNP P.G.)))))) (, ,)) (VP (VP (VBD were) (RB not) (VP (VBN lysed) (PP (IN by) (NP (NN C3/5))))) (CC and) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (VP (VB present) (NP (NN peptide) (NN BCR1/25)))))))) (. .))))
(S1 (S (S (NP (NP (NN Incubation)) (PP (IN of) (NP (NN APL) (NNS cells))) (PP (IN with) (NP (NN IFN-gamma)))) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP (NP (NN HLA) (NN class) (CD II) (NNS molecules)) (CC and) (NP (NP (NN recognition)) (PP (IN by) (NP (DT the) (NN C3/5) (NN clone))))))))) (. .))))
(S1 (S (S (SBAR (IN Since) (S (NP (NN APL) (NNS cells)) (VP (VBP do) (RB not) (VP (VB express) (NP (NN HLA) (NN class) (CD II) (NNS molecules)))))) (, ,) (NP (PRP we)) (VP (VBD tested) (PP (PP (IN in) (NP (NP (CD two) (NNS donors)) (PRN (-LRB- -LRB-) (NP (NP (NNP D.E.)) (CC and) (NP (NNP C.H.R.))) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NNS patients) (NP (NP (NN S.R.)) (CC and) (NP (NN P.G.)))))) (SBAR (CC whether) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN 9-mer) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NN BCR1/9)) (-RRB- -RRB-))))) (VP (MD would) (VP (VB generate) (NP (DT a) (ADJP (NN CD8/HLA) (NN class) (JJ I-restricted)) (NN response))))))) (. .))))
(S1 (S (S (NP (DT No) (JJ peptide-specific) (NN T-cell) (NP (NP (NN line)) (CC or) (NP (NN clone)))) (VP (MD could) (VP (VB be) (VP (VBN generated) (PP (IN from) (NP (CC both) (NP (NNS donors)) (CC and) (NP (NNS patients))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP are) (VP (VBN discussed) (PP (IN in) (NN relation) (TO to) (NP (NP (JJ possible) (JJ therapeutic) (NNS approaches)) (PP (TO to) (NP (NP (DT the) (NN immunotherapy)) (PP (IN of) (NP (NN APL))))))))) (. .))))
